{"title": "PDF", "author": "PDF", "url": "https://tuprints.ulb.tu-darmstadt.de/3002/1/Dissertation_Fabio_Lo_Monte.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \n \n \nDesign, Synthese und Optimierung von \nGSK-3-Inhibitoren und ihre Evaluation \nin Modellen der Alzheimer-Demenz \n \n \n \nVom Fachbereich Chemie  \nder Technischen Universit\u00e4t Darmstadt \n \nzur Erlangung des akademischen Grades eines  \nDoctor rerum naturalium (Dr. rer. nat.) \n \ngenehmigte  \nkumulative Dissertation  \n \nvorgelegt von  \n \nFabio Lo Monte, Master of Science   \naus Hilden \n \n \nReferent:  Prof. Dr. Boris Schmidt \nKorreferenten: Prof. Dr. Harald Kolmar \n   Prof. Dr. Daniel Rauh (TU Dortmund) \n \nTag der Einreichung:  26. M\u00e4rz 2012 \nTag der m\u00fcndlichen Pr\u00fcfung: 21. Mai 2012 \n \nDarmstadt 2012 \n \nD17  \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDie vorliegende Arbeit wurde unter der Leitung von Herrn Prof. Dr. Boris Schmidt am \nClemens Sch\u00f6pf-Institut f\u00fcr Organische Chemie und B iochemie der Technischen \nUniversit\u00e4t Darmstadt von M\u00e4rz 2009 bis M\u00e4rz 2012 a ngefertigt.  \n Teile dieser Arbeit sind bereits ver\u00f6ffentlicht ode r zur Ver\u00f6ffentlichung eingereicht \n \n1. Thomas Kramer*, Boris Schmidt, Fabio Lo Monte \u2021 Small-molecule inhibitors of \nGSK-3 - Structural insights and their application t o Alzheimer's disease \nmodels, International Journal of Alzheimer's Disease 2012 , im Druck.  \n \n2. Fabio Lo Monte*, Thomas Kramer*, Alexander Bol\u00e4n der, Batya Plotkin, Hagit \nEldar-Finkelman, Ana Fuertes, Juan Dominguez, Boris  Schmidt \u2021 Synthesis \nand biological evaluation of glycogen synthase kina se 3 (GSK-3) inhibitors: An \nfast and atom efficient access to 1-aryl-3-benzylur eas, Bioorganic & Medicinal \nChemistry Letters  2011 , 21, 5610-15. dx.doi.org/10.1016/j.bmcl.2011.06.13 1  \n \n3. Fabio Lo Monte*,\u2021 , Thomas Kramer, Jiamin Gu, Upendra Rao Anumala, \nLuciana Marinelli, Valeria La Pietra, Ettore Novell ino, Ana Fuertes, Juan \nManuel Dominguez, Batya Plotkin, Hagit Eldar-Finkel man, Boris Schmidt \u2021 \nIdentification of Glycogen Synthase Kinase-3 Inhibi tors with a Selective Sting \nfor Glycogen Synthase Kinase-3 \u03b1, Journal of Medicinal Chemistry 2012 , 55, \n4407-4424. dx.doi.org/10.1021/jm300309a   \n \n4. Fabio Lo Monte*,\u2021 , Thomas Kramer, Jiamin Gu, Martin Brodrecht, Johan nes \nPilakowski, Ana Fuertes, Juan Manuel Dominguez, Bat ya Plotkin, Hagit Eldar-\nFinkelman, Boris Schmidt \u2021 Structure-based optimization of oxadiazole-based \nGSK-3 inhibitors, European Journal of Medicinal Chemistry 2012 , zur \nPublikation angenommen.   \n \n5. Boris Schmidt, Fabio Lo Monte, Thomas Kramer, Ha git Eldar-Finkelman, Fred \nVan Leuven Verbindungen als Glykogen Synthase Kinas e 3 (GSK-3) \nInhibitoren f\u00fcr die Behandlung von GSK-3-vermittelt en Erkrankungen, \nDeutsche Patentanmeldung  2011 , Nr.: 10 2011 106 990.2. \n \n6. Thomas Kramer*, Fabio Lo Monte*, Stefan G\u00f6ring, Ghislaine Marlyse Okala \nAmombo, Boris Schmidt \u2021 Small molecule kinase inhibitors for LRRK2 and the ir \napplication to Parkinson\u00b4s disease models, ACS Chemical Neuroscience \n2012 , 3, 151-160. dx.doi.org/10.1021/cn200117j \n \n7. Ghislaine Marlyse Okala Amombo*, Thomas Kramer*,  Fabio Lo Monte*, \nStefan G\u00f6ring, Steven Smith, Stephanie Kolb, Robert  Schubenel, Karlheinz \nBaumann, Boris Schmidt \u2021 Inhibitor modification - An inhibition shift from  \n\u03b3-secretase to FLT-3, Bioorganic & Medicinal Chemistry Letters , wird \nvoraussichtlich im Juli 2012 eingereicht.   \n*Erstautor ; \u2021Korrespondenzautor  \n Danksagung \n \nMeinem Doktorvater Herrn Prof. Dr. Boris Schmidt da nke ich f\u00fcr die interessante und \nspannende Themenstellung, die st\u00e4ndige Gespr\u00e4chs- u nd Diskussionsbereitschaft \nsowie f\u00fcr das mir entgegengebrachte Vertrauen. \n \nEin weiterer Dank geht an meine Laborkollegen Thoma s, Jiamin, Upendra, Stefan, \nAzadeh, Marlyse, Daniel, Alex, Andrea, Eva, Binia u nd Nicole f\u00fcr das gute \nArbeitsklima und die nette Zusammenarbeit. \n \nMeinen Studenten Steven, Stefan, Martin, Johannes u nd Matthias danke ich f\u00fcr die \nlustige Zeit im Labor und deren Mitarbeit am meinen  Projekt. \n \nDen \u201eKicker-Kollegen\u201c danke ich f\u00fcr die unglaublich  lustige Zeit am Tischfu\u00dfball. \n \nFrau Sahinalp und Frau Rudolf danke ich f\u00fcr die net ten Unterhaltungen und das \nAnfertigen meiner Massenspektren.   \n \nDem Seventh Framework Programme  (FP7) der europ\u00e4ischen Union danke ich f\u00fcr \ndie finanzielle Unterst\u00fctzung dieser Arbeit. Ein we iterer Dank geht an das \nNeuro.GSK3 -Konsortium f\u00fcr die gute Zusammenarbeit und biologi sche Testung \nmeiner Verbindungen.  \n \nMeiner Lebensgef\u00e4hrtin, meinen Eltern, meinen Freun den und meiner ganzen \nFamilie gilt ein gro\u00dfer Dank f\u00fcr die bedingungslose  Unterst\u00fctzung w\u00e4hrend meines \ngesamten Studiums und der Promotion. \n   \n   Inhaltsverzeichnis         \n \nAbk\u00fcrzungsverzeichnis             I \n             \n1.  Einleitung             1 \n1.1  Alzheimer-Demenz (AD)           1 \n1.2  APP-Metabolismus und A \u03b2-Peptide         3 \n1.2.1  Modulatoren und Inhibitoren der \u03b3-Sekretase        5 \n1.2.2  Inhibitoren der \u03b2-Sekretase          8 \n1.3  Entstehung der intrazellul\u00e4ren Neurofibrillenb \u00fcndel (NFTs)     10 \n \n2.  Glykogen Synthase Kinase 3 (GSK-3)        13 \n2.1  Struktur und Funktion von Proteinkinasen       13 \n2.2  Bindungstypen von Kinaseinhibitoren        16 \n2.3  Struktur und Substrate von GSK-3        18 \n2.4  Die Rolle von GSK-3 in der AD und literaturbek annte      19 \n  Inhibitoren \n2.5  Weitere Funktionen von GSK-3         24 \n2.6  Etablierte Tiermodelle f\u00fcr GSK-3         26 \n2.7  Molekulare Interaktionen          27 \n2.8  Entwicklung von Wirkstoffen         30 \n \n3.  Aufgabenstellung und Zielsetzung der Arbeit      33 \n \n4.  Kumulativer Teil der Dissertation        35 \n4.1  Untersuchungen zu GSK-3         36 \n4.1.1  Das Target  GSK-3 im Bereich der Alzheimer-Demenz     36 \n4.1.2  Effiziente Synthese und Evaluierung von GSK- 3-Inhibitoren     88 \n4.1.3  Synthese selektiver GSK-3 \u03b1-Inhibitoren mittels      122 \nbiphenylischer Systeme \n4.1.4  Strukturbasierte Optimierung von Oxadiazolde rivaten     164 \n4.1.5  Oxadiazolderivate und deren Verwendung als       224 \nGSK-3-Inhibitoren  \n4.2  Untersuchungen zu anderen Kinasen       254  \n 4.2.1  Die Parkinson-Krankheit und das Potential vo n LRRK2    254 \n4.2.2  Die Behandlung der akuten myeloischen Leuk\u00e4m ie     266  \ndurch FLT-3   \n \n5.  Zusammenfassung         297 \n   \n6.  Ausblick           301 \n \n7.  Literaturverzeichnis         303 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n  I Abk\u00fcrzungsverzeichnis         \n \nA\u03b2   Amyloid- \u03b2-Peptid \nAbb.   Abbildung \nAD   Alzheimer-Demenz \nADAM   a disintegrin and metalloprotease  \nAICD   APP intracellular domain \nALS   amyotrophische Lateralsklerose \nAPC   adenomatous polyposis coli  \nAPH-1  anterior pharynx defective-1  \nAPOE   Apoliprotein E \nAPP   Amyloid-Vorl\u00e4uferprotein \nATP   Adenosintriphosphat \n\u03b2-Sekretase  \u03b2-site APP-cleaving enzyme 1 ; BACE-1 \nBSc   Boris Schmidt Substanzdatenbankeintrag \nbzw.   beziehungsweise \nCDK5   cyclin dependant kinase 5  \nCOX   Cyclooxygenase \nDVL   dishevelled \nEOAD   early onset AD patient  \nERK2   extracellular signal-regulated kinase-2  \nFDA   Food and Drug Administration \nFLT-3   FMS-like tyrosine kinase-3  \nFRAT   frequently rearranged during advanced T-cell lympho ma  \nGPCRs  G-protein-coupled receptors  \nGSK-3  Glykogen Synthase Kinase 3  \nHSP 90  heat shock protein 90  \nIC 50   mittlere inhibitorische Konzentration \nIRS   insulin-receptor substrate  \nLOAD   late onset AD patient \nLRRK2  leucine-rich repeat kinase 2  \nkDa   Kilodalton \nMAP   Mikrotubuli-assoziiertes Protein \nMARK  1  microtubule affinity-regulating kinase 1   \nII NCSTN  Nicastrin \nNFTs   neurofibrillary tangles ; Neurofibrillenb\u00fcndel \nPDK1   3-phosphoinositide-dependant protein kinase-1  \nPEN-2  presenilin enhancer-2  \nPHFs   paired helical filaments ; paarige helikale Filamente \nPI3K   phosphatidylinositol 3-kinase  \nPIP 2   phosphatidylinositol(4,5)bisphosphate \nPIP 3   phosphatidylinositol(3,4,5)bisphosphate  \nPK   Proteinkinase \nPKA   cAMP-dependant protein kinase  \nPKI   Proteinkinase-Inhibitoren \nPP1 \u03b2.Gm  protein phosphatase 1  \nPS   Presenilin \nPSA   polar surface area ; polare Molek\u00fcloberfl\u00e4che \nTab.   Tabelle \nTCF   transcription factor  \nz.B.   zum Beispiel \nZNS   Zentralnervensystem \n \n \nVerzeichnis der Aminos\u00e4uren  \n \nAla   Alanin \nArg   Arginin \nAsn  Asparagin \nAsp   Asparagins\u00e4ure \nCys   Cystein \nGln   Glutamin \nGlu   Glutamins\u00e4ure \nGly   Glycin \nHis   Histidin \nIle   Isoleucin Leu   Leucin \nLys  Lysin \nMet   Methionin \nPhe   Phenylalanin \nPro   Prolin \nSer   Serin \nThr   Threonin \nTrp   Tryptophan \nTyr   Tyrosin \nVal   Valin  \nSeite 1 1. Einleitung         \n \n1.1 Alzheimer-Demenz (AD) \nVor mehr als hundert Jahren beschrieb Dr. Alois Alz heimer in der st\u00e4dtischen \nNervenheilanstalt Frankfurt am Main eine bis dahin unbekannte Krankheit. Seine \ndamalige Patientin Auguste Deter litt mit zunehmend er Verschlechterung an \nGed\u00e4chtnisverlust, Desorientiertheit und Verfolgung swahn. Einige Jahre sp\u00e4ter starb \ndie Patientin und die histologische Untersuchung ih res Gehirns durch Alois \nAlzheimer f\u00fchrte zur Identifizierung zweier ungew\u00f6h nlicher Proteinablagerungen. 1-2 \nHeute ist diese Erkrankung unter dem Namen Alzheime r-Demenz (AD) bekannt und \ndie Ablagerungen werden als extrazellul\u00e4re Amyloid- Plaques und intrazellul\u00e4re \nNeurofibrillenb\u00fcndel ( neurofibrillary tangles , NFTs) bezeichnet (Abb. 1).  \n \n       \nAbb. 1: Histologische Fluoreszenzf\u00e4rbung der extrazellul\u00e4re n Amyloid-Plaques (links, gr\u00fcn) und der \nintrazellul\u00e4ren Neurofibrillenb\u00fcndel (rechts, gr\u00fcn) . 3  \n \nDie Amyloid-Plaques, welche aus Polymeren des Amylo id-\u03b2-Peptides (A \u03b2) bestehen, \nund die NFTs, Ablagerungen des hyperphosphorylierte n und Mikrotubuli-assoziierten \nTau-Proteins, sind nach wie vor Kennzeichen der AD.4 Die endg\u00fcltige AD-Diagnose \nkann gegenw\u00e4rtig nur post mortem  gestellt werden. 5 Infolgedessen wird zurzeit \nverst\u00e4rkt an bildgebenden Verfahren und Biomarkern geforscht, um AD fr\u00fchzeitig zu \ndiagnostizieren und die Wirkung von Therapeutika zu  untersuchen.6 Heutzutage \nklassifiziert man die Krankheit nach fr\u00fchem Krankhe itsausbruch ( early onset  AD  \npatient , EOAD) und sp\u00e4tem Krankheitsausbruch ( late onset  AD  patient , LOAD). \nEOAD ist eine seltene Form der AD und die heutige h ohe Lebenserwartung f\u00fchrt \n \nSeite 2 dazu, dass die Krankheit bei der Mehrzahl der Patie nten in h\u00f6herem Alter ausbricht.7 \nDrei Genmutationen, die mit EOAD in Verbindung steh en, konnten bisher identifiziert \nwerden. Diese Gene kodieren f\u00fcr das Amyloid-Vorl\u00e4uf erprotein (APP), Presenilin 1  \n(PS1) und Presenilin  2 (PS2). Die genetische Ursache f\u00fcr LOAD ist derzeit  nicht \nvollst\u00e4ndig aufgekl\u00e4rt, jedoch spielt das Apolipopr otein E (APOE) eine sehr wichtige \nRolle bei der Entstehung. 8 Im Jahr 2009 wurden weltweit mehr als 35 Millionen  F\u00e4lle \nvon AD registriert und Sch\u00e4tzungen zufolge wird sic h diese Zahl bis 2050 \nverdoppeln. 4 Die Kosten, die hierdurch auf das Gesundheitssyste m zukommen, sind \nimmens.  \nDerzeit gibt es f\u00fcnf Medikamente auf dem Markt, die  darauf abzielen die Symptome \nder AD zu lindern, nicht jedoch die ihr zugrunde li egende Pathologie (Abb. 2).7,9   \nDer Verlust an cholinergen Neuronen und Defizite im  Acetylcholin-\nNeurotransmittersystem sind Symptome, die bereits i n einem fr\u00fchen Stadium von AD \nzu beobachten sind. 7 Donepzil ( 1), Rivastigmin ( 2), Galantamin ( 3) und  \nHuperzin-A ( 4) sind Inhibitoren der Acetylcholinesterase, welche  die Defizite im \nAcetylcholin-Neurotransmittersystem vermindern.7-9 Verbindung 4 ist derzeit nur in \nChina zugelassen.9 Tacrin ( 5) ist ebenfalls ein Acetylcholinesterase-Inhibitor und  \ndie erste Verbindung, die zur Behandlung der AD-Sym ptome zugelassen wurde.  \n \n \n \nAbb. 2: Zugelassene Medikamente zur symptomatischen Behandl ung von AD.  \n \n \nSeite 3 Aufgrund von Nebenwirkungen wurde diese Verbindung jedoch in einigen  \nL\u00e4ndern vom Markt genommen. 10  Memantin ( 6) ist ein nicht-kompetitiver NMDA  \n(N-Methyl-D-Aspartat) Rezeptor-Antagonist und wird be i AD-Patienten mit mittlerem \nbis schwerem Krankheitsbild eingesetzt. Diese Verbi ndung kann als  \nMonotherapie oder in Kombination mit einem Acetylch olinesterase-Inhibitor \nverwendet werden. 9 Desweiteren werden entz\u00fcndungshemmende Medikamente   \nwie COX-1- (Cyclooxygenase) und COX-2-Inhibitoren u ntersucht, da h\u00e4ufig \nEntz\u00fcndungsvorg\u00e4nge im Gehirn von AD-Patienten zu b eobachten sind.11-12  Auch an \neiner A \u03b2-Immuntherapie wird seit einigen Jahren geforscht. Man erhofft sich durch \ndie Impfung eine Reduktion von A \u03b2 und damit einhergehend eine Verringerung der \nAmyloid-Plaques. Derzeit befinden sich zehn dieser Impfstoffe in den klinischen \nPhasen. 8 Substanzen, die gezielt die Bildung von Amyloid-Pl aques und NFTs \nverhindern, befinden sich derzeit in klinischen Stu dien und k\u00f6nnten in Zukunft eine \nwichtige Rolle in der Behandlung von AD-Patienten e innehmen.   \n \n1.2 APP-Metabolismus und A \u03b2-Peptide \nDie Bildung von Amyloid-Plaques beginnt mit dem Abb au des APP. Beim APP \nhandelt es sich um ein Typ-1-Membranprotein, welche s in verschiedenen Geweben \ndes Organismus, in der Peripherie und im Zentralner vensystem (ZNS) hergestellt \nwird. APP kann auf zwei verschiedenen Wegen abgebau t werden, dem nicht-\namyloidogenen Weg und dem amyloidogenen Weg (Abb. 3 ). 5,7  Drei verschiedene \nSekretasen sind f\u00fcr den Abbau von APP verantwortlic h, die \u03b1-, \u03b2- und \u03b3-Sekretase. \nBeim nicht-amyloidogenen Weg spaltet die \u03b1-Sekretase APP in das wasserl\u00f6sliche \nsAPP \u03b1 und das membrangebundene C83. Durch die \u03b3-Sekretase wird das C83 dann \nweiter zum k\u00fcrzeren p3-Peptid \u00fcberf\u00fchrt, welches sc hnell abgebaut wird und in der \nPathologie der AD keine Rolle spielt. 5,7-8 Die \u03b1-Sekretase geh\u00f6rt zur Familie der \nADAM-Metalloproteasen ( a disintegrin and metalloprotease ) von denen drei \n(ADAM 9, ADAM 10 und ADAM 17) mit dem nicht-amyloid ogenen Weg in \nVerbindung gebracht werden. 5 Beim pathogenen amyloidogenen Weg wird APP \ndurch die \u03b2-Sekretase (\u03b2-site APP-cleaving enzyme 1  oder BACE-1) zum sAPP \u03b2 und \nC99-Fragment abgebaut. Die darauffolgende Spaltung des C99-Fragments durch die \n\u03b3-Sekretase f\u00fchrt schlie\u00dflich zur Bildung von A \u03b2 und AICD ( APP intracellular \ndomain ). Die Rolle von AICD in der Entstehung der AD ist derzeit nicht vollst\u00e4ndig  \nSeite 4 gekl\u00e4rt und Bestandteil einer kontroversen Debatte in der Alzheimer-Forschung. 13  \nA\u03b2-Peptide k\u00f6nnen in verschiedenen L\u00e4ngen vorkommen ( 38-43 Aminos\u00e4uren), \nwobei das dominierende Molek\u00fcl das A \u03b240 -Peptid ist. Es macht ca. 80-90% aller A \u03b2-\nPeptide aus, gefolgt von A \u03b242  mit einem Anteil von 5-10%. 5,7  A\u03b242  aggregiert \nbereitwillig und bildet den Ausgangspunkt f\u00fcr gr\u00f6\u00dfe re Oligomere, Fibrillen und \nletztlich den Amyloid-Plaques. Die fr\u00fchen Aggregate  und Plaques bestehen \nhaupts\u00e4chlich aus A \u03b242 . Sie k\u00f6nnen jedoch, wenn die Konzentration der \nAmyloidaggregate einen Schwellenwerte \u00fcberschreitet , auch A \u03b240 enthalten. 5,7  \n \n \n \n \n \n \n \n \n \n \n \n \nAbb. 3: Prozessierung von APP durch die \u03b1-, \u03b2- und \u03b3-Sekretase und Bildung der Amyloid-Plaques. \n \nObwohl A \u03b2 in AD-Gehirnen im Vergleich zu Kontroll-Gehirnen s tark erh\u00f6ht ist, konnte \nein direkter Zusammenhang zwischen den Amyloid-Plaq ues und der Pathologie der \nAD bisher nicht definitiv gekl\u00e4rt werden. Dennoch b estimmt derzeit die \nAmyloidhypothese die Modelle zur Entstehung der AD.  Die Hypothese besagt, dass \ndie Akkumulation von A \u03b2 im ZNS die Hauptursache von AD darstellt, wodurch eine \npathogene Kaskade initiiert wird. 7  \nInfolgedessen ergeben sich verschiedene Therapieans \u00e4tze, die in der \npharmazeutischen Industrie und an Hochschulen erfor scht werden. 7 Alle Ans\u00e4tze \nnicht -amyloidogener Weg  amyloidogener Weg  \nAPP  Amyloid \nPlaques sAPP \u03b2 \np3  sAPP \u03b1 \nC83  C99  A\u03b2 \n\u03b1-Sekretase  \u03b2-Sekretase  \u03b3\u03b3 \u03b3\u03b3-Sekretase  \u03b3\u03b3 \u03b3\u03b3-Sekretase  \nAICD  \n \nSeite 5 richten sich gegen die Bildung von A \u03b2 und somit gegen die  \nSekretasen. Der Fokus liegt hierbei auf den Inhibit oren und Modulatoren  \nder \u03b3-Sekretase sowie den Inhibitoren der \u03b2-Sekretase. Auch der Ansatz von  \n\u03b1-Sekretase-Aktivatoren wurde verfolgt, jedoch konnt en bisher noch keine \naussagekr\u00e4ftigen Hinweise den Nutzen f\u00fcr AD-Patient en belegen. 9                                          \n  \n1.2.1 Modulatoren und Inhibitoren der \u03b3\u03b3 \u03b3\u03b3-Sekretase \nDie \u03b3-Sekretase ist eine Protease mit vielen potenzielle n Substraten und ist in den \nmeisten Geweben des Organismus zu finden. Sie spalt et ihre Substrate in der \nlipophilen Umgebung der Transmembrandom\u00e4ne und ist selbst \u00fcber  \nmehrere Transmembrandom\u00e4nen in der Zellmembran vera nkert. Das im APP- \nMetabolismus durch die Spaltungsreaktion der \u03b2-Sekretase entstandene  \nC99-Fragment wird ebenfalls von der \u03b3-Sekretase innerhalb der \nTransmembrandom\u00e4ne gespalten, was letztlich zur Bil dung der A \u03b2-Peptide f\u00fchrt. 7,14  \nDie \u03b3-Sekretase ist ein hochmolekularer Komplex und best eht aus mindestens vier \nunterschiedlichen Proteinen, dem PS1 oder PS2, NCST N (Nicastrin), APH-1 \n(anterior pharynx defective-1 ) und PEN-2 ( presenilin enhancer-2 ), die im Verh\u00e4ltnis \n1:1:1:1 stehen (Abb. 4).  \n \n \n \n \n \n \n \n \n \nAbb. 4: Schematische Darstellung des \u03b3-Sekretase-Komplexes. \n D385  D257  C \nC C N \nN N C \nN PS1  NCSTN  \nAPH -1 PEN -2 \n1 2 3 4 5 6 7 8 9  \nSeite 6 Aufgrund fehlender struktureller Informationen ist bisher wenig \u00fcber die Rolle der \neinzelnen Bestandteile bekannt, jedoch sind alle Un tereinheiten f\u00fcr die Bildung des \naktiven Enzymkomplexes unverzichtbar.7-8  \nEs wird heute davon ausgegangen, dass PS1 und PS2 d ie katalytische  \nUntereinheit des Komplexes bilden. 7 Humanes PS1 ist ein ~50 kDa  \ngro\u00dfes Transmembranprotein, und das Homolog PS2 ist  lediglich vier  \nAminos\u00e4uren k\u00fcrzer. Im aktiven \u03b3-Sekretase-Komplex wird Presenilin 1 , bestehend \naus neun Transmembrandom\u00e4nen, wahrscheinlich durch Autoproteolyse in ein \nN-terminales (~30 kDa, Transmembrandom\u00e4ne 1-6) und ein C-terminales (~20 kDa, \nTransmembrandom\u00e4ne 7-9) Fragment gespalten. Dadurch  nimmt Presenilin 1  seine \naktive enzymatische Konformation ein. Zwei Aspartat reste (D257  und D385 beim \nhumanen PS1), die sich zwischen der Transmembrandom \u00e4ne 6 und 7 befinden, \nbilden hierbei vermutlich das katalytische Zentrum.15  Die beiden Aspartatreste \nk\u00f6nnten eine \u00e4hnliche Funktion haben wie bei andere n Aspartatproteasen und die \nAufgabe \u00fcbernehmen, ein Wassermolek\u00fcl zu aktivieren , das dann die Peptidbindung \ndes Substrats nukleophil angreift. Wird einer diese r Aspartatreste ersetzt, geht die  \n\u03b3-Sekretase-Aktivit\u00e4t und F\u00e4higkeit zur Autoproteoly se vollst\u00e4ndig verloren. 7 \nMutationen in der PS-Untereinheit stehen in direkte r Verbindung zur \u03b3-Sekretase-\nAktivit\u00e4t und es wurde gezeigt, dass diese Mutation en zu einer Erh\u00f6hung des C99-\nFragments f\u00fchren und infolgedessen vermehrt A \u03b242 gebildet wird. 16  Presenilin  \ninteragiert desweiteren mit \u03b2-Catenin, weswegen es auch mit der Entstehung von \nverschiedenen Krebsarten in Verbindung gebracht wir d. 15  Bei den drei anderen \nUntereinheiten wird davon ausgegangen, dass sie in der Bildung und Stabilit\u00e4t des \nKomplexes involviert sind. \u00dcber das NCSTN wurde ber ichtet, dass die gro\u00dfe \nextrazellul\u00e4re Dom\u00e4ne wichtig f\u00fcr die Bindung des S ubstrats sei und spezifisch die \nverk\u00fcrzten Typ-1-Membranproteine nach Abtrennung ih rer extrazellul\u00e4ren Dom\u00e4ne \nerkennt. 7,15,17  Bis zu 16 Reste des NCSTN k\u00f6nnen glykosyliert werd en, jedoch \nscheint es, dass die Glykosylierung keinen Einfluss  auf die Funktion der \u03b3-Sekretase \nhat. 15,18  \u00dcber die Rolle von APH-1 und PEN-2 ist bisher sehr  wenig bekannt. 7 APH-1 \nkann in zwei Isoformen im Menschen auftreten, APH-1 A und APH-1B, jedoch konnte \nin Zellkulturexperimenten gezeigt werden, dass sich  die Menge des gebildeten A \u03b2 \nnicht unterscheidet. APH-1 besteht aus sieben Trans membrandom\u00e4nen, und  \nAPH-1A kann dar\u00fcber hinaus in einer langen und eine r kurzen Variante  \nSeite 7 vorkommen. 14-15  Studien zu PEN-2 haben gezeigt, dass diese Unterei nheit, welche \naus zwei Transmembrandom\u00e4nen besteht, neben der Sta bilit\u00e4t der \u03b3-Sekretase auch \nEinfluss auf den katalytischen Mechanismus des Enzy ms haben k\u00f6nnte. 15,19   \nDerzeit befinden sich sieben \u03b3-Sekretase-Inhibitoren in der klinischen Erprobung:   \nLY-450139, MK-0752, E-2012, BMS-708163, PF-3084014,  GSI-953 und  \nNIC5-15. 9,20,21  LY-450139 hat gezeigt, dass sie die A \u03b2-Konzentration im Plasma und \ndie A \u03b2-Produktion im ZNS verringern kann. \u00c4hnliche Ergebn isse wurden auch f\u00fcr  \nPF-3084014 ver\u00f6ffentlicht. 9 Weitere \u03b3-Sekretase-Inhibitoren wurden in den letzten \nJahren in der wissenschaftlichen Literatur und in P atenten dokumentiert (Abb. 5). 7,14  \n       \n \n \nAbb. 5: Beispiele f\u00fcr \u03b3-Sekretase-Inhibitoren. \n  \nBei einer transgenen PDAPP-Maus hat die orale Appli kation von DAPT ( 7) innerhalb \nvon drei Stunden eine schnelle Abnahme des A \u03b2-Gehalts im Gehirn zur Folge.22  Die \nWirksamkeit dieser Verbindung wurde auch in anderen  Mausmodellen best\u00e4tigt. 7 \nLY411575 ( 8) konnte denselben Effekt wie Verbindung 7 in der transgenen Maus \nund im nicht-transgenen Rattenmodell zeigen. 23  Eine h\u00e4ufig auftretende \nNebenwirkung von \u03b3-Sekretase-Inhibitoren ist die Inhibition des Notch -Signalwegs, \nwelcher eine wichtige Rolle in der Zelldifferenzier ung, embryonalen Entwicklung und \nEntwicklung von Organen spielt. 9,24  Die Applikation von Verbindung 8 an M\u00e4usen \n \nSeite 8 zeigte Nebenwirkungen, die auf den Notch-Signalweg zur\u00fcckzuf\u00fchren sind.  \nBMS-299897 ( 9) hat in zellul\u00e4ren Tests eine 15-fach h\u00f6here Affin it\u00e4t f\u00fcr APP \ngegen\u00fcber Notch gezeigt und MRK-560 ( 10 ) konnte in einer transgenen Maus den \nA\u03b2-Gehalt im Gehirn reduzieren, ohne dass Anzeichen e iner Notch-Hemmung \nauftraten. 7,25  Die mechanistische Basis der Selektivit\u00e4t von Verb indung 9 und 10  ist \nderzeit noch ungekl\u00e4rt. 7 \u03b3-Sekretase-Modulatoren schaffen eine Alternative zu  den \nklassischen Inhibitoren und k\u00f6nnen den APP-Metaboli smus beeinflussen ohne \nst\u00f6rende Wirkung auf den Notch-Signalweg zu haben. Manche nichtsteroidale \nEntz\u00fcndungshemmer, wie Ibuprofen, Flurbiprofen und Indomethacin agieren als  \n\u03b3-Sekretase-Modulatoren und senken die A \u03b240 - und A \u03b242-Produktion bei \ngleichzeitiger Zunahme von A \u03b238 . Tarenflurbil, das R-Enantiomer von Flurbiprofen, \nwurde in einer Klinischen-Phase-III-Studie an Patie nten mit milder AD getestet, \nkonnte jedoch keine positiven Resultate hervorbring en.7,9  Ein anderer Modulator, \nCHF-5074, befindet sich derzeit in Phase I einer kl inischen Studie und konnte in \nTiermodellen gute Ergebnisse aufzeigen.9  \n                    \n1.2.2 Inhibitoren der \u03b2-Sekretase \nDie \u03b2-Sekretase ist wie APP ein Typ-1-Transmembranprotei n und geh\u00f6rt zur Gruppe \nder Aspartatproteasen. Sie besitzt eine gro\u00dfe extra zellul\u00e4re Dom\u00e4ne, welche die \nkatalytischen Asparagins\u00e4urereste enth\u00e4lt, eine kur ze intrazellul\u00e4re Dom\u00e4ne und \neine Transmembrandom\u00e4ne. Die h\u00f6chste Expression wur de im ZNS nachgewiesen, \ndoch sie ist auch in peripheren Geweben zu finden. 7-8 BACE-2 ( \u03b2-Sekretase 2) ist \ndas Homolog von BACE-1 ( \u03b2-Sekretase 1) und besitzt eine strukturelle \u00c4hnlich keit \nvon 68%. Es wird vorwiegend in der Peripherie expri miert und tr\u00e4gt nicht zur A \u03b2-\nGenerierung bei. 26  Die h\u00f6chste Aktivit\u00e4t besitzt die \u03b2-Sekretase bei pH-Wert ~4-5, \nwas darauf hindeutet, dass sie haupts\u00e4chlich in End osomen aktiv ist. 7,27  Der  \nN-Terminus von A \u03b2-Peptiden stellt die bevorzugte Spaltstelle von BAC E-1 in APP \ndar.7 Bei Abwesenheit der \u03b2-Sekretase wird kein A \u03b2 gebildet, was in M\u00e4usen durch \ngenetische Inaktivierung des BACE-1-Gens gezeigt we rden konnte.26  Bisher wurden \nnoch keine Mutationen im BACE-1-Gen nachgewiesen, d ie mit AD in Verbindung \ngebracht werden k\u00f6nnen. Nichtsdestotrotz wurde eine  erh\u00f6hte Aktivit\u00e4t dieser \nSekretase in AD-Patienten festgestellt.8 Neben APP besitzt die \u03b2-Sekretase auch \nandere Substrate, die den Nutzen von Inhibitoren ei nschr\u00e4nken k\u00f6nnten. 28  Viele  \nSeite 9 Verbindungen, die in der Literatur beschrieben wurd en, sind in zellfreien und \nzellul\u00e4ren Tests aktiv, doch es fehlen Daten die ei ne Aktivit\u00e4t nach oraler Gabe in \nTiermodellen best\u00e4tigen (Abb. 6). 7 \n \n \n \nAbb. 6: Beispiele f\u00fcr \u03b2-Sekretase-Inhibitoren. \n \nObwohl schon viele Inhibitoren f\u00fcr Aspartatprotease n entdeckt worden sind, verlief \ndie Suche nach \u03b2-Sekretase-Inhibitoren bisher sehr langsam. CTS-211 66 ist bisher \ndie einzige Verbindung in der klinischen Erprobung.7-8 Aufgrund ihrer Aktivit\u00e4t im \nAPP-Metabolismus sollte die \u03b2-Sekretase in Zukunft dennoch als Zielprotein ( Target ) \nf\u00fcr ein AD-Therapeutikum Beachtung finden.     \n \n \n \n \n \n \n \n \nSeite 10 1.3 Entstehung der intrazellul\u00e4ren Neurofibrillenb\u00fc ndel (NFTs) \nAxonaler Transport ist eine Voraussetzung f\u00fcr das F unktionieren von Neuronen. \nDieser Transport verl\u00e4uft entlang von Mikrotubuli u nd wird durch Motorproteine wie \nDyneine und Kinesine vermittelt. Die Mikrotubuli si nd Bestandteil des Cytoskeletts \nund binden Mikrotubuli-assoziierte Proteine (MAPs),  die verantwortlich f\u00fcr die \nRegulation ihrer Stabilit\u00e4t sind.7,29  Das Tau-Protein ist hydrophil, im nativen Zustand \nungefaltet und wasserl\u00f6slich. Es wird vorwiegend in  neuronalen Axonen exprimiert \nund ist das wichtigste MAP.7,30  Es gibt sechs Isoformen des humanen Tau-Proteins \nin den Neuronen, welche durch alternatives Splei\u00dfen  der Exone 2, 3 und 10 des \nChromosoms 17q21.3 entstehen. Sie sind zwischen 352  und 441 Aminos\u00e4uren lang \nund enthalten im C-terminalen Teil drei bis vier si ch wiederholende Einheiten zu je 31 \nAminos\u00e4uren.7,31  Hierbei handelt es sich um mikrotubulibindende Dom \u00e4nen, die \nmitverantwortlich f\u00fcr die Bildung von paarigen heli kalen Filamenten ( paired helical \nfilaments , PHFs) sind.7,30  Das Tau-Protein enth\u00e4lt bis zu 79 Serin/Threonin-R este, \nwovon ungef\u00e4hr 30 unter physiologischen Bedingungen  effektiv als \nPhosphorylierungsstellen agieren k\u00f6nnen.30  Partiell phosphoryliertes Tau dient der \nStabilisierung von Mikrotubuli, wodurch ein Gleichg ewicht zwischen \nmikrotubuligebundenem und freiem l\u00f6slichen Tau aufr echt erhalten wird. Dadurch \nwird der axonale Transport und die Struktur der Neu ronen gesichert (Abb. 7).7,32  Eine \nHyperphosphorylierung des Tau-Proteins verringert d ie Bindung von Tau an \nMikrotubuli, wodurch es zur Aggregation und zur Bil dung von PHFs kommt. 33  Bisher \nwurden 25 Phosphorylierungsstellen identifiziert, d ie in Verbindung zur AD stehen. \nBesonders die Phosphorylierung von Ser262, Thr231 u nd Ser235 f\u00fchrt dazu, dass \ndie Bindung von Tau an Mikrotubuli deutlich sinkt. 33  Weiterhin wurde gezeigt, dass \ndie Phosphorylierung von Ser214 und Ser262 die Tau- Aggregation verhindern \nkann. 34  Die Missfaltung und Aggregation von PHFs f\u00fchrt zu unl\u00f6slichen NFTs, \nwodurch die Menge an Tau und die Stabilisierung von  Mikrotubuli verringert wird. 33  \nInfolgedessen k\u00f6nnen die Motorproteine den Transpor t von Organellen, wie \nMitochondrien, Peroxisomen und proteingef\u00fcllten Ves ikeln nicht mehr ausf\u00fchren, \nwobei bestimmte Bereiche wie Synapsen und das Ende der Axone \nMangelerscheinungen erleiden. Der dadurch entstehen de Verlust an Synapsen und \nNervenzellen sind charakteristische Kennzeichen bei  AD-Patienten. 7 Bislang wurde \ndavon ausgegangen, dass nur NFTs zytotoxisch sind. Untersuchungen an  \nSeite 11 transgenen M\u00e4usen haben jedoch gezeigt, dass auch P HFs und andere \nhyperphosphorylierte und l\u00f6sliche Tau-Aggregate Neu rodegeneration induzieren \nk\u00f6nnen. 30  Neben den Amyloid-Plaques geh\u00f6ren die NFTs zu den typischen \nMerkmalen der AD-Pathologie. 8 Tau-Ablagerungen wurden jedoch auch mit anderen \nneurodegenerativen Erkrankungen wie Morbus Pick und  amyotrophe Lateralsklerose \nin Verbindung gebracht. 7   \n \n \n \n \n \n \n \n \n \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAbb. 7: Schematische Darstellung der  Entstehung von NFTs. \n \nEs wird heute davon ausgegangen, dass die Hyperphos phorylierung von Tau durch \nein Ungleichgewicht der Aktivit\u00e4ten von Kinasen und  Phosphatasen zustande \nkommt.7,33  Mehrere Kinasen haben gezeigt, dass sie Tau in vitro  phosphorylieren \nk\u00f6nnen, wie ERK 2 ( extracellular signal-regulated kinase -2), MARK 1 \n(MAP/microtubule affinity-regulating kinase 1 ), PKA ( cAMP-dependent protein paarige  helik ale Filamente  \n(PHFs) mikrotubulibindende  \nDom\u00e4nen \nC N \ndurch Phosphorylierung \nabgel\u00f6stes Tau \nl\u00f6sliches  \nTau intrazellul\u00e4re  \nNeurofibrillenb\u00fcndel \n(NFTs) Tau gebunden \nan Mikrotubuli Mikrotubuli  Mikrotubuli  \nP \nP P \nP \nP P P P P \nP P \nP P P \nP \nP \nP P \nP P P \nP P P P P P P P P P P P \nP P P \nP \nP P P P \nP \nP \nP P P \nP P \nP \nP P P P P \nP \nP P \nP \nP P \nP P \nP \nP P \nP P P P P \nP P \nP P P P P P \nP \nP P P P P P P \nP \nP P \nP \n \nSeite 12 kinase ), CDK 5 (c yclin dependant kinase  5) und GSK-3 (Glykogen Synthase \nKinase 3). Viele Befunde weisen jedoch darauf hin, dass CDK 5 und GSK-3 die \nrelevanten Kinasen f\u00fcr die Tau-Pathologie sind. 7-8,30,33  Die Inhibition dieser Kinasen \nist derzeit eine der Hauptstrategien, um gezielt di e Hyperphosphorylierung von Tau \nund die Entstehung von NFTs zu unterbinden (siehe K apitel 2.4).8 Dar\u00fcber hinaus \nwerden derzeit auch andere Ans\u00e4tze untersucht. Die Aktivierung von Phosphatasen \nund damit einhergehend die Dephosphorylierung von T au ist einer dieser Ans\u00e4tze. \nEs wurde berichtet, dass eine Inhibition der Protea se PP-2A ( protein phosphatase-\n2A ) zu einer Hyperphosphorylierung von Tau f\u00fchrt. Dem zufolge k\u00f6nnte PP-2A als \nTarget f\u00fcr Aktivatoren genutzt werden, die eine Hyperphosp horylierung von Tau \nvermeiden. Allerdings wurden bisher noch keine phar makologischen Ans\u00e4tze hierzu \npubliziert. 31  Auch Substanzen, die gezielt die Tau-Aggregation u nd die \nFibrillenbildung unterbinden sollen, werden derzeit  untersucht (Abb. 8). Hierdurch \nerhofft man sich, neben dem Abbau der toxischen Spe zies auch einen Anstieg von \nmonomeren Tau, welches direkt zur Stabilisierung de r Mikrotubuli dienen kann. 31,33      \n   \n \n \nAbb. 8: Beispiele f\u00fcr Inhibitoren der Tau-Aggregation und F ibrillenbildung. \n \nDen direkten Abbau von Tau-Aggregaten und Fibrillen  erhofft man sich momentan \ndurch Inhibitoren von HSP 90 ( heat shock protein 90 ). Diese Proteine fungieren als \nChaperone, und sind somit wichtig f\u00fcr die korrekte Faltung von Proteinen. Eine \n \nSeite 13 Hemmung von HSP 90 f\u00fchrt zum Abbau der Chaperon-geb undenen Proteine im \nProteasom. In transgenen Tau-exprimierenden M\u00e4usen wurde gezeigt, dass HSP \n90-Inhibitoren zu einer Reduktion von hyperphosphor yliertem Tau f\u00fchren. 31,33,35  \nDar\u00fcber hinaus wird derzeit an einer Tau-gerichtete n Immuntherapie gearbeitet, und \nan Substanzen die die Stabilit\u00e4t der Mikrotubuli er h\u00f6hen sollen. 31,35   \n \n         \n2. Glykogen Synthase Kinase 3 (GSK-3)  \n \n2.1 Struktur und Funktion von Proteinkinasen \nProteinkinasen (PK) sind an der Regulation von fast  allen Zellprozessen beteiligt. Sie \nkontrollieren den Metabolismus, die Transkription, die Apoptose, den \nMembrantransport und andere grundlegende Abl\u00e4ufe im  K\u00f6rper.36-37  Sie katalysieren \nhierbei den Transfer des \u03b3-Phosphats von ATP (Adenosintriphosphat) auf spezif ische \nAminos\u00e4uren des Proteins, bei Eukaryoten \u00fcblicherwe ise Serin-, Threonin- und \nTyrosin-Reste. Durch diese Phosphat\u00fcbertragung werd en verschiedene intrazellul\u00e4re \nSignalwege vermittelt. Das menschliche Genom kodier t f\u00fcr 518 PK was einem Anteil \nvon 1.7% aller Gene entspricht.36,38-39  Durch den hohen Anteil am Genom wird \nersichtlich, weshalb Mutationen und Dysregulationen  von PK eine entscheidende \nRolle bei der Entstehung von Krankheiten einnehmen.  Diese Tatsache macht sie zu \nden zweitwichtigsten Targets  in der Arzneimittelentwicklung nach den GPCRs  \n(G-protein-coupled receptors ). Der Hauptteil aller PK ist in zwei Untereinheite n \naufgeteilt, einer N-terminalen Untereinheit, gepr\u00e4g t von \u03b2-Faltblatt-Strukturen und \neiner \u03b1-Helix, sowie einer C-terminalen Untereinheit, welc he \u00fcberwiegend \u03b1-helikal \naufgebaut ist (Abb. 9). 37,40-41  Die ATP-Bindungstasche liegt zwischen diesen \nUntereinheiten und wird als flexible Gelenk-Region ( hinge-region ) bezeichnet. Die \nAktivierungsschleife ( activation loop ) der Kinasen beinhaltet ein Serin-, ein Threonin- \nund ein Tyrosin-Rest, welche alle phosphoryliert we rden k\u00f6nnen. Diese Schleife \nbesetzt, im unphosphorylierten Zustand der Reste, T eile der ATP-Bindungstasche. 40    \n \n \n  \nSeite 14                     \n \nAbb. 9: Allgemeine  Struktur einer Kinase dargestellt an GSK-3.    \n \nDie Phosphorylierung dieser Aminos\u00e4uren bewirkt ein e Konformations\u00e4nderung, die \ndie Aktivierungsschleife aus der ATP-Bindungstasche  entfernt und somit ATP die \nBindung und \u00dcbertragung eines Phosphatrestes auf da s Substrat erm\u00f6glicht. Die \nGlycin-reiche Schleife (glycine-rich loop oder P-loop ) ist ebenfalls Teil der ATP-\nBindungstasche und hat eine konservierte GXGXXG-Seq uenz. 40  Das DFG-Motiv \n(D/Asparagins\u00e4ure, F/Phenylalanin, G/Glycin) ist ei n Abschnitt der \nAktivierungsschleife und hochkonserviert. Die Aspar agins\u00e4ure bzw. das Aspartat-Ion \ndieses Motivs ist katalytisch im Phosphattransfer i nvolviert und typischerweise Teil \neiner Salzbr\u00fccke (Abb. 9 und Abb. 10). Das DFG-Moti v kann je nach Konformation \n(DFG-in  und DFG- out ) eine weitere hydrophobe Region zug\u00e4nglich machen.  Hierbei \nkann die DFG- out Konformation f\u00fcr die Synthese von Inhibitoren eine entscheidende \nRolle spielen (siehe Kapitel 2.2). Eine der wichtig sten Aminos\u00e4uren in der ATP-\nBindungstasche ist der Gatekeeper . Die Gr\u00f6\u00dfe und das Volumen dieses Restes \nGlycin -reiche S chleife  \n(glycine-rich loop oder P-loop ) Gelenk -Region  \n(hinge region ) N-Terminus  \nC-Terminus  DFG -Motiv  \nAktivierungsschleife  \n(activation loop )  \nSeite 15 \nbestimmen den Zugang zur hydrophoben Region und k\u00f6n nen oft zur Selektivit\u00e4t \neines Inhibitors beitragen (Abb. 10). 40  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAbb. 10: Schematische Darstellung relevanter Bereiche in der  ATP-Bindungstasche. \n \nMehrere niedermolekulare Proteinkinase-Inhibitoren (PKI) befinden sich derzeit in \nden klinischen Phasen und acht Verbindungen erhielt en bisher die Marktzulassung \nvon der FDA ( Food and Drug Administration ) in den USA (Abb. 11). Gleevec \uf6da (21 ) \nwar der erste zugelassene niedermolekulare PKI. 42  Alle bislang zugelassenen PKI \nhaben die Onkologie als Indikationsgebiet, dennoch befinden sich momentan viele \nPKI mit anderen Indikationsgebieten in den klinisch en Phasen. Viele PKI im Bereich \nder Onkologie scheitern bereits in den klinischen P hasen, bedingt durch eine sich \nentwickelnde Tumorresistenz. Dieses Problem kann je doch in Abh\u00e4ngigkeit des \nInhibitionstyps unterbunden werden. 43    \n \nhydrophobe  \nRegion Gelenk -Region  \n(hinge-region ) \nATP -Bindestelle  \nDFG -Motiv  \n     und \n hydrophobe                    \nRegion bzw. \n      allosterische  \n        Bindetasche \n Gatekeeper \nSalzbr\u00fccke  \naus \nkonservierten \nund \nkatalytischen \nResten \nAktivierungsschleife  \n(activation loop )  \nSeite 16  \n \nAbb. 11: Beispiele f\u00fcr Kinase-Inhibitoren die von der FDA zu gelassen wurden. \n \n2.2 Bindungstypen von Kinaseinhibitoren \nIn Abh\u00e4ngigkeit ihrer Inhibition lassen sich PKI in  verschiedene Gruppen einteilen. \nAls Typ-I-Inhibitoren werden Verbindungen bezeichne t, die an die ATP-Bindestelle \nbinden und dadurch die Aktivit\u00e4t der Kinase hemmen (Abb. 10). Hierbei konkurrieren \ndie Verbindungen direkt mit ATP um die Bindestelle.  Das DFG-Motiv befindet sich in \nder DFG- in -Konformation, wodurch sich die Kinase im enzymatis ch aktiven Zustand \nbefindet. 43  Typ-I-Inhibitoren wechselwirken charakteristischer weise \u00fcber 1-3 \nWasserstoffbr\u00fcckenbindungen mit der Gelenk-Region d er Kinase. Dar\u00fcber hinaus \nkann die hydrophobe Region, deren Zugang durch den Gatekeeper  kontrolliert wird, \nf\u00fcr die Aktivit\u00e4t und Selektivit\u00e4t dieser Inhibitor en ausschlaggebend sein. 43-45  Ein \nh\u00e4ufig auftretender Nachteil von Typ-I-Inhibitoren ist die Inhibitorresistenz, welche \ndurch eine Mutation am Gatekeeper  hervorgerufen wird. 43  Dadurch verlieren diese \nVerbindungen ihre Wirksamkeit und klinische Relevan z f\u00fcr bestimmte \nPatientengruppen. Durch die strukturelle \u00c4hnlichkei t der PK innerhalb der ATP-\n\uf6da  \nSeite 17 Bindestelle ergeben sich zudem Schwierigkeiten in d er Entwicklung von selektiven \nInhibitoren. 46  Ein potentieller Vorteil von Typ-I-Inhibitoren erg ibt sich aus der \nTatsache, dass der enzymatisch aktive Zustand einer  Kinase in erkrankten Zellen mit \nhoher Wahrscheinlichkeit vorzufinden ist. 45   \nDurch das Umklappen des DFG-Motivs in die DFG- out -Konformation wird eine \nweitere hydrophobe Region zug\u00e4nglich, welche auch a ls allosterische Bindetasche \nbezeichnet wird. Die PK befindet sich hierdurch im enzymatisch inaktiven Zustand, \nwelcher durch Typ-II-Inhibitoren stabilisiert werde n kann. 43-44  Inhibitoren des Typs II \nbinden an die Gelenk-Region der Kinase und in die f reigegebene allosterische \nBindetasche.46  Durch die allosterische Bindetasche werden weniger  konservierte \nProteinseitenketten zur Wechselwirkung f\u00fcr Inhibito ren zug\u00e4nglich gemacht, wodurch \neine h\u00f6here Selektivit\u00e4t erzielt werden kann. Inter essanterweise k\u00f6nnen nicht alle \nKinasen eine DFG- out -Konformation einnehmen, wodurch Typ-II-Inhibitoren  keinen \nAnsatzpunkt f\u00fcr alle Kinasen darstellen. 45-46   \nZu den Typ-III-Inhibitoren werden Verbindungen gez\u00e4 hlt, die ausschlie\u00dflich in die \nallosterische Tasche der inaktiven Kinase binden. S ie gehen keine \nWechselwirkungen mit der Gelenk-Region ein und k\u00f6nn en Ausgangspunkt f\u00fcr Typ-II-\nInhibitoren sein. 43,45  Inhibitoren dieser Klasse weisen \u00fcblicherweise ein e erh\u00f6hte \nSelektivit\u00e4t auf, da sie mit einzigartigen Bereiche n der Kinase interagieren. 47  \nVerbindungen, die die enzymatische Aktivit\u00e4t eine K inase allosterisch modulieren \nund mit Taschen au\u00dferhalb des aktiven Zentrums der Kinase wechselwirken, werden \nals Typ-IV-Inhibitoren bezeichnet. 43   \nIrreversible Kinaseinhibitoren stellen eine weitere  Form der Inhibition dar, welche f\u00fcr \naktive und inaktive Kinasen Verwendung findet. Der Inhibitor wird hierbei mit einem \nMichael-Akzeptor versehen, der eine kovalente Bindu ng mit einer konservierten \nCystein-Seitenkette der Kinase eingeht. Es wird ver mutet, dass mehr als 200 \nKinasen das Potential f\u00fcr solche Inhibitoren aufwei sen. Drei kovalente Inhibitoren \nhaben 2009 Blockbuster -Status in den USA erreicht, und mehrere Verbindung en \ndieser Art befinden sich in der klinischen Erprobun g.43,45,47-48  \n  \n  \nSeite 18 2.3 Struktur und Substrate von GSK-3  \nGSK-3 ist eine Serin/Threonin PK und wurde vor mehr  als 30 Jahren entdeckt. Lange \nZeit galt sie als fest verkn\u00fcpft mit dem Glykogenst offwechsel und damit \neinhergehend mit der Phosphorylierung und Inaktivie rung des Enzyms \nGlykogensynthase.49-50  Heute jedoch ist bekannt, dass GSK-3 eine wichtige  Rolle in \neiner Vielzahl von Funktionen des menschlichen Orga nismus einnimmt, wie z.B. in \nder Zellteilung, der Apoptose, der Proteinsynthese und der Mikrotubuli-Dynamik. 49,51  \nDiese Tatsache macht GSK-3 zu einem interessanten Target  f\u00fcr die Entwicklung von \nMedikamenten. 50  Zwei Isoformen von GSK-3, GSK-3 \u03b1 und GSK-3 \u03b2, werden in \nS\u00e4ugetierzellen ubiquit\u00e4r exprimiert. GSK-3 \u03b2 hat eine Masse von 47 kDa, w\u00e4hrend \nGSK-3\u03b1 durch eine zus\u00e4tzliche Glycin-reiche Sequenz am N- Terminus eine Masse \nvon 51 kDa aufweist. Innerhalb ihrer Kinasedom\u00e4ne s ind beide Isoformen zu 98% \nidentisch. Sie weisen jedoch au\u00dferhalb dieser Dom\u00e4n e signifikante Unterschiede \nauf. 49-50,52  Eine untergeordnete Splei\u00dfvariante von GSK-3 \u03b2, GSK-3\u03b22, wurde 2002 \nentdeckt. Sie enth\u00e4lt eine Insertion von 13 Aminos\u00e4 uren innerhalb ihrer \nKinasedom\u00e4ne. 50,53  Die Kristallstruktur von GSK-3 \u03b2 wurde 2001 unabh\u00e4ngig \nvoneinander von drei Arbeitsgruppen gel\u00f6st und publ iziert (Abb. 9).41,54-55  GSK-3\u03b2 \nbesitzt den im Kapitel 2.1 beschriebenen typischen Aufbau von PK. Dabei ist die  \nN-terminale Untereinheit von GSK-3 \u03b2 gepr\u00e4gt von \u03b2-Faltblatt-Strukturen zwischen \nden Aminos\u00e4ureresten 25-138. Die Aminos\u00e4urereste 13 9-343 bilden die C-terminale \nUntereinheit, welche \u00fcberwiegend \u03b1-helikal aufgebaut ist. Die Aminos\u00e4uren Glu97 \nund Lys85 bilden eine Salzbr\u00fccke im aktiven Zentrum  aus, welche f\u00fcr die Aktivit\u00e4t \nvon einigen Inhibitoren ausschlaggebend ist. 41  Die Struktur von GSK-3 \u03b1 konnte \nbisher noch nicht gel\u00f6st werden.  \nMehr als 40 vermeintliche Substrate sind bisher bek annt, die von GSK-3 \nphosphoryliert werden k\u00f6nnen (Tab. 1). 49-50,56  Einige dieser Substrate m\u00fcssen \nzun\u00e4chst durch andere Kinasen an Serin-/Threonin-Re sten phosphoryliert werden, \ndamit die Phosphorylierung durch GSK-3 stattfinden kann. 51  Die Konsensussequenz \ndaf\u00fcr lautet Ser/Thr-X-X-X-pSer/pThr, wobei das ers te Serin bzw. Threonin die \nAminos\u00e4ure darstellt, die von GSK-3 phosphoryliert wird. 49  Die Enzymaktivit\u00e4t von \nGSK-3 kann durch Phosphorylierung eines N-terminale n Serins, Ser21 bei GSK-3 \u03b1 \nund Ser9 bei GSK-3 \u03b2, signifikant reduziert werden. In Gegensatz dazu k ann die  \nSeite 19 Phosphorylierung eines Tyrosins, Tyr279 bei GSK-3 \u03b1 und Tyr216 bei GSK-3 \u03b2, die \nAktivit\u00e4t von GSK-3 steigern. 56  \n \n \nTab. 1: Beispiele f\u00fcr vermeintliche Substrate von GSK-3.  \n \n2.4 Die Rolle von GSK-3 in der AD und literaturbeka nnte Inhibitoren \nGSK-3 wird mit einer Vielzahl von Krankheiten in Ve rbindung gebracht, wie z.B.  \nTyp-2-Diabetes mellitus, Krebs, bipolare affektive St\u00f6rungen, Schlaganfall, \nSchizophrenie und AD.56-59  Infolgedessen wurden bereits viele Inhibitoren f\u00fcr  GSK-3 \npubliziert und patentiert. Lithium (Li+) war der erste Inhibitor der f\u00fcr GSK-3 entdeckt \nwurde. 60  Der genaue Mechanismus der Inhibition ist bisher n icht bekannt, aber zwei \nHypothesen wurden vorgeschlagen. Die erste Hypothes e besagt, dass Lithium (Li+) \nein kompetitiver Inhibitor von GSK-3 ist und in Kon kurrenz mit Magnesium (Mg 2+) \nsteht, nicht jedoch mit dem Substrat oder ATP. Bei der zweiten Hypothese wird \ndavon ausgegangen, dass Lithium eine inhibierende W irkung auf den Kaliummangel Signalproteine/Stoffwechsel Transkriptionsfaktoren Strukturproteine \nAcetylCoA carboxylase \nAmyloid precursor protein \nAPC \nATP-citrate lyase \nAxin \nCubitus interruptus \nCyclic-AMP-dependent protein kinase \nCyclin D1 \nCyclin E \nelF2B \nGlycogen synthase \nhnRNP \nInsulin receptor subtrate-1 \nMyelin basic protein \nNGF receptor \nNucleoporin p62 \nP21 \nPresenilin-1 \nProtein kinase A (RII subunit) \nProtein phosphatase 1 \nProtein phosphatase inhibitor-2 \nPyruvate dehydrogenase  AP-1 (Jun family) \n\u03b2-catenin \nC/EBP \nCREB \nGATA4 \nGlucocorticoid receptor (rat) \nHIF-1 \nHSF-1 \nMash1 \nMITF \nc-Myb \nc-Myc \nNeuroD \nNFAT \nNF-\u03baB (p65/p105) \nNotch \np53 \nTimeless \nTCF DF3/MUC1 \nDynamin-like protein \nKinesin light chain \nMAP1B \nMAP2 \nNeural cell-adhesion \nProtein (NCAM) \nNeurofilaments \nNinein \nTau \nTelokin (KRP)  \nSeite 20 hat.57,61-62  Neben dem Li+-Ion wurde auch Beryllium (Be 2+ ) als GSK-3-Inhibitor \nidentifiziert. 63   \nDie Amyloid-Plaques und die NFTs sind die charakter istischen Merkmale der AD und \nbeide Proteinablagerungen werden mit GSK-3 in Verbi ndung gebracht. 58  Erh\u00f6hte \nWerte von GSK-3 \u03b2 wurden durch verschiedene Forschungsgruppen im Hir ngewebe \nvon verstorbenen AD-Patienten gefunden. 64  Mehrere PK sind in der Lage Tau zu \nphosphorylieren, jedoch scheint es so, dass GSK-3 \u03b2 die dominanteste dieser \nKinasen ist. 65-66  Bis zum heutigen Zeitpunkt sind \u00fcber 30 Phosphoryl ierungsstellen \nan Tau bekannt, die potentiell von GSK-3 \u03b2 phosphoryliert werden k\u00f6nnen. 65  GSK-3\u03b1 \nund GSK-3 \u03b2 haben in vitro  und in vivo  gezeigt, dass sie f\u00e4hig sind eine \nHyperphosphorylierung von Tau zu verursachen. Folgl ich wird angenommen, dass \nGSK-3 in der Entstehung von NFTs involviert ist. In  Neuronen wurde gezeigt, dass \neine Inhibition von GSK-3 \u03b2 die Phosphorylierung von Tau reduziert. Dadurch wi rd die \nAssoziation von Tau mit den Mikrotubuli verbessert und deren Stabilit\u00e4t erh\u00f6ht. 64  \nAuch in GSK-3 transgenen M\u00e4usen konnte eine Tau-Hyp erphosphorylierung und \nNeurodegeneration festgestellt werden, die durch ei ne Behandlung mit Lithium \nunterbunden werden konnte. 66-69  In der Fruchtfliege ( Drosophila melanogaster ) f\u00fchrte \ndie \u00dcberexpression von Tau in Kombination mit der P hosphorylierung durch das \nGSK-3-Homolog Shaggy  zur Bildung von NFTs und zur Neurodegeneration. 66,70  Eine \nMerkf\u00e4higkeitsst\u00f6rung bei Ratten wurde nach einer t empor\u00e4ren Aktivierung von \nGSK-3 und Tau-Hyperphosphorylierung nachgewiesen. 71  Die Behandlung von \nneugeborenen Ratten mit Lithiumchlorid f\u00fchrte zu ei ner Reduktion der  \nTau-Phosphorylierung in neuronalen und nicht-neuron alen Zellen. 72-75  \u00c4hnliche \nErgebnisse wurden auch mit anderen literaturbekannt en GSK-3-Inhibitoren \nbeobachtet (Abb. 12). Eine 30-t\u00e4gige Behandlung von  transgenen M\u00e4usen mit dem \nInhibitor AR-A014418 ( 27 ) f\u00fchrte zu einer Reduktion der Phosphorylierung vo n Tau. \n\u00c4hnliche Ergebnisse wurden auch mit den TDZDs (Thia diazolidinone)  in transgenen \nM\u00e4usen erzielt. Diese konnten neben der Reduktion d er Tau-Hyperphosphorylierung \nauch zu einer Verringerung der Amyloid-Plaques im C ortex und im Hippocampus \nbeitragen. 57  Das A \u03b2-Peptid ist in der Lage, GSK-3 zu aktivieren und di e Inhibition \ndieser Kinase mit dem GSK-3-Inhibitor AR-A014418 ( 27 ) hat gezeigt, dass die durch \nA\u03b2 induzierte Neurotoxizit\u00e4t verringert werden kann. 76-78  Zudem wird vermutet, dass \nGSK-3\u03b1, nicht jedoch GSK-3 \u03b2, in der Lage ist, die A \u03b2-Produktion zu f\u00f6rdern. 79  Diese  \nSeite 21 Annahme ist jedoch momentan Bestandteil einer kontr oversen Debatte und wird \nnicht von allen Wissenschaftlern akzeptiert, da bis her nur wenige Daten \u00fcber  \nGSK-3\u03b1 publiziert wurden. 80-81  Neben den literaturbekannten GSK-3-Inhibitoren, di e \nzu den Strukturklassen der Indirubine, Maleimide, P aullone, TDZDs und Thiazole \nz\u00e4hlen, wurden in den letzten Jahren auch andere St rukturklassen, wie Oxadiazole \nund metallorganische Verbindungen, synthetisiert (A bb. 12).  \n \n \n \n      \n \nAbb. 12: Beispiele f\u00fcr literaturbekannte GSK-3-Inhibitoren.  \n \nSeite 22 Diese Substanzen konnten bisher in vitro  und in vivo  sehr gute Ergebnisse im \nBereich der AD aufweisen. 82-88  MMBO ( 37 ) z\u00e4hlt zu diesen Verbindungen und konnte \nim Hippocampus einer transgenen Maus signifikant di e Tau-Phosphorylierung \nreduzieren und zur Verbesserung der kognitiven F\u00e4hi gkeiten beitragen. 84  Die \ngenannten Studien und die Menge an Patenten machen deutlich, dass GSK-3 ein \nvielversprechendes Target  f\u00fcr die AD-Therapie ist. NP-12 (Tideglusib) geh\u00f6rt  zur \nKlasse der TDZDs und ist derzeit der am weitesten f ortgeschrittene GSK-3-Inhibitor \nin den klinischen Phasen. 89  Die TDZDs geh\u00f6ren zu den nicht-ATP-kompetitiven \nInhibitoren und machen nur einen geringen Teil alle r bisher publizierten Inhibitoren \naus. 90  Der Hauptteil aller publizierten Inhibitoren ist A TP-kompetitiv und konkurriert \ndirekt mit ATP um die ATP-Bindestelle. Alle ATP-kom petitiven Inhibitoren, die im \nBereich der AD ver\u00f6ffentlicht wurden, weisen auch e ine Aktivit\u00e4t gegen\u00fcber anderen \nKinasen auf. 57  Dieses Selektivit\u00e4tsproblem birgt viele Risiken in  der Wirkstoffsuche, \nda ungew\u00fcnschte Nebenwirkungen auftreten k\u00f6nnen. 45  Aufgrund der hohen \nstrukturellen \u00c4hnlichkeit der ATP-Bindestelle in GS K-3\u03b1 und GSK-3 \u03b2 wurde bisher \nnoch kein Inhibitor publiziert, der effizient zwisc hen diesen zwei Isoformen \ndifferenzieren kann. 57,75  Erste Ans\u00e4tze belegen jedoch, dass die Diskriminie rung \neiner Isoform m\u00f6glich ist. 91   \nDer Wnt-Signalweg hat einen entscheidenden Einfluss  auf die Differenzierung, \nProliferation und das Schicksal einer Zelle. GSK-3 hat eine Schl\u00fcsselfunktion in \ndiesem Signalweg und bildet, bei Abwesenheit des Wn t-Signalproteins, einen \nKomplex mit APC ( adenomatous polyposis coli ), Axin und \u03b2-Catenin (Abb. 13). \nHierbei phosphoryliert GSK-3 APC, Axin und \u03b2-Catenin, wodurch es zu einem Abbau \nvon \u03b2-Catenin kommt. Die Bindung des Wnt-Signalproteins an den Rezeptor Frizzled \nf\u00fchrt zur Aufl\u00f6sung dieses Komplexes und zur Bindun g von GSK-3 an DVL \n(dishevelled ) und FRAT ( frequently rearranged during advanced T-cell lympho ma ). \nDadurch findet die Phosphorylierung von \u03b2-Catenin nicht mehr statt und es kommt zu \neiner Akkumulation, welche die Translokation von \u03b2-Catenin in den Nukleus f\u00f6rdert. \n\u03b2-Catenin und TCF ( transcription factor) binden anschlie\u00dfend an die DNA und es \nkommt zur Transkription bestimmter Onkogene. 50,64,66,72,89  Die Beteiligung von GSK-3 \nan diesem Signalweg hat Bedenken an der Verwendung von GSK-3-Inhibitoren \ngeweckt, da die Vermutung besteht, dass diese zur E ntstehung von Krebs beitragen \nk\u00f6nnten. Diese Annahme hat sich jedoch bis zum heut igen Zeitpunkt nicht in vivo   \nSeite 23 best\u00e4tigen lassen. Zudem wird der GSK-3-Inhibitor L ithium bereits seit 60 Jahren als \nStandardtherapeutikum zur Behandlung von bipolaren affektiven St\u00f6rungen \nverwendet, ohne eine erh\u00f6hte Krebsentstehung verurs acht zu haben. 89  Dennoch \nsollte angesichts der Beteiligung von GSK-3 an mehr eren Signalwegen eine \nkomplette Inhibition vermieden werden.     \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAbb. 13: Schematische Darstellung des Wnt-Signalwegs. \n \n Aktiver Protein komplex  \nAbbau  \n \nZellkern \nTranskription  \n\u03b2-catenin  \nAkkumulation  \nAxin  APC  \nFRAT  DVL  GSK -3 \nP P GSK -3 APC  \nAxin  \u03b2-catenin  P \nFRAT  DVL  \nWnt  \nFrizzled  \nTCF  \u03b2-catenin   \nSeite 24 2.5 Weitere Funktionen von GSK-3 \nDurch die Beteiligung von GSK-3 an verschiedenen Si gnalwegen werden in diesem \nAbschnitt weitere Beispiele f\u00fcr die Verwendung von GSK-3-Inhibitoren erl\u00e4utert. \nDiabetes mellitus geh\u00f6rt zu den h\u00e4ufigsten Stoffwec hselerkrankungen und  \nes wird zwischen zwei Patientengruppen unterschiede n, den Typ-1- und Typ-2-\nDiabetikern. Typ-1-Diabetiker m\u00fcssen mehrmals t\u00e4gli ch Insulin spritzen, wohingegen \nTyp-2-Diabetiker das Insulin zwar produzieren k\u00f6nne n, jedoch eine Resistenz \ngegen\u00fcber diesem Hormon aufweisen. Im Normalfall be g\u00fcnstigt Insulin durch \nUnterdr\u00fcckung der GSK-3-Aktivit\u00e4t die Dephosphoryli erung und Aktivierung der \nGlykogensynthase (Abb. 14). In diesem Signalweg kom mt es durch die Bindung von \nInsulin an den Insulinrezeptor zur Phosphorylierung  und Aktivierung von IRS1/2 \n(insulin-receptor substrate ). Dies wiederrum f\u00fchrt zur Interaktion mit PI3K \n(phosphatidylinositol 3-kinase ), wodurch es zur Umsetzung von PIP 2 \n(phosphatidylinositol(4,5)bisphosphate ) zu PIP 3 (phosphatidylinositol(3,4,5)tris-\nphosphate ) kommt. Durch die Bindung von PIP 3 an PDK1 ( 3-phosphoinositide-\ndependant protein kinase-1 ) kommt es zur Phosphorylierung und Aktivierung der  \nProteinkinase AKT (auch als PKB bekannt). AKT phosp horyliert und inhibiert GSK-3, \nwodurch es zur Dephosphorylierung und Aktivierung d er Glykogensynthase durch \nPP1 \u03b2.Gm ( protein phosphatase 1 ) kommen kann. Dadurch kann die \nGlykogensynthase effizienter Glukose in Glykogen um wandeln und den \nGlukosespiegel im Blut senken. Bei Diabetikern k\u00f6nn ten GSK-3-Inhibitoren den \nEffekt von Insulin nachahmen und dadurch die Umwand lung von Glukose zu \nGlykogen beg\u00fcnstigen. 56,72,92  Eine Vielzahl von Inhibitoren wurde bereits zu die sem \nZweck in vitro  und in vivo  evaluiert und einige Beispiele sind in Abbildung 1 2 gezeigt. \nDie GSK-3-Inhibitoren SB-216763 ( 30 ) und SB-415286 ( 31 ) konnten in humanen \nLeberzellen zeigen, dass es durch die Inhibition vo n GSK-3 zu einer Aktivierung der \nGlykogensynthase kommt und dadurch die Umwandlung v on Glukose zu Glykogen \nbeschleunigt wird. Auch in verschiedenen Tiermodell en f\u00fcr Typ-2-Diabetes konnte \nnachgewiesen werden, dass die Verabreichung von GSK -3-Inhibitoren, wie z.B. \nVerbindungen 34  und 35 , zu einer Erniedrigung des Glukosespiegels im Blut  f\u00fchrt. 72  \nDurch diese Beispiele wird ersichtlich, dass GSK-3 ein interessantes therapeutisches \nTarget  f\u00fcr die Insulinresistenz darstellt.   \nSeite 25 \nGlykogensynthese \n Insulinrezeptor  \n Insulin  \n \nPIP 2 PIP 3 PDK1  \nIRS1/2  AKT  PI3K  \n(verminderte Aktivit\u00e4t)  GSK -3 \nPP 1\u03b2.GM  (erh\u00f6hte Aktivit\u00e4t)  P \nGlykogensynthase  Glykogensynthase   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAbb. 14: Einfluss von GSK-3 auf die Glykogensynthese.  \n \nAufgrund der regulatorischen Eigenschaften von GSK- 3 in verschiedenen \nSignalwegen wird diese Kinase auch als Target  f\u00fcr verschiedene Krebsarten, wie \nBauchspeicheldr\u00fcsenkrebs und Eierstockkrebs, in Bet racht gezogen. 57,93-94  Die \nVerwendung von Lithiumchlorid konnte bereits in ver schiedenen Prostatakrebszellen \neine signifikante Reduktion der Zellproliferation h ervorrufen. Die akute Inhibition von \nGSK-3\u03b2 in Darmkrebszellen durch TDZD-8 ( 28 ) konnte sogar dem Tumorwachstum \nentgegenwirken. Desweiteren hat Verbindung 28  auch in anderen Krebszellen \npositive Ergebnisse erzielt. Auch die Verwendung an derer literaturbekannter GSK-3-\nInhibitoren zeigte vielversprechende Resultate. 57,95   \nSeit l\u00e4ngerer Zeit ist bekannt, dass GSK-3 Entz\u00fcndu ngsvorg\u00e4nge f\u00f6rdern kann, \nweshalb Inhibitoren dieser Kinase zu einer Linderun g dieser Entz\u00fcndungen  \nSeite 26 eingesetzt werden k\u00f6nnten. TDZD-8 ( 28 ), SB-216763 ( 30 ) und SB-415286 ( 31 ) \nwurden zu diesem Zweck getestet und haben gezeigt, dass GSK-3-Inhibitoren die \nEntwicklung von Entz\u00fcndungen reduzieren k\u00f6nnen.57   \nDar\u00fcber hinaus wird vermutet, dass die erh\u00f6hte Akti vit\u00e4t der Proteinkinase C  \n(\u03b1, \u03b2 und \u03b6) und GSK-3 das Absterben der Neuronen bei ALS-Pati enten \n(amyotrophische Lateralsklerose) steigert. Die Beha ndlung von ALS-Tiermodellen \nmit dem GSK-3-Inhibitor AR-A014418 ( 27 ) f\u00fchrte zu einer verz\u00f6gerten Entwicklung \nder Krankheit und einer Verl\u00e4ngerung der Lebensspan ne und best\u00e4tigte die \nVerwendbarkeit dieser Inhibitoren.57  Auch der Einsatz von GSK-3-Inhibitoren bei \naffektiven St\u00f6rungen wurde durch AR-A014418 ( 27 ) und TDZD-8 ( 28 ) best\u00e4tigt.  \nEin neuer und interessanter Einsatz von GSK-3-Inhib itoren in der regenerativen \nMedizin hat sich durch die Tatsache ergeben, dass G SK-3 eine wichtige Rolle bei \nder Differenzierung, der Wachstumskontrolle und der  Mobilit\u00e4t von Stammzellen zu \nhaben scheint.96-97  \n                   \n2.6 Etablierte Tiermodelle f\u00fcr GSK-3  \nIn den letzten Jahren wurden verschiedene Tiermodel le f\u00fcr die Erforschung  \nvon neurodegenerativen Erkrankungen und Taupathien entwickelt. Die \n\u00dcberexpression von GSK-3 \u03b2 in einer transgenen Maus resultierte in einer \nNeurodegeneration und best\u00e4tigte, dass diese M\u00e4use zur Untersuchung von AD-\nassoziierten Erkrankungen verwendet werden k\u00f6nnen. 67  Eine doppelt transgene \nMaus, welche humanes APP und Tau \u00fcberexprimiert, wu rde 2005 entwickelt. Diese \nMaus konnte bereits die Wirksamkeit von verschieden en GSK-3-Inhibitoren in vivo  \nbest\u00e4tigen. 98-99  Die APP-V7171xTau-P301L-Maus kombiniert die Amyloi d-Plaque- \nmit der Tau-Pathologie und wird zusammen mit der GS K-3\u03b2xTauP301L-Maus, \nwelche nur die Tau-Pathologie entwickelt, zur Unter suchung der molekularen Signale \nin denen GSK-3 involviert ist, verwendet. 100  Zwei weitere transgene M\u00e4use, 3xTg-AD \nund TAPP-M\u00e4use, wurden entwickelt, um die Interakti onen zwischen APP bzw. A \u03b2 \nund Tau zu untersuchen. 101-102  Die transgene JNPL3-Maus, welche eine Tau-\nPathologie entwickelt, wird sehr h\u00e4ufig zur Untersu chung der Effektivit\u00e4t von GSK-3-\nInhibitoren benutzt.103-104    \nSeite 27 Neben den transgenen M\u00e4usen hat sich der transgene Zebrafisch in den letzten \nJahren zur Untersuchung der Tau-Pathologie und Neur odegeneration als Tiermodell \nbew\u00e4hrt. Er erm\u00f6glicht eine schnelle und effiziente  in vivo  Evaluierung von GSK-3-\nInhibitoren und ist verglichen mit der Maus kosteng \u00fcnstig in der Haltung. 105-106   \nGSK-3-Inhibitoren k\u00f6nnen aber auch mittels Wildtyp- Zebrafisch-Embryonen evaluiert \nwerden, wobei die Zugabe des Inhibitors 4-24 Stunde n nach der Befruchtung \nerfolgen muss. Durch die Inhibition von GSK-3 bzw. des Wnt-Signalwegs entstehen \nspezifische Ph\u00e4notypen, die eine Aussage \u00fcber die in vivo  Effektivit\u00e4t dieser \nInhibitoren erlauben. 106  Weitere transgene Zebrafische wurden entwickelt, u m die \nBeteiligung von GSK-3 an der Kardiogenese zu unters uchen. Hierbei wurde \nfestgestellt, dass GSK-3 \u03b1 essentiell f\u00fcr das \u00dcberleben von Herzmuskelzellen ist. 107   \nZur Untersuchung von neurodegenerativen Erkrankunge n, wie der AD, haben sich \nauch wirbellose Modellsysteme etabliert. Zu erw\u00e4hne n sind hierbei die Fruchtfliege \n(Drosophila melanogaster ) und der Fadenwurm ( Caenorhabditis elegans ). In beiden \nTiermodellen konnte die Bildung von Tau-Filamenten nachgewiesen werden. 108  \nDennoch wird die Effektivit\u00e4t von GSK-3-Inhibitoren  haupts\u00e4chlich in Wirbeltieren \nuntersucht, da diese Modellsysteme dem Menschen evo lution\u00e4r und morphologisch \n\u00e4hnlicher sind. \n    \n2.7 Molekulare Interaktionen  \nStrukturbasiertes Wirkstoffdesign versucht, molekul are Interaktionen zwischen dem \nLigand und dem Target zu identifizieren und zu optimieren, um eine Erh\u00f6hu ng der \nAktivit\u00e4t und Selektivit\u00e4t zu erreichen. Eine Krist allstruktur des Liganden im Komplex \nmit dem Zielprotein kann viele Hinweise f\u00fcr m\u00f6glich e Interaktionen geben.  \nDennoch gibt eine solche Kristallstruktur nur einen  statischen Einblick, da solche \nKomplexe in der Realit\u00e4t nicht nur durch eine Struk tur charakterisiert werden k\u00f6nnen.  \nJede Ligandenbindung in der ATP-Bindungstasche des Proteins verdr\u00e4ngt \nWassermolek\u00fcle aus dieser, welche kristallographisc h nur schwer erfasst werden \nk\u00f6nnen. Viele dieser Wassermolek\u00fcle sind austauschb ar, jedoch gibt es auch \nwelche, die als Teil der Proteinstruktur betrachtet  werden m\u00fcssen. Diese k\u00f6nnen \nbeispielsweise die Flexibilit\u00e4t eines Proteins beei nflussen und direkt oder \u00fcber ein \nWassernetzwerk die Interaktion zwischen dem Ligand und dem Protein vermitteln. \nWasserstoffbr\u00fcckenbindungen sind die wichtigsten In teraktionen in biologischen  \nSeite 28 Erkennungsprozessen. Hierzu z\u00e4hlen unter anderem di e Wechselwirkungen \nzwischen NH und einer Carbonylgruppe, zwischen eine r Hydroxylgruppe und  \neiner Carbonyl-, Ether- oder Estergruppe und Wasser stoffbr\u00fcckenbindungen  \nzu aromatischen Heterozyklen. Die Bindungsabst\u00e4nde liegen im Normalfall zwischen \n2.6-3.2 \u00c5, wobei ungeladene Wasserstoffbr\u00fcckenbindu ngen l\u00e4nger sind als \ngeladene. 109  Hydroxylgruppen und NH-Gruppen k\u00f6nnen auch Wassers toffbr\u00fccken  \nzu aromatischen Systemen ausbilden (Abb. 15). Der A bstand zwischen dem \nWasserstoffbr\u00fccken-Donoratom und dem Zentroid des a romatischen Ringes  \nbetr\u00e4gt im allgemeinen 3.2-3.8 \u00c5. 110  Auch CH-Gruppen sind f\u00e4hig \nWasserstoffbr\u00fcckenbindungen auszubilden, und diese Wechselwirkungen sind \nallgegenw\u00e4rtig in biologischen Systemen. Hierbei k\u00f6 nnen neben Heteroaromaten \nauch aromatische Ringe als Wasserstoffbr\u00fccken-Akzep toren agieren. Diese im \nVergleich recht schwache Wechselwirkung ist sehr of t bei PKI zu beobachten. 109-110   \nKurze Wasserstoffbr\u00fcckenbindungen weisen meist eine  st\u00e4rkere Interaktion auf und \nsind bei Salzbr\u00fccken zwischen Carboxylat und Ammoni um zu finden. Der Hauptteil \naller PKI mit direkter Wechselwirkung zur hinge-region  bildet eine \nWasserstoffbr\u00fcckenbindung mit einem NH dieser Regio n aus. Besteht diese \nInteraktion nicht, liegt das NH der hinge-region  solvatisiert vor. 109  Intramolekulare \nWasserstoffbr\u00fcckenbindungen innerhalb eines Ligande n k\u00f6nnen auch die \nWechselwirkung mit dem Target  beeinflussen. 111   \nDie Halogene Chlor, Brom, und Iod sind imstande mit  Elektrophilen, Nukleophilen \nund mit anderen Halogen zu interagieren. Im Gegensa tz zu Fluor besitzen die \nschwereren Halogene einzigartige elektronische Eige nschaften, wenn sie an einer \nArylgruppe oder elektronenziehender Alkylgruppe geb unden sind. Durch eine \nAnisotropie der Elektronendichteverteilung bilden d ie nichtbindenden Elektronen im \n\u00e4u\u00dferen Ring eine negative Ladung aus. Im inneren R ing entsteht dadurch ein \npositiver Bereich ( \u03c3-hole ), der in der Lage ist mit freien Elektronenpaaren der \nCarbonylgruppe zu interagieren. 109,112  Die Bindungsabst\u00e4nde liegen zwischen  \n2.9-3.5 \u00c5 und sind im Vergleich zu Wasserstoffbr\u00fcck enbindungen schw\u00e4cher. \nDennoch kann ein Austausch von Wasserstoff durch Ha logene die Bindungsaffinit\u00e4t \nvon Inhibitoren enorm steigern. 109-110,113    \nSeite 29 Das Fluor der C-F-Gruppe ist ein schwacher Wasserst offbr\u00fccken-Akzeptor. Dennoch \nist die Interaktion C-F\u2022\u2022\u2022H-N h\u00e4ufig bei den Wechse lwirkungen zwischen Inhibitor und \nTarget  vorzufinden. Der C-F-Dipol kann desweiteren, wie a lle anderen Halogene \nauch, mit aromatischen Ringen interagieren und orth ogonale multipolare \nWechselwirkungen eingehen. 109-110,113  Orthogonal multipolare Wechselwirkungen \nkennzeichnen enge, orthogonale Kontakte zwischen zw ei dipolaren funktionellen \nGruppen. Solche Interaktionen k\u00f6nnen beispielsweise  zwischen C=O\u2022\u2022\u2022C=O, \nC\u2261N\u2022\u2022\u2022C=O und C-X\u2022\u2022\u2022C=O (X = Halogen) auftreten und e ssentiell f\u00fcr die Stabilit\u00e4t \nder Proteinkonformation sein. Dar\u00fcber hinaus k\u00f6nnen  sie die Selektivit\u00e4t einiger \nLiganden beeinflussen und \u00e4u\u00dferst gerichtet sein, w odurch enge \nWechselwirkungsabst\u00e4nde entstehen. Die Beschaffenhe it der C 1=O 1\u2022\u2022\u2022C 2=O 2-\nWechselwirkung kann am besten als dipolar elektrost atisch beschrieben werden, \nwobei die auf dem C 2-Atom lokalisierte positive Partialladung ein elekt rostatisch \nanziehendes Zentrum f\u00fcr das partiell negativ gelade ne O 1-Atom ist. Die \nBindungsabst\u00e4nde dieser Interaktionen liegen im Ber eich von 2.9-4.0 \u00c5. 109,114-116   \nAren-Aren-Wechselwirkungen sind sehr h\u00e4ufig in biol ogischen Systemen vorzufinden \nund f\u00fcr die molekulare Erkennung, die Katalyse und den Transport unentbehrlich. \nZudem tragen sie zur Proteinstruktur, der Protein-L igand-Komplexierung und der \nModulation physikalischer Eigenschaften des aktiven  Enzyms bei (Abb. 15). Die \naromatischen Ringe k\u00f6nnen hierbei drei verschiedene  Geometrien einnehmen, die \nals parallel verschobene, Face-to-Face  und T-f\u00f6rmige Edge-to-Face  Geometrie \nbezeichnet werden. Elektronenziehende Gruppen wie C N und NO 2 k\u00f6nnen die \nStabilit\u00e4t solcher dimeren Systeme steigern, wohing egen Elektronendonor-\nSubstituenten, wie OH und NH 2, die Wechselwirkung destabilisieren k\u00f6nnen. Die \nBindungsabst\u00e4nde aromatischer \u03c0-\u03c0-Wechselwirkungen liegen im Bereich von 3.4-\n3.8 \u00c5. 109-110  \nSchwefel-Aren-Wechselwirkungen sind h\u00e4ufig in biolo gischen Systemen vorzufinden. \nInsbesondere Methionin- und Cystein-Seitenketten k\u00f6 nnen solche Interaktionen im \nBereich von 3.6-4.3 \u00c5 eingehen. 109-110   \n \n   \nSeite 30  \n \nAbb. 15: Molekulare Interaktionen mit aromatischen Systemen.   \n \nArginin- und Lysin-Seitenketten sowie Purine sind i mstande Kationen- \u03c0-Interaktionen \nauszubilden. Diese Art von Wechselwirkung ist sehr oft in der Natur anzutreffen und \nz\u00e4hlt zu den st\u00e4rksten biologischen Kr\u00e4ften in Komp lexierungsprozessen. Ferner \nsind sie essentiell f\u00fcr viele Erkennungsprozesse in  denen Neurorezeptoren involviert \nsind. Eine eher nebens\u00e4chliche Bedeutung in biologi schen Systemen haben \nAnionen-\u03c0-Interaktionen, da elektronenreiche aromatische Ver bindungen negative \nLadungen im Bereich ihres \u03c0-Systems meiden. 109-110                            \n \n2.8 Entwicklung von Wirkstoffen \nDas Auffinden und Optimieren von selektiven PKI f\u00fcr  die effektive Behandlung \nverschiedener Krankheiten hat sich im Laufe der let zten Jahre zu einem \nvielversprechenden Ansatz entwickelt. Jedoch ist di e Identifizierung der Targets , die \nf\u00fcr die Anwendung von Kinase-Inhibitoren in Frage k ommen, ein vielschichtiger \nProzess. Hierbei werden mit Hilfe der Bioinformatik , Zellbiologie, Strukturbiologie      \n \nSeite 31 und durch in vivo  Studien Daten generiert, die letztendlich einen Be zug  \ndes Zielproteins zur Krankheit best\u00e4tigen. Im Ansch luss daran versuchen \nPharmafirmen neue Leitstrukturen f\u00fcr spezifische Ki nasen aufzufinden. Dies \ngeschieht z.B. mit Hilfe des High-Throughput-Screenings , in dem automatisiert \nriesige Substanzbibliotheken auf ihre Effektivit\u00e4t hin getestet und neue Leitstrukturen \nf\u00fcr die Entwicklung von Arzneistoffen abgeleitet we rden. Bei der Auswahl einer \nLeitstruktur sollte jedoch nicht nur auf die Aktivi t\u00e4t und Selektivit\u00e4t einer Verbindung \ngeachtet werden. Vielmehr sollten potentiell toxisc he Eigenschaften und \nphysikochemische Parameter der Substanz bei der Ent scheidungsfindung mit \neinbezogen werden. Durch die steigende Anzahl an Kr istallstrukturen, die bereits von \nKinasen gel\u00f6st wurden, hat sich bei der Findung von  Leitstrukturen zus\u00e4tzlich die \nfragmentbasierte X-ray crystallography  etabliert. 117-119  Nachdem eine passende \nLeitstruktur ausgew\u00e4hlt wurde, findet der Optimieru ngsprozess dieser Verbindung \nstatt. Falls eine Kristallstruktur der Kinase berei ts publiziert worden ist, dient \nmolekulares Docking  dem Chemiker zus\u00e4tzlich bei der Synthese von Inhib itoren. Mit \nHilfe dieser Methodik k\u00f6nnen Substanzen virtuell au f Bindung an ein Zielprotein \ngetestet und Synthesestrategien entwickelt werden.  \nBeim Modifizierungs- und Derivatisierung-Prozess vo n Leitstrukturen versuchen \nChemiker bestimmte Kriterien einzuhalten. Zu den wi chtigsten Kenngr\u00f6\u00dfen geh\u00f6ren \ndie Rule of Five , welche stark mit der L\u00f6slichkeit und Permeabilit\u00e4 t von Substanzen \nassoziiert sind. Die Rule of Five besagt, dass das Molekulargewicht einer Verbindung \n< 500 g/mol, die Anzahl der Wasserstoffbr\u00fccken-Akze ptoren < 10, die Anzahl der \nWasserstoffbr\u00fccken-Donoren < 5 und der logP-Wert < 5 sein soll. Eine weitere \nKenngr\u00f6\u00dfe ist der logD-Wert, welcher die Verteilung  einer Substanz zwischen \nOctanol und Wasser unter verschiedenen pH-Werten be schreibt, wohingegen der \nlogP den pH-Wert nicht ber\u00fccksichtigt. 120-121  Die polare Molek\u00fcloberfl\u00e4che ( polar \nsurface area , PSA) ist definiert als die Summe der Oberfl\u00e4che v on polaren Atomen in \neinem Molek\u00fcl. Der PSA ist ein guter Parameter zur Vorhersage des molekularen \nTransports einer Verbindung, wie die intestinale Ab sorption und die Penetration der \nBlut-Hirn-Schranke. Die Blut-Hirn-Schranke sch\u00fctzt das ZNS vor Sch\u00e4digungen und  \nist entscheidend f\u00fcr die neuronalen Funktionen. 122  Bei Molek\u00fclen mit einem  \nPSA > 140 \u00c52 geht man davon aus, dass die Penetration von Zellme mbranen eher \nschlecht ist, wohingegen ein PSA \u2264 60 \u00c52 f\u00fcr leicht absorbierbare Molek\u00fcle steht. Der  \nSeite 32 TPSA ( topological polar surface area ) errechnet sich aus der Summe der PSA-Werte \neinzelner polarer Fragmente des Molek\u00fcls und dient ebenfalls der Vorhersage des \nmolekularen Transports. 123-124   \nDurch das Einbringen einzelner Substituenten, wie F luor, oder bestimmter \nfunktioneller Gruppen, wie einer Sulfon- und CN-Gru ppe, kann die Basizit\u00e4t einzelner \nMolek\u00fcle gesenkt werden. Hierdurch kann eine verbes serte orale Bioverf\u00fcgbarkeit \nerreicht werden. Zudem ist Fluor in der Lage die me tabolische Stabilit\u00e4t von \nWirkstoffen zu erh\u00f6hen und den logD-Wert zu senken.  20% aller der sich auf dem \nMarkt befindenden Arzneimittel beinhalten einen Flu orsubstituenten. 125-127  Nach  \nOptimierung der Leitstruktur und der in vitro  und in vivo  Evaluierung werden die \nWirkstoffe in klinischen Studien erprobt. Von der E ntwicklung bis zur Einf\u00fchrung von \nArzneimitteln vergehen 10-12 Jahre. Bei ZNS-Medikam enten erh\u00f6ht sich die \nZeitspanne auf bis zu 16 Jahre, da hier erschwerend  die \u00dcberwindung der Blut-Hirn-\nSchranke hinzukommt. 128   \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 33 3. Aufgabenstellung und Zielsetzung der Arbeit  \n \nAlle bisherigen Ma\u00dfnahmen zur Behandlung der Alzhei mer-Demenz (AD) dienen \ndem Ziel die Symptome zu lindern, nicht jedoch die ihr zugrunde liegende \nPathologie. Aus diesem Grunde werden seit einiger Z eit verschiedene \nTherapiem\u00f6glichkeiten dieser Erkrankung untersucht.  Der Fokus wird hierbei auf die \nSynthese von Wirkstoffen gelegt, die eine Entstehun g der Amyloid-Plaques und \nintrazellul\u00e4ren Neurofibrillenb\u00fcndel unterbinden so llen. Diese Proteinablagerungen \nsind die charakteristischen Merkmale der AD, und be ide werden mit der Glykogen \nSynthase Kinase 3 (GSK-3)  in Verbindung gebracht. Viele in vitro  und in vivo  Studien \nmachen dies deutlich, wodurch GSK-3 ein vielverspre chendes Target  f\u00fcr die AD-\nTherapie ist. Daraus ergeben sich folgende Aufgaben stellungen, die im Rahmen der \nvorliegenden Arbeit untersucht und bearbeitet  werd en sollten: \n \n/head2right/head2right /head2right/head2right Der Einsatz literaturbekannter GSK-3-Inhibitoren ha t gezeigt, dass diese \nVerbindungen imstande sind, die Tau-Hyperphosphoryl ierung und die \nBildung von Amyloid-Plaques zu reduzieren. Aufgrund  dessen bestand die \nerste Aufgabenstellung dieser Arbeit im Design und der Synthese \nverschiedener ATP-kompetitiver GSK-3-Inhibitoren. Z ur Untersuchung  \nder Struktur-Aktivit\u00e4ts-Beziehung sollten verschied ene Grundger\u00fcste \n(scaffolds ) eingesetzt werden. \n \n/head2right/head2right /head2right/head2right Alle bisher publizierten ATP-kompetitiven GSK-3-Inh ibitoren, die \nver\u00f6ffentlicht oder patentiert wurden, weisen eine Aktivit\u00e4t gegen\u00fcber \nanderen Kinasen auf. Besonders die strukturelle \u00c4hn lichkeit der ATP-\nBindetasche in GSK-3 \u03b1 und GSK-3 \u03b2 deuten darauf hin, dass die effiziente \nDiskriminierung einer Isoform nicht m\u00f6glich ist. Du rch dieses \nSelektivit\u00e4tsproblem k\u00f6nnen Nebenwirkungen auftrete n, die den Einsatz \ndieser Verbindungen zu risikoreich machen w\u00fcrden. A ufgrund dessen \nsollte mit Hilfe des molekularen Dockings  und der Struktur-Aktivit\u00e4ts-\nBeziehung untersucht werden, ob die Synthese selekt iver Inhibitoren \nm\u00f6glich ist.     \nSeite 34 /head2right/head2right /head2right/head2right GSK-3-Inhibitoren k\u00f6nnen mittels Wildtyp-Zebrafisch -Embryonen in vivo \nevaluiert werden, wobei durch die Inhibition von GS K-3 bzw. des Wnt-\nSignalwegs spezifische Ph\u00e4notypen entstehen. Zu die sem Zweck sollten \nim Anschluss an die in vitro  Evaluierung, die besten Inhibitoren im \nZebrafisch getestet werden, um eine Aussage \u00fcber di e in vivo  Effektivit\u00e4t \nbzw. Toxizit\u00e4t dieser Inhibitoren zu treffen. \n \nZwei weitere Kinasen wurden im Rahmen dieser Arbeit  als Teilprojekte untersucht \nund werden im kumulativen Teil n\u00e4her beschrieben.         \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 35 4. Kumulativer Teil der Dissertation  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 36 4.1 Untersuchungen zu GSK-3 \n \n4.1.1 Das Target  GSK-3 im Bereich der Alzheimer-Demenz  \n \nDer Inhalt dieses Kapitels wurde bereits zur Publik ation angenommen: \n \nThomas Kramer*, Boris Schmidt, Fabio Lo Monte \u2021  \nSmall-molecule inhibitors of GSK-3 \u2013 Structural ins ights and their application to \nAlzheimer's disease models, International Journal of Alzheimer's Disease 2012 , im \nDruck.  \n \n \nGSK-3 wird mit einer Vielzahl von Krankheiten assoz iiert, jedoch steht die Alzheimer-\nDemenz (AD) momentan im Fokus der Forschung. Hierbe i wird diese Kinase mit den \ncharakteristischen Merkmalen der AD, den Amyloid-Pl aques und intrazellul\u00e4ren \nNeurofibrillenb\u00fcndel, in Verbindung gebracht. Diese  Tatsache macht deutlich, \nweshalb in den letzten Jahren eine Vielzahl von Ver \u00f6ffentlichungen zu GSK-3 \npubliziert wurden. Lithium war der erste Inhibitor f\u00fcr GSK-3 durch den eine Tau-\nHyperphosphorylierung und Neurodegeneration in tran sgenen M\u00e4usen gestoppt \nwerden konnte.  \nSeitdem wurden unterschiedlichste ATP-kompetitive G SK-3-Inhibitoren publiziert und \npatentiert. In diesem Kapitel werden die verschiede nen Strukturklassen diskutiert und \ntabellarisch zusammengefasst. Die in vitro  und in vivo  Daten der einzelnen  \nGSK-3-Inhibitoren sollen das Potential und die Effe ktivit\u00e4t der Verbindungen im \nBereich der AD verdeutlichen. Die wichtigsten Krist allstrukturen der Inhibitoren im \nKomplex mit dem Zielprotein geben Hinweise auf bere its bekannte sowie m\u00f6gliche \nneue Interaktionen und sollen Wissenschaftlern Anre gungen f\u00fcr neue Strukturen \ngeben. Die wichtigsten Aminos\u00e4uren innerhalb der AT P-Bindestelle, die relevant f\u00fcr  \ndie Aktivit\u00e4t bzw. Selektivit\u00e4t eines Inhibitors se in k\u00f6nnten, wurden grafisch \ndargestellt (Abb. 16). \n \n  \nAbb. 16: Schematischer Einblick in die ATP \nrelevanter Bereiche. \n \nRelevante Tiermodelle im Bereich der AD werden eben falls vorgestellt, wobei der \nZebr afisch als neueres Modell eine k \ndarstellt. Verbindungen, die sich gegenw\u00e4rtig in den pr\u00e4klinischen oder klin ischen \nPhasen befinden, werden separat diskutiert. \nDieses Review soll verdeutlichen \nBereich der AD-Forsc hung ist \n \n \n \n \n   \n  \n \n \n \n \n \n \nSeite 37 Schematischer Einblick in die ATP -Bindungstasche von GSK-3 \u03b2 \nRelevante Tiermodelle im Bereich der AD werden eben falls vorgestellt, wobei der \nafisch als neueres Modell eine k osteng\u00fcnstigere Alternative zu Mausmodellen \ndie sich gegenw\u00e4rtig in den pr\u00e4klinischen oder klin ischen \nwerden separat diskutiert.  \nReview soll verdeutlichen , dass GSK-3 ein vielversprechendes \nhung ist  und auch in Zukunft Beachtung finden \n \n mit Kennzeichnung \nRelevante Tiermodelle im Bereich der AD werden eben falls vorgestellt, wobei der \nAlternative zu Mausmodellen \ndie sich gegenw\u00e4rtig in den pr\u00e4klinischen oder klin ischen \nvielversprechendes Target  im \nZukunft Beachtung finden  sollte.  \n \nSmall-molecule inhibitors of GSK \ninsights and their application to Alzheimer\u00b4s disea se \nmodels \nThomas Kramer, Boris Schmidt and Fabio Lo Monte \n \nClemens Sch\u00f6pf - Institute of Organic Chemistry and Biochemistry, Technische U niversit\u00e4t Darmstadt, 64287 Darmstadt, \nGermany \nFax: +496151-163278; Tel: +496151- 164531. \nE-mail:  schmidt_boris@t-online.de , Fabio.Lo \n \nO\nH\nNH\nN\nON\nS\nNO2NSNO\nN N\nOSCN\nN\nN\nO\nSeite 38 molecule inhibitors of GSK -3 \u2013 \ninsights and their application to Alzheimer\u00b4s disea se \nThomas Kramer, Boris Schmidt and Fabio Lo Monte  \nof Organic Chemistry and Biochemistry, Technische U niversit\u00e4t Darmstadt, 64287 Darmstadt, \n164531.  \nFabio.Lo -Monte@gmx.de \nOH\nN\nHNO\nNO2N\nHNHNHO\nOBr\nCl ClNH\nN\nH\nNO O\nNCl\nClHO\nB\nN\nHO\nOHNH\nN\nHNO\nNO\nNH\nO Structural \ninsights and their application to Alzheimer\u00b4s disea se \nof Organic Chemistry and Biochemistry, Technische U niversit\u00e4t Darmstadt, 64287 Darmstadt, \n \n \n NNH2\nNO2H\nNN\nHN\nN\nl\nH\nNO O\nNN\nBrF\nRu\nO N\nHO \nSeite 39 Keywords \n \nAlzheimer\u00b4s disease; GSK-3; inhibitors; activity; s electivity; X-ray; pre-/clinical trials  \n \n \nAbstract \n \nThe world health organization (WHO) estimated that 18 million people are struck by \nAlzheimer\u00b4s disease (AD). The USA, France, Germany and other countries launched major \nprogrammes targeting the identification of risk fac tors, the improvement of caretaking and \nfundamental research aiming to postpone the onset o f AD. The glycogen synthase kinase 3 \n(GSK-3) is implicated in multiple cellular processe s and has been linked to the pathogenesis \nof several diseases including diabetes mellitus, ca ncer and AD. Inhibition of GSK-3 leads to \nneuroprotective effects, decreased \u03b2-amyloid production and a reduction in tau \nhyperphosphorylation, which are all associated with  AD. Various classes of small molecule \nGSK-3 inhibitors have been published in patents and  original publications. Herein we present \na comprehensive summary of small molecules reported  to interact with GSK-3. We illustrate \nthe interactions of the inhibitors with the active site. Furthermore, we refer to the biological \ncharacterisation in terms of activity and selectivi ty for GSK-3, elucidate in vivo  studies and \npre-/clinical trials. \n \n \nIntroduction \n \nProtein kinases regulate diverse cellular functions  and thus are frequently exploited in drug \ndiscovery programmes. 1 They regulate signal transduction processes by pho sphorylating \nserine, threonine and tyrosine residues in key prot eins. The signalling pathways involved \ncontribute to the pathology in many diseases. 2,3  Glycogen synthase kinase 3 (GSK-3) was \nidentified in the late 1970s and is a constitutivel y active, ubiquitous expressed \nserine/threonine kinase, which participates in a nu mber of physiological processes ranging \nfrom glycogen metabolism to gene transcription. 4 Initially, the focus of pharmaceutical \ncompanies concerning GSK-3 was on diabetes mellitus , but since GSK-3 was linked to \nAlzheimer\u2019s disease (AD), the focus has moved from diabetes to AD. GSK-3 has been linked \nto all primary abnormalities associated with AD. GS K-3 interacts with different components of \nthe plaque producing amyloid system, participates i n phosphorylating the microtubule binding  \nSeite 40 protein tau that contributes to the formation of ne urofibrillary tangles, and has an influence on \npresenilin and other AD-associated proteins. 4-8 Two related isoforms of GSK-3 are present in \nmammalians, GSK-3 \u03b1 and \u03b2, which share 98% homology in their catalytic domai ns and have \nsimilar biochemical properties. 9 The isoforms are similar in their catalytic domain s, yet differ \nsignificantly in their N-terminal regions. 10  Alois Alzheimer\u2019s first report of the \nneuropathological hallmarks of AD dates back to 190 7. 11,12  The histopathology of the AD \nbrain is characterized by the presence of abnormal filamentous tau-protein inclusions in \nnerve cells and extracellular amyloid deposits. 13,14  Partially phosphorylated tau contains \nsequence motifs that support association with tubul in, which entails the stabilization of \nmicrotubules in AD-uneffected cells. The pathologic al hyperphosphorylation of these motifs \ndestabilizes microtubules and consequently interfer es with tubulin binding. The misfolding of \nhyperphosphorylated tau involves the E/Z-isomerisat ion of a phosphorylated Ser-Pro motive, \nwhich leads to the formation of insoluble neurofibr illary tangles (NFTs) and intraneuronal \naggregates of paired helical filaments (PHFs). 9,15  GSK-3 phosphorylates multiple sites on tau \nboth in  vitro  and in vivo .9 It exerts a central and crucial role in the pathog enesis of both \nfamilial and sporadic forms of AD. Early onset form s of familial Alzheimer\u00b4s disease (FAD) \nhave been linked to mutations in amyloid precursor protein (APP), presenilin-1 (PS-1) and \npresenilin-2 (PS-2). These mutations adversely affe ct APP processing and result in the \nincreased production of the 40-42 amino acid long \u03b2-Amyloid (A \u03b2) peptides, which are the \nmajor component of amyloid deposits. Several risk f actors have been associated with \nsporadic Alzheimer\u00b4s disease (SAD). The most preval ent factors are aging and the presence \nof specific ApoE isoforms, which have been implicat ed in A \u03b2 clearance. Sporadic \nAlzheimer\u00b4s disease can be caused by the activation  of \u03b2-secretase, which results in \nenhanced formation of A \u03b2. Enhanced A \u03b2 production or deficiency in A \u03b2 clearance will result \nin the deposition of A \u03b2 aggregates. 4,16  Recent work suggests that enhanced GSK-3 activity \nincreases A \u03b2 production. 17  Several studies support that GSK-3 inhibition lead s to decreased \nA\u03b2 production and a reduction in tau hyperphosphoryla tion. 1 \nA plethora of GSK-3 inhibitors has been described a nd most of the biological effects were \nreported for in vitro  and cellular studies. 17  These studies, the number of patent applications \nand a successful phase II trial indicate that GSK-3  is a promising drug target for AD therapy, \nbut the ultimate proof of concept has not been pres ented yet. GSK-3 is highly enriched in the \nbrain and several publications indicate that the GS K-3\u03b2 isoform is a key kinase required for \nabnormal hyperphosphorylation of tau. 18,19  Kurt Spittaels et al.  generated a double transgenic \nmouse overexpressing human protein tau and constitu tively active human GSK-3 \u03b2 and \nascertained that this kinase is implicated in aberr ant tau phosphorylation and in addition \nreduced tau binding  capacity to microtubules. 15,20  The homology of the ATP-binding pocket in \nGSK-3\u03b1 and GSK-3 \u03b2 presents an obstacle for the development of isofor m selective  \nSeite 41 inhibitors. All GSK-3 inhibitors developed until no w are able to inhibit the two isoforms with \nsimilar potency, except \u039b\u039b \u039b\u039b-OS1  (36 ), which showed a selectivity (up to 7-fold) for  \nGSK-3\u03b1.8,21,22  \nThe structures of GSK-3 \u03b2 co-crystallized with several inhibitors have been solved by X-ray \ncrystallography recently. These structures provide a remarkable possibility to design both \nnovel and selective GSK-3 inhibitors. There are two  fundamental options to inhibit GSK-3: \nnon-ATP competitive inhibition and ATP competitive inhibition. \nThe non-ATP competitive inhibitors, e.g. substrate competitive inhibitors, usually engage in a \nweak binding interaction with the enzyme. 23  Non-ATP competitive inhibitors do not compete \nwith the high intracellular ATP-concentration and t hus offer a distinct pharmacological \nadvantage. Moreover, the involvement of GSK-3 in se veral essential signalling pathways \nimposes a limit on the GSK-3 inhibition, complete i nhibition will result in adverse events.   \nThus GSK-3 inhibitors suitable for AD therapy have to strike a balance between the different \npathways. This delicate balance may be achieved by moderate inhibition in combination with \nexcellent pharmacokinetics. Thiadiazolindiones (TDZ Ds) are non-ATP competitive GSK-3 \ninhibitors, which delivered a candidate for phase I Ib trials recently. 24  The extended phase II \ntrial (60 days treatment) did not reveal adverse ef fects. 25  However, the majority of the known \nGSK-3 inhibitors are ATP competitive and target the  ATP binding pocket of GSK-3. Several \nsmall-molecule inhibitor/GSK-3 complexes can be ext racted from the Protein Data Bank \n(PDB). 26  A closer view at the interactions of these inhibit ors with GSK-3 will be provided in \nthe following chapters. \n \n \nSmall-molecule inhibitors of glycogen synthase kina se 3  \n \nSeveral ATP competitive GSK-3 inhibitors from diffe rent structural classes are highlighted in \nthis review. The in vitro  and in vivo  data are summarized if available. It should be not ed that \nthe IC 50  values strongly depend on assay conditions and thu s may vary 100-fold depending \non ATP and enzyme concentration as well as incubati on time. The interactions between the \ninhibitors and the ATP binding pocket are depicted.  \nLithiumchloride  was the first GSK-3 inhibitor to be discovered. Ho wever, there are several \nother biological targets for lithium resulting in a dverse events and a rather small therapeutic \nwindow. This effectively rules out the use of LiCl in the therapy of AD. The mechanism by \nwhich lithium  inhibits GSK-3 is unknown, but two hypotheses were  proposed: a) lithium  \n(Li +) is a competitive inhibitor of GSK-3 with respect to magnesium  (Mg 2+ ), but neither \ncompetitive to substrate nor to ATP, b) lithium  inhibits potassium  deprivation.25,27,28    \nSeite 42 This review focusses on small organic molecules tha t target specifically GSK-3, thus the \nactivity of lithium salts will not be reviewed. Als o covalent or irreversible inhibitors, like the \nTDZD NP-12 , will be noted, but not further discussed as well as the FRATtide , a peptide \nderived from FRAT1, which binds to GSK-3 and blocks  GSK-3 from interacting with axin.29,30   \n \n \nMaleimide derivatives \n \nMaleimide derivatives have been reported as scaffol ds for ATP competitive GSK-3 inhibitors. \nResearchers at SmithKline Beecham Pharmaceuticals r eported that 3-anilino-4-\narylmaleimides 1-3 (Table 1) are potent and selective inhibitors of G SK-3. 31  The compounds \n \nTable 1: Examples of maleimide inhibitors with biological ac tivity against GSK-3, selectivity, X-Ray and refere nce.  \n \n \nNo. R1 R2 IC 50  (nM): Kinase Panel: In Vivo X-Ray  Year/ \nLit. \n1  \n \u03b1: 20 - - - 2001 31  \n2   \u03b1: 26  \u03b2 + 24 - - 2001 31  \n3   \u03b1: 76 - - 1Q4L 2001, \n2003 31,32  \n\u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \ndisplayed GSK-3 inhibition (IC 50 ) at low nanomolar concentrations. The selectivity of \ncompound 2 was evaluated using a panel of 25 kinases. The maj ority of the kinases showed \nless than 30% inhibition at an inhibitor concentrat ion of 10 \u00b5M. The complex of 3 (named  \nI-5) with GSK-3 \u03b2 (Figure 1) elucidated the binding mode to the ATP pocket. 32  Herein the \nmaleimide nitrogen interacts with the carbonyl oxyg en of Asp133 and the oxygen of \ncompound 3 with the backbone nitrogen of Val135. Two addition al interactions are observed \nbetween a carboxylate oxygen and Arg141 and with Gl n185. Compound 4 (SB-216763 ) H\nNO O\nR1R2\nO2NHN Cl\nOH\nCl\nO2NHN\nClOHO\nClHN\nClOHO \nSeite 43 inhibited GSK-3 \u03b1 with an IC 50  of 34 nM (Table 2). Derivative 4 exhibited little or no \n \n \nFigure 1.  Compound 3 (I-5) in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The \ndistance is denoted in \u00c5. PDB code 1Q4L. 32   \n \nTable 2: Examples of indolyl-maleimide inhibitors with biolo gical activity against GSK-3, selectivity, X-Ray an d reference.  \n \n \nNo. R1 X R2 R3 R4 IC 50 /K i (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n4 H C H Me \n \u03b1: 34 a \u03b2 + 24 Yes - 2000, \n2001, \n2007 33-35  \n5 H N - \n  \u03b2: 25 b \u03b2 + 79 Yes - 2004 36  \n6 H N - \n  \u03b2: 6 b \u03b2 + 79 Yes - 2004 36  \n7 H N - \n  \u03b2: 4 a - - - 2004 37  \n8 H N - \n  \u03b2: 26 a \u03b2 + 69 Yes 1Q3D c 2004 37  \n9 H C \n  \u03b2: 1.3 a \u03b2 + 36 Yes - 2004 38  \nH\nNO O\nR4\nNX\nR3 R2R1\nCl\nCl\nOHNN\nOHNNO\nO\nOHO\nOHNCl\nCF3\nN\nNO\nONN \nSeite 44 10 H C \n  GSK-3: 2.0 a GSK-3 + \n3 Yes - 2005 39  \n11 H C \n  GSK-3: 0.7 a GSK-3 + \n3 Yes - 2005 39  \n12 Br C H \n  \u03b2: 140 a \u03b2 + 5 Yes 1Q3D c 2009 40  \n13 F C H Me \n \u03b2: 0.6 a \u03b1 & \u03b2 + \n315 Yes 1R0E  2010 41  \n14 H C H H  \u03b2: 4470 a - - - 2011 42  \n15 H C H Me  \u03b2: 890 a - - - 2011 42  \na IC 50  value; b Ki value; c Docking studies, PDB code; \u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \ninhibition of the 24 kinases tested in the panel. 33  Incubation of cerebrellar granule neurones \nwith this compound reduced the death rate in a conc entration dependent manner in response \nto either stimulus. The maximal neuroprotection was  observed with 3 \u00b5M of SB-216763 .34  A \n60% reduction in GSK-3 \u03b2 activity levels was observed in the hippocampus, b ut not in the \ncortex of SB-216763  treated animals versus vehicle treated rats. 35  The compounds 5-11  \nrevealed good potencies against GSK-3. Concerning c ompounds 7 and 9-11  much higher \npotencies (IC 50 < 4 nM) were ascertained in comparison to compound 1 (Table 2).37-39  The \ncompounds 10  and 11  demonstrated very good GSK-3 inhibition and improv ed selectivity \nagainst PKC \u03b2II, CDK2 and CDK4, and inhibit tau phosphorylation in a neuronal cell line.39  \nWhereas compound 12  was analyzed by in silico docking the binding mode  of 13   \n(IC 50  = 0.6 nM) was determined by X-ray crystallographic  analysis (Figure 2). 41   \n N\nNONN\nN\nNO\nNNN\nN\nNN\nN\nH\nNOH\nOH\nO\nO \nSeite 45  \nFigure 2.  Compound 13  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 1R0E. 41   \n \nSimilar to compound 3, the maleimide nitrogen of 13  interacts with the carbonyl oxygen of \nAsp133 and its oxygen with the backbone nitrogen of  Val135. Furthermore, compound 13  \nforms a crucial hydrogen bond to Gln185. Maleimide 13  was screened against 315 kinases \nto provide data on kinase selectivity in order to p redict potential safety issues. It was found \nthat compound 13  inhibits only 36 kinases with >90% inhibition at 1 0 \u00b5M. 41  Compound 14  \nand 15  are reversible GSK-3 inhibitors in the low micromo lar or high nanomolar range and \ncan be used as chemical precursors for the correspo nding halomethylketones (HMKs). \nThese HMKs are irreversible inhibitors, they alkyla te Cys199, which is located in the ATP \nbinding site of GSK-3. 42 Further maleimide derivatives are listed in Table 3 .  \n \nTable 3: Examples of bisindolyl maleimide and benzofuranyl-i ndolyl maleimide inhibitors with biological activit y against GSK-3, selectivity, X-\nRay and reference.  \n \n \nNo. R1 X R2 R3 Y Z R4 IC 50 /K i \n(nM): Kinase \nPanel: In Vivo X-Ray Year/ \nLit. \n16 H CH Me \n N CH H \u03b2: 2.8 a - Yes - 1999 43  \n17 H N \n N N H \u03b2: 48 a \u03b2 + 54 Yes - 2003 44  \nH\nNO O\nNXYZ\nR2R3R1R4\nSNH\nNH2\nOO\n3 \nSeite 46 18 H N \n N N H \u03b2: 34 a \u03b2 + 54 Yes 1H8F c 2003 44  \n19 H CH \n N CH H \u03b2: 25 a \u03b2 + 18 Yes - 2003 45  \n20 H CH \n N CH H \u03b2: 4a - Yes - 2003 45  \n21 H N \n N N H \u03b2: 11 b \u03b2 + 65 Yes - 2004 46  \n22 H N \n N N H \u03b2: 36 b \u03b2 + 65 Yes 1H8F c + \n1AQ1 c 2004 46  \n23 H CH \n N CH H \u03b2: 3a \u03b1 &  \u03b2 + \n98 - 2OW3 2007 47  \n24 5-Br CH Me - O CH H \u03b2: 7.0 a \n(4.6 b) \u03b2 + 22 Yes 1Q3D c 2007 48  \n25 5-F CH Me - O CH 6-CH 2 \nOH \u03b2: 0.35 a \u03b2 + 1 - 1R0E c 2009 49  \n26 7-CH 2 \nOH CH Me - O CH H \u03b2: 5.4 a \u03b2 + 1 - 1R0E c 2009 49  \n27 7-CH 2 \nOMe CH Me - O CH H \u03b2: 0.23 a \u03b2 + 1 Yes - 2009 49  \na IC 50  value; b Ki value; c Docking studies, PDB code; \u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \nAll of them, compounds 16-27 , showed IC 50 /K i values in the low nanomolar range.43-49   \nThe majority of these structures was synthesized by  Johnson & Johnson Pharmaceutical  \nR & D. The compounds 17  and 18  were evaluated against a broad panel of 55 protein  \nkinases. 10 \u00b5M of derivative 17  or 18  inhibited GSK-3 \u03b2 kinase activity by 100% in the \npresence of 10 \u00b5M ATP. Compound 18  exhibited excellent selectivity for GSK-3 \u03b2 except for \nthe moderate selectivity against PKC \u03b2II. Meanwhile the bis-7-azaindolylmaleimide 17  \nexhibited high selectivity at GSK-3 \u03b2 against all kinases tested. 44  The activity of compound 23  \nwas tested in a kinase panel containing 100 diverse  protein kinases. An IC 50  of 3 nM and a \n460-fold selectivity for GSK-3 \u03b2 over PKC \u03b2II was reported. 47  The X-ray structure analysis of \nco-crystallized compound 23  and GSK-3 \u03b2 is illustrated in Figure 3. OO\n2\nO\nNO\nO\nON\nOH\nS\nN\nN \nSeite 47  \nFigure 3.  Compound 23  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 2OW3. 47   \n \nThe maleimide establishes key hydrogen bond contact s with the residues Asp133 and \nVal135. The compounds 25  and 26  were docked into the ATP binding site of GSK-3 \u03b2 (PDB \ncode 1R0E). Similar to the other maleimide derivati ves, the maleimide nitrogen interacts with \nthe carbonyl oxygen of Asp133 and the oxygen with t he backbone NH of Val135. In addition \nto these main interactions, the hydroxymethyl group  of compound 26  interacts with the side \nchain of Arg141. 49  The benzo[e]isoindole-1,3-dione 28  (Table 4) displays an IC 50  of 304 nM \nin the presence of 100 \u00b5M ATP.  \n \nTable 4: Examples of maleimide inhibitors with biological ac tivity against GSK-3, selectivity, X-Ray and refere nce.  \n \n \nNo. X R1 IC 50  (nM): Kinase Panel: In Vivo X-Ray  Year/ \nLit. \n28 N Et \u03b2: 304 \u03b2 + 21 Yes 1UV5 a 2009 50  \n29 CH Et \u03b2: 92  \u03b2 + 2 Yes 1UV5 a 2010 51  \n30 CH Me \u03b2: 270  \u03b2 + 2 Yes 1UV5 a 2010 51  \na Docking studies, PDB code; \u03b2 = GSK-3 \u03b2. \n \nH\nNO O\nX\nR1\nOO \nSeite 48 It was evaluated in a panel of 22 representative ki nases. 5 \u00b5M of compound 28  inhibited 91% \nof GSK-3 \u03b2 activity as well as 71% of CDK2/cyclin A and 53% o f KDR (VEGFR2).50  The \ninhibition of GSK-3 leads to ectopic activation of the Wnt pathway during zebrafish \ndevelopment, resulting in a headless embryo. Thus z ebrafish embryos, which were treated \nwith compound 28 , had highly restricted brain defects that ranged f rom smaller eyes and \nforebrain to a complete loss of these structures. 50  Compound 29  displayed a lower IC 50  in \nvitro  than 30 , whereas compound 30  displayed better in vivo  efficacy. 25 \u00b5M of derivative 30  \nresulted in the eyeless phenotype of zebrafish embr yos after 3 days of incubation.51  The \nsynthetic activity dedicated to this structural cla ss has been strong and is ongoing.52-56   \n \n \nStaurosporine and organometallic inhibitors \n \nStaurosporine  (31 ) is a natural product from the bacterium Streptomyces staurosporeus .57  It \nexerts antimicrobial, hypotensive and cytotoxic act ivity. 58  Staurosporine  (31 ) is also a potent \nGSK-3\u03b2 inhibitor with a reported IC 50  value of 15 nM (Table 5). 59  The co-crystal \n \nTable 5: Staurosporine  and organometallic inhibitors with biological acti vity against GSK-3, selectivity, X-Ray and referenc e. \n \n                   \nNo. X R1 R2 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray Year/ \nLit. \n31 CH 2 \n \u03b2: 15 \u03b2 + 2 - 1Q3D 1977, 1994, \n2001, \n2003 32,57-59  \n \n \nNo. R3 R4 R5 R6 R7 IC 50 /K i \n(nM): Kinase \nPanel: In Vivo X-Ray Year \n/ \nLit. \n32 H H \n H \u03b1:  3, \u03b2: 10 \u03b1 & \u03b2 + 8 Yes - 2004 \n60  XH\nNO\nNN\nR1R2\nO\nO\nNH\nH\nNO\nN\nR5O\nN\nR6R7R3\nR4\nRu\nO \nSeite 49 33 OH Br \n H \u03b1:  0.35 a \n\u03b2: 0.55 a \u03b1 & \u03b2 \n+ 55 Yes - 2006 \n61  \n34 OH H \n F \u03b2: 0.04 a \n(0.005 b) - - 2JLD 2008 \n62  \n35 OH H \n H \u03b1:  0.5 a \n\u03b2: 1.00 a - - 3M1S 2011 \n63  \n36 H H \n NH 2 \u03b1: 0.9 a \n\u03b2: 6 a \u03b1 & \u03b2 \n+ 100 - 3PUP 2011 \n22  \na IC 50  value; b Ki value; \u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \nstructure of Staurosporine  (31 ) with GSK-3 \u03b2 is elucidated in Figure 4. Again, the maleimide \n31  interacts with the Asp133 carbonyl oxygen and the backbone nitrogen of Val135. These \nare the only direct hydrogen bonds observed between  GSK-3\u03b2 and this inhibitor. 32  The other  \n \n \nFigure 4.  Compound 31  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 1Q3D. 32   \n \npolar interactions, e.g. water-mediated interaction s, are not denoted. The organometallic \nruthenium complex 32  is a remarkably potent inhibitor of GSK-3 (Table 5 ). The IC 50  for  \nGSK-3\u03b1 is 3 nM  and 10 nM for GSK-3 \u03b2. The compound was evaluated against 10 kinases \nand displayed activity against GSK-3 and RSK1 (IC 50 = 100 nM) only. The authors observed \na water-mediated contact between the carbonyl ligan d and the carbamide of Gln185 and \nassumed that this contributes to the specificity fo r GSK-3. 60  Compound 33  showed improved \nselectivity. A test panel of more than 50 kinases w as not significantly inhibited at 100 nM. \nCompound 33  was reported to activate the Wnt signaling pathway  in cell culture experiments Ru\nOOO\nRu\nON\nHO\nO\nOH\nRu\nO\nRuHN\nClO\n \nSeite 50 at nanomolar concentrations. The treatment of zebra fish embryos in early development by \ncompound 33  caused malformations, e.g. a head structure lackin g the eyes and a stunted \ntail. 61  The S-diastereomer of compound 34 is a weaker GSK-3 \u03b2 inhibitor than the  \nR-diastereomer: IC 50  of 0.22 nM at 100 \u00b5M. Compound 34  (R-diastereomer, Table 5) exerts \nthe highest reported potency against GSK-3 \u03b2 with an IC 50  of 40 pM. Unfortunately, the \nevaluation in a kinase panel was not reported yet. 62  The complex of derivative 34  with  \nGSK-3\u03b2 (Figure 5) provided insight into the binding mode in the ATP pocket of GSK-3 \u03b2. The \ninteractions between the imide NH and the carbonyl oxygen of Asp133 and between the \nimide carbonyl and the NH of Val135 are typical. An other interaction is marked between the \ncarbonyl oxygen of Val135 and the indolyl OH. The c ompound 34  and the analogues 35   \n((R)-DW 12 ) & 36  (\u039b\u039b \u039b\u039b-OS1 ) contain a carbonyl, which interacts with the flex ible glycine-rich \nloop of GSK-3 \u03b2 (Figure 6 & 7).  \n \n \nFigure 5.  Compound 34  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 2JLD. 62   \n \n  \nFigure 6.  Compound 35 in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 3M1S. 63   \n \nSeite 51  \nFigure 7.  Compound 36 in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 3PUP. 22   \n \nThereby Ile62, Gly63, Phe67 and Val70 form a small hydrophobic  pocket (Figure 6 right, \ncompound 35 ). The structure activity analysis of ruthenium-bas ed GSK-3 inhibitors lacking \nthe carbonyl revealed the contribution of this carb onyl to potency and selectivity. 22,62,63   \n \n \nIndole derivatives \n \nSeveral pharmaceutical companies have reported and patented indole derivatives as GSK-3 \ninhibitors. 64-71  Indirubins are likewise indole derivatives. They a re related to the naturally \noccurring indigo dyes and their pharmacological pro perties have long been known in \ntraditional Chinese medicine, for example in the tr eatment of leukemias. 15  Except for the dye \nindirubin 38 , all other noted indole derivatives ( 37 , 39-50 ) revealed an IC 50  below 100 nM. \nCompound 37 , the indirubin-3\u00b4-monoxime , was reported to display an IC 50  of 22 nM on \nGSK-3 inhibition (Table 6).  \nTable 6: Examples of indirubine inhibitors with biological a ctivity against GSK-3, selectivity, X-Ray and refer ence.  \n \n \nNo. X R1 R2 R3 IC 50  (nM): Kinase -\nPanel  In Vivo X-Ray  Year/Lit. \nN\nHNHX\nOR1R2\nR3 \nSeite 52 37 N OH H H \u03b2:  22 \u03b2 + 2 Yes 1Q41 2001, \n2003, \n2007 32,35,59  \n38 O - H H \u03b2:  600 \u03b2 + 2 - - 2001 59  \n39 N OH H Br \u03b1/\u03b2:  5 \u03b1/\u03b2 + 19 Yes 1UV5 +  \n1Q41 a 2003, \n2004 72,73  \n40 N OAc H Br \u03b1/\u03b2:  10 \u03b1/\u03b2 + 19 - - 2003 72  \n41 O - H Br \u03b2:  45 \u03b2 + 2 - - 2004 73  \n42 N OAc Cl Cl \u03b2:  4 \u03b2 + 2 - - 2004 73  \n43 N OAc CH 3 Br \u03b2:  7 \u03b2 + 2 - - 2004 73  \n44 N  H Br \u03b1/\u03b2:  3.3 \u03b1/\u03b2 + 2 Yes 1UV5 a 2008 74  \n45 N  H Br \u03b1/\u03b2:  5.0 \u03b1/\u03b2 + 2 Yes 1UV5 a 2008 74  \n46 N  H Br \u03b1/\u03b2:  14 \u03b1/\u03b2 + 2 Yes - 2008 74  \n47 O - NH 2 H \u03b1/\u03b2:  80 \u03b1/\u03b2 + 4 Yes  - 2009 75  \n48 O - NHAc  H \u03b1/\u03b2:  7.5 \u03b1/\u03b2 + 4 Yes  - 2009 75  \n49 N OH H  NO 2 \u03b1/\u03b2:  40 \u03b1/\u03b2 + 4 - - 2009 75  \n50 N OH NO 2 H \u03b1/\u03b2:  2.1 \u03b1/\u03b2 + 4 - - 2009 75  \na Docking studies; PDB code; \u03b2 = GSK-3 \u03b2; \u03b1/\u03b2 = GSK-3 \u03b1/\u03b2. \n \nThis unselective compound is a strong inhibitor of the closely related kinases CDK1 and \nCDK5. 59  Compound 37  did not affect p-tau levels in neither cortex nor hippocampus of P12 \nrats despite the high concentration of the compound  in the brain  \n(13 \u00b5M). 35  Three important interactions of compound 37  and GSK-3 \u03b2 are displayed in the  \nX-ray in Figure 8. 32  Maternal Wnt activity is necessary for dorsal axis  formation in Xenopus  \n ONNH\nONNOH\nONNO\nOH \nSeite 53  \nFigure 8.  Compound 37  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 1Q41. 32   \n \nlaevis  embryos, whereas head formation requires the inhib ition of zygotic Wnt activity. The \nXenopus  laevis  embryos were treated with compound 39 (BIO ) or LiCl , respectively; in order \nto challenge these two GSK3 regulated events in vivo . LiCl  treatment leads to a hyper dorso-\nanteriorization at the expense of trunk and tail wh en applied during early cleavage stage. 39  \nexerted the same effect on the embryos. Compound 39  inhibited GSK-3 with an IC 50  of 5 nM, \nbut also CDK1, CDK2 and CDK5 in a nanomolar range. 72,73  The binding mode of 39  in the \nATP pocket of GSK-3 \u03b2 has been determined by X-ray crystallographic anal ysis. The four  \nmajor interactions between the inhibitor and GSK-3 \u03b2 are shown in Figure 9. The nitrogen \n \n \nFigure 9.  Compound 39 in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 1UV5. 72   \n \ninteracts with the carbonyl oxygen of Asp133 and th e oxygen with the backbone nitrogen of \nVal135. Moreover, interactions with the oxygens of Val135 and Pro136 as well as the van der \nWaals contact between the bromine and Leu132 were o bserved. Compounds 41 and  43 are \n \nSeite 54 potent GSK-3 inhibitors and very selective against CDK1/cyclin B and CDK5/p25.73  In 2007, \nthis class of indirubine derivatives was patented b y Meijer et al. 76  This patent lists in vivo  \nactivity for several compounds. The derivatives 44-46  feature an extended amino side chain \nat position R 1. They were prepared to enhance selectivity and wat er  solubility versus \ncompound 39 . These compounds were reported to inhibit \u03b2-catenin S33/37/T41 \nphosphorylation by GSK-3. Compounds 44-46  were also less cytotoxic than compound 39 in \nthe MTS reduction assay of SH-SY5Y neuroblastoma ce lls. 74  The compounds 47-50  are \npotent, yet unselective GSK-3 inhibitors. 75   \n \n \nPaullone derivatives \n \nPaullones have been reported as potent ATP competit ive inhibitors of CDKs and GSK-\n3\u03b2.77,78  Compounds 51-55  revealed that a defined derivatisation of one subs tituent only can \nincrease the GSK-3 \u03b2 inhibition up to 155-fold. Alsterpaullone 55  (9-nitro-paullone ) is one of \nthe most potent GSK-3 \u03b2 inhibitors and competes with ATP for binding to GS K-3\u03b2 (Table 7).  \n \nTable 7: Examples of paullone inhibitors with biological act ivity against GSK-3, selectivity, X-Ray and referen ce.  \n \n \nNo. X  Y R1 R2\n R3 IC 50  (nM): Kinase \nPanel: In \nVivo X-Ray  Year/ \nLit. \n51 CH CH  H H  H \u03b2:  620 \u03b1/\u03b2 + 2 - - 1999, \n2000 77,7 \n8 \n52 CH  CH  H H Cl \u03b2:  24 \u03b1/\u03b2 + 2 - - 1999, \n2000 77,7 \n8 \n53 CH  CH  H H Br \u03b2:  23 \u03b1/\u03b2 + 2 - - 1999, \n2000 77,7 \n8 \n54 CH  CH  H H CN \u03b2:  10  \u03b1/\u03b2 + 2 - - 1999, \n2000 77,7 \n8 YXH\nN\nHNO\nR3R2R1 \nSeite 55 55 CH  CH  H H  NO 2 \u03b1: 4 \n\u03b2:  4 \u03b1 & \u03b2 + \n23 Yes 1Q3W 1999, \n2000, \n2003, \n2007 32,3 \n5,77,78  \n56 CH  CH   H Br \u03b2:  30 \u03b2 + 2 - - 2002 79  \n57 CH  CH  H  Br \u03b2:  40 \u03b2 + 2 - - 2002 79  \n58 CH  N H H Br \u03b2:  18 \u03b2 + 2 - - 2004 80  \n59 N CH  H H Br \u03b2:  6000 \u03b2 + 2 - - 2004 80  \n60 CH  CH  H  NO 2 \u03b2:  6 \u03b2 + 2 - - 2005 81  \n61 CH  CH  H  NO 2 \u03b2:  2.5 \u03b2 + 2 - - 2005 81  \n62 CH  CH  H  NO 2 \u03b2:  6.5 \u03b2 + 2 - - 2005 81  \n63 CH  CH  H  NO 2 \u03b2:  34 \u03b2 + 2 - - 2005 81  \n64 CH  CH  H  NO 2 \u03b2:  0.8 \u03b2 + 21 - - 2005 81  \n\u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \nCompound 55 was evaluated in a kinase panel with 25 kinases and  exhibited high selectivity \nfor GSK-3 \u03b1/\u03b2, CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and C DK5/p35. All measured \nIC 50  values were in the nanomolar range. Alsterpaullone  55  was reported to inhibit the in vivo  \nphosphorylation of tau at AD specific sites by GSK- 3\u03b2.77  Paullone 55  formulated in 20% \nDMSO/25% Tween-80 and injected s.c.  led to a reduction in 43 kDa tau phosphorylation i n \ncortex after 2 h, though not in the 49 kDa isoform.  Furthermore, the phosphorylation levels of \nthe 43 kDa and 49 kDa isoforms in the hippocampus w ere significantly decreased.35  Most of \nthe paullone derivatives were patented by Meijer et al.  in 2001. 82  The binding mode of 55 has \nbeen determined by X-ray crystallographic analysis (Figure 10). 32  The interactions of \nalsterpaullone and GSK-3 \u03b2 include two hydrogen bonds with Val135 and one int eraction \nbetween the nitro group and the side chain amino gr oup of Lys85. The compounds 56 and  \n57  inhibited GSK-3 as well as CDK1/cyclin B and CDK5/ p25 in the nanomolar range.79  The \nexchange of nitrogen and carbon in compound 58 and 59  decreased the inhibitory activity, \nbut provided selectivity to 58, which is void of CDK-inhibitory effects. 80  H2NO\nH2NO\nH2N\nH2N\nHO\nO\nO\nO\nNC \nSeite 56  \nFigure 10.  Compound 55  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 1Q3W. 32  \n \nHowever, compound 58 was testet against three kinases (GSK-3 \u03b2, CDK1/cyclin B, CDK5/p2) \nonly. The derviatisation of the R 2 motif, see compounds 57  and 60-64  in Table 7, leads to the \nmost potent inhibitor 64 . Compound 64 , with an IC 50  of 0.8 nM is likewise non-selective for \nGSK-3. It preferentially inhibited the CDK/GSK-3 fa mily in the nanomolar range and  \nVEGFR-2, VEGFR-3 and Src in the submicromolar range . 81   \n \n \nPyrazolamide derivatives \n \nGlaxoSmithKline identified another class of GSK-3 i nhibitors in 2003 (Table 8). The precursor \nwas identified by a pharmacophore search of the in house database. The compounds 65-67  \nwere profiled against a panel of 25 kinases includi ng GSK-3 \u03b2. \n \nTable 8: Examples of pyrazolamide inhibitors with biological  activity against GSK-3, selectivity, X-Ray and ref erence.  \n \n \nNo. X Y Z R1 R2 R3 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n65 C N CH H Ph Propyl \u03b1: 56 \u03b2 + 24 - - 2003 83  \n66 C N CH H 2-F-Ph Propyl \u03b1: 18 \u03b2 + 24 - - 2003 83  \nXYZ\nN\nHNNH\nR2\nR1R3\nO \nSeite 57 67 C N CH H 3-Pyridyl Propyl \u03b1: 11 \u03b2 + 24 - - 2003 83  \n68 N N CH - Ph Propyl \u03b1: 4 \u03b2 + 24 - PDB \nn.p. a 2003 84  \n69 N CH CH - Ph Propyl \u03b1: 7 - - - 2003 84  \n70 N N CH - Ph  \u03b1: 22 \u03b2 + 24 - PDB \nn.p. a 2003 84  \n71 C N CH Ph H  \u03b1: 425 - - - 2003 85  \n72 C N CH Ph-4-OMe H  \u03b1: >5000 - - - 2003 85  \n73 C N CH Ph-4-OH H  \u03b1: 8 \u03b1 + 23 - PDB \nn.p. a 2003 85,86  \n74 C N CH Ph-4-OH Br  \u03b1: 0.8 \u03b1 + 23 - PDB \nn.p. a 2003 85,86  \n75 C N CH Ph Br  \u03b1: 75 \u03b1 + 23 - - 2003 86  \n76 C CH CH 5-Indolyl H  \u03b1: 42 \u03b1 + 1 - - 2003 86  \n77 C N CH 2-Furyl Br  \u03b1: 7 \u03b2 + 23 - - 2003 86  \n \n \nNo. IC 50 /K i (nM): Kinase \nPanel: In Vivo X-Ray Ye \nar/\nLit. \n78 \u03b1: 2.3 \n\u03b2: 2.0  \u03b1 & \u03b2 + \n27 Yes - 200 \n987  \na Not published as PDB; \u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \nAn excellent selectivity was obtained against the m ajority of the kinases. However, a \nsignificant inhibition of CDK2/cyclin A was reporte d. 83  Compounds  68  and 69  displayed \nimproved potency, but nevertheless inhibit CDK2/cyc lin A. Only compound 70  showed an \nexcellent GSK-3 potency and improved CDK-2/cyclin A  selectivity. 84  The IC 50  comparison of \ncompounds 71-73  revealed that the Ph-4-OH motif is the best. The m ost potent inhibitor 74 \n(IC 50 = 0.8 nM) was tested against a panel of kinases and  showed a reduction in the overall \nselectivity profile. 85,86  Compounds 75-77 showed an excellent selectivity against CDK-2/cycli n \nA. In addition, compound 77 demonstrated an excellent overall selectivity profi le against all N\nNHN\nN\nHO\nO\nHN\nO\nN \nSeite 58 kinases of the panel. 86  Unfortunately, no further studies were published c oncerning this \nseries. Takeda Pharmaceutical disclosed compound 78  in 2009. It is a very potent inhibitor of \nGSK-3 with an IC 50  of 2.3 nM for GSK-3 \u03b1 and 2.0 nM for GSK-3 \u03b2. It had no inhibitory effect \non 23 kinases, and only a weak inhibition was detec ted for CDK1/cyclin B, CDK2/ cyclin A, \nCDK5 and JNK1. The cold-water stress model (CWS) wi th male C57BL/6Njcl mice was used \nto evaluate the in vivo  efficacy of compound 78 . CWS transiently induces in  vivo tau \nhyperphosphorylation as reported in previous studie s. The compound displayed highly potent \ninhibition of in vivo  phosphorylation in CWS mice and reduced sarkosyl i nsoluble tau in old \nhomozygous JNPL3 mice. Furthermore, compound 78  inhibited tau phosphorylation at  \nGSK-3 directed sites in rat primary neuronal cells and mouse brain tissue.87  Several \nstructures containing a pyrazole core have shown pr omising results in animal models of \ndiabetes, for structural information see denoted re ferences. The pyrazolamides developed by \nWyeth-Ayerst Research, now Pfizer, showed significa nt plasma glucose lowering activity (16-\n42% reduction) in genetically obese, diabetic db/db  mice. 88,89  Novartis published a series of \ncompounds with ED 50  values for glucose reduction in ob/ob mice of 3.0 mg/kg/day.90  In 2011 \nthe Merck Research Laboratories disclosed a potent human glucagon receptor antagonist \nwith good pharmacokinetic profiles in four preclini cal species. One of these compounds \nshowed excellent oral pharmacodynamic efficacy in r hesus monkeys and transgenic mice by \nblocking glucagon-induced hyperglycemia. 91   \n \n \nPyrimidine and furopyrimidine derivatives \n \nGSK-3 inhibitors bearing the pyrimidine moiety are listed in Table 9 and 10. This series is \n \nTable 9: Examples of pyrimidine inhibitors with biological a ctivity against GSK-3, selectivity, X-Ray and refer ence.  \n \n \nNo. R1 R2 R3 R4 IC 50 /K i (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n79 \n  H \u03b2: 2.5 a - Yes - 2004 92  N\nNR4R1R2R3\nNN\nOSO\nONHN \nSeite 59 80 \n  H \u03b2: 100 a - Yes 1GNG c 2001, \n2004 29,92  \n81 \n  H \u03b2: 4.0 a - Yes 1GNG c 2001, \n2004 29,92  \n82 \n H \n \u03b2: 2400 a - - - 2008 93  \n83 \n H \n \u03b2: 1700 a - - - 2008 93  \n84 \n H \n \u03b1: 1020 a \n\u03b2: 960 a - - - 2008 93  \n85 \n H \n \u03b1: 1900 a \n\u03b2: 760 a - - - 2008 93  \n86 \n H \n \u03b1: 350 a \n\u03b2: 180 a - - - 2008 93  \na IC 50  value; b Ki value; c Docking studies, PDB code (n.d.: not denoted) ; \u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \ncharacterized by a high number of patent applicatio ns, particularly by Vertex \nPharmaceuticals. 94-119  Compounds 79  and 81 inhibited GSK-3 \u03b2 in the nanomolar range. The  \nin silico  docking of compound 80  into the ATP-binding pocket of GSK-3 \u03b2 suggested that 80   \n \nTable 9: Continued. \n \n \nNo \n. R1 R2 R3 R4 IC 50 /K i \n(nM): Kinase \nPanel: In \nVivo X-Ray  Year/ \nLit. \n87 \n H \n \u03b1: 6700 a \n\u03b2: 3500 a - - - 2008 93  NN\nNNHN\nNN\nH\nN\nNNNHN\nNN\nONH\nNN\nO NH\nNNO\nNH\nHOO\nNNONH\nHOO\nNNCl\nNH\nHOO\nN\nNR4R1R2R3\nNH\nNO NH\nHOO \nSeite 60 88 \n NO 2 H \n \u03b1: 270 a \n\u03b2: 150 a - - - 2008 93  \n89 \n CF 3 H \n \u03b1: 750 a \n\u03b2: 490 a - - - 2008 93  \n90 \n H \n \u03b1: 330 a \n\u03b2: 628 a \u03b1 & \u03b2 \n+ 1 - 1Q5K c 2008 93  \n91 \n NO 2 H \n \u03b1: 74 a \n\u03b2: 92 a \u03b1 & \u03b2 \n+ 1 - - 2008 93  \n92 \n H \n \u03b1: 9 a \n\u03b2: 13 a \u03b1 & \u03b2 \n+ 1 - - 2008 93  \n93 \n CF 3 H \n \u03b1: 61 a \n\u03b2: 41 a \u03b1 & \u03b2 \n+ 1 Yes - 2008 93  \n94 H Me \n  GSK-3: \n7b GSK-3 + \n4 - 3I4B 2009 120  \n95 \n  H \n \u03b1: 10 \n\u03b2: 6.7 a \n(9.8 b) \u03b1 & \u03b2 \n+ 20 Yes - 2003, \n2007 35,121  \n96 \n  H \n \u03b1: 0.65 \n\u03b2: 0.58 a \n(0.87 b) \u03b1 & \u03b2 \n+ 20 Yes - 2003, \n2007 35,121  \na IC 50  value; b Ki value; c Docking studies, PDB code (n.d.: not denoted) ; \u03b1 = GSK-3 \u03b1; \u03b2 = GSK-3 \u03b2. \n \nmakes two hydrogen bonds with the hinge region and one interaction with the positively \ncharged Arg141. 29,92  Unfortunately, the activity of these compounds in a kinase panel was \nnot disclosed. The compounds 82-90  are weak inhibitors of GSK-3 and there are no publ ic \ndata for in vivo  activity nor selectivity. Docking of 90  into the PDB structure 1Q5K of GSK-3 \u03b2 \nsuggested that one nitrogen and the secondary amine  form hydrogen bonds to the hinge \nregion at the Val135 NH and carbonyl, respectively.  The following compounds 91-93  showed \nIC 50  values below 100 nM, but 91  and 92 inhibit Aurora A in the nanomolar range. Derivative  \n93  (GSK-3\u03b1 IC 50 = 61 nM, GSK-3 \u03b2 IC 50 = 41 nM) inhibited Aurora A at micromolar  \n HNNH\nHOO\nHNNH\nHOO\nNN\nN NH\nHNNH\nOO\nOH\nNN\nNNH\nOO\nOH\nHOHNNH\nOH\nN\nHO\nNHHONH\nCl ClNH\nNN\nCNH\nNN\nH\nCl ClNH\nNN\nNO2H\nNN\nHNH2 \nSeite 61 Table 10: Examples of furopyrimidine inhibitors with biologic al activity against GSK-3, selectivity, X-Ray and r eference.  \n \n \nNo. R1 R2 R3 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n97  H \n \u03b2: 5 \u03b2 + 2 Yes - 2004 122  \n98  H \n \u03b2: 32 \u03b2 + 2 - - 2004 122  \n99  H \n \u03b2: 23 \u03b2 + 2 Yes - 2004 122  \n100  H \n \u03b2: 5 \u03b2 + 24 Yes PDB \nn.d. a 2004 122  \n101  \n NH 2 \u03b2: 30 \u03b2\b + 9 Yes PDB \nn.d. a 2008 123  \n102  \n NH 2 \u03b2: 23 - - - 2008 123  \na Docking studies, PDB code (n.d.: not denoted);  \u03b2 = GSK-3 \u03b2. \n \nconcentration only. In vivo  studies of this compound in rats showed 34% oral b ioavailability \nand good exposure. 93  Compound 94, a lead compound for ERK2 inhibition, is a non-selec tive \nGSK-3 inhibitor and inhibited all 5 kinases in the panel, which included GSK-3.120  The \ncomplex of compound 94  with GSK-3 \u03b2 (Figure 11) provided the binding mode in the \n \n \n \n \n \n \n \n \nFigure 11 . Compound 94  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The distance \nis denoted in \u00c5. PDB code 3I4B. 120   NNO\nR3R1\nR2\nNN\nHO\nON\nHO\nN\nHO\nNN\nHO\nNNH\nSOO\nNNH\nSOO\nS\n \nSeite 62 ATP pocket of GSK-3. The secondary amine interacts with the carbonyl oxygen of Val135 \nand the nitrogen of compound 94  with the backbone NH of Val135. Two additional \ninteractions are present between OH and Asp200 and between the carbonyl and the primary \namine of Lys85. The arylimidazoles 95 (CHIR 99021 ) and 96 (CHIR 98014 ) are very effective \nATP competitive inhibitors of murine and rat GSK-3 (IC 50  < 10 nM). Both compounds \nexhibited 500 to 10000-fold selectivity for GSK-3 v ersus 20 other kinases tested. These \nGSK-3 inhibitors rapidly lower blood glucose levels  in diabetic rodent models and enhance \nglucose transport as well as GS activation in insul in-resistant oxidative skeletal muscle from \ntype 2 diabetic rats. 121  The nitropyridine 96  exerts a very potent reduction of Ser 396  tau \nphosphorylation in a human neuronal cell line. P12 rats were injected i.v. with  \n30 mg/kg of CHIR 98014  (96, dissolved in DMSO) to test the efficacy on tau phos phorylation \nin vivo , resulting in a maximal brain concentration of 7 \u00b5 M. Tissue analysis by western \nblotting using a p-tau Ser 396  antibody showed approximately 40% reduction in the  \nphosphorylation of 43 kDa and 49 kDa tau in the cor tex and a significant 3-fold reduction of \nthe 43 kDa isoform in the hippocampus. Moreover, a 50% reduction of GSK-3 \u03b2 activity was \nobserved in compound 96 treated animals versus vehicle. 35  The denoted furopyrimidines 97-\n102  inhibited GSK-3 \u03b2 with an IC 50  below 40 nM (Table 10). Compound  100  (GSK-3\u03b2 \nIC 50  = 5 nM) displayed excellent selectivity against 24  kinases, including CDK2/cyclin A, \nwhich was inhibited with an IC 50 of 0.46 \u00b5M. Compound 100  was examined in a glycogen \naccumulation assay in L6 cells and exhibited excell ent induction of glycogen accumulation \n(EC 50  = 0.39 \u00b5M). 122  Compound 101  was also profiled by cross screening against a var iety of \nkinases and showed an excellent overall selectivity  against all kinases tested including \nCDK2. The docking of 101  into the ATP-binding site of GSK-3 \u03b2 provided a likely interaction. \nOne nitrogen and NH 2 of aminopyrimidine are anchored to the carbonyl mo iety and NH of \nVal135 via hydrogen bond interactions. The 3-pyridi ne moiety is located close to Lys85 of the \nconserved salt bridge (Lys85/Glu97). The EC 50  value of compound 101  in the glycogen \naccumulation assay in L6 cells was 3.2 \u00b5M and thus 9-fold higher than for compound 100 .123   \n \n \nOxadiazole derivatives \nThe Tables 11-13 list GSK-3 inhibitors featuring th e oxadiazole moiety. The depicted  \n1,2,5-oxadiazoles, 103-109 , revealed IC 50  values from 0.1 \u00b5M to more than 1.1 \u00b5M. \nCompounds 104-106  were screened for inhibitory activity against a pa nel of 32 kinases at  \n  \n  \nSeite 63 Table 11: Examples of 1,2,5-oxadiazole inhibitors with biolog ical activity against GSK-3, selectivity, X-Ray and  reference.  \n \n \nNo. R1 R2 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n103 NH 2 \n \u03b2: 410 - - - 2003 124  \n104 NH 2 \n \u03b2: 100 \u03b2 + 31 Yes - 2003 124  \n105 NH 2 \n \u03b2: 1160 \u03b2 + 31 Yes - 2003 124  \n106 NH 2 \n \u03b2: 280 \u03b2 + 31 Yes - 2003 124  \n107 NH 2 \n \u03b2: 210 \u03b2 + 3 - - 2009 125  \n108 NH 2 \n \u03b2: 240 \u03b2 + 3 - - 2009 125  \n109 NH 2 \n \u03b2: 290 \u03b2 + 3 - - 2009 125  \n\u03b2 = GSK-3 \u03b2 \n \n100 \u00b5M ATP concentration. All compounds gave at lea st 100-fold selectivity for GSK-3 \ncompared to CDK2. However, 10 \u00b5M of compound 104  inhibited other kinases like MSK1 \nand DYRK1A, the latter activity is of interest for neurodegenerative diseases. The above \nmentioned compounds 104-106  displayed both sufficient cell penetration and sui table water \nsolubility. 124  The dioxolane 110  was identified as GSK-3 \u03b2 inhibitor (IC 50  = 65 nM, Table 12) \nby high throughput screening. The X-ray analysis of  the GSK-3 \u03b2 co-crystallized compound  \n \n \n N N\nOR1R2\nNNN\nN\nON\nHNN\nNNN\nN\nON\nHNN\nNNN\nN\nON\nHN\nNNN\nN\nNNH\nN\nNN\nNN\nNN \nSeite 64 Table 12: Examples of 1,3,4-oxadiazole inhibitors with biolog ical activity against GSK-3, selectivity, X-Ray and  reference.  \n \n \nNo. R1 R2 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray Year/ \nLit. \n110 \n  \u03b2: 65 - - 3F7Z 2009 126  \n111 \n  \u03b2: 44 - - - 2009 126  \n112 \n  \u03b2: 3.1 - - - 2009 126  \n113 \n \n \u03b2: 3.5 - - - 2009 126  \n114 \n \n \u03b2: 2.3 \u03b2 + 23 Yes 3F88 2009 126  \n115 Me \n \u03b2: 140 - - - 2009 127  \n116 Me \n \u03b1: 37; \n\u03b2: 34 (53) a \u03b2 + 22 Yes 3GB2 2009, \n2011 127,128  \n117 Me \n \u03b2: 190 - - - 2009 127  \n118 Me \n \u03b2: 20 \u03b2 + 22 Yes - 2009 127  \n119 \n  \u03b2: 17  \u03b2  + 1 Yes 1UV5 b 2010 129  \n120 \n  \u03b2: 53  - - - 2010 129  \n121 \n  \u03b2: 18 - - - 2010 129  NN\nOR1R2\nS\nOF\nOO\nS\nOF\nO\nS\nOF3C\nNS\nSNC\nOO\nSNC\nNNO\nOSO\nOSO\nOSO\nOSO\nH\nN\nClNO2\nHN\nOCF3\nHN\nOCN \nSeite 65 122 \n  \u03b2: 7 - - 1UV5 b 2010 129  \na Results of different publications; b Docking studies, PDB code (n.d.: not denoted);  \u03b2 = GSK-3 \u03b2. \n \nconfirmed the interaction with the ATP-binding site  (Figure 12). One oxygen and a \nneighbouring hydrogen atom of the benzodioxole esta blish hydrogen bonds with the amide \nNH hydrogen and carbonyl oxygen of Val135 in the hi nge region.  \n \n \nFigure 12 . Compound 110  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The \ndistance is denoted in \u00c5. PDB code 3F7Z. 126   \n \nThe nitrogen atoms of the oxadiazole engage in  an unique hydrogen bond relay network \nbetween Lys85-Glu97-Asp200 via two water molecules (Interactions not shown). Further \ninteractions are denoted in Figure 12. After an ext ensive derivatisation, e.g. 111-114 , \ncompound 114 (Figure 13) exerts a 28-fold increased activity (GS K-3\u03b2 IC 50  = 2.3 nM) \ncompared to its homologue 110  (Table 12). The selectivity of 114  was evaluated in a panel of \nmore than 20 kinases to reveal more than 1000-fold selectivity against CDK1, CDK2 and \nCDK5. In addition, rat cassette dosing experiments of compound 114 were performed, which \nrevealed low oral bioavailability.  \n \n \n \n \n \n HN\nONO2\n \nSeite 66 Table 13: Examples of 1,2,4-oxadiazole inhibitors with biolog ical activity against GSK-3, selectivity, X-Ray and  reference.  \n \n \nNo. R1 R2 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n123 \n  \u03b2: 350 \u03b2 + 8 Yes - 2008 130  \n124 \n  \u03b2: 410 \u03b2 + 8 Yes - 2008 130  \n125 \n  \u03b2: 690 \u03b2 + 8 Yes - 2008 130  \n126 \n  \u03b2: 710 - Yes - 2008 130  \n127 \n  \u03b2: 1130 - Yes - 2008 130  \n\u03b2 = GSK-3 \u03b2. \n \n \nFigure 13.  Compound 114  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The \ndistance is denoted in \u00c5. PDB code 3F88. 126   \n N\nN\nOR1R2\nH\nN\nONNN\nH\nN\nONNO\nN\nH\nN\nONNN\nH\nN\nONNN\nH\nN\nONNN\n \nSeite 67 The co-crystal structure of 114  bound to GSK-3 \u03b2 was not fully characterized due to the \ncleavage of the S-C bond in the X-ray beam (Figure 13). 126  The co-crystal structure indicated \nthat the nitrogen of the benzimidazole forms a hydr ogen bond with the backbone NH of the \nhinge region at Val135 and one nitrogen of the oxad iazole ring makes a hydrogen bond with \nthe NH of Asp200. The hydrogen atom on the carbon o f the benzimidazole made an \nadditional hydrogen bond with the carbonyl oxygen o f Val135. 126  The compounds 115  and \n116  are enantiomers just as compounds 117  and 118 . The S-isomers 116  and 118 were \nfound to be eutomers. It was reported that the S-is omers possessed good oral absorption in \nnon-fasted Crl:CD(SD)IGS rats with a bioavailabilit y of 72.8% for derivative 116  and 65.5% \nfor derivative 118 . Furthermore, the compounds exhibited favourable b lood-brain barrier \n(BBB) permeability. Compounds 116  and 118  were tested for inhibitory activity against more \nthan 20 kinases and displayed no significant activi ty. This indicates that these compounds \nare highly selective GSK-3 inhibitors. The binding mode of 116  in the ATP pocket of GSK-3 \u03b2 \nhas been determined by X-ray crystallographic analy sis (Figure 14). 127  One of the nitrogen \natoms of the oxadiazole was revealed to interact vi a a hydrogen bond with the  \n \n \nFigure 14.  Compound 116  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The \ndistance is denoted in \u00c5. PDB code 3GB2. 127   \n \nside chain of Lys85 and the other with Asp200. The oxygen atom and one carbon hydrogen \nof the benzofuran ring interact with the main chain  of Val135. Another interaction was \nobserved between one carbon hydrogen and the carbon yl of Asp133. Derivatives 116  and \n118  were tested in vivo  using the CWS model in mice. Here, tau phosphoryla tion was \ninduced at several GSK-3 \u03b2 directed sites such as Ser199, Thr205, Thr231 and Ser396 in \nmice. As reported, tau phosphorylation was signific antly reduced by 35% for compound 116  \nand 38% for compound 118 .127  Compound 116  was further investigated and revealed \nsignificantly decreased hippocampal tau phosphoryla tion as well as suppression of tau \npathology without affecting amyloid \u03b2 pathology. 128   \n \nSeite 68 A multistage virtual screening of 289903 molecules resulted in 59 hits of potential GSK-3 \u03b2 \ninhibitors, e.g. compound 119 . Biological tests confirmed the IC 50  of 17 nM and good \nselectivity versus CDK2. It crosses the BBB and has  a good hepatic glycogen effect in mice. \nThe derivatisation, e.g. 120-122 , of compound 119  lead to compound 122  with an IC 50   \nof 7 nM. Surprisingly, docking experiments of compo und 122  revealed a different binding \nmode in comparison to the co-crystallized oxadiazol es 110 , 114  and 116 . The in silico  \ndocked oxadiazole motif coordinates to the GSK-3 \u03b2 \bhinge region, Val135, Tyr134 and \nAsp133, instead of binding to the polar region, Lys 85, Cys199 and Asp200. 129   \nThe last denoted oxadiazoles are the 1,2,4-oxadiazo les 123-127 , which  exert moderate \ninhibition of GSK-3 \u03b2 only (Table 13). A subset of these oxadiazoles ( 123 -125 ) exhibited weak \ninhibition of Pim-1 and no detectable inhibition to wards seven other kinases tested at  \n10 \u00b5M concentration. 130   \n \n \nThiazole derivatives \n \nThe benzothiazoles 128  and 129 (Table 14) are non-selective GSK-3 inhibitors and s howed \nmoderate activity against CDKs. 131 This stands in contrast to the thiazolylurea 130   \n(AR-A014418 ), which strongly inhibited GSK-3 (IC 50 = 104 nM) but not any other kinase in \nthe panel. \n \nTable 14: Examples of thiazole inhibitors with biological act ivity against GSK-3, selectivity, X-Ray and referen ce.  \n \n \nNo. R1 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n128 \n \u03b1/\u03b2: 130 \u03b1/\u03b2 + 2 - 1J1B b 2008 131  \n129 \n \u03b1/\u03b2: 560 \u03b1/\u03b2 + 2 - - 2008 131  \n \n N\nSR1\nN\nNO\nHN\nNH\nHN\nNH\nN \nSeite 69  \nNo. R2 R3 IC 50 /K i (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n130 \n NO 2 \u03b2: 104 b (38 c) \u03b2 + 26 Yes 1Q5K 2003, 2005, \n2007 35,132,133  \na Docking studies, PDB code; b IC 50  value; c Ki value; \u03b1/\u03b2 = GSK-3 \u03b1/\u03b2; \u03b2 = GSK-3 \u03b2. \n \nAR-A014418  inhibited tau phosphorylation in transfected 3T3-f ibroblasts in a dose-\ndependent fashion exhibiting an IC 50  of 2.7 \u00b5M. The neuronal loss was reduced in the \norganotypic culture (N2A cells) and compound 130  by itself did not affect neuronal viability. \nThe co-crystal structure analysis of AR-A014418  and GSK-3 \u03b2 revealed that this compound \nbinds to the hinge region via three hydrogen bond i nteractions (Figure 15). 132  Furthermore, \n \n \nFigure 15.  Compound 130  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The \ndistance is denoted in \u00c5. PDB code 1Q5K. 132  \n \ncompound 130  significantly reduced insoluble tau levels in the brainstem of JNPL3 mice \nwhen compared with vehicle treated animals. 133  Surprisingly, another research group \nreported that AR-A014418  showed no effect on the phosphorylation levels of neither 43 kDa \nnor 49 kDa tau in the cortex or hippocampus of post natal model rats. 35  Novel compounds \nbased on the scaffold of AR-A014418  were synthesized recently. They showed improved in \nvitro  activity and reduced toxicity in the wild-type zeb rafish embryo assay. 134   \n \n N\nSR2\nR3\nHN\nHN\nO O\n \nSeite 70 Miscellaneous heterocyclic derivatives with GSK-3 a ctivity \n \nTable 15 lists GSK-3 inhibitors featuring a benzimi dazole core. There are neither in vivo \nassays nor selectivity data published for these pot ential metal chelators 131-134 . However, \ncompound 134  (GSK-3\u03b2 IC 50  = 15 nM) was co-crystallized with GSK-3 \u03b2 (Figure 16).135   \n \n \nFigure 16.  Compound 134  in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The \ndistance is denoted in \u00c5. PDB code 2O5K. 135   \n \nTable 15: Examples of miscellaneous heterocyclic inhibitors w ith biological activity against GSK-3, selectivity,  X-Ray and reference.  \n \n \nNo. R1 R2 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n131 H  - - - 1I09 a 2007 135  \n132 H \n \u03b2: 580 - - - 2007 135  \n133 H \n \u03b2: 25 - - - 2007 135  \n134 Cl \n \u03b2: 15 - - 2O5K 2007 135  \nH\nN\nN\nR1R1OH\nHNO\nR2\nN\nHS\nOO\nN\nHS\nOO \nSeite 71  \n \nNo. R3 Ki (nM): Kinase \nPanel: In Vivo X-Ray Year/ \nLit. \n135 \n \u03b2: 5800 \u03b2 + 4 - PDB n.d. a 2008 136  \n136 \n \u03b2: 4100 \u03b2 + 4 - PDB n.d. a 2008 136  \n137 \n \u03b2: 1500 \u03b2 + 4 - PDB n.d. a 2008 136  \n \n \nNo. IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/ \nLit. \n138 \u2212 - Yes - 2005 137  \na Docking studies, PDB code (n.d.: not denoted); \u03b2 = GSK-3 \u03b2. \n \nHerein, the secondary amine interacts with the carb onyl oxygen of Val135 and the phenolic \nOH of 134  with the carbonyl of Asp133. Two more interactions  are established between the \nSO 2 of compound 134 and the arginines Arg141 and Arg220. The 1-aza-9-ox afluorenes 135-\n137  are moderately active GSK-3 \u03b2 inhibitors, but showed activity for CDKs. 136   \nThere is no report for an in vitro  IC 50 of the synthetic xanthine propentofylline  (PPF, \ncompound 138 ), but studies in the Tg mouse model of AD indicate d that PPF exerts a dual \neffect: reduction of both pathological amyloidogene sis and tau phosphorylation while \nreducing the ratio of activated versus inactivated GSK-3\u03b2.137  \n \n \n \n \n \n \n NOHO\nR3\nO\nO\nNH2\nO\nN\nN\nNNNO\nOO \nSeite 72 Table 15: Continued. \n \n \nNo. R1 R2 Ki (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n139 H \n \u03b2: 1490 - - 1Q3D b 2010 138  \n140 \n  \u03b2: 0.8 \u03b2  + 13 - - 2010 138  \n141 \n  \u03b2: 2 \u03b2  + 13 - - 2010 138  \n142 \n  \u03b2: < 2 - - 3L1S 2010 138  \n143 \n  \u03b2: 4.5 \u03b2  + 13 - - 2010 138  \n \n \nNo. IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n144 \u03b1: 34 \u03b2  + 39 Yes 1Q3D b 2011 139  \n \n \nNo. R3 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n145  \u03b2: 4200 - Yes 1Q4lb 2009 140  \n146 \n \u03b2: 6400 - - - 2009 140  \n147 SCH 2CH 3 \u03b2: 7800 - - - 2009 140  \n \n \nNo. R4 IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n148 \n \u03b2: 17.4  \u03b2 + 2 a Yes - 2011 141  NHN\nONH\nN\nR2R1\nCl\nO O\nO\nN\nO\nO Cl\nNO\nH\nN\nNHO\nN N\nHNH\nNO O\nR3\nN\nS\nNNNO\nR4\nON \nSeite 73 149 \n \u03b2: 8.5  \u03b2 + 2 a Yes - 2011 141  \n150 \n \u03b2: 16.1 \u03b2 + 2 a Yes - 2011 141  \na Further it was noted that the compound was screene d against a broad panel of kinases;  b Docking studies, PDB code; \u03b2 = GSK-3 \u03b2. \n \nThe pyrazolone 139  was identified as potential scaffold in a compound  screen for novel  \nGSK-3 inhibitors. Derivatisation has increased the potency of the derivatives (IC 50 ) from  \n1.49 mM to 0.8 nM.  \n \n \nFigure 17.  Compound 142 in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are show n. The \ndistance is denoted in \u00c5. PDB code 3L1S. 138   \n \nThe compounds 140 , 141  and 143  showed selectivity in a kinase panel of 14 kinases . A  \nco-crystallisation was realized with compound 142  (Figure 17) and provided the \ninteractions of the pyrazole moiety with the GSK-3 backbone amino acids Asp133 and \nVal135.  \n \n \n \n \n NOH\nN\nO\nO\n \nSeite 74 Table 15: Continued. \n \n \nNo. Name  IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n151 Manzamine A \u03b2: 10200 \u03b1 & \u03b2 + 4 Yes - 2007 142  \n \n \nNo. Name  IC 50  (nM): Ki nase \nPanel: In Vivo X-Ray  Year/Lit. \n152 Meridianin D \u03b2: 2500 \u03b2 + 5 Yes - 2004 143  \n \n \nNo. Name  IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n153 Hymenialdisine \u03b2: 10 \u03b2  + 31 Yes - 2000 144  \n \n \nNo. Name IC 50  (nM): Kinase \nPanel: In Vivo X-Ray  Year/Lit. \n154 Dibromocantharelline \u03b2: 3000  \u03b2  + 3 - 1H8F a 2010, 2011 144,145  \na Docking studies, PDB code; \u03b2 = GSK-3 \u03b2. \n \nIn addition, the methoxy substituents make hydrogen -bonding contacts with both Asp200 and \nLys85. These interactions and the hydrophobic conta cts of the phenyl rings are thought to be \nresponsible for the potency and selectivity. 138  A recent docking study of the pyrazolone 144  N\nHN\nNOH\nN\nH\nN\nNN\nNH2Br\nNH\nON\nHBrN\nHNOH2N\nNN\nHBrBr\nONHNNH2\nH \nSeite 75 confirmed the interactions of compound 142 with GSK-3 \u03b2. It is an active (IC 50  of 34 nM) and \nselective (kinase panel of 40 kinases) structural a nalogue to the previously described \nmaleimides 9-27  (Table 2 and 3). Furthermore, compound 144  was evaluated in a model of \noxidative stress induced by homocysteic acid and di splayed full neuroprotective activity at  \n1 \u00b5M. Additionally, it was able to reduce locomotor ac tivity in the chlordiazepoxide/ \namphetamine-induced hyperactivity model in vivo .139  The compounds 145-147  are moderate \nGSK-3 inhibitors and were not tested against other kinases to evaluate their selectivity. \nCompound 145  increased the glycogen content in the liver of Spr ague-Dawley rats in a dose-\ndependent manner. 140   \nCompound 1  is a HTS hit, which was co-crystallized with GSK-3 \u03b2 and solved by X-ray \ncrystallography (Figure 18). The overlap of the inh ibitor Compound 1  with a pyridone \nderivative revealed interactions with the catalytic  triad, especially Lys85, and the protein \nbackbone amino acid Val135 of GSK-3 \u03b2.26,141  This leads to the latest ATP competitive  \nGSK-3 inhibitors, the pyridones 148-150 . Compound 150  revealed potent in vitro  inhibition \nwith an IC 50  of 16.1 nM against GSK-3 \u03b2. It was selective in a broad panel of kinases, \nincluding CK2 and CLK1. Compared to compound 148 , compound 150  exhibited an \nimproved in vitro  human liver microsome intrinsic clearance value of  16.3 mL/min/kg. The in \nvivo  CNS penetration assay demonstrated a good free bra in to free plasma ratio and the \nassessment of potential genetic toxicology hazards was negative for compound 150 .141  Last  \n \n \nFigure 18.  The HTS hit named Compound 1 in the ATP binding pocket of GSK-3 \u03b2; important protein-inhibitor interactions are \nshown. The distance is denoted in \u00c5. PDB code 3Q3B.141   \n \nbut not least, there were several GSK-3 inhibitors isolated from marine organisms. These \nalkaloids have the potential to provide new scaffol ds comparable to the established \nindirubines. Manzamines, meridianins, hymenialdisine  and dibromo-cantharelline  inhibit \n \nSeite 76 GSK-3\u03b2 in the \u00b5M range and display promising selectivity and in vivo  results (Table 15, \ncompound 151-154 ). 142-145   \n \n \nActivity and selectivity profiling \n \nA plethora of GSK-3 inhibitors was discovered in re cent years and most of these displayed \ngood to excellent inhibition of this kinase. Howeve r, selectivity and safety against other \nkinases remains to be a challenge. The structural a nalysis of the ATP competitive inhibitors \nmay guide the development of more selective GSK-3 i nhibitors. All ATP competitive inhibitors \nestablish hydrogen bonds with the backbone atoms of  Asp133 and Val135. Contact to these \namino acids is a key to enhance affinity to GSK-3 b ut it does not provide selectivity over \nother kinases. Moreover, Pro136 appears in several complexes to strengthen the interaction \nof the inhibitor with the backbone (Figure 19). One  region of GSK3 may offer privileged \naccess to enhanced activity and selectivity: it is the region characterized by the \namino acids Lys85, Glu97 and Asp200. Lys85 was obse rved to form a salt-bridge with Glu97 \nand simultaneously with Asp200, which is expected t o be less significant and potent as the \none with Glu97. 146   \n \nFigure 19.  Schematic view in the ATP binding pocket of GSK-3 \u03b2; Important areas for activity and selectivity are denoted; PDB \ncode 1I09. 147   \nThe interaction of an inhibitor with this region ho lds potential to increase activity and \nselectivity for GSK-3. This interaction can be medi ated via water molecules, as observed for \nAR-A014418  (130 ), or be established by direct contact. We observed  in our dataset that a \n \nSeite 77 direct interaction with this region may cause a los s of selectivity (data not shown). There is a \nsalt-bridge formed by Glu137 and Arg141  in the entrance area of the ATP pocket of GSK-3 \u03b2. \nThis region seems to contribute to the activity and  selectivity of several inhibitors. \nAnother important interaction between GSK-3 and an organometallic inhibitor was reported \nby Bregman et al. They observed a water-mediated contact between th e carbonyl ligand of \nthe inhibitor and the carboxylate of Gln185. 61  This water molecule was also found in other \nGSK-3\u03b2 inhibitor complexes and seems to be responsible fo r an increased activity and \nespecially for an improved selectivity towards GSK- 3. \nDocking studies with our inhibitors confirmed this interaction and further explain the \nselectivity of these inhibitors (data not shown). F eng et al. observed that the ruthenium-\ncoordinated CO ligand of their inhibitor interacts with the flexible glycine-rich loop formed by \nIle62, Gly63, Phe67 and Val70. This pocket, which i s not shown in Figure 18, seems to be \ncrucial for potency and selectivity. 22  Figure 19 illustrates in a simple scheme how to en hance \nactivity and selectivity of inhibitors. The interac tion with at least two of the three areas deems \nnecessary to provide active and selective inhibitor s. \n \n \nExamples of in vivo  tests \n \nOver the last decade, several animal models have be en developed to study tauopathies and \nother neurodegenerative disorders in vivo . Despite some obvious advantages of the diverse \nAD invertebrate systems, the vertebrate animal mode ls of AD are generally favoured (for \ndetailed invertebrate reviews, see following ref. 148-150 ). Vertebrate models are evolutionary \nand morphologically closer related to humans, which  makes the direct translation of \nexperimental results easier and more reliable. A co nditionally GSK-3 \u03b2 overexpressing mouse \nwas reported by Lucas et al.  in 2001. They demonstrated that GSK-3 \u03b2 overexpression in vivo  \nresults in neurodegeneration and proposed that thes e mice can be used to study some \naspects of AD. 151  In 2005 P\u00e9rez et al.  and Ribe et al. developed and characterized a double \ntransgenic mouse line based on overexpression of hu man mutant APP and tau. 152,153  They \ntreated this transgenic mouse model with NP12 , a non-ATP competitive GSK-3 \u03b2 inhibitor, \nand observed lower levels of tau phosphorylation, d ecreased amyloid deposition and \nprevention of memory deficits. 18  The APP-V7171 x Tau-P301L mice with combined amylo id \nand tau pathology and the GSK-3 \u03b2 x Tau-P301L mice with tauopathy only were reported  by \nTerwel et al. in 2008. These models offer the possibility to ex plore molecular signals that act \nupstream and downstream of, or in parallel with GSK -3 isozymes. 154  Two transgenic mice \nmodels were developed to study the interaction betw een APP or A \u03b2 and tau: the triple- \nSeite 78 transgenic model (3 x Tg-AD) harboring PS1 M146V , APP Swe  and tau P301L  transgenes and the \nTAPP mice. 155,156  The transgenic mice have been the major species us ed for modelling AD \nand frontotemporal dementia (FTD). JNPL3 mice are w ell characterized transgenic mice that \nexpress human 4R0N tau with a FTDP-17 (P301L) mutat ion. 157  In particular, the levels of \nsarkosyl insoluble tau in JNPL3 mice increase in an  age-dependent manner and co-migrate \nwith insoluble tau from AD and FTDP-17 brains. Thus , treatment with GSK-3 inhibitors \nshould result in a significant reduction of sarkosy l insoluble tau, see for example compound \n78 .87,133  Besides JNPL3 mice the transgenic zebrafish larvae  have advanced as an AD model \nsystem. It combines many of the advantages of inver tebrate and vertebrate models. The \nlatest model is a Gal4/UAS-based vector system that  efficiently generates transgenic \nzebrafish overexpressing high levels of human Tau-P 301L or other disease-associated \nproteins. This tau-transgenic fish model could be a n effective in vivo  screening tool to identify \nquickly promising GSK-3 inhibitors and eliminate co mpounds without reasonable in vivo  \nactivity early in the screening process. 158,159   \nGSK-3 inhibitors have also specific effects on earl y wild-type zebrafish development when \ntreatment occurs between 4 and 24 hpf. Thus this an imal model can be used to test the \nefficacy of GSK-3 inhibitors in vivo .134,158  Furthermore, there are two in vivo model systems \nwith transiently induced tau hyperphosphorylation t hat were used to evaluate the activity of \nGSK-3 inhibitors. One of them is the cold-water str ess (CWS) model, which causes a rapid \nand reversible enhancement of tau phosphorylation i n the mouse brain at several GSK-3 \u03b2 \ndirected sites such as pS199, pThr205, pThr231 and pSer396. 126,160  The CWS-model proves \nthe significant reduction of tau phosphorylation in  LiCl- or compound 78  treated mice.87,161  \nThe in vivo  activities of several other GSK-3 inhibitors (e.g.  compound 55  and 96 ) were \ndemonstrated in the postnatal rat model. 35  This in vivo  model takes advantage of the well \ncharacterized GSK-3 \u03b2 expression level in the early and later life cycle  of rats. 162,163   \n \n \nCompounds in Preclinical and Clinical Trials \nCurrently several GSK-3 inhibitors pass through pre clinical or clinical trials. Subsequently \nGSK-3 inhibitors are listed with the therapeutic in dication AD. These examples are taken \nfrom the database of PharmaProjects by searching fo r the criteria GSK-3 and Alzheimer \n(March 2010), the MED-D report of GESENT (May 2009)  and ClinicalTrials.gov (August \n2011). \nThe Wayne State University is currently in phase IV  with Lithium carbonate  against bipolar \ndisorder whereas the University of Sao Paulo is in phase II with Lithium carbonate  against \nGSK-3 for AD and cognitive impairment. Lithium  against AD was submitted by the National  \nSeite 79 Institute of Neurological Disorder and Stroke and i s in phase II, but there was no update \nsince March 2008. Two compounds from Noscira, NP-12  (TDZD) and NP-103 , are in the pre-\n/clinical trials. NP-12 (NP031112 , Tideglusib ) is currently in a phase IIb clinical trial for AD . \nAt the moment NP-103 , CG-301338  from CrystalGenomics and a GSK-3 \u03b2 inhibitor from \nTakeda are in preclinical trials. The development s tatus of XD-4241  from Cambrex,  \nSB-415286  from GlaxoSmithKline, a GSK-3 \u03b2 inhibitor from Amphora, SAR-502250  from \nSanofi-Aventis, CEP-16805  from Cephalon and a GSK-3 \u03b2 inhibitor from Lundbeck are not \nreported. The failure or progress of these compound s into preclinical and clinical trials will \nstimulate or discourage further research. \n \n \nSummary \n \nThe moderate inhibition of GSK-3 by selective inhib itors with excellent pharmacokinetic \nproperties and excellent blood-brain barrier permea tion holds high potential for the treatment \nof AD. The failure of the first potent GSK-3 inhibi tor by Astra-Zeneca indicates the complexity \nof this target and the therapeutic window of GSK-3 inhibition in adult mammals. Information \non the failure is rather limited, it may be due to potential toxicity of the chemical scaffold: \nP450 mediated metabolism of thiazoles has resulted in hepatotoxicity and thus failure of \nphase III candidates previously. \nBiological characterization has advanced GSK-3 as a  potential drug target, and the inhibition \nof this protein kinase by small molecules resulted in significant inhibition of tau \nphosphorylation. We have described a wide range of molecules that inhibit GSK-3 and \ndiscussed their properties. We focused on several i nhibitors interacting with the ATP-binding \npocket of GSK-3 \u03b2. The water molecule interactions are not incorpora ted in the figures, \nhowever they may play a crucial role in the hydroge n bond network between the inhibitor and \nthe amino acids. The amino acids, which are respons ible for strong interaction with the \nenzyme, have been identified. Noteworthy are Asp133 , Val135, Glu137, Arg141, Gln185, \nAsp200 and Arg220, which constitute important amino  acids for interactions with the binding \npocket of GSK-3. The conserved salt bridge Lys85/Gl u97 materializes as an interesting \ninteraction partner. We summarized crucial biologic al findings and provided an overview on \nthe in vivo  effects of some inhibitors. Additional in vivo  assays can be retrieved via the \nreferences denoted in the tables next to the struct ures. We summarized the GSK-3 inhibitors, \nwhich are in pre-/clinical trials with the therapeu tic indication AD. Yet, a review will be biased \nand we request your pardon or input, if your favour ite inhibitor or in vivo  studies are not \nadequately referred to.  \nSeite 80 Outlook \n \nGSK-3 is an intriguing enzyme, which plays importan t roles in the pathogenesis of several \ndiseases, e.g. diabetes, cancer and AD. The literat ure is immense and quite often provides \nconflicting statements and observations for this ki nase. For example, a few studies observed \nthat Pin1 (peptidyl-prolyl cis-trans isomerase) kno ckout mice display tau \nhyperphosphorylation and that this enzyme might hav e an inhibitive role in phosphorylating \ntau and GSK-3 \u03b2, thus protecting against AD. 164  Whereas another study ascertained that the \nGSK-3 inhibitor BIO  (compound 39 ) may be useful in regenerative medicine, by revers ibly \nmaintaining human embryonic stem cells in an undiff erentiated state. 165  A plethora of GSK-3 \ninhibitors has been published since it has been lin ked to AD. Naturally, the vast majority \nthereof was reported by pharmaceutical companies. M any potent inhibitors with good \nselectivity have been disclosed so far. The challen ge of medicinal chemists will be to develop \ninhibitors, which translate their potent enzymatic inhibition into cellular settings and finally \nhumans, who will tolerate a moderate GSK-3 inhibiti on only. A mild GSK-3 inhibition (~35%) \nis needed, because such an inhibition level provide s sufficient insulin sensitization without \nelevation of \u03b2-catenin levels. Thus a moderate inhibition minimiz es significant mechanism-\nbased toxicities, ranging from hypoglycemia to tumo rigenesis. 166,167  A further indication of a \nmoderate GSK-3 inhibition is the application of lit hium for the treatment of bipolar disorder. \nThe GSK-3 inhibitor lithium is estimated to inhibit  approximately 25% of total GSK-3 activity. \nIt was used for the treatment of bipolar disorder s ince the 1950s without association of \nhypoglycemia, increased levels of tumorigenesis, or  deaths from cancer. 168  Nevertheless, the \nestablished in vivo studies have to be accompanied by the investigation  of pleiotropic activity \nand the determination of a safe therapeutic window for chronic GSK-3 inhibition in humans. \nThe X-ray analysis of co-crystallized structures re vealed how the inhibitors interact with the \nATP-binding pocket and provide information about es sential interaction partners to improve \npotency and selectivity. The comparison of the IC 50  values will be much easier, if only one \nstringent GSK-3 in vitro  assay would be utilized, which employs a defined f inal ATP and \ninhibitor concentration as well as a standardized i ncubation time. Currently, L. T. Alon et al. \ndetermined that GSK3 \u03b2 is responsible for the phosphorylation of the embr yonic tau isoforms \nin birds, which harbors the GSK3 \u03b2 gene only. In consideration of their and former st udies L. \nT. Alon et al.  assume that GSK3 \u03b1 and \u03b2 have distinct roles in phosphorylating tau in adul t \nand embryonic brain in non-vertebrates. Furthermore , they raise the hypothesis that specific \ninhibition of GSK3 \u03b1 may be useful for therapeutic intervention in AD.169  This supposition is \nenhanced by former siRNA experiments.170  But all GSK-3 inhibitors developed until now \ninhibit the two isoforms of GSK-3 equipotently, exc ept \u039b\u039b \u039b\u039b-OS1  (36 ) (~7-fold more selective for  \nSeite 81 GSK3 \u03b1). Still most of the GSK-3 inhibitors fail in model  animals despite of their good \ninhibitory activity in cell free assays. This is fr equently due to the lack of selectivity, \ninsufficient cell permeation and poor blood-brain b arrier permeability. Appropiate animal \nmodels were developed in transparent zebrafish to s tudy preclinical efficacy, metabolic \nstability and toxicity, but their potential is not fully exploited. These in vivo  tests are fast (3 \ndays), relatively inexpensive and suitable for larg er screening efforts in 96 well formats. \nFurthermore, it has been observed that resistance a rises during the therapy. The problem is \nthat most of the kinase inhibitors are ATP competit ive type-I-inhibitors. A new generation of \ntype-II-inhibitors, which binds to the ATP site and  extends into an allosteric site, may provide \na solution. 15,171,172  Such novel type-II-inhibitors must be active, sele ctive and permeate the \nhuman blood-brain barrier, which bears further limi tations for drug development. However, \nseveral pharmaceutical companies continue to develo p ATP competitive GSK-3 \ninhibitors. 173,174  Just a few pharmaceutical companies have started p re-/clinical trials \naddressing the druggability of GSK-3 inhibition. No scira launched the phase IIb trial ARGO of \nTideglusib  (NP-12 ) to treat mild-to-moderate AD patients in April 20 11. The trial period will \nbe 65 weeks with 2 dosage regimes of Tideglusib  (500 and 1000 mg/day oral suspension, \nClinicalTrials.gov Identifier: NCT01350362). The on going clinical trials may lead to a \nparadigm shift, if the GSK-3 inhibitors display eff icacy and safety.  \n \n \nAbbreviations \nAD   Alzheimer\u00b4s disease \nApoE   Apolipoprotein E \nAPP   amyloid precursor protein \nATP   adenosine triphosphat \nA\u03b2   \u03b2-Amyloid \nBBB   blood-brain barrier \nCDK   cyclin-dependent kinase \nCWS   cold-water stress \nDMSO   dimethyl sulfoxide \nDYRK1A  dual specificity tyrosine phosphorylation-r egulated kinase 1A \nEC 50    half maximal effective concentration \nERK   Extracellular signal-regulated kinase \nFAD   familial Alzheimer\u00b4s disease  \nSeite 82 FTD   frontotemporal dementia \nGESENT           Gesellschaft f\u00fcr experimentelle un d klinische  Neurotherapeutika \nGS   glycogen synthase  \nGSK-3   glycogen synthase kinase 3 \nHMK   halomethylketon \ni.v.    intravenous \nIC 50   half maximal inhibitory concentration  \nJNK   c-Jun N-terminal kinase \nKDR   kinase insert domain receptor \nMED-D  Medikamentenentwicklung f\u00fcr Demenzen in Deut schland \nMSK1   mitogen-and stress-activated protein kinase \nMTS  (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-met hoxyphenyl)-2-(4-\nsulfophenyl)-2 H-tetrazolium \nNFTs   neurofibrillary tangles \nPDB       Protein Data Bank \nPHFs   paired helical filaments \nPim-1           proto-oncogene serine/threonine-Pro tein kinase \nPin1   peptidyl-prolyl cis-trans isomerase \nPKC \u03b2II   protein kinase C \u03b2II \nPPF   Propentofylline \nPS-1/2   presenilin-1/2 \nRSK1   also known as RPS6KA1, ribosomal protein S6 kinase alpha-1 \nSAD   sporadic Alzheimer\u00b4s disease \ns.c.    subcutane \nTDZD   thiadiazolidine \nVEGFR  vascular endothelial growth factor receptor \nWHO   world health organization \nWnt   signaling pathway \nX-ray   X-radiation \n \n \n  \nSeite 83 References \n \n(1) Chico, L. K.; Van Eldik, L. J.; Watterson, D. M . (2009) Targeting protein kinases in central nervo us system disorders. Nat Rev Drug \nDiscov  8, 892-909. \n(2) Bossemeyer, D. (1995) Protein kinases--structur e and function. FEBS Lett  369 , 57-61. \n(3) Peifer, C.; Alessi, D. R. (2008) Small-molecule  inhibitors of PDK1. ChemMedChem  3, 1810-1838. \n(4) Hooper, C.; Killick, R.; Lovestone, S. (2008) T he GSK3 hypothesis of Alzheimer's disease. J Neurochem  104 , 1433-1439. \n(5) Ferrer, I.; Gomez-Isla, T.; Puig, B.; Freixes, M.; Ribe, E.; Dalfo, E.; Avila, J. (2005) Current a dvances on different kinases involved in \ntau phosphorylation, and implications in Alzheimer' s disease and tauopathies. Curr Alzheimer Res  2, 3-18. \n(6) Hernandez, F.; Gomez de Barreda, E.; Fuster-Mat anzo, A.; Lucas, J. J.; Avila, J. (2010) GSK3: a po ssible link between beta amyloid \npeptide and tau protein. Exp Neurol  223 , 322-325. \n(7) Leroy, A.; Landrieu, I.; Huvent, I.; Legrand, D .; Codeville, B.; Wieruszeski, J. M.; Lippens, G. ( 2010) Spectroscopic studies of \nGSK3{beta} phosphorylation of the neuronal tau prot ein and its interaction with the N-terminal domain of apolipoprotein E. J Biol Chem  \n285 , 33435-33444. \n(8) Martinez, A.; Castro, A.; Dorronsoro, I.; Alons o, M. (2002) Glycogen synthase kinase 3 (GSK-3) inh ibitors as new promising drugs for \ndiabetes, neurodegeneration, cancer, and inflammati on. Med Res Rev  22 , 373-384. \n(9) Eldar-Finkelman, H. (2002) Glycogen synthase ki nase 3: an emerging therapeutic target. Trends Mol Med  8, 126-132. \n(10) Frame, S.; Cohen, P. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J  359 , 1-16. \n(11) Alzheimer, A. (1907) \u00dcber eine eigenartige Erk rankung der Hirnrinde. Allgemeine Zeitschrift f\u00fcr Psychiatrie und psychisc h-gerichtiliche \nMedizin  64 , 146-148. \n(12) Alzheimer, A.; Stelzmann, R. A.; Schnitzlein, H. N.; Murtagh, F. R. (1995) An English translation  of Alzheimer's 1907 paper, \"\u00dcber eine \neigenartige Erkankung der Hirnrinde\". Clin Anat  8, 429-431. \n(13) Dickson, D.; Weller, R. O. (2011) Neurodegener ation: The Molecular Pathology of Dementia and Move ment Disorders. Wiley-Blackwell  \n2nd edition , 62-91. \n(14) Duyckaerts, C.; Delatour, B.; Potier, M. C. (2 009) Classification and basic pathology of Alzheime r disease. Acta Neuropathol  118 , 5-36. \n(15) Mazanetz, M. P.; Fischer, P. M. (2007) Untangl ing tau hyperphosphorylation in drug design for neu rodegenerative diseases. Nat Rev \nDrug Discov  6, 464-479. \n(16) Hernandez, F.; Avila, J. (2008) The role of gl ycogen synthase kinase 3 in the early stages of Alz heimers' disease. FEBS Lett  582 , \n3848-3854. \n(17) Cohen, P.; Goedert, M. (2004) GSK3 inhibitors:  development and therapeutic potential. Nat Rev Drug Discov  3, 479-487. \n(18) Sereno, L.; Coma, M.; Rodriguez, M.; Sanchez-F errer, P.; Sanchez, M. B.; Gich, I.; Agullo, J. M.;  Perez, M.; Avila, J.; Guardia-\nLaguarta, C.; Clarimon, J.; Lleo, A.; Gomez-Isla, T . (2009) A novel GSK-3beta inhibitor reduces Alzhei mer's pathology and rescues \nneuronal loss in vivo. Neurobiol Dis  35 , 359-367. \n(19) Takashima, A. (2009) Drug development targetin g the glycogen synthase kinase-3beta (GSK-3beta)-me diated signal transduction \npathway: role of GSK-3beta in adult brain. J Pharmacol Sci  109 , 174-178. \n(20) Spittaels, K.; Van den Haute, C.; Van Dorpe, J .; Geerts, H.; Mercken, M.; Bruynseels, K.; Lasrado , R.; Vandezande, K.; Laenen, I.; \nBoon, T.; Van Lint, J.; Vandenheede, J.; Moechars, D.; Loos, R.; Van Leuven, F. (2000) Glycogen syntha se kinase-3beta \nphosphorylates protein tau and rescues the axonopat hy in the central nervous system of human four-repe at tau transgenic mice. J Biol \nChem  275 , 41340-41349. \n(21) Bhat, R. V.; Budd Haeberlein, S. L.; Avila, J.  (2004) Glycogen synthase kinase 3: a drug target f or CNS therapies. J Neurochem  89 , \n1313-1317. \n(22) Feng, L.; Geisselbrecht, Y.; Blanck, S.; Wilbu er, A.; Atilla-Gokcumen, G. E.; Filippakopoulos, P. ; Kraling, K.; Celik, M. A.; Harms, K.; \nMaksimoska, J.; Marmorstein, R.; Frenking, G.; Knap p, S.; Essen, L. O.; Meggers, E. (2011) Structurall y sophisticated octahedral \nmetal complexes as highly selective protein kinase inhibitors. J Am Chem Soc  133 , 5976-5986. \n(23) Eldar-Finkelman, H.; Licht-Murava, A.; Pietrok ovski, S.; Eisenstein, M. (2010) Substrate competit ive GSK-3 inhibitors - strategy and \nimplications. Biochim Biophys Acta  1804 , 598-603. \n(24) Martinez, A.; Alonso, M.; Castro, A.; Perez, C .; Moreno, F. J. (2002) First non-ATP competitive g lycogen synthase kinase 3 beta (GSK-\n3beta) inhibitors: thiadiazolidinones (TDZD) as pot ential drugs for the treatment of Alzheimer's disea se. J Med Chem  45 , 1292-1299. \n(25) Martinez, A. (2008) Preclinical efficacy on GS K-3 inhibitors: towards a future generation of powe rful drugs. Med Res Rev  28, 773-796. \n(26) PDB codes: 3PUP (15), 1Q4L (25), 1Q3D (25), 1Q 41 (25), 1Q3W (25), 1R0E (34), 2OW3 (40),  2JLD (55 ), 3M1S (56), 1UV5 (65), \n3I4B (113), 3F7Z (119), 3F88 (119), 3GB2 (120), 1Q5 K (124), 2O5K (127), 3L1S (130), 3Q3B (136), 1I09 ( 138). \n(27) Mora, A.; Sabio, G.; Gonzalez-Polo, R. A.; Cue nda, A.; Alessi, D. R.; Alonso, J. C.; Fuentes, J. M.; Soler, G.; Centeno, F. (2001) \nLithium inhibits caspase 3 activation and dephospho rylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J \nNeurochem  78 , 199-206. \n(28) Ryves, W. J.; Harwood, A. J. (2001) Lithium in hibits glycogen synthase kinase-3 by competition fo r magnesium. Biochem Biophys Res \nCommun  280 , 720-725. \n(29) Bax, B.; Carter, P. S.; Lewis, C.; Guy, A. R.;  Bridges, A.; Tanner, R.; Pettman, G.; Mannix, C.; Culbert, A. A.; Brown, M. J.; Smith, D. \nG.; Reith, A. D. (2001) The structure of phosphoryl ated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin \nphosphorylation. Structure  9, 1143-1152. \n(30) Dom\u00ednguez, J. M.; Fuertes, A.; Orozco, L.; del  Monte-Mill\u00e1n, M.; Delgado, E.; Medina, M. (2011) E vidence for the irreversible inhibition \nof glycogen synthase kinas-3beta by tideglusib. J Biol Chem  in Press . \n(31) Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haig h, D.; Ife, R. J.; Saunders, M.; Slingsby, B. P.; S tacey, R.; Ward, R. W. (2001) 3-Anilino-4-\narylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett  11 , 635-639. \n(32) Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H.  M.; Flocco, M. (2003) Structural \ncharacterization of the GSK-3beta active site using  selective and non-selective ATP-mimetic inhibitors . J Mol Biol  333 , 393-407. \n(33) Coghlan, M. P.; Culbert, A. A.; Cross, D. A.; Corcoran, S. L.; Yates, J. W.; Pearce, N. J.; Rausc h, O. L.; Murphy, G. J.; Carter, P. S.; \nRoxbee Cox, L.; Mills, D.; Brown, M. J.; Haigh, D.;  Ward, R. W.; Smith, D. G.; Murray, K. J.; Reith, A . D.; Holder, J. C. (2000) Selective \nsmall molecule inhibitors of glycogen synthase kina se-3 modulate glycogen metabolism and gene transcri ption. Chem Biol  7, 793-803. \n(34) Cross, D. A.; Culbert, A. A.; Chalmers, K. A.;  Facci, L.; Skaper, S. D.; Reith, A. D. (2001) Sele ctive small-molecule inhibitors of \nglycogen synthase kinase-3 activity protect primary  neurones from death. J Neurochem  77 , 94-102. \n(35) Selenica, M. L.; Jensen, H. S.; Larsen, A. K.;  Pedersen, M. L.; Helboe, L.; Leist, M.; Lotharius,  J. (2007) Efficacy of small-molecule \nglycogen synthase kinase-3 inhibitors in the postna tal rat model of tau hyperphosphorylation. Br J Pharmacol  152 , 959-979. \n(36) O'Neill, D. J.; Shen, L.; Prouty, C.; Conway, B. R.; Westover, L.; Xu, J. Z.; Zhang, H. C.; Marya noff, B. E.; Murray, W. V.; Demarest, K. \nT.; Kuo, G. H. (2004) Design, synthesis, and biolog ical evaluation of novel 7-azaindolyl-heteroaryl-ma leimides as potent and selective \nglycogen synthase kinase-3beta (GSK-3beta) inhibito rs. Bioorg Med Chem  12 , 3167-3185. \n(37) Zhang, H. C.; Ye, H.; Conway, B. R.; Derian, C . K.; Addo, M. F.; Kuo, G. H.; Hecker, L. R.; Croll , D. R.; Li, J.; Westover, L.; Xu, J. Z.; \nLook, R.; Demarest, K. T.; Andrade-Gordon, P.; Dami ano, B. P.; Maryanoff, B. E. (2004) 3-(7-Azaindolyl )-4-arylmaleimides as potent, \nselective inhibitors of glycogen synthase kinase-3.  Bioorg Med Chem Lett  14 , 3245-3250. \n(38) Engler, T. A.; Henry, J. R.; Malhotra, S.; Cun ningham, B.; Furness, K.; Brozinick, J.; Burkholder , T. P.; Clay, M. P.; Clayton, J.; \nDiefenbacher, C.; Hawkins, E.; Iversen, P. W.; Li, Y.; Lindstrom, T. D.; Marquart, A. L.; McLean, J.; Mendel, D.; Misener, E.; Briere, D.; \nO'Toole, J. C.; Porter, W. J.; Queener, S.; Reel, J . K.; Owens, R. A.; Brier, R. A.; Eessalu, T. E.; W agner, J. R.; Campbell, R. M.; \nVaughn, R. (2004) Substituted 3-imidazo[1,2-a]pyrid in-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7, 1-hi]indol-7-yl)pyrrole-2,5-dion es \nas highly selective and potent inhibitors of glycog en synthase kinase-3. J Med Chem  47 , 3934-3937.  \nSeite 84 (39) Engler, T. A.; Malhotra, S.; Burkholder, T. P. ; Henry, J. R.; Mendel, D.; Porter, W. J.; Furness,  K.; Diefenbacher, C.; Marquart, A.; Reel, \nJ. K.; Li, Y.; Clayton, J.; Cunningham, B.; McLean,  J.; O'Toole J, C.; Brozinick, J.; Hawkins, E.; Mis ener, E.; Briere, D.; Brier, R. A.; \nWagner, J. R.; Campbell, R. M.; Anderson, B. D.; Va ughn, R.; Bennett, D. B.; Meier, T. I.; Cook, J. A.  (2005) The development of \npotent and selective bisarylmaleimide GSK3 inhibito rs. Bioorg Med Chem Lett  15 , 899-903. \n(40) Ye, Q.; Xu, G.; Lv, D.; Cheng, Z.; Li, J.; Hu,  Y. (2009) Synthesis and biological evaluation of n ovel 4-azaindolyl-indolyl-maleimides as \nglycogen synthase kinase-3beta (GSK-3beta) inhibito rs. Bioorg Med Chem  17 , 4302-4312. \n(41) Gong, L.; Hirschfeld, D.; Tan, Y. C.; Heather Hogg, J.; Peltz, G.; Avnur, Z.; Dunten, P. (2010) D iscovery of potent and bioavailable \nGSK-3beta inhibitors. Bioorg Med Chem Lett  20 , 1693-1696. \n(42) Perez, D. I.; Palomo, V.; Perez, C.; Gil, C.; Dans, P. D.; Luque, F. J.; Conde, S.; Martinez, A. (2011) Switching reversibility to \nirreversibility in glycogen synthase kinase 3 inhib itors: clues for specific design of new compounds. J Med Chem  54 , 4042-4056. \n(43) Hers, I.; Tavare, J. M.; Denton, R. M. (1999) The protein kinase C inhibitors bisindolylmaleimide  I (GF 109203x) and IX (Ro 31-8220) \nare potent inhibitors of glycogen synthase kinase-3  activity. FEBS Lett  460 , 433-436. \n(44) Kuo, G. H.; Prouty, C.; DeAngelis, A.; Shen, L .; O'Neill, D. J.; Shah, C.; Connolly, P. J.; Murra y, W. V.; Conway, B. R.; Cheung, P.; \nWestover, L.; Xu, J. Z.; Look, R. A.; Demarest, K. T.; Emanuel, S.; Middleton, S. A.; Jolliffe, L.; Be avers, M. P.; Chen, X. (2003) \nSynthesis and discovery of macrocyclic polyoxygenat ed bis-7-azaindolylmaleimides as a novel series of potent and highly selective \nglycogen synthase kinase-3beta inhibitors. J Med Chem  46 , 4021-4031. \n(45) Zhang, H. C.; White, K. B.; Ye, H.; McComsey, D. F.; Derian, C. K.; Addo, M. F.; Andrade-Gordon, P.; Eckardt, A. J.; Conway, B. R.; \nWestover, L.; Xu, J. Z.; Look, R.; Demarest, K. T.;  Emanuel, S.; Maryanoff, B. E. (2003) Macrocyclic b isindolylmaleimides as inhibitors \nof protein kinase C and glycogen synthase kinase-3.  Bioorg Med Chem Lett  13 , 3049-3053. \n(46) Shen, L.; Prouty, C.; Conway, B. R.; Westover,  L.; Xu, J. Z.; Look, R. A.; Chen, X.; Beavers, M. P.; Roberts, J.; Murray, W. V.; \nDemarest, K. T.; Kuo, G. H. (2004) Synthesis and bi ological evaluation of novel macrocyclic bis-7-azai ndolylmaleimides as potent and \nhighly selective glycogen synthase kinase-3 beta (G SK-3 beta) inhibitors. Bioorg Med Chem  12 , 1239-1255. \n(47) Zhang, H. C.; Bonaga, L. V.; Ye, H.; Derian, C . K.; Damiano, B. P.; Maryanoff, B. E. (2007) Novel  bis(indolyl)maleimide pyridinophanes \nthat are potent, selective inhibitors of glycogen s ynthase kinase-3. Bioorg Med Chem Lett  17 , 2863-2868. \n(48) Kozikowski, A. P.; Gaisina, I. N.; Yuan, H.; P etukhov, P. A.; Blond, S. Y.; Fedolak, A.; Caldaron e, B.; McGonigle, P. (2007) Structure-\nbased design leads to the identification of lithium  mimetics that block mania-like effects in rodents.  possible new GSK-3beta therapies \nfor bipolar disorders. J Am Chem Soc  129 , 8328-8332. \n(49) Gaisina, I. N.; Gallier, F.; Ougolkov, A. V.; Kim, K. H.; Kurome, T.; Guo, S.; Holzle, D.; Luchin i, D. N.; Blond, S. Y.; Billadeau, D. D.; \nKozikowski, A. P. (2009) From a natural product lea d to the identification of potent and selective ben zofuran-3-yl-(indol-3-yl)maleimides \nas glycogen synthase kinase 3beta inhibitors that s uppress proliferation and survival of pancreatic ca ncer cells. J Med Chem  52 , 1853-\n1863. \n(50) Zhong, H.; Zou, H.; Semenov, M. V.; Moshinsky,  D.; He, X.; Huang, H.; Li, S.; Quan, J.; Yang, Z.;  Lin, S. (2009) Characterization and \ndevelopment of novel small-molecules inhibiting GSK 3 and activating Wnt signaling. Mol Biosyst  5, 1356-1360. \n(51) Zou, H.; Zhou, L.; Li, Y.; Cui, Y.; Zhong, H.;  Pan, Z.; Yang, Z.; Quan, J. (2010) Benzo[e]isoindo le-1,3-diones as potential inhibitors of \nglycogen synthase kinase-3 (GSK-3). Synthesis, kina se inhibitory activity, zebrafish phenotype, and mo deling of binding mode. J Med \nChem  53 , 994-1003. \n(52) Kozikowski, A.; Gaysina, I. (2008) WO 2008/077138 A1 . \n(53) Kozikowski, A.; Gaysina, I. (2010) US 2010/0004308 A1 . \n(54) Von Matt, P.; Wagner, J. (2009) Novartis AG. EP 2075249 A2 . \n(55) Zhang, H.; Maryanoff, B.; Ye, H. (2008) Jansse n Pharmaceutica N.V. US 7439363 B2 . \n(56) Zhang, H.; Maryanoff, B.; Ye, H. (2008) Jansse n Pharmaceutica N.V. EP 1654255 B1 . \n(57) Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.;  Awaya, J.; Tsuchya, H.; Takahashi, Y.; Masuma, R. (1977) A new alkaloid AM-2282 OF \nStreptomyces origin. Taxonomy, fermentation, isolat ion and preliminary characterization. J Antibiot (Tokyo)  30 , 275-282. \n(58) Funato, N.; Takayanagi, H.; Konda, Y.; Toda, Y .; Harigaya, Y.; Iwai, Y.; Omura, S. (1994) Absolut e Configuration of Staurosporine By \nX-Ray Analysis. Tetrahedron Lett  35 , 1251-1254. \n(59) Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Bier nat, J.; Wu, Y. Z.; Mandelkow, E. M.; \nEisenbrand, G.; Meijer, L. (2001) Indirubins inhibi t glycogen synthase kinase-3 beta and CDK5/p25, two  protein kinases involved in \nabnormal tau phosphorylation in Alzheimer's disease . A property common to most cyclin-dependent kinase  inhibitors? J Biol Chem  \n276 , 251-260. \n(60) Bregman, H.; Williams, D. S.; Atilla, G. E.; C arroll, P. J.; Meggers, E. (2004) An organometallic  inhibitor for glycogen synthase kinase \n3. J Am Chem Soc  126 , 13594-13595. \n(61) Atilla-Gokcumen, G. E.; Williams, D. S.; Bregm an, H.; Pagano, N.; Meggers, E. (2006) Organometall ic compounds with biological \nactivity: a very selective and highly potent cellul ar inhibitor for glycogen synthase kinase 3. Chembiochem  7, 1443-1450. \n(62) Atilla-Gokcumen, G. E.; Pagano, N.; Streu, C.;  Maksimoska, J.; Filippakopoulos, P.; Knapp, S.; Me ggers, E. (2008) Extremely tight \nbinding of a ruthenium complex to glycogen synthase  kinase 3. Chembiochem  9, 2933-2936. \n(63) Atilla-Gokcumen, G. E.; Di Costanzo, L.; Megge rs, E. (2011) Structure of anticancer ruthenium hal f-sandwich complex bound to \nglycogen synthase kinase 3beta. J Biol Inorg Chem  16 , 45-50. \n(64) Beher, D.; Bettai, M.; Churcher, I.; Munzo, B. ; Prasit, B.; Quddus, A.; Stock, N.; Wrigley, J. (2 009) Merck and Co., Inc. EP 1708997 B1 . \n(65) Berg, S.; Hellberg, S.; Nyl\u00f6f, M.; Xue, Y. (20 08) Astra Zeneca AB. US 7399780 B2 . \n(66) Berg, S.; Hellberg, S.; Nyl\u00f6f, M.; Xue, Y. (20 08) Astra Zeneca AB. EP 1492785 B1 . \n(67) Green, J.; Miller, A.; Jimenez, J.; Marhefka, C.; Cao, J.; Court, J.; Bandarage, U.; Gao, H.; Nan thakumar, S. (2009) Vertex \nPharmaceuticals Inc. US 7514448 B2 . \n(68) Heckel, A.; Roth, G.; Kley, J.; Hoerer, S.; Up hues, I. (2005) Boehringer Ingelheim Pharma GmbH & Co. KG. WO 2005/087727 A1 . \n(69) Heckel, A.; Roth, G.; Kley, J.; Hoerer, S.; Up hues, I. (2007) Boehringer Ingelheim International GmbH. US 7262206 B2 . \n(70) Heckel, A.; Roth, G.; Kley, J.; Hoerer, S.; Up hues, I. (2007) Boehringer Ingelheim International GmbH. US 7176231 B2 . \n(71) Heckel, A.; Roth, G.; Kley, J.; Hoerer, S.; Up hues, I. (2009) Boehringer Ingelheim International GmbH. US 7560480 B2 . \n(72) Meijer, L.; Skaltsounis, A. L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Rya n, X. P.; Vonica, C. A.; Brivanlou, A.; \nDajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. (2003) GSK -3-selective inhibitors derived \nfrom Tyrian purple indirubins. Chem Biol  10 , 1255-1266. \n(73) Polychronopoulos, P.; Magiatis, P.; Skaltsouni s, A. L.; Myrianthopoulos, V.; Mikros, E.; Tarricon e, A.; Musacchio, A.; Roe, S. M.; Pearl, \nL.; Leost, M.; Greengard, P.; Meijer, L. (2004) Str uctural basis for the synthesis of indirubins as po tent and selective inhibitors of \nglycogen synthase kinase-3 and cyclin-dependent kin ases. J Med Chem  47 , 935-946. \n(74) Vougogiannopoulou, K.; Ferandin, Y.; Bettayeb,  K.; Myrianthopoulos, V.; Lozach, O.; Fan, Y.; John son, C. H.; Magiatis, P.; \nSkaltsounis, A. L.; Mikros, E.; Meijer, L. (2008) S oluble 3',6-substituted indirubins with enhanced se lectivity toward glycogen synthase \nkinase -3 alter circadian period. J Med Chem  51 , 6421-6431. \n(75) Beauchard, A.; Laborie, H.; Rouillard, H.; Loz ach, O.; Ferandin, Y.; Le Guevel, R.; Guguen-Guillo uzo, C.; Meijer, L.; Besson, T.; \nThiery, V. (2009) Synthesis and kinase inhibitory a ctivity of novel substituted indigoids. Bioorg Med Chem  17 , 6257-6263. \n(76) Meijer, L.; Greengard, P.; Knockaert, M.; Skal tsounis, A. (2007) US 2007/0276025 A1 . \n(77) Leost, M.; Schultz, C.; Link, A.; Wu, Y. Z.; B iernat, J.; Mandelkow, E. M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; \nGussio, R.; Senderowicz, A. M.; Sausville, E. A.; K unick, C.; Meijer, L. (2000) Paullones are potent i nhibitors of glycogen synthase \nkinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem  267 , 5983-5994. \n(78) Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Ku nick, C. (1999) Paullones, a series of \ncyclin-dependent kinase inhibitors: synthesis, eval uation of CDK1/cyclin B inhibition, and in vitro an titumor activity. J Med Chem  42 , \n2909-2919. \n(79) Knockaert, M.; Wieking, K.; Schmitt, S.; Leost , M.; Grant, K. M.; Mottram, J. C.; Kunick, C.; Mei jer, L. (2002) Intracellular Targets of \nPaullones. Identification following affinity purifi cation on immobilized inhibitor. J Biol Chem  277 , 25493-25501.  \nSeite 85 (80) Kunick, C.; Lauenroth, K.; Leost, M.; Meijer, L.; Lemcke, T. (2004) 1-Azakenpaullone is a selecti ve inhibitor of glycogen synthase \nkinase-3 beta. Bioorg Med Chem Lett  14 , 413-416. \n(81) Kunick, C.; Zeng, Z.; Gussio, R.; Zaharevitz, D.; Leost, M.; Totzke, F.; Schachtele, C.; Kubbutat , M. H.; Meijer, L.; Lemcke, T. (2005) \nStructure-aided optimization of kinase inhibitors d erived from alsterpaullone. Chembiochem  6, 541-549. \n(82) Meijer, L.; Kunick, C. (2001) WO 2001/60374 A1 . \n(83) Witherington, J.; Bordas, V.; Garland, S. L.; Hickey, D. M.; Ife, R. J.; Liddle, J.; Saunders, M. ; Smith, D. G.; Ward, R. W. (2003) 5-aryl-\npyrazolo[3,4-b]pyridines: potent inhibitors of glyc ogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett  13 , 1577-1580. \n(84) Witherington, J.; Bordas, V.; Haigh, D.; Hicke y, D. M.; Ife, R. J.; Rawlings, A. D.; Slingsby, B.  P.; Smith, D. G.; Ward, R. W. (2003) 5-\naryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett  13 , 1581-1584. \n(85) Witherington, J.; Bordas, V.; Gaiba, A.; Garto n, N. S.; Naylor, A.; Rawlings, A. D.; Slingsby, B.  P.; Smith, D. G.; Takle, A. K.; Ward, R. \nW. (2003) 6-aryl-pyrazolo[3,4-b]pyridines: potent i nhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett  13 , 3055-\n3057. \n(86) Witherington, J.; Bordas, V.; Gaiba, A.; Naylo r, A.; Rawlings, A. D.; Slingsby, B. P.; Smith, D. G.; Takle, A. K.; Ward, R. W. (2003) 6-\nheteroaryl-pyrazolo[3,4-b]pyridines: potent and sel ective inhibitors of glycogen synthase kinase-3 (GS K-3). Bioorg Med Chem Lett  13 , \n3059-3062. \n(87) Uno, Y.; Iwashita, H.; Tsukamoto, T.; Uchiyama , N.; Kawamoto, T.; Kori, M.; Nakanishi, A. (2009) Efficacy of a novel, orally active \nGSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)p ropyl]carbamoyl]-1H-pyrazol-4-yl]pyridi ne-3-carbox amide in tau transgenic mice. \nBrain Res  1296 , 148-163. \n(88) Kees, K. L.; Caggiano, T. J.; Steiner, K. E.; Fitzgerald, J. J., Jr.; Kates, M. J.; Christos, T. E.; Kulishoff, J. M., Jr.; Moore, R. D.; \nMcCaleb, M. L. (1995) Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db  mice. J Med Chem  38 , 617-\n628. \n(89) Kees, K. L.; Fitzgerald, J. J., Jr.; Steiner, K. E.; Mattes, J. F.; Mihan, B.; Tosi, T.; Mondoro,  D.; McCaleb, M. L. (1996) New potent \nantihyperglycemic agents in db/db mice: synthesis a nd structure-activity relationship studies of (4-su bstituted benzyl) \n(trifluoromethyl)pyrazoles and -pyrazolones. J Med Chem  39 , 3920-3928. \n(90) Bebernitz, G. R.; Argentieri, G.; Battle, B.; Brennan, C.; Balkan, B.; Burkey, B. F.; Eckhardt, M .; Gao, J.; Kapa, P.; Strohschein, R. J.; \nSchuster, H. F.; Wilson, M.; Xu, D. D. (2001) The e ffect of 1,3-diaryl-[1H]-pyrazole-4-acetamides on g lucose utilization in ob/ob mice. J \nMed Chem  44 , 2601-2611. \n(91) Shen, D. M.; Brady, E. J.; Candelore, M. R.; D allas-Yang, Q.; Ding, V. D.; Feeney, W. P.; Jiang, G.; McCann, M. E.; Mock, S.; Qureshi, \nS. A.; Saperstein, R.; Shen, X.; Tong, X.; Tota, L.  M.; Wright, M. J.; Yang, X.; Zheng, S.; Chapman, K . T.; Zhang, B. B.; Tata, J. R.; \nParmee, E. R. (2011) Discovery of novel, potent, se lective, and orally active human glucagon receptor antagonists containing a \npyrazole core. Bioorg Med Chem Lett  21 , 76-81. \n(92) Peat, A. J.; Garrido, D.; Boucheron, J. A.; Sc hweiker, S. L.; Dickerson, S. H.; Wilson, J. R.; Wa ng, T. Y.; Thomson, S. A. (2004) Novel \nGSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett  14 , 2127-2130. \n(93) Lum, C.; Kahl, J.; Kessler, L.; Kucharski, J.;  Lundstrom, J.; Miller, S.; Nakanishi, H.; Pei, Y.;  Pryor, K.; Roberts, E.; Sebo, L.; Sullivan, \nR.; Urban, J.; Wang, Z. (2008) 2,5-Diaminopyrimidin es and 3,5-disubstituted azapurines as inhibitors o f glycogen synthase kinase-3 \n(GSK-3). Bioorg Med Chem Lett  18 , 3578-3581. \n(94) Bebbington, D.; Binch, H.; Knegtel, R.; Golec,  J.; Patel, S.; Charrier, J.; Kay, D.; davies, R.; Li, P.; Wannamaker, M.; Forster, C.; \nPierce, A. (2003) Vertex Pharmaceuticals Inc. US 6660731 B2 . \n(95) Bebbington, D.; Binch, H.; Knegtel, R.; Golec,  J.; Patel, S.; Charrier, J.; Kay, D.; Davies, R.; Li, P.; Wannamaker, M.; Forster, C.; \nPierce, A. (2006) Vertex Pharmaceuticals Inc. US 7008948 B2 . \n(96) Bebbington, D.; Charrier, J. (2003) Vertex Pha rmaceuticals Inc. US 6656939 B2 . \n(97) Bebbington, D.; Charrier, J.; Davies, R.; Ever itt, S.; Kay, D.; Knegtel, R.; Patel, S. (2006) Ver tex Pharmaceuticals Inc. US 6989385 B2 . \n(98) Bebbington, D.; Charrier, J.; Davies, R.; Gole c, J.; Kay, D.; Knegtel, R.; Patel, S. (2002) Verte x Pharmaceuticals Inc. WO 2002/059111 \nA2 . \n(99) Bebbington, D.; Charrier, J.; Davies, R.; Gole c, J.; Kay, D.; Knegtel, R.; Patel, S. (2003) Verte x Pharmaceuticals Inc. US 6653301 B2 . \n(100) Bebbington, D.; Charrier, J.; Golec, J.; Mill er, A.; Knegtel, R. (2002) Vertex Pharmaceuticals I nc. WO 2002/057259 A2 . \n(101) Bebbington, D.; Charrier, J.; Golec, J.; Mill er, A.; Knegtel, R. (2003) Vertex Pharmaceuticals I nc. US 6664247 B2 . \n(102) Bebbington, D.; Charrier, J.; Golec, J.; Pier ard, F. (2004) Vertex Pharmaceuticals Inc. US 6727251 B2 . \n(103) Bebbington, D.; Charrier, J.; Golec, J.; Pier ard, F. (2008) Vertex Pharmaceuticals Inc. US 7427681 B2 . \n(104) Davies, R.; Bebbington, D.; Knegtel, R.; Wann amaker, M.; Li, P.; Forster, C.; Pierce, A. (2008) Vertex Pharmaceuticals Inc. US 739081 \nB2 . \n(105) Davies, R.; Li, P.; Golec, J.; Charrier, J.; Knegtel, R.; Bebbington, D. (2003) Vertex Pharmaceu ticals Inc. US 6610677 B2 . \n(106) Freyne, E.; Love, C.; Cooymans, L.; Vandermae ssen, N.; Buijnsters, P.; Willems, M.; Embrechts, W . (2008) Janssen Pharmaceutica. \nUS 7449465 B2 . \n(107) Freyne, E.; Love, C.; Cooymans, L.; Vandermae ssen, N.; Buijnsters, P.; Willems, M.; Embrechts, W . (2009) Janssen Pharmaceutica. \nUS 7560458 B2 . \n(108) Garcia, A.; Gallet, T.; Taki Li, A.; Lochead,  A.; Marguerie, S.; Nedelec, A.; Saady, M.; Yaiche,  P. (2009) Sanofi-Aventis Mitsubishi \nPharma Corp. US 7566720 B2 . \n(109) George, P.; Lochead, A.; Saady, M.; Slowinski , F.; Yaiche, P. (2009) Sanofi-Aventis Mitsubishi P harma Corp. US 7507743 B2 . \n(110) Goff, D.; Harrison, S.; Nuss, J.; Ring, D.; Z hou, X. (2002) Chiron Corp. US 6417185 B1 . \n(111) Kataoka, K.; Kosugi, T.; Ishii, T.; Takeuchi,  T.; Tsutsumi, T.; Nakano, A.; Knoki, G.; Yamamoto,  Y.; Sakai, Y. (2009) Teijin Limited. US \n7528140 B2 . \n(112) Kataoka, K.; Kosugi, T.; Ishii, T.; Takeuchi,  T.; Tsutsumi, T.; Nakano, A.; Yamamoto, Y.; Yoshio ka, N. (2004) Teijin Limited. EP \n1477490 A1 . \n(113) Knegtel, R.; Bebbington, D.; Binch, H.; Golec , J.; Patel, S.; Charrier, J.; Kay, D.; Davies, R.;  Li, P.; Wannamaker, M.; Forster, C.; \nPierce, A. (2003) Vertex Pharmaceuticals Inc. US 6613776 B2 . \n(114) Lochead, A.; Marguerie, S.; Saady, M.; Yaiche , P. (2009) Sanofi-Aventis Mitsubishi Pharma Corp. US 7608624 B2 . \n(115) Nakano, M.; Maeda, Y. (2005) Smithkline Beech am Corp. WO 2005/061516 A1 . \n(116) Nuss, J.; Harrison, S.; Ring, D.; Boyce, R.; Brown, S.; Goff, D.; Johnson, K.; Pfister, K.; Ramu rthy, S.; Renhowe, P.; Seely, L.; \nSubramanian, S.; Wagman, A.; Zhou, X. (2002) Chiron  Corp. US 6489344 B1 . \n(117) Nuss, J.; Harrison, S.; Ring, D.; Boyce, R.; Brown, S.; Goff, D.; Johnson, K.; Pfister, K.; Ramu rthy, S.; Renhowe, P.; Seely, L.; \nSubramanian, S.; Wagman, A.; Zhou, X. (2006) Chiron  Corp. US 7037918 B2 . \n(118) Nuss, J.; Harrison, S.; Ring, D.; Boyce, R.; Johnson, K.; Pfister, K.; Ramurthy, S.; Seely, L.; Wagman, A.; Desai, M.; Levine, B. (2006) \nChiron Corp. US 7045519 B2 . \n(119) Tsutsumi, T.; Sugiura, S.; Koga, M.; Matsumot o, Y.; Ishii, T.; Nakano, A.; Sakai, Y.; Takarada, R.; Ogawa, H. (2009) Teijin Pharma \nLimited. US 7557113 B2 . \n(120) Aronov, A. M.; Tang, Q.; Martinez-Botella, G. ; Bemis, G. W.; Cao, J.; Chen, G.; Ewing, N. P.; Fo rd, P. J.; Germann, U. A.; Green, J.; \nHale, M. R.; Jacobs, M.; Janetka, J. W.; Maltais, F .; Markland, W.; Namchuk, M. N.; Nanthakumar, S.; P oondru, S.; Straub, J.; ter \nHaar, E.; Xie, X. (2009) Structure-guided design of  potent and selective pyrimidylpyrrole inhibitors o f extracellular signal-regulated \nkinase (ERK) using conformational control. J Med Chem  52 , 6362-6368. \n(121) Ring, D. B.; Johnson, K. W.; Henriksen, E. J. ; Nuss, J. M.; Goff, D.; Kinnick, T. R.; Ma, S. T.;  Reeder, J. W.; Samuels, I.; Slabiak, T.; \nWagman, A. S.; Hammond, M. E.; Harrison, S. D. (200 3) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of \nglucose transport and utilization in vitro and in v ivo. Diabetes  52 , 588-595. \n(122) Maeda, Y.; Nakano, M.; Sato, H.; Miyazaki, Y. ; Schweiker, S. L.; Smith, J. L.; Truesdale, A. T. (2004) 4-Acylamino-6-arylfuro[2,3-\nd]pyrimidines: potent and selective glycogen syntha se kinase-3 inhibitors. Bioorg Med Chem Lett  14 , 3907-3911.  \nSeite 86 (123) Miyazaki, Y.; Maeda, Y.; Sato, H.; Nakano, M. ; Mellor, G. W. (2008) Rational design of 4-amino-5 ,6-diaryl-furo[2,3-d]pyrimidines as \npotent glycogen synthase kinase-3 inhibitors. Bioorg Med Chem Lett  18 , 1967-1971. \n(124) Olesen, P. H.; Sorensen, A. R.; Urso, B.; Kur tzhals, P.; Bowler, A. N.; Ehrbar, U.; Hansen, B. F . (2003) Synthesis and in vitro \ncharacterization of 1-(4-aminofurazan-3-yl)-5-dialk ylaminomethyl-1H-[1,2,3]triazole-4-carboxyl ic acid  derivatives. A new class of \nselective GSK-3 inhibitors. J Med Chem  46 , 3333-3341. \n(125) Bandarage, U.; Hare, B.; Parsons, J.; Pham, L .; Marhefka, C.; Bemis, G.; Tang, Q.; Moody, C. S.;  Rodems, S.; Shah, S.; Adams, C.; \nBravo, J.; Charonnet, E.; Savic, V.; Come, J. H.; G reen, J. (2009) 4-(Benzimidazol-2-yl)-1,2,5-oxadiaz ol-3-ylamine derivatives: potent \nand selective p70S6 kinase inhibitors. Bioorg Med Chem Lett  19 , 5191-5194. \n(126) Saitoh, M.; Kunitomo, J.; Kimura, E.; Hayase,  Y.; Kobayashi, H.; Uchiyama, N.; Kawamoto, T.; Tan aka, T.; Mol, C. D.; Dougan, D. R.; \nTextor, G. S.; Snell, G. P.; Itoh, F. (2009) Design , synthesis and structure-activity relationships of  1,3,4-oxadiazole derivatives as novel \ninhibitors of glycogen synthase kinase-3beta. Bioorg Med Chem  17 , 2017-2029. \n(127) Saitoh, M.; Kunitomo, J.; Kimura, E.; Iwashit a, H.; Uno, Y.; Onishi, T.; Uchiyama, N.; Kawamoto,  T.; Tanaka, T.; Mol, C. D.; Dougan, D. \nR.; Textor, G. P.; Snell, G. P.; Takizawa, M.; Itoh , F.; Kori, M. (2009) 2-{3-[4-(Alkylsulfinyl)phenyl ]-1-benzofuran-5-yl}-5-methyl-1,3,4-\noxadiazol e derivatives as novel inhibitors of glyc ogen synthase kinase-3beta with good brain permeabi lity. J Med Chem  52 , 6270-\n6286. \n(128) Onishi, T.; Iwashita, H.; Uno, Y.; Kunitomo, J.; Saitoh, M.; Kimura, E.; Fujita, H.; Uchiyama, N .; Kori, M.; Takizawa, M. (2011) A novel \nglycogen synthase kinase-3 inhibitor 2-methyl-5-(3- (4-((S)-methylsulfinyl)phenyl)-1-benzofuran-5-yl)-1 ,3,4-oxadiazole decreases tau \nphosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer\u00b4s disease. J Neurochem  early view . \n(129) Khanfar, M. A.; Hill, R. A.; Kaddoumi, A.; El  Sayed, K. A. (2010) Discovery of novel GSK-3beta i nhibitors with potent in vitro and in vivo \nactivities and excellent brain permeability using c ombined ligand- and structure-based virtual screeni ng. J Med Chem  53 , 8534-8545. \n(130) Koryakova, A. G.; Ivanenkov, Y. A.; Ryzhova, E. A.; Bulanova, E. A.; Karapetian, R. N.; Mikitas,  O. V.; Katrukha, E. A.; Kazey, V. I.; \nOkun, I.; Kravchenko, D. V.; Lavrovsky, Y. V.; Korz inov, O. M.; Ivachtchenko, A. V. (2008) Novel aryl and heteroaryl substituted N-[3-\n(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5- carboxamides as selective GSK-3 inhibitors. Bioorg Med Chem Lett  18 , 3661-3666. \n(131) Loge, C.; Testard, A.; Thiery, V.; Lozach, O. ; Blairvacq, M.; Robert, J. M.; Meijer, L.; Besson,  T. (2008) Novel 9-oxo-thiazolo[5,4-\nf]quinazoline-2-carbonitrile derivatives as dual cy clin-dependent kinase 1 (CDK1)/glycogen synthase ki nase-3 (GSK-3) inhibitors: \nsynthesis, biological evaluation and molecular mode ling studies. Eur J Med Chem  43 , 1469-1477. \n(132) Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Or mo, M.; Nilsson, Y.; Radesater, A. C.; Jerning, E.;  Markgren, P. O.; Borgegard, T.; Nylof, \nM.; Gimenez-Cassina, A.; Hernandez, F.; Lucas, J. J .; Diaz-Nido, J.; Avila, J. (2003) Structural insig hts and biological effects of \nglycogen synthase kinase 3-specific inhibitor AR-A0 14418. J Biol Chem  278 , 45937-45945. \n(133) Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Mey erson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFra ncois, J.; Feinstein, B.; Burns, M.; \nKrishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Di ckson, D.; Duff, K. (2005) Inhibition of glycogen s ynthase kinase-3 by lithium \ncorrelates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A  102 , 6990-6995. \n(134) Monte, F. L.; Kramer, T.; Bolander, A.; Plotk in, B.; Eldar-Finkelman, H.; Fuertes, A.; Dominguez , J.; Schmidt, B. (2011) Synthesis and \nbiological evaluation of glycogen synthase kinase 3  (GSK-3) inhibitors: an fast and atom efficient acc ess to 1-aryl-3-benzylureas. \nBioorg Med Chem Lett  21 , 5610-5615. \n(135) Shin, D.; Lee, S. C.; Heo, Y. S.; Lee, W. Y.;  Cho, Y. S.; Kim, Y. E.; Hyun, Y. L.; Cho, J. M.; L ee, Y. S.; Ro, S. (2007) Design and \nsynthesis of 7-hydroxy-1H-benzoimidazole derivative s as novel inhibitors of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett  \n17 , 5686-5689. \n(136) Voigt, B.; Krug, M.; Schachtele, C.; Totzke, F.; Hilgeroth, A. (2008) Probing novel 1-aza-9-oxaf luorenes as selective GSK-3beta \ninhibitors. ChemMedChem  3, 120-126. \n(137) Chauhan, N. B.; Siegel, G. J.; Feinstein, D. L. (2005) Propentofylline attenuates tau hyperphosp horylation in Alzheimer's Swedish \nmutant model Tg2576. Neuropharmacology  48 , 93-104. \n(138) Arnost, M.; Pierce, A.; ter Haar, E.; Lauffer , D.; Madden, J.; Tanner, K.; Green, J. (2010) 3-Ar yl-4-(arylhydrazono)-1H-pyrazol-5-ones: \nHighly ligand efficient and potent inhibitors of GS K3beta. Bioorg Med Chem Lett  20 , 1661-1664. \n(139) Chen, W.; Gaisina, I. N.; Gunosewoyo, H.; Mal ekiani, S. A.; Hanania, T.; Kozikowski, A. P. (2011 ) Structure-guided design of a highly \nselective glycogen synthase kinase-3beta inhibitor:  a superior neuroprotective pyrazolone showing anti mania effects. ChemMedChem  \n6, 1587-1592. \n(140) Khanfar, M. A.; Asal, B. A.; Mudit, M.; Kaddo umi, A.; El Sayed, K. A. (2009) The marine natural- derived inhibitors of glycogen synthase \nkinase-3beta phenylmethylene hydantoins: In vitro a nd in vivo activities and pharmacophore modeling. Bioorg Med Chem  17 , 6032-\n6039. \n(141) Coffman, K.; Brodney, M.; Cook, J.; Lanyon, L .; Pandit, J.; Sakya, S.; Schachter, J.; Tseng-Love ring, E.; Wessel, M. (2011) 6-amino-4-\n(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3beta inhibitors. Bioorg Med Chem Lett  21 , 1429-1433. \n(142) Hamann, M.; Alonso, D.; Martin-Aparicio, E.; Fuertes, A.; Perez-Puerto, M. J.; Castro, A.; Moral es, S.; Navarro, M. L.; Del Monte-\nMillan, M.; Medina, M.; Pennaka, H.; Balaiah, A.; P eng, J.; Cook, J.; Wahyuono, S.; Martinez, A. (2007 ) Glycogen synthase kinase-3 \n(GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloi ds. Potential for Alzheimer's \ndisease. J Nat Prod  70 , 1397-1405. \n(143) Gompel, M.; Leost, M.; De Kier Joffe, E. B.; Puricelli, L.; Franco, L. H.; Palermo, J.; Meijer, L. (2004) Meridianins, a new family of \nprotein kinase inhibitors isolated from the ascidia n Aplidium meridianum. Bioorg Med Chem Lett  14 , 1703-1707. \n(144) Meijer, L.; Thunnissen, A. M.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; \nBiernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. (2000) Inhibition of cyclin-dependent kinases , GSK-3beta and CK1 by \nhymenialdisine, a marine sponge constituent. Chem Biol  7, 51-63. \n(145) Zhang, N.; Zhong, R.; Yan, H.; Jiang, Y. (201 1) Structural features underlying selective inhibit ion of GSK3beta by \ndibromocantharelline: implications for rational dru g design. Chem Biol Drug Des  77 , 199-205. \n(146) Pande, V.; Ramos, M. J. (2005) Structural bas is for the GSK-3beta binding affinity and selectivi ty against CDK-2 of 1-(4-aminofurazan-\n3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-car boxylic acid derivatives. Bioorg Med Chem Lett  15 , 5129-5135. \n(147) ter Haar, E.; Coll, J. T.; Austen, D. A.; Hsi ao, H. M.; Swenson, L.; Jain, J. (2001) Structure o f GSK3beta reveals a primed \nphosphorylation mechanism. Nat Struct Biol  8, 593-596. \n(148) Gotz, J.; Ittner, L. M. (2008) Animal models of Alzheimer's disease and frontotemporal dementia.  Nat Rev Neurosci  9, 532-544. \n(149) Iijima-Ando, K.; Iijima, K. (2010) Transgenic  Drosophila models of Alzheimer's disease and tauop athies. Brain Struct Funct  214 , 245-\n262. \n(150) Wentzell, J.; Kretzschmar, D. (2010) Alzheime r's disease and tauopathy studies in flies and worm s. Neurobiol Dis  40 , 21-28. \n(151) Lucas, J. J.; Hernandez, F.; Gomez-Ramos, P.;  Moran, M. A.; Hen, R.; Avila, J. (2001) Decreased nuclear beta-catenin, tau \nhyperphosphorylation and neurodegeneration in GSK-3 beta conditional transgenic mice. EMBO J  20 , 27-39. \n(152) Perez, M.; Ribe, E.; Rubio, A.; Lim, F.; Mora n, M. A.; Ramos, P. G.; Ferrer, I.; Isla, M. T.; Av ila, J. (2005) Characterization of a double \n(amyloid precursor protein-tau) transgenic: tau pho sphorylation and aggregation. Neuroscience  130 , 339-347. \n(153) Ribe, E. M.; Perez, M.; Puig, B.; Gich, I.; L im, F.; Cuadrado, M.; Sesma, T.; Catena, S.; Sanche z, B.; Nieto, M.; Gomez-Ramos, P.; \nMoran, M. A.; Cabodevilla, F.; Samaranch, L.; Ortiz , L.; Perez, A.; Ferrer, I.; Avila, J.; Gomez-Isla,  T. (2005) Accelerated amyloid \ndeposition, neurofibrillary degeneration and neuron al loss in double mutant APP/tau transgenic mice. Neurobiol Dis  20 , 814-822. \n(154) Terwel, D.; Muyllaert, D.; Dewachter, I.; Bor ghgraef, P.; Croes, S.; Devijver, H.; Van Leuven, F . (2008) Amyloid activates GSK-3beta to \naggravate neuronal tauopathy in bigenic mice. Am J Pathol  172 , 786-798. \n(155) Lewis, J.; Dickson, D. W.; Lin, W. L.; Chisho lm, L.; Corral, A.; Jones, G.; Yen, S. H.; Sahara, N.; Skipper, L.; Yager, D.; Eckman, C.; \nHardy, J.; Hutton, M.; McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice exp ressing mutant tau and APP. \nScience  293 , 1487-1491. \n(156) Oddo, S.; Caccamo, A.; Shepherd, J. D.; Murph y, M. P.; Golde, T. E.; Kayed, R.; Metherate, R.; M attson, M. P.; Akbari, Y.; LaFerla, F. \nM. (2003) Triple-transgenic model of Alzheimer's di sease with plaques and tangles: intracellular Abeta  and synaptic dysfunction. \nNeuron  39 , 409-421.  \nSeite 87 (157) Lewis, J.; McGowan, E.; Rockwood, J.; Melrose , H.; Nacharaju, P.; Van Slegtenhorst, M.; Gwinn-Ha rdy, K.; Paul Murphy, M.; Baker, \nM.; Yu, X.; Duff, K.; Hardy, J.; Corral, A.; Lin, W . L.; Yen, S. H.; Dickson, D. W.; Davies, P.; Hutto n, M. (2000) Neurofibrillary tangles, \namyotrophy and progressive motor disturbance in mic e expressing mutant (P301L) tau protein. Nat Genet  25 , 402-405. \n(158) Paquet, D.; Bhat, R.; Sydow, A.; Mandelkow, E . M.; Berg, S.; Hellberg, S.; Falting, J.; Distel, M.; Koster, R. W.; Schmid, B.; Haass, C. \n(2009) A zebrafish model of tauopathy allows in viv o imaging of neuronal cell death and drug evaluatio n. J Clin Invest  119 , 1382-1395. \n(159) Paquet, D.; Schmid, B.; Haass, C. (2010) Tran sgenic Zebrafish as a Novel Animal Model to Study T auopathies and Other \nNeurodegenerative Disorders in vivo. Neurodegenerative Dis  7, 99-102. \n(160) Okawa, Y.; Ishiguro, K.; Fujita, S. C. (2003)  Stress-induced hyperphosphorylation of tau in the mouse brain. FEBS Lett  535 , 183-189. \n(161) Yoshida, S.; Maeda, M.; Kaku, S.; Ikeya, H.; Yamada, K.; Nakaike, S. (2006) Lithium inhibits str ess-induced changes in tau \nphosphorylation in the mouse hippocampus. J Neural Transm  113 , 1803-1814. \n(162) Leroy, K.; Brion, J. P. (1999) Developmental expression and localization of glycogen synthase ki nase-3beta in rat brain. J Chem \nNeuroanat  16 , 279-293. \n(163) Takahashi, M.; Tomizawa, K.; Ishiguro, K. (20 00) Distribution of tau protein kinase I/glycogen s ynthase kinase-3beta, phosphatases \n2A and 2B, and phosphorylated tau in the developing  rat brain. Brain Res  857 , 193-206. \n(164) Min, S. H.; Cho, J. S.; Oh, J. H.; Shim, S. B .; Hwang, D. Y.; Lee, S. H.; Jee, S. W.; Lim, H. J. ; Kim, M. Y.; Sheen, Y. Y.; Kim, Y. K. \n(2005) Tau and GSK3beta dephosphorylations are requ ired for regulating Pin1 phosphorylation. Neurochem Res  30 , 955-961. \n(165) Sato, N.; Meijer, L.; Skaltsounis, L.; Greeng ard, P.; Brivanlou, A. H. (2004) Maintenance of plu ripotency in human and mouse \nembryonic stem cells through activation of Wnt sign aling by a pharmacological GSK-3-specific inhibitor . Nat Med  10 , 55-63. \n(166) Gould, T. D.; Gray, N. A.; Manji, H. K. (2003 ) Effects of a glycogen synthase kinase-3 inhibitor , lithium, in adenomatous polyposis coli \nmutant mice. Pharmacol Res  48 , 49-53. \n(167) Martinez, A.; Castro, A.; Medina, M. (2006) G lycogen Synthase Kinase-3 (GSK-3) and Its Inhibitor s. John Wiley & Sons, Hoboken, NJ, \nUSA , 3-23. \n(168) Martinez, A.; Gil, C.; Perez, D. I. (2011) Gl ycogen Synthase Kinase 3 Inhibitors in the Next Hor izon for Alzheimer's Disease Treatment. \nInt J Alzheimers Dis  2011, 1-7. \n(169) Alon, L. T.; Pietrokovski, S.; Barkan, S.; Av rahami, L.; Kaidanovich-Beilin, O.; Woodgett, J. R. ; Barnea, A.; Eldar-Finkelman, H. (2011) \nSelective loss of glycogen synthase kinase-3alpha i n birds reveals distinct roles for GSK-3 isozymes i n tau phosphorylation. FEBS Lett  \n585 , 1158-1162. \n(170) Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klei n, P. S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta \npeptides. Nature  423 , 435-439. \n(171) Davis, M. I.; Hunt, J. P.; Herrgard, S.; Cice ri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; T reiber, D. K.; Zarrinkar, P. P. (2011) \nComprehensive analysis of kinase inhibitor selectiv ity. Nat Biotechnol  29 , 1046-1051. \n(172) Rauh, D. (2010) Inaktive Kinasekonformationen  stabilisieren. Nachrichten aus der Chemie  58 , 118-121. \n(173) Okada, K.; Sato, T.; Kohno, Y.; Nomura, M. (2 010) Kyorin Pharmaceutical Co., Ltd. WO 2010/104205 A1 . \n(174) Turner, S. C.; Bakker, M. H. M.; Hornberger, W.; Wolter, F. E. (2010) Abbott GmbH & Co. KG. WO 2010/109005 A1 . \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 88 4.1.2 Effiziente Synthese und Evaluierung von GSK-3 -Inhibitoren  \n \nDer Inhalt dieses Kapitels wurde bereits ver\u00f6ffentl icht: \n \nFabio Lo Monte*, Thomas Kramer*, Alexander Bol\u00e4nder , Batya Plotkin, Hagit Eldar-\nFinkelman, Ana Fuertes, Juan Dominguez, Boris Schmi dt \u2021  \nSynthesis and biological evaluation of glycogen syn thase kinase 3 (GSK-3) inhibitors: \nAn fast and atom efficient access to 1-aryl-3-benzy lureas, Bioorganic & Medicinal \nChemistry Letters  2011 , 21, 5610-5615. dx.doi.org/10.1016/j.bmcl.2011.06. 131  \nMit freundlicher Genehmigung von Elsevier Ltd. \n \n \nAR-A014418 ( 27 ) ist ein potenter und selektiver GSK-3-Inhibitor, der von der \nPharmafirma AstraZeneca publiziert und patentiert w urde. Aufgrund toxischer Daten \nin den klinischen Studien wurde eine analoge Strukt ur dieses Inhibitors nicht weiter \nverfolgt. Diese Verbindung wurde, aufgrund des stru kturellen Aufbaus, als \nLeitstruktur f\u00fcr die Inhibition von GSK-3 im Bereic h der Alzheimer-Demenz (AD) \nausgew\u00e4hlt. Der in unserem Assay  bestimmte IC 50 -Wert dieser Verbindung lag bei \n330 nM. \nDie Synthese des Harnstoffderivats 27  wird bei 100\u00b0C durchgef\u00fchrt und erfordert im \nAnschluss eine chromatographische Aufreinigung. Dur ch verschiedene \nUntersuchungen konnte eine schnelle und effiziente Synthesemethodik f\u00fcr \nHarnstoffderivate dieser Art etabliert werden. Die Synthese konnte bei \nRaumtemperatur durchgef\u00fchrt werden und erforderte k eine chromatographische \nAufreinigung. Dadurch war es m\u00f6glich viele Struktur en in k\u00fcrzester Zeit herzustellen. \nDie erhaltenen Strukturen wurden umkristallisiert u nd konnten anschlie\u00dfend durch \neine Suzuki-Kupplung bzw. Mikrowellensynthese weite r modifiziert werden (Abb. 17). \nDie Endprodukte konnten ebenfalls ohne chromatograp hische Aufreinigung isoliert \nwerden, indem sie kurz umkristallisiert wurden. Mit  Hilfe dieser Methode konnten die \nhergestellten Derivate f\u00fcr eine intensive Untersuch ung der Struktur-Aktivit\u00e4ts-\nBeziehung eingesetzt werden. Aufgrund dessen war es  m\u00f6glich, mehrere aktive und \nselektive GSK-3-Inhibitoren zu synthetisieren.  \n  \n \nAbb. 17: Schematische Darstellung der Synthesemethodik \n \nDie aktivste Verbindung, die durch diese Methodik h ergestellt werden konnte, hatte \neinen IC 50 -Wert von 98 nM \nAR-A014418 ( 27 ). Das molekulare \n\u00e4hnliches Bindungsverhalten wie AR \nder Struktur-Aktivit\u00e4ts- Beziehung. \nZebrafisch- Embryo nachgewiesen werden \nGegensatz zu Struktur 27  keine Toxizit\u00e4t aufwiesen.       \n \nDie im Rahmen dieser Arbeit von Fabio Lo Monte synt hetisierten Verbindungen: \n \nBSc4102 (4) , BSc4104 (44), BSc4106 (50), BSc4108 (48), BSc4111  (45), BSc4113 \n(51), BSc4115 (52), BSc4117 (49), BSc4145 (21), BSc 4147 (27), BSc4149 (24), \nBSc4151 (28), BSc4153 (25), BSc4155 (19), BSc4157 ( 23), BSc4159 (13), BSc4161 \n(10), BSc4163 (30), BSc4168 (18), BS \nBSc4192 (15), BSc4194 (32), BSc4196 (34), BSc4198 ( 36), BSc4200 (38), BSc4202 \n(58), BSc4206 (39), BSc4242 (60), BSc4244 (63), BSc 4248 (29), BSc4250 (66) \nIn Klammern die Verbindungsnummer in \nSeite 89 Schematische Darstellung der Synthesemethodik . \nDie aktivste Verbindung, die durch diese Methodik h ergestellt werden konnte, hatte \nWert von 98 nM f\u00fcr GSK-3 \u03b2 und ist somit dreimal aktiver als \nDas molekulare Docking  einer unserer Verbindungen \n\u00e4hnliches Bindungsverhalten wie AR -A014418 ( 27 ) und best\u00e4tigte die Ergebnisse \nBeziehung. Zudem konnte durch eine in vivo \nEmbryo nachgewiesen werden , dass die synthetisierten  \nkeine Toxizit\u00e4t aufwiesen.        \nDie im Rahmen dieser Arbeit von Fabio Lo Monte synt hetisierten Verbindungen: \n, BSc4104 (44), BSc4106 (50), BSc4108 (48), BSc4111  (45), BSc4113 \n(51), BSc4115 (52), BSc4117 (49), BSc4145 (21), BSc 4147 (27), BSc4149 (24), \nBSc4151 (28), BSc4153 (25), BSc4155 (19), BSc4157 ( 23), BSc4159 (13), BSc4161 \n(10), BSc4163 (30), BSc4168 (18), BS c4170 (7), BSc4188 (2), BSc4190 \nBSc4192 (15), BSc4194 (32), BSc4196 (34), BSc4198 ( 36), BSc4200 (38), BSc4202 \n(58), BSc4206 (39), BSc4242 (60), BSc4244 (63), BSc 4248 (29), BSc4250 (66) \ndie Verbindungsnummer in  der Publikation.   \nDie aktivste Verbindung, die durch diese Methodik h ergestellt werden konnte, hatte \nsomit dreimal aktiver als  \neiner unserer Verbindungen zeigte ein \nbest\u00e4tigte die Ergebnisse \nin vivo  Evaluation im \n Verbindungen im \nDie im Rahmen dieser Arbeit von Fabio Lo Monte synt hetisierten Verbindungen:  \n, BSc4104 (44), BSc4106 (50), BSc4108 (48), BSc4111  (45), BSc4113 \n(51), BSc4115 (52), BSc4117 (49), BSc4145 (21), BSc 4147 (27), BSc4149 (24), \nBSc4151 (28), BSc4153 (25), BSc4155 (19), BSc4157 ( 23), BSc4159 (13), BSc4161 \nc4170 (7), BSc4188 (2), BSc4190 (6), \nBSc4192 (15), BSc4194 (32), BSc4196 (34), BSc4198 ( 36), BSc4200 (38), BSc4202 \n(58), BSc4206 (39), BSc4242 (60), BSc4244 (63), BSc 4248 (29), BSc4250 (66)   \nSeite 90  \n \n \n \n \n \nSeite 91  \n \n \n \n \n \nSeite 92  \n \n \n \n \n \nSeite 93  \n \n \n \n \nSeite 94  \n \n \n \n \n \nSeite 95  \n \n \n \n \n \n \n \n \n \nSeite 96 Supporting Information \n \nSynthesis and biological evaluation of glycogen syn thase kinase 3 (GSK-3) \ninhibitors: an fast and atom efficient access to 1- aryl-3-benzylureas  \n \nFabio Lo Monte* a, Thomas Kramer* a, Alexander Bol\u00e4nder a, Batya Plotkin b, Hagit Eldar-Finkelman b,  \nAna Fuertes c, Juan M. Dominguez c and Boris Schmidt \u2020a  \na Clemens Sch\u00f6pf - Institute of Organic Chemistry an d Biochemistry, \nTechnische Universit\u00e4t Darmstadt, 64287 Darmstadt, Hessen, \nGermany, Fax: +496151-163278; Tel: +496151-164531; \n b Department of Human Molecular Genetics and Biochemi stry, Sackler School of Medicine,  \nTel Aviv University, Tel Aviv 69978, Israel, \nc Noscira S. A. Tres Cantos 28760, Madrid, Spain  \n\u2020 E-mail: schmidt_boris@t-online.de \n*These authors contributed equally to this work.  \n \n \n \n \n \nContent: \n \nGeneral procedure                 2  \nChemical Data                     3  \nGSK-3\u03b2 in vitro  assay               36      \nKinase panel                36   \nSeite 97 General procedure  \n \n1.) Synthesis of the urea derivatives  \nThe amine (0.80 mmol) was added to a stirred mixtur e of 5 ml saturated sodium bicarbonate solution \n(NaHCO 3) and 5 ml dichloromethane (DCM) at 0 \u00b0C. Afterward s triphosgene (0.28 mmol) was added \nslowly. After 2.5 h at 0 \u00b0C 10 ml of DCM were added  and the organic layer separated from the \naqueous phase. The aqueous phase was washed twice w ith 10 ml of DCM. The combined organic \nlayers were washed with ammonium chloride (NH 4Cl) and brine and later dried over sodium sulfate, \nfiltered and concentrated to approximately 0.5 ml. To the residue was added dry tetrahydrofuran \n(THF, 1.5 ml). It was added dropwise to a solution of n-buthyllithium (0.80 mmol, 1.6 M in n-hexane) \ndeprotonated amine (0.80 mmol) in 1.5 ml tetrahydro furan and stirred at room temperature overnight. \nThe reaction solution was added to a vigorous stirr ed water to give the solid crude urea. The solid wa s \nfiltered off and recrystallised from methanol or et hanol. \n \n2.) Suzuki coupling  \nAn urea derivative with a bromo substituent (0.15 m mol), boronic acid (0.19 mmol),  \nsodium ethoxide (0.31 mmol) and 1 mol-% of palladiu m acetate or 1 mol-% of \ntetrakis(triphenylphosphine)palladium(0) were suspe nded in 1 ml dry ethanol and stirred for 0.5 - 3 h \nat 110 \u00b0C. Afterwards the solution was filtered and  the solvent evaporated. The residue was added to \nwater and extracted three times with ethyl acetate.  The combined organic layers were dried over \nsodium sulfate, filtered and the solvent was evapor ated. The solid was recrystallised from ethanol or \nmethanol.    \n \n3.) Microwave synthesis  \nEntry 9, 1 2, 13  or  29 (0.10 mmol), sodium azide (NaN 3, 1.20 mmol) and ammonium chloride (NH 4Cl, \n1.20 mmol) were added to 1 ml of N,N-dimethylformamide (DMF)  and stirred for 2 h at 10 0 \u00b0C under \nmicrowave irradiation. After cooling to room temper ature the reaction solution was added to water, \nacidified with 2 N HCl and extracted three times wi th ethyl acetate. The combined organic layers were \ndried over sodium sulfate, filtered and the solvent  evaporated off to provide the product.    \n \n  \nSeite 98 F\nH\nNH\nN\nONBrF\nH\nNH\nN\nON\nIChemical Data  \nThe 1H-NMR spectra were recorded on a Bruker AC 300 spec trometer at 300 MHz and Bruker  \nAC 500 spectrometer at 500 MHz. The 13 C-NMR spectra were recorded on a Bruker AC 300 \nspectrometer at 75 MHz and Bruker AC 500 spectromet er at 125 MHz. Chemical shifts are reported as \nppm downfield from Me 4Si. Mass spectrometry was performed on a Bruker-Fra nzen Esquire LC mass \nspectrometer and a MAT 95 double focussing sector f ield MS.  Microwave experiments were carried \nout using a Biotage \u00ae Initiator \u2122 microwave apparatus. All microwave experiments wer e carried out in \nsealed microwave process vials utilizing the standa rd absorbance level (300 W maximum power). \nHigh performance liquid chromatographies were carri ed out on an Agilent 1100 (column: reversed \nphase, Zorbax Eclipse XDB-C8, 4.6 x 150 mm; 254 nm) .  Melting points were recorded on a SMP 10 \nBibby Stuart Scientific apparatus. \n \n \n1-(4-fluorobenzyl)-3-(5-iodopyridin-2-yl)urea (1) \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.35 (2H, d, J = 6.0 Hz), 6.91 (2H, m), 7. 17 (1H, d,  \nJ = 8.8 Hz), 7.28 (2H, m), 7.85 (1H, dd, J = 8.8, J  = 2.4); 8.24 (1H, dd, J = 2.2 Hz, J = 0.6 Hz), 8.4 8 \n(1H, s), 8.64 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):  \u03b4 [ppm] = 43.7, 82.3, 115.4, 116.1, 116.3, 130.5, 13 0.6, 137.5, \n137.6, 147.3, 153.7, 154.3, 156.0, 162.2, 164.1 \nEI-MS:  m/z  371 (M +) \nMelting Point: 169-171 \u00b0C \nHPLC-Retention Time:  6.7 min   \n  \n  \n1-(6-bromopyridin-2-yl)-3-(4-fluorobenzyl)urea (2) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.34 (2H, d, J = 5.9 Hz), 7.16 (3H, m), 7. 35 (2H, m), \n7.40 (1H, m), 7.62 (1H, m), 7.70 (1H, d, J = 8.2 Hz ), 9.56 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.2, 110.8, 115.4, 115.5, 120.8, 129.4, 1 36.2, 138.5, \n141.4, 153.8, 154.5 \nEI-MS:  m/z  323 (M +) \nMelting Point: 170 \u00b0C \nHPLC-Retention Time:  6.7 min     \n  \nSeite 99 O\nH\nNH\nN\nONBr\nF\nH\nNH\nN\nON\nBr\nO\nH\nNH\nN\nON\nBr1-(6-bromopyridin-2-yl)-3-(4-methoxybenzyl)urea (3)  \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.39 (3H, s), 4.34 (2H, d, J = 5.8 Hz), 6. 96 (2H, d,          \nJ = 8.6 Hz), 7.20 (1H, dd, J = 7.6 Hz, J = 0.6 Hz),  7.29 (2H, d, J = 8.7 Hz), 7.38 (1H, t, J = 5.7 Hz) , \n7.68 (1H, m), 7.76 (1H, dd, J = 8.2 Hz, J = 0.5 Hz) , 9.51 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 43.6, 56.5, 111.7, 115.3, 121.7, 129.9, 13 2.9, 139.6, \n142.5, 155.0, 155.5, 159.7 \nEI-MS:  m/z  335 (M +) \nMelting Point:  158 \u00b0C \nHPLC-Retention Time:  6.2 min     \n \n \n1-(5-bromopyridin-2-yl)-3-(4-fluorobenzyl)urea (4) \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.42 (2H, d, J = 5.8 Hz), 7.22 (2H, m), 7. 40 (2H, d,  \nJ = 8.6 Hz), 7.59 (1H, d, J = 8.9 Hz), 7.95 (1H, dd , J = 8.9 Hz, J = 2.5 Hz), 8.05 (1H, s), 8.35 (1H, d,  \nJ = 2.5 Hz), 9.44 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.2, 111.0, 113.8, 115.4, 129.5, 136.3, 1 40.9, 147.7, \n152.2, 154.4, 154.8 \nEI-MS:  m/z  323 (M +) \nMelting Point: 178-180 \u00b0C \nHPLC-Retention Time:  6.6 min     \n \n \n1-(5-bromopyridin-2-yl)-3-(4-methoxybenzyl)urea (5)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.37 (3H, s), 4.43 (2H, d, J = 5.8 Hz), 6. 90 (2H, \nd, J = 8.6 Hz), 7.22 (2H, d, J = 8.6 Hz), 7.54 (1H,  d, J = 8.9 Hz), 7.88 (1H, dd, J = 8.9 Hz,  \nJ = 2.5 Hz), 7.91 (1H, s), 8.27 (1H, d, J = 2.2 Hz) , 9.32 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.2, 55.5, 111.2, 113.7, 114.1, 128.8, 13 2.0, 140.8, \n147.8, 152.5, 154.7, 158.6 \nEI-MS:  m/z  335 (M +) \nMelting Point: 148-150 \u00b0C \nHPLC-Retention Time:  6.7 min     \n \n \n  \nSeite 100 O\nH\nNH\nN\nON\nBr\nF\nH\nNH\nN\nON\nCl\nO\nH\nNH\nN\nON\nCl1-(4-bromopyridin-2-yl)-3-(4-methoxybenzyl)urea (6)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 4.30 (2H, d, J = 5.8 Hz), 6. 90 (2H, d,          \nJ = 8.6 Hz), 7.17 (1H, dd, J = 5.4 Hz, J = 1.8 Hz),  7.23 (2H, d, J = 8.6 Hz), 7.79 (1H, d,  \nJ = 1.6 Hz), 8.00 (1H, s), 8.07 (1H, d, J = 5.5 Hz) , 9.36 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.0, 54.8, 113.6, 113.7, 119.6, 128.3, 13 1.4, 132.8, \n148.3, 154.1, 154.2, 158.1 \nEI-MS:  m/z  335 (M +) \nMelting Point: 176 \u00b0C \nHPLC-Retention Time:  5.3 min     \n \n \n1-(4-chloropyridin-2-yl)-3-(4-fluorobenzyl)urea (7)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.36 (2H, d, J = 6.0 Hz), 7.05 (1H, dd, J = 5.5 Hz,  \nJ = 1.9 Hz), 7.15 (2H, m), 7.35 (2H, m), 7.62 (1H, d, J = 1.8 Hz), 8.11 (1H, s), 8.16 (1H, d,  \nJ = 5.7 Hz), 9.44 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.3, 111.2, 115.4, 117.4, 129.4, 136.4, 1 44.2, 149.0, \n154.9, 160.5, 162.5 \nEI-MS:  m/z  279 (M +) \nMelting Point: 195-197 \u00b0C \nHPLC-Retention Time:  5.2 min     \n \n \n1-(4-chloropyridin-2-yl)-3-(4-methoxybenzyl)urea (8 ) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.97 (3H, s), 4.54 (2H, d, J = 5.9 Hz), 7. 12 (2H, d,          \nJ = 8.7 Hz), 7.29 (1H, dd, J = 5.5 Hz, J = 1.9 Hz),  7.47 (2H, d, J = 8.7 Hz), 7.87 (1H, d, J = 1.8 Hz) , \n8.23 (1H, s), 8.40 (1H, d, J = 5.7 Hz), 9.62 (1H, s ) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 40.7, 53.6, 109.2, 112.3, 115.6, 127.0, 13 0.1, 142.3, \n147.2, 152.9, 153.0, 156.8 \nEI-MS:  m/z  291 (M +) \nMelting Point: 186-188 \u00b0C \nHPLC-Retention Time:  4.9 min     \n \n  \nSeite 101 H\nNO\nH\nN\nON\nN+\nO\u2013OH\nNF\nH\nN\nON\nN+\nO\u2013OO\nH\nNH\nN\nON\nC\nN1-(4-cyanopyridin-2-yl)-3-(4-methoxybenzyl)urea (9)  \n \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.72 (3H, s), 4.29 (2H, d, J = 5.8 Hz), 6. 89 (2H, m), 7.23 \n(2H, m), 7.34 (1H, dd, J = 1.3 Hz, J = 5.1 Hz), 7.7 3 (1H, t, J = 5.6 Hz), 7.94 (1H, s), 8.41 (1H, dd,  \nJ = 0.6 Hz, J = 5.1 Hz), 9.55 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.1, 55.0, 113.4, 113.8, 116.9, 118.0, 12 0.7, 128.5, \n131.4, 149.0, 153.7, 154.2, 158.3 \nEI-MS:  m/z  282 (M +) \nHRMS:  calcd. for C 15 H14 N4O2 282.1117, found 282.1099. \nHPLC-Retention Time:  6.06 min     \n \n \n1-(4-fluorobenzyl)-3-(5-nitropyridin-2-yl)urea (10)  \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.38 (2H, m), 6.96 (2H, m), 7.30 (2H, m), 7.56 (1H, d,  \nJ = 8.0 Hz), 8.35 (2H, m), 8.90 (1H, s), 9.24 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):  \u03b4 [ppm] = 43.9, 112.6, 116.2, 116.4, 130.6, 134.8, 1 37.1, 140.3, \n145.5, 155.2, 158.8 \nEI-MS:  m/z  291 (M +) \nMelting Point: 207-209 \u00b0C \nHPLC-Retention Time:  6.3 min     \n \n \n1-(4-methoxybenzyl)-3-(5-nitropyridin-2-yl)urea (11 ) \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 4.32 (2H, d, J = 5.6 Hz), 6. 76 (2H, d,          \nJ = 8.4 Hz), 7.18 (2H, d, J = 8.3 Hz), 7.59 (1H, d,  J = 9.2 Hz), 8.19 (1H, s), 8.34 (1H, dd, J = 9.2 H z,  \nJ = 2.4 Hz), 8.90 (1H, d, J = 2.2 Hz), 9.15 (1H, s)  \n13 C-NMR (DMSO-d 6, 125 MHz):  \u03b4 [ppm] = 44.1, 55.9, 112.5, 115.1, 130.0, 132.8, 13 4.7, 140.2, \n145.5, 155.1, 158.9, 160.3 \nEI-MS:  m/z  302 (M +) \nHRMS:  calcd. for C 14 H14 N4O4 302.1015, found 302.0972. \nMelting Point: 189-191 \u00b0C \nHPLC-Retention Time:  6.1 min     \n  \nSeite 102 H\nNO\nH\nN\nON\nC\nNH\nNF\nH\nN\nON\nC\nN\nH\nNH\nN\nON\nC\nNBr1-(4-fluorobenzyl)-3-(5-cyanopyridin-2-yl)urea (12)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.43 (2H, d, J = 5.6 Hz), 7.21 (2H, m), 7. 41 (2H, m), \n7.75 (1H, d, J = 8.8 Hz), 8.11 (1H, m), 8.16 (1H, d d, J = 8.8 Hz,  J = 2.2 Hz), 8.69 (1H, m), 9.84 (1H, \nm) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.4, 101.3, 111.7, 114.2, 115.4, 115.6, 1 17.9, 128.7, \n129.4, 129.5, 136.1, 136.1, 141.6, 152.1, 154.4, 15 6.0, 160.6, 162.5 \nEI-MS:  m/z  270 (M +) \nHRMS:  calcd. for C 14 H11 N4OF 270.0918, found 270.0897. \nMelting Point: 221-222 \u00b0C \nHPLC-Retention Time:  5.7 min     \n \n \n1-(4-methoxybenzyl)-3-(5-cyanopyridin-2-yl)urea (13 ) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.79 (3H, s), 4.37 (2H, d, J = 5.0 Hz), 6. 96 (2H, d,          \nJ = 8.7 Hz), 7.29 (2H, d, J = 8.7 Hz), 7.76 (1H, d,  J = 8.9 Hz), 8.00 (1H, s), 8.15 (1H, dd, J = 8.8 H z,  \nJ = 2.3 Hz), 8.69 (1H, dd, J = 2.2 Hz, J = 0.6 Hz),  9.79 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.0, 54.8, 100.7, 111.1, 113.6, 117.3, 12 8.3, 131.1, \n141.0, 151.6, 153.7, 155.5, 158.1  \nEI-MS:  m/z  282 (M +) \nHRMS:  calcd. for C 15 H14 N4O2 282.1117, found 282.1104. \nMelting Point: 198-201 \u00b0C \nHPLC-Retention Time:  5.7 min     \n \n \n1-(4-bromobenzyl)-3-(5-cyanopyridin-2-yl)urea (14) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.43 (2H, d, J = 6.0 Hz), 7.34 (2H, d, J =  8.4 Hz), 7.60 \n(2H, d, J = 8.4 Hz), 7.75 (1H, d, J = 8.9 Hz), 8.15  (1H, d, J = 5.7 Hz), 8.18 (1H, dd,  \nJ = 8.8 Hz, J = 2.3 Hz), 8.72 (1H, d, J = 2.2 Hz), 9.89 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.4, 101.2, 111.6, 117.7, 120.1, 129.4, 1 29.6, 131.3, \n131.5, 139.4, 141.5, 152.0, 154.3, 155.9 \nEI-MS:  m/z  331 (M +) \nMelting Point: 224-226 \u00b0C \nHPLC-Retention Time:  6.5 min     \n  \nSeite 103 F\nH\nNH\nN\nONS\nN+\nO\u2013OH\nNH\nN\nON\nC\nNOCF\nFF\nH\nNH\nN\nON\nC\nNO\nO1-(5-cyanopyridin-2-yl)-3-(4-(trifluoromethyl)benzy l)urea (15) \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.48 (2H, d, J = 6.0 Hz), 7.39 (2H, d, J =  8.6 Hz), 7.49 \n(2H, d, J = 8.6 Hz), 7.75 (1H, d, J = 8.9 Hz), 8.17  (1H, dd, J = 8.8 Hz, J = 2.3 Hz), 8.18 (1H, s), 8. 71 \n(1H, dd, J = 2.3 Hz, J = 0.6 Hz), 9.88 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):  \u03b4 [ppm] = 42.4, 101.4, 117.9, 121.4, 129.3, 139.6, 1 41.6, 147.6, \n152.2, 154.4, 156.1 \nEI-MS:  m/z  336 (M +) \nMelting Point: 204 \u00b0C \nHPLC-Retention Time:  6.7 min     \n \n \n1-(benzo[d][1,3]dioxol-5-ylmethyl)-3-(5-cyanopyridi n-2-yl)urea (16) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.29 (2H, d, J = 5.9 Hz), 5.99 (2H, s), 6. 79 (1H, dd,          \nJ = 7.97 Hz, J = 1.6 Hz), 6.86 (1H, d, J = 7.9 Hz),  6.88 (1H, d, J = 1.6 Hz), 7.70 (1H, d, J = 8.9 Hz) , 7.96 \n(1H, t, J = 5.6 Hz), 8.10 (1H, dd, J = 8.8 Hz, J = 2.3 Hz), 8.64 (1H, dd, J = 2.3 Hz, J = 0.6 Hz), 9.7 4     \n(1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.9, 101.2, 101.3, 108.2, 108.5, 111.7, 1 17.9, 120.7, \n133.7, 141.6, 146.5, 147.7, 152.2, 154.3, 156.1 \nEI-MS:  m/z  296 (M +) \nMelting Point: 218 \u00b0C \nHPLC-Retention Time:  5.6 min     \n \n \n1-(4-fluorobenzyl)-3-(5-nitrothiazol-2-yl)urea (17)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.28 (2H, d, J = 6 Hz), 7.1 (2H, d, J = 8. 9 Hz), 7.29 (1H, \ns), 7.30 (2H, d, J = 8.7 Hz), 8.44 (1H, s), 11.64 ( 1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.8, 115.3, 115.5, 129.6, 129.7, 135.5, 1 43.7, 164.6 \nEI-MS:  m/z  296 (M +) \nMelting Point: 168-170 \u00b0C \nHPLC-Retention Time:  6.1 min     \n \n  \nSeite 104 O\nH\nNH\nN\nONS\nN+\nO\u2013O\nH\nNF\nH\nN\nONS\nOO\nO\nH\nNH\nN\nONSO\nO1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea (18 ) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.79 (3H, s), 4.36 (2H, d, J = 5.9 Hz), 6. 96 (2H, d,        \nJ = 8.7 Hz), 7.29 (1H, s), 7.30 (2H, d, J = 8.7 Hz) , 8.56 (1H, s), 11.67 (1H, s)  \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 40.7, 53.1, 111.8, 126.7, 128.7, 141.5, 15 6.5, 162.8  \nEI-MS:  m/z  308 (M +) \nMelting Point: 211-213 \u00b0C \nHPLC-Retention Time:  6.2 min     \n \n \nEthyl-2-(3-(4-fluorobenzyl)ureido)-4-methylthiazole -5-carboxylate (19) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 1.26 (3H, t, J = 7.1 Hz), 2.48 (3H, s), 4. 21 (2H, q,         \nJ = 7.1 Hz), 4.33 (2H, d, J = 5.9 Hz), 7.14 (1H, s) , 7.17 (2H, d, J = 8.9 Hz), 7.35 (2H, d, J = 8.6 Hz ), \n10.94 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 12.7, 15.3, 40.8, 58.7, 111.3, 113.6, 127. 8, 134.0, 152.1, \n154.9, 158.8, 160.2, 160.7 \nEI-MS:  m/z  337 (M +) \nMelting Point: 293-295 \u00b0C \nHPLC-Retention Time:  6.4 min     \n \n \nEthyl-2-(3-(4-methoxybenzyl)ureido)-4-methylthiazol e-5-carboxylate (20)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 1.27 (3H, t, J = 7.1 Hz), 2.48 (3H, s), 3. 74 (3H, s), 4.21 \n(2H, q, J = 7.1 Hz), 4.26 (2H, d, J = 5.8 Hz), 6.90  (2H, d, J = 8.6 Hz), 7.02 (1H, s), 7.23 (2H, d,  \nJ = 8.6 Hz), 10.83 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 14.6, 17.4, 42.8, 55.4, 60.5, 113.1, 114.2 , 129.1, 131.5, \n153.9, 156.8, 158.8, 162.1, 162.6 \nEI-MS:  m/z  349 (M +) \nMelting Point: 243-247 \u00b0C \nHPLC-Retention Time:  6.3 min     \n \n \n  \nSeite 105 H\nNH\nN\nONSOH\nNH\nN\nONSF\nH\nNF\nH\nN\nONS\nBr1-(4-fluorobenzyl)-3-(4-p-tolylthiazol-2-yl)urea (2 1) \n \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 2.36 (3H, s), 4.38 (2H, d, J = 6.0 Hz), 7. 07 (1H, t,           \nJ = 5.7 Hz), 7.21 (1H, m), 7.24 (2H, d, J = 7.9 Hz) , 7.40 (3H, m), 7.78 (2H, d, J = 8.1 Hz), 10.73  \n(1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 21.2, 42.6, 106.1, 115.4, 125.8, 129.5, 13 2.1, 136.2, \n137.2, 149.0, 154.4, 160.1, 160.6, 162.6 \nEI-MS:  m/z  341 (M +) \nMelting Point: 179-180 \u00b0C \nHPLC-Retention Time:  7.5 min     \n \n \n1-(4-methoxybenzyl)-3-(4-p-tolylthiazol-2-yl)urea ( 22) \n \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 2.31 (3H, s), 3.74 (3H, s), 4.28 (2H, d, J  = 5.9 Hz), 6.91 \n(2H, d, J = 8.7 Hz), 6.94 (1H, m), 7.20 (2H, d, J =  8.0 Hz), 7.25 (2H, d, J = 8.7 Hz), 7.36 (1H, s), 7 .74 \n(2H, d, J = 8.1 Hz), 10.60 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 21.1, 42.7, 55.4, 106.0, 114.2, 125.8, 129 .0, 129.6, \n131.8, 132.2, 137.2, 149.0, 154.3, 158.7, 160.1 \nEI-MS:  m/z  353 (M +) \nMelting Point: 163 \u00b0C \nHPLC-Retention Time:  7.4 min     \n \n \n1-(6-bromobenzo[d]thiazol-2-yl)-3-(4-fluorobenzyl)u rea (23) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.41 (2H, d, J = 5.8 Hz), 7.22 (2H, d, J =  8.8 Hz), 7.29 \n(1H, s), 7.42 (2H, d, J = 8.2 Hz), 7.54 (1H, dd, J = 8.5 Hz, J = 1.7 Hz), 7.60 (1H, d,       \nJ = 8.5 Hz), 8.16 (1H, d, J = 1.0 Hz), 10.97 (1H, s ) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.7, 114.7, 115.5, 121.6, 124.2, 129.1, 1 29.7, 134.1, \n135.9, 154.2, 160.7, 160.9, 162.6 \nEI-MS:  m/z  380 (M +) \nMelting Point: 203-205 \u00b0C \nHPLC-Retention Time:  7.4 min      \nSeite 106 H\nNO\nH\nN\nONS\nC\nFF\nFH\nNH\nN\nONSO\nF\nH\nNF\nH\nN\nONS\nC\nFF\nF1-(6-fluorobenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl )-urea (24) \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 4.31 (2H, d, J = 5.8 Hz), 6. 91 (2H, d,         \nJ = 8.6 Hz), 7.12 (1H, s), 7.20 (1H, m), 7.27 (2H, d, J = 8.6 Hz), 7.61 (1H, m), 7.79 (1H, m) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.8, 55.4, 108.2, 113.9, 114.2, 121.0, 12 9.0, 131.5, \n133.0, 154.1, 157.6, 158.7, 159.5, 160.1 \nEI-MS:  m/z  331 (M +) \nMelting Point: 296-299 \u00b0C \nHPLC-Retention Time:  6.6 min     \n \n \n1-(4-fluorobenzyl)-3-(6-trifluormethyl)benzo[d]thia zol-2-yl)urea (25) \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.41 (2H, d, J = 5.9 Hz), 7.22 (2H, d, J =  8.9 Hz), 7.34 \n(1H, s), 7.42 (2H, d, J = 8.6 Hz), 7.71 (1H, dd, J = 8.5 Hz, J = 1.6 Hz), 7.82 (1H, d,     \nJ = 8.4 Hz), 8.43 (1H, s), 11.16 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.7, 115.5, 119.8, 120.3, 123.0, 124.0, 1 26.1, 129.7, \n132.5, 135.8, 154.2, 160.7, 162.6, 163.3 \nEI-MS:  m/z  369 (M +) \nMelting Point: 188-190 \u00b0C \nHPLC-Retention Time:  7.4 min     \n \n \n1-(4-methoxybenzyl)-3-(6-trifluormethyl)benzo[d]thi azol-2-yl)urea (26) \n \n \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 4.32 (2H, d, J = 5.8 Hz), 6. 92 (2H, d,        \nJ = 8.6 Hz), 7.18 (1H, s), 7.26 (2H, d, J = 8.6 Hz) , 7.66 (1H, dd, J = 8.5 Hz, J = 1.6 Hz), 7.76 (1H, d,  \nJ = 8.4 Hz), 8.36 (1H, s), 11.01 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 43.0, 55.4, 114.3, 119.8, 120.3, 123.0, 12 3.3, 124.0, \n126.1, 129.1, 131.4, 152.4, 154.0, 158.8, 163.3 \nEI-MS:  m/z  381 (M +) \nMelting Point: 225-227 \u00b0C \nHPLC-Retention Time:  7.3 min     \n  \nSeite 107 H\nNO\nH\nN\nONS\nN+\nO\u2013O\nH\nNF\nH\nN\nONS\nN+\nO\u2013OF1-(4-methoxybenzyl)-3-(6-nitrobenzo[d]thiazol-2-yl) urea (27) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 4.32 (2H, d, J = 5.8 Hz), 6. 92 (2H, d,       \nJ = 8.6 Hz), 7.23 (1H, s), 7.26 (2H, d, J = 8.6 Hz) , 7.75 (1H, d, J = 8.9 Hz), 8.21 (1H, dd,                  \nJ = 8.9 Hz, J = 2.4 Hz), 8.94 (1H, d, J = 2.3 Hz), 11.23 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.9, 55.4, 114.4, 118.7, 119.8, 122.0, 12 9.1, 131.3, \n132.6, 142.7, 155.8, 155.9, 158.7, 165.7 \nEI-MS:  m/z  358 (M +) \nHRMS:  calcd. for C 16 H14 N4O4S 358.0736, found 358.0717. \nMelting Point: 270 \u00b0C \nHPLC-Retention Time:  6.8 min     \n \n \n1-(3,4-difluorobenzyl)-3-(6-nitrobenzo[d]thiazol-2- yl)urea (28) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.37 (2H, d, J = 5.9 Hz), 7.18 (1H, m), 7. 4 (3H, m), 7.76 \n(1H, d, J = 8.9 Hz), 8.22 (1H, dd, J = 8.9 Hz, J = 2.5 Hz), 8.94 (1H, d, J = 2.3 Hz), 11.42 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 43.9, 118.0, 119.2, 120.3, 121.3, 123.4, 1 25.7, 134.0, \n138.9, 144.1, 149.2, 150.1, 151.2, 152.0, 167.1 \nEI-MS:  m/z  364 (M +) \nMelting Point: 210 -212 \u00b0C \nHPLC-Retention Time:  7.1 min     \n \n \n1-(6-cyanobenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl) urea (29) \n \nO\nH\nNH\nN\nONS\nCN\n \n1H-NMR (DMSO-d 6, 300 MHz):  \u03b4 [ppm] = 3.73 (3H, s), 4.31 (2H, d, J = 5.8 Hz), 6. 90 (2H, m), 7.25 \n(3H, m), 7.75 (2H, d, J = 1.1 Hz), 8.45 (1H, m), 11 .34 (1H, s) \n13 C-NMR (DMSO-d 6, 75 MHz):   \u03b4 [ppm] = 42.4, 55.0, 104.2, 113.7, 119.3, 120.1, 12 0.1, 126.3, \n128.6, 129.4, 130.9, 132.2, 152.3, 153.6, 158.3, 16 3.6 \nEI-MS:  m/z  338 (M +) \nHRMS:  calcd. for C 17 H14 N4O2S 338.0838, found 338.0840. \nHPLC-Retention Time:  6.59 min     \nThe precursor of compound 29 (2-aminobenzo[d]thiazole-6-carbonitrile) was synthe sized according to \nfollowing literature: Structural Chemistry, 2003, 1 4, 6, 587-595. \n  \nSeite 108 H\nNO\nH\nN\nOOH\nNF\nH\nN\nOF\nF\nH\nNH\nN\nON1,3-bis(4-fluorobenzyl)urea (30)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.26 (4H, d, J = 6.0 Hz), 6.51 (2H, t, J =  6.0 Hz), 7.18 \n(4H, d, J = 8.9 Hz), 7.33 (4H, d, J = 8.7 Hz) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.6, 115.1, 115.3, 129.2, 129.3, 137.4, 1 37.5, 158.4, \n160.4, 162.4 \nEI-MS:  m/z  276 (M +) \nMelting Point: 218 -220 \u00b0C \nHPLC-Retention Time:  5.9 min   \n \n \n1,3-bis(4-methoxybenzyl)urea (31)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.78 (6H, s), 4.20 (4H, d, J = 6.0 Hz), 6. 33 (2H, t,         \nJ = 5.9 Hz), 6.92 (4H, d, J = 8.7 Hz), 7.22 (4H, d,  J = 8.7 Hz) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.8, 55.4, 114.0, 128.7, 133.1, 158.3, 15 8.4 \nEI-MS:  m/z  300 (M +) \nMelting Point: 178 -180 \u00b0C \nHPLC-Retention Time:  5.5 min     \n \n \n1-(4-fluorobenzyl)-3-(6-phenylpyridin-2-yl)urea (32 ) \n \n \n \n \n1H-NMR (DMSO-d 6, 300 MHz):  \u03b4 [ppm] = 4.41 (2H, d, J = 5.5 Hz), 7.18 (2H, m), 7. 29 (1H, d,  \nJ = 8.1 Hz), 7.40 (5H, m), 7.46 (1H, dd, J = 7.6 Hz , J = 0.6 Hz), 7.77 (3H, m), 8.78 (1H, t, J = 5.5 H z), \n9.45 (1H, s) \n13 C-NMR (DMSO-d 6, 75 MHz):   \u03b4 [ppm] = 42.3, 110.5, 113.4, 115.1, 115.4, 126.2, 1 28.7, 129.0, \n129.5, 129.6, 135.6, 135.7, 138.1, 139.3, 153.2, 15 3.5, 154.4 \nEI-MS: m/z  321 (M +)   \nMelting Point: 204-206 \u00b0C \nHPLC-Retention Time: 6.8  min \n \n \n \n  \nSeite 109 O\nH\nNH\nN\nON\nF\nH\nNH\nN\nONF\nF\nH\nNH\nN\nONO1-(4-methoxybenzyl)-3-(6-phenylpyridin-2-yl)urea (3 3) \n \n \n \n \n1H-NMR (DMSO-d 6, 300 MHz):  \u03b4 [ppm] = 3.75 (3H, s), 4.35 (2H, d, J = 5.3 Hz), 6. 93 (2H, m), 7.25 \n(1H, m), 7.30 (2H, m), 7.37 (3H, m), 7.45 (1H, m), 7.75 (3H, m), 8.80 (1H, s), 9.42 (1H, s) \n13 C-NMR (DMSO-d 6, 75 MHz):   \u03b4 [ppm] = 42.5, 55.2, 110.5, 113.3, 114.0, 126.2, 12 8.5, 129.1, \n131.2, 138.1, 139.3, 153.2, 153.4, 154.6, 158.4 \nEI-MS: m/z  333 (M +)    \nMelting Point:  202-203 \u00b0C   \nHPLC-Retention Time: 6.7  min  \n \n \n1-(4-fluorobenzyl)-3-(6-(3-fluorophenyl)pyridin-2-y l)urea (34) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.54 (2H, d, J = 5.6 Hz), 7.31 (2H, m), 7. 38 (1H, m), \n7.55 (4H, m), 7.67 (1H, d, J = 7.6 Hz), 7.80 (2H, m ), 7.93 (1H, m), 8.60 (1H, t, J = 5.1 Hz), 9.57 \n(1H,s)       \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 43.7, 112.6, 114.3, 114.5, 115.3, 116.5, 1 16.6, 116.8, \n117.2, 117.4, 123.7, 130.8, 130.9, 132.1, 132.2, 13 7.3, 140.9, 154.7, 156.1, 161.7 \nEI-MS: m/z  339 (M +)     \nMelting Point:  158-159 \u00b0C   \nHPLC-Retention Time: 7.3  min \n \n \n1-(4-fluorobenzyl)-3-(6-(3-methoxyphenyl)pyridin-2- yl)urea (35) \n \n \n \n \n \n1H-NMR (DMSO-d 6, 300 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 4.42 (2H, d, J = 5.6 Hz), 6. 97 (1H, m), 7.17 \n(2H, d, J = 8.8 Hz), 7.35 (6H, m), 7.47 (1H, d, J =  7.8 Hz), 7.76 (1H, t, J = 8.3 Hz), 8.74 (1H, t,  \nJ = 5.3 Hz), 9.43 (1H, s)       \n13 C-NMR (DMSO-d 6, 75 MHz):   \u03b4 [ppm] = 42.1, 55.0, 110.6, 111.5, 113.6, 114.8, 11 5.0, 115.3, \n118.6, 129.2, 129.3, 129.8, 135.8, 139.2, 139.7, 15 3.1, 153.4, 154.8, 159.6 \nEI-MS: m/z  351 (M +)    \nMelting Point: 131 \u00b0C \nHPLC-Retention Time: 7.0  min \n \n  \nSeite 110 O\nH\nNH\nN\nONO\nF\nH\nNH\nN\nONO\nF\nH\nNH\nN\nONN1-(4-methoxybenzyl)-3-(6-(3-methoxyphenyl)pyridin-2 -yl)urea (36) \n \n \n \n \n1H-NMR (DMSO-d 6, 300 MHz):  \u03b4 [ppm] = 3.74 (6H, m), 4.35 (2H, d, J = 5.5 Hz), 6. 90 (2H, d, \nJ = 8.2 Hz), 6.97 (1H, m), 7.30 (5H, m), 7.40 (1H, s), 7.47 (1H, d, J = 7.6 Hz), 7.75 (1H, m), 8.71 (1 H, \ns), 9.40 (1H, s)       \n13 C-NMR (DMSO-d 6, 75 MHz):   \u03b4 [ppm] = 42.3, 55.1, 110.6, 111.5, 113.5, 113.8, 11 4.7, 118.5, \n128.7, 129.6, 131.4, 139.4, 139.7, 153.2, 153.4, 15 4.7, 158.3, 159.6 \nEI-MS: m/z  363 (M +)     \nMelting Point: 186 \u00b0C \nHPLC-Retention Time: 6.8  min \n \n \n1-(6-(3-benzyloxy)phenyl)pyridin-2-yl)-3-(4-fluorob enzyl)urea (37) \n \n \n \n \n \n \n \n1H-NMR (DMSO-d 6, 300 MHz):  \u03b4 [ppm] = 4.41 (2H, d, J = 5.7 Hz), 5.11 (2H, s), 7. 10 (3H, m), 7.37 \n(10H, m), 7.47 (1H, d, J = 7.1 Hz), 7.53 (1H, m), 7 .76 (1H, m), 8.74 (1H, t,  \nJ = 5.1 Hz), 9.43 (1H, s) \n13 C-NMR (DMSO-d 6, 75 MHz):   \u03b4 [ppm] = 42.1, 69.2, 110.6, 112.7, 113.6, 115.0, 11 5.5, 118.7, \n127.7, 127.9, 128.4, 129.2, 129.3, 129.8, 135.8, 13 6.9, 139.2, 139.7, 153.1, 153.3, 154.7, 158.8  \nEI-MS: m/z  427 (M +)     \nMelting Point: 159-160 \u00b0C   \nHPLC-Retention Time: 8.2  min \n \n \n1-(2,4\u00b4-bipyridin-6-yl)-3-(4-fluorobenzyl)urea (38)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.41 (2H, d, J = 5.5 Hz), 7.20 (2H, m), 7. 42 (2H, m), \n7.49 (1H, d, J = 8.2 Hz), 7.64 (1H, d, J = 7.4 Hz),  7.77 (2H, d, J = 4.5 Hz), 7.85 (1H, t,  \nJ = 7.7 Hz), 8.47 (1H, s), 8.61 (2H, d, J = 4.5 Hz) , 9.51 (1H, s)       \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.7, 112.8, 114.7, 115.5, 115.7, 120.8, 1 29.9, 130.0, \n130.2, 130.3, 139.9, 145.4, 150.6, 151.4, 153.8, 15 4.9 \nEI-MS: m/z  322 (M +)      \nMelting Point:  206 \u00b0C   \nHPLC-Retention Time:  3.5  min  \nSeite 111 F\nH\nNH\nN\nON\nO\nH\nNH\nN\nONO\nH\nNH\nN\nONN1-(2,4\u00b4-bipyridin-6-yl)-3-(4-methoxybenzyl)urea (39 ) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.76 (3H, s), 4.35 (2H, d, J = 5.3 Hz), 6. 95 (2H, m), 7.32 \n(2H, m), 7.44 (1H, d, J = 8.2 Hz), 7.63 (1H, d, J =  7.5 Hz), 7.72 (2H, d, J = 4.5 Hz), 7.84 (1H, m), 8 .52 \n(1H, s), 8.57 (2H, d, J = 4.5 Hz), 9.49 (1H,s)       \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.3, 54.7, 112.1, 113.6, 113.7, 120.1, 12 8.7, 130.8, \n139.2, 144.7, 149.9, 150.5, 153.2, 154.1, 158.3 \nEI-MS: m/z  334 (M +)      \nMelting Point:   192 \u00b0C   \nHPLC-Retention Time:  2.8 min \n \n \n1-(4-fluorobenzyl)-3-(5-phenylpyridin-2-yl)urea (40 )  \n \n \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 4.44 (2H, d, J = 4.9 Hz), 7.00 (2H, d, J =  8.9 Hz), 7.27 \n(2H, m), 7.35 (4H, m), 7.55 (2H, d, J = 8.0 Hz), 7. 90 (1H, dd, J = 8.7 Hz,  J = 2.5 Hz), 8.37 (1H, d,  \nJ = 2.2 Hz), 8.79 (1H, s), 9.16 (1H, s)  \n13 C-NMR (Acetone-d 6, 125 MHz):  \u03b4 [ppm] = 45.5, 115.0, 118.1, 129.5, 130.8, 132.2, 1 32.4, 132.9, \n139.6, 139.9, 140.8, 147.6, 156.2, 164.1, 166.0 \nEI-MS:  m/z  321 (M +) \nMelting Point: 168-170 \u00b0C \nHPLC-Retention Time:  5.8 min   \n \n \n1-(4-methoxybenzyl)-3-(5-phenyl)pyridin-2-yl)urea ( 41) \n \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 4.35 (2H, d, J = 5.8 Hz), 6. 77 (2H, d,  \nJ = 8.6 Hz), 7.18 (2H, d, J = 8.7 Hz), 7.22 (2H, m) , 7.32 (2H, t, J = 7.6 Hz), 7.51 (2H, d,  \nJ = 8.0 Hz), 7.85 (1H, dd, J = 8.6 Hz, J = 2.5 Hz),  8.31 (1H, d, J = 2.2 Hz), 8.8 (1H, s), 8.98 (1H, s ) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 43.8, 55.9, 113.2, 115.1, 127.6, 128.7, 12 9.9, 130.2, \n130.9, 133.4, 137.9, 138.8, 145.6, 154.4, 156.4, 16 0.2 \nEI-MS:  m/z  333 (M +) \nMelting Point: 134 \u00b0C \nHPLC-Retention Time:  5.7 min   \n  \nSeite 112 F\nH\nNH\nN\nON\nFO\nH\nNH\nN\nONF\nH\nNH\nN\nON1-(4-fluorobenzyl)-3-(5-p-tolylpyridin-2-yl)urea (4 2) \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 2.3 (3H, s), 4.41 (2H, d, J = 5.9 Hz), 6.9 5 (2H, d,         \nJ = 8.8 Hz), 7.14 (2H, d, J = 7.9 Hz), 7.19 (1H, d,  J = 8.6), 7.30 (2H, m), 7.38 (2H, d, J = 8.1 Hz), 7.84 \n(1H, dd, J = 8.6 Hz, J = 2.4 Hz), 8.30 (1H, d, J = 2.2 Hz), 8.8 (1H, s), 9.15 (1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 23.8, 46.0, 115.3, 118.4, 118.6, 129.8, 13 2.8, 133.2, \n138.2, 140.1, 140.7, 147.7, 156.4, 158.8, 164.4, 16 6.4 \nEI-MS:  m/z  335 (M +) \nMelting Point: 182 \u00b0C \nHPLC-Retention Time:  6.1 min   \n \n \n1-(4-methoxybenzyl)-3-(5-p-tolylpyridin-2-yl)urea ( 43) \n \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 2.22 (3H, s), 3.63 (3H, s), 4.34 (2H, d, J  = 5.8 Hz), 6.76 \n(2H, d, J = 8.7 Hz), 7.14 (2H, d, J = 8.0 Hz), 7.19  (3H, m), 7.38 (2H, d, J = 8.1 Hz), 7.82 (1H, dd,  \nJ = 8.6 Hz, J = 2.5 Hz), 8.25 (1H, d, J = 2.3 Hz), 8.73 (1H, s), 8.98 (1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 22.4, 44.8, 56.8, 113.8, 116.0, 128.4, 130 .8, 131.8, \n131.9, 134.4, 136.8, 138.7, 139.3, 146.2, 155.1, 15 7.2, 161.1  \nEI-MS:  m/z  347 (M +) \nMelting Point: 122-124 \u00b0C \nHPLC-Retention Time:  6.0 min   \n \n \n1-(4-fluorobenzyl)-3-(5-(3-fluorophenyl)pyridin-2-y l)urea (44)  \n \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 4.40 (2H, d, J = 4.5 Hz), 6.97 (3H, m), 7. 30 (4H, m), \n7.37 (2H, m), 7.90 (1H, dd, J = 8.7 Hz, J = 2.5 Hz) , 8.37 (1H, d, J = 2.3 Hz), 8.72 (1H, s), 9.02  \n(1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 44.0, 113.6, 114.8, 115.9, 116.9, 124.1, 1 30.2, 131.1, \n132.8, 138.2, 141.8, 146.5, 155.2, 164.2, 164.8, 16 6.2 \nEI-MS:  m/z  339 (M +) \nMelting Point: 176 \u00b0C \nHPLC-Retention Time:  6.2 min   \n  \nSeite 113 O\nH\nNH\nN\nON\nF\nF\nH\nNH\nN\nON\nO\nO\nH\nNH\nN\nON\nO1-(5-(3-fluoroyphenyl)pyridin-2-yl)-3-(4-methoxyben zyl)urea (45) \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 4.35 (2H, d, J = 5.8 Hz), 6. 76 (2H, d, \nJ = 8.7 Hz), 6.98 (1H, m), 7.18 (2H, d, J = 8.5 Hz) , 7.25 (1H, d, J = 8.7 Hz), 7.30 (1H, d, J = 10.5 H z), \n7.36 (2H, m), 7.88 (1H, dd, J = 8.7 Hz, J = 2.5 Hz) , 8.36 (1H, d, J = 2.4 Hz), 8.80 (1H, s), 8.92 (1H,  s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 43.8, 55.9, 113.0, 114.1, 114.2, 115.1, 11 5.3, 123.5, \n129.5, 129.9, 132.2, 133.4, 138.0, 141.2, 145.9, 15 4.8, 156.2, 160.2, 163.6, 165.6  \nEI-MS:  m/z  351 (M +) \nMelting Point: 162 \u00b0C \nHPLC-Retention Time:  6.0 min   \n \n \n1-(4-fluorobenzyl)-3-(5-(3-methoxyphenyl)pyridin-2- yl)urea (46)  \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 3.72 (3H, s), 4.41 (2H, d, J = 5.9 Hz), 6. 80 (1H, dd,     \nJ = 1.7 Hz,  J = 8.3 Hz), 6.96 (2H, m), 7.06 (2H, m), 7.22 (2H, m), 7.31 (2H, m), 7.86 (1H, dd,  \nJ = 8.6 Hz,  J = 2.5 Hz), 8.33 (1H, d, J = 2.3 Hz), 8.77 (1H, s) , 9.12 (1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 43.8, 56.0, 113.0, 114.4, 116.4, 119.9, 13 0.6, 130.9, \n131.4, 137.8, 138.1, 140.2, 145.7, 154.4, 156.4, 16 1.7, 162.2, 164.8 \nEI-MS:  m/z  351 (M +) \nMelting Point: 124 \u00b0C \nHPLC-Retention Time:  5.9 min   \n \n \n1-(4-methoxybenzyl)-3-(5-(3-methoxyphenyl)pyridin-2 -yl)urea (47)  \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 3.73 (3H, s), 4.34 (2H, d, J  = 5.8 Hz), 6.77 \n(2H, d, J = 8.7 Hz), 6.79 (1H, d, J = 8.4 Hz), 7.06  (2H, d, J = 8.4 Hz), 7.19 (2H, d, J = 8.7 Hz), 7.2 4 \n(2H, d, J = 7.8 Hz), 7.85 (1H, dd, J = 8.6 Hz,  J = 2.5 Hz), 8.32 (1H, d, J = 2.9 Hz), 8.76 (1H, s) , 8.97 \n(1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 43.8, 55.9, 56.0, 112.9, 113.1, 114.3, 115 .1, 119.8, \n123.5, 129.9, 130.7, 131.4, 133.4, 138.0, 140.2, 14 5.7, 154.5, 156.4, 160.2, 161.7 \nEI-MS:  m/z  363 (M +) \nMelting Point: 140-142 \u00b0C \nHPLC-Retention Time:  5.8 min \n  \nSeite 114 F\nH\nNH\nN\nON\nOO\nH\nNH\nN\nON\nOF\nH\nNH\nN\nON\nO1-(4-fluorobenzyl)-3-(5-(3-isopropoxyphenyl)pyridin -2-yl)urea (48)  \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 1.18 (3H, d, J = 2.2 Hz), 1.19 (3H, d, J =  2.2 Hz), 4.41 \n(2H, d, J = 5.9 Hz), 4.58 (1H, m), 6.77 (1H, m),  6 .95 (2H, m), 7.03 (2H, m), 7.21 (2H, m), 7.30 (2H, \nm), 7.85 (1H, dd, J = 8.6 Hz, J = 2.5 Hz), 8.32 (1H , d, J = 2.4 Hz), 8.81 (1H, s), 9.14 (1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 20.9, 41.8, 68.8, 111.1, 113.2, 114.3, 114 .4, 117.8, \n128.6, 129.1, 129.5, 136.2, 138.4, 143.8, 152.5, 15 4.6, 158.1, 160.4, 162.2 \nEI-MS:  m/z  379 (M +) \nMelting Point: 99-100 \u00b0C \nHPLC-Retention Time:  6.7 min \n \n \n1-(5-(3-isopropoxyphenyl)pyridin-2-yl)-3-(4-methoxy benzyl)urea (49)  \n \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 1.17 (3H, d, J = 2.0 Hz), 1.19 (3H, d, J =  2.0 Hz), 3.62 \n(3H, s), 4.35 (2H, d, J = 5.8 Hz), 4.57 (1H, m), 6. 75 (2H, d, J = 8.7 Hz), 6.77 (1H, m), 7.02 (2H, m),  \n7.20 (4H, m), 7.83 (1H, dd, J = 8.6 Hz, J = 2.5 Hz) , 8.31 (1H, d, J = 2.5 Hz), 8.98 (1H, s), 9.07 (1H,  s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 22.7, 43.9, 55.8, 70.7, 113.0, 115.0, 115. 1, 116.1, \n119.7, 129.8, 130.7, 131.4, 133.4, 138.1, 140.2, 14 5.6, 154.5, 156.6, 159.9, 160.4  \nEI-MS:  m/z  391 (M +) \nMelting Point: 126-128 \u00b0C \nHPLC-Retention Time:  6.5 min \n \n \n1-(5-(3-benzyloxy)phenyl)pyridin-2-yl)-3-(4-fluorob enzyl)urea (50)  \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 4.40 (2H, d, J = 5.8 Hz), 5.07 (2H, s), 6. 86 (1H, dd,  \nJ = 2.5 Hz,  J = 7.5 Hz), 6.95 (2H, d, J = 8.8 Hz), 7.08 (1H, d,  J = 7.0 Hz), 7.25 (8H, m), 7.37 (2H, d,  \nJ = 7.5 Hz), 7.86 (1H, dd, J = 8.6 Hz,  J = 2.5 Hz), 8.34 (1H, d, J = 2.1 Hz), 8.74 (1H, s) , 9.09 (1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 43.8, 71.0, 113.0, 114.1, 115.3, 116.2, 12 0.1, 120.7, \n129.0, 129.7, 130.5, 130.8, 131.4, 137.8, 138.1, 13 8.8, 140.3, 145.8, 154.5, 156.4, 160.9, 164.1 \nEI-MS:  m/z  427 (M +) \nMelting Point: 144 \u00b0C \nHPLC-Retention Time:  7.6 min \n  \nSeite 115 O\nH\nNH\nN\nON\nF\nFFO\nH\nNH\nN\nON\nO\nF\nH\nNH\nN\nON\nF\nF1-(5-(3-(benzyloxy)phenyl)pyridin-2-yl)-3-(4-methox ybenzyl)urea (51)  \n \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 4.34 (2H, d, J = 5.7 Hz), 5. 06 (2H, s), 6.76 \n(2H, d, J = 8.7 Hz), 6.88 (1H, dd, J = 8.2 Hz, J = 2.4 Hz ), 7.08 (1H, d, J = 8.3 Hz), 7.20 (8H, m), 7 .37 \n(2H, d, J = 7.5 Hz), 7.86 (1H, dd, J = 8.6 Hz,  J = 2.5 Hz), 8.32 (1H, d, J = 2.2 Hz), 8.55 (1H, s) , 8.90 \n(1H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 45.2, 57.3, 72.3, 112.9, 114.3, 115.4, 116 .4, 121.5, \n130.2, 130.4, 131.2, 131.3, 132.1, 132.6, 134.8, 13 9.4, 140.2, 141.7, 147.2, 155.8, 157.5, 161.6, 162. 3  \nEI-MS:  m/z  439 (M +) \nMelting Point: 167 \u00b0C \nHPLC-Retention Time:  7.3 min \n \n \n1-(4-methoxybenzyl)-3-(5-(3-trifluoromethyl)phenyl) pyridin-2-yl)urea (52)  \n \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 4.34 (2H, d, J = 5.8 Hz), 6. 77 (2H, d,  \nJ = 8.6 Hz), 7.18 (2H, d, J = 8.6 Hz), 7.28 (1H, d,  J = 8.6 Hz), 7.57 (2H, m), 7.83 (2H, m), 7.95 (1H,  \ndd, J = 8.6 Hz, J = 2.5 Hz), 8.41 (1H, d, J = 2.3 H z), 8.77 (1H, s), 8.88 (1H, s)  \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 43.9, 55.8, 113.0, 115.1, 124.1, 125.2, 12 8.3, 130.0, \n131.2, 131.4, 132.0, 132.2, 133.3, 138.2, 140.0, 14 6.1, 155.0, 156.2, 160.2  \nEI-MS:  m/z  401 (M +) \nMelting Point: 166 \u00b0C \nHPLC-Retention Time:  6.8 min   \n \n \n1-(5-(2,3-difluorophenyl)pyridin-2-yl)-3-(4-fluorob enzyl)urea (53) \n \n \n \n1H-NMR (Acetone-d6, 500 MHz):  \u03b4 [ppm] 4.59 (2H, d, J = 5.9 Hz), 7.12 (2H, m), 7.36  (3H, m), 7.45 \n(1H, d, J = 8.7 Hz), 7.48 (2H, m), 7.97 (1H, d, J =  8.6 Hz), 8.44 (1H, s), 9.18 (1H, s), 9.23 (1H, s)  \n13 C-NMR (Acetone-d6, 125 MHz):   \u03b4 [ppm] = 43.6, 112.8, 116.3, 117.7, 124.7, 126.2, 1 26.5, 130.4, \n137.6, 139.8, 147.5, 154.8, 156.4, 162.1, 164.1 \nEI-MS:  m/z  357 (M +) \nMelting Point: 153 \u00b0C \nHPLC-Retention Time:  6.7 min  \nSeite 116 O\nH\nNH\nN\nON\nFF\nF\nH\nNH\nN\nON\nO\nH\nNH\nN\nON1-(5-(2,3-difluorophenyl)pyridin-2-yl)-3-(4-methoxy benzyl)urea (54) \n \n \n1H-NMR (Acetone-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 4.34 (2H, d, J = 5.9 Hz), 6. 76 (2H, d,       \nJ = 8.7 Hz), 7.20 (5H, m), 7.30 (1H, d, J = 8.6 Hz) , 7.85 (1H, m), 8.32 (1H, s), 8.74 (1H, s), 8.82 (1 H, s) \n13 C-NMR (Acetone-d 6, 125 MHz):   \u03b4 [ppm] = 45.1, 57.1, 114.0, 116.2, 118.8, 118.9, 12 5.8, 127.4, \n127.7, 130.3, 130.4, 131.2, 134.5, 141.0, 148.7, 15 6.3, 157.3, 161.4  \nEI-MS:  m/z  369 (M +) \nMelting Point: 160-162 \u00b0C \nHPLC-Retention Time:  6.5 min   \n \n \n1-(4-fluorobenzyl)-3-(5-vinylpyridin-2-yl)urea (55)  \n \n \n \n \n1H-NMR (Acetone-d6, 500 MHz):  \u03b4 [ppm] = 4.58 (2H, d, J = 6.0 Hz), 5.30 (1H, d, J =  10.9 Hz), \n5.90 (1H, d, J = 17.7 Hz), 6.83 (1H, dd, J = 10.9 H z, J = 17.7 Hz), 7.13 (2H, m), 7.40 (1H, d,            \nJ = 8.6 Hz), 7.48 (2H, m), 7.60 (2H, d, J = 8.3 Hz) , 7.67 (2H, d, J = 8.3 Hz), 8.05 (1H, d,                   \nJ = 8.6 Hz), 8.52 (1H, s), 8.90 (1H, s), 9.25 (1H, s)  \n13 C-NMR (Acetone-d6, 125 MHz):   \u03b4 [ppm] = 43.6, 113.0, 114.7, 116.1, 116.3, 127.7, 1 28.1, 130.4, \n137.6, 137.8, 138.1, 138.2, 145.5, 154.3, 156.3, 16 4.0 \nEI-MS:  m/z  347 (M +) \nMelting Point: 172 \u00b0C \nHPLC-Retention Time:  6.5 min   \n \n \n1-(4-methoxybenzyl)-3-(5-vinylpyridin-2-yl)urea (56 ) \n \n \n \n1H-NMR (Acetone-d6, 500 MHz):  \u03b4 [ppm] = 3.81 (3H, s), 4.53 (2H, d, J = 5.9 Hz), 5. 30 (1H, d,  \nJ = 10.7 Hz), 5.89 (1H, d, J = 17.7 Hz), 6.83 (1H, dd, J = 10.7, J = 17.7 Hz), 6.93 (2H, d,                 \nJ = 8.6 Hz), 7.37 (2H, d, J = 8.6 Hz), 7.39 ( 1H, d , J = 8.7 Hz), 7.59 (2H, d, J = 8.3 Hz), 7.67       \n(2H, d, J = 8.3 Hz), 8.04 ( 1H, d, J = 8.7 Hz), 8.5 1 (1H, s), 8.96 (1H, s), 9.16 (1H, s) \n13 C-NMR (Acetone-d6, 125 MHz):   \u03b4 [ppm] = 43.9, 55.8, 113.0 114.7, 115.0, 127.6, 128 .1, 129.9, \n130.3, 133.4, 137.6, 137.7, 138.0, 138.2, 145.5, 15 4.4, 156.2, 160.1  \nEI-MS:  m/z  359 (M +) \nMelting Point: 159 \u00b0C \nHPLC-Retention Time:  6.4 min  \n  \nSeite 117 O\nH\nNH\nN\nON\nO\nH\nNH\nN\nON\nF\nO\nH\nNH\nN\nON\nO1-(4-methoxybenzyl)-3-(4-phenylpyridin-2-yl)urea (5 7)  \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 4.33 (2H, d, J = 5.8 Hz), 6. 90 (2H, d,  \nJ = 8.7 Hz), 7.25 (3H, m), 7.50 (3H, m), 7.68 (2H, m), 7.75 (1H, s), 8.23 (1H, d,  \nJ = 5.4 Hz), 8.60 (1H, s), 9.45 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.4, 55.4, 109.1, 114.1, 115.1, 127.0, 12 8.8, 129.5, \n129.6, 132.3, 137.9, 147.8, 149.5, 154.6, 155.3, 15 8.6 \nEI-MS: m/z  333 (M +)   \nMelting Point: 202 \u00b0C   \nHPLC-Retention Time: 5.9  min \n \n \n1-(4-(3-fluorophenyl)pyridin-2-yl)-3-(4-methoxybenz yl)urea (58)  \n \n \n \n1H-NMR (DMSO-d 6, 300 MHz):  \u03b4 [ppm] = 3.72 (3H, s), 4.33 (2H, d, J = 5.8 Hz), 6. 90 (2H, m), 7.30 \n(4H, m), 7.55 (3H, m), 7.72 (1H, d,  J = 0.9 Hz), 8 .24 (1H, dd, J = 5.4 Hz, J = 0.5 Hz), 8.4 (1H, t,  \nJ = 5.7 Hz), 9.31 (1H, s)       \n13 C-NMR (DMSO-d 6, 75 MHz):   \u03b4 [ppm] = 42.1, 55.0, 108.8, 113.3, 113.6, 113.8, 11 4.8, 115.8, \n116.1, 122.8, 128.4, 131.2, 131.3, 131.8, 139.9, 14 0.1, 147.6, 147.8, 154.1, 154.7, 158.2 \nEI-MS: m/z  351 (M +)   \nMelting Point: 166-168 \u00b0C   \nHPLC-Retention Time: 5.6  min \n \n \n1-(4-methoxybenzyl)-3-(4-(3-methoxyphenyl)pyridin-2 -yl)urea (59)  \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 3.84 (3H, s), 4.35 (2H, d, J  = 5.8 Hz), 6.91 \n(2H, m), 7.06 (1H, dd, J = 8.2 Hz, J = 2.5 Hz), 7.2 0 (1H, m), 7.26 (4H, m), 7.44 (1H, m), 7.67 (1H, s) , \n8.23 (1H, d, J = 5.3 Hz), 8.51 (1H, s), 9.30 (1H, s )       \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 44.6, 57.5, 57.4, 111.3, 114.7, 116.6, 117 .2, 117.4, \n121.4, 130.9, 132.8, 134.3, 141.5, 149.8, 151.6, 15 6.6, 157.3, 160.7, 162.3 \nEI-MS: m/z  363 (M +)   \nMelting Point:  158 \u00b0C   \nHPLC-Retention Time:  5.6 min  \nSeite 118 O\nH\nNH\nN\nON\nO\nO\nH\nNH\nN\nON\nS1-(4-methoxybenzyl)-3-(4-(2-methoxyphenyl)pyridin-2 -yl)urea (60) \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.71 (3H, s), 3.74 (3H, s), 4.46 (2H, d, J  = 5.8 Hz), 6.77 \n(2H, m), 6.91 (1H, dd, J = 0.5 Hz, J = 8.2 Hz), 6.9 7-7.00 (3H, m), 7.22-7.25 (3H, m), 7.28-7.32 (1H, \nm), 8.03 (1H, d, J = 5.9 Hz), 8.50 (1H, s), 9.51 (1 H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.2, 54.3, 54.6, 110.4, 111.0, 111.3, 112 .9, 115.6, \n117.0, 120.0, 126.3, 127.6, 129.4, 130.5, 137.2, 15 2.1, 155.2, 155.6, 157.7 \nESI-MS:  m/z  364 (M+H) \nHRMS:  calcd. for C 21 H21 N3O3 363.1583, found 363.1542. \nHPLC-Retention Time:  5.71 min     \n \n \n1-(4-methoxybenzyl)-3-(4-(thiophen2-yl)pyridin-2-yl )urea (61) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.71 (3H, s), 4.44 (2H, d, J = 5.7 Hz), 6. 78 (2H, m), 7.05 \n(1H, dd, J = 1.2 Hz, J = 5.6 Hz), 7.07 (1H, dd, J =  3.7 Hz, J = 5.0 Hz), 7.15 (1H, s), 7.18 (1H, s), 7 .23 \n(2H, m), 7.39 (1H, d, J = 4.8 Hz), 7.46 (1H, d, J =  2.9 Hz), 7.95 (1H, m), 9.2 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.3, 54.2, 106.9, 112.8, 113.0, 125.2, 12 7.7, 130.1, \n154.9, 157.8 \nESI-MS:  m/z  340 (M+H) \nHRMS:  calcd. for C 18 H17 N3O2S 339.1042, found 339.1006. \nHPLC-Retention Time:  5.29 min     \n \n \n1-(2-fluoro-3,4'-bipyridin-2'-yl)-3-(4-methoxybenzy l)urea (62) \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.74 (3H, s), 4.34 (2H, d, J = 5.9 Hz), 6. 91 (2H, d,  \nJ = 8.7 Hz), 7.17 (1H, m), 7.25 (2H, d, J = 8.6 Hz) , 7.54 (1H, m), 7.72 (1H, s), 8.17 (1H, m), 8.29 (1 H, \nd, J = 5.7 Hz), 8.30 (1H, s, br), 8.34 (1H, m), 9.3 7 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.1, 55.0, 111.0, 113.5, 113.7, 116.5, 12 2.8, 128.2, \n128.4, 131.7, 141.3, 147.4, 147.8, 148.1, 153.9, 15 4.6, 158.3 \nEI-MS:  m/z  352 \nHPLC-Retention Time:  4.23 min     \n O\nH\nNH\nN\nON\nNF \nSeite 119 H\nNF\nH\nN\nON\nC\nNNNHN\nH\nNO\nH\nN\nON\nC\nNNNHNO\nH\nNH\nN\nON\nHN\nNNN1-(4-(1H-tetrazol-5-yl)pyridin-2-yl)-3-(4-methoxybe nzyl)urea (63) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.66 (3H, s), 4.26 (2H, d, J = 5.7 Hz), 6. 83 (2H, m), 7.18 \n(2H, m), 7.43 (1H, d, J = 4.7 Hz), 8.00 (1H, s), 8. 18 (1H, s), 8.31 (1H, d, J = 5.0 Hz), 9.40 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.1, 55.0, 108.6, 113.7, 114.1, 128.4, 13 1.6, 148.4, \n154.2, 154.5, 158.2 \nEI-MS:  m/z  325 (M +) \nHPLC-Retention Time:  3.34 min     \n \n \n1-(5-(2H-tetrazol-5-yl)pyridin-2-yl)-3-(4-fluoroben zyl)urea (64) \n \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 4.44 (2H, d, J = 5.7 Hz), 7.21 (2H, d, J =  8.9 Hz), 7.42 \n(2H, d, J = 8.3 Hz), 7.75 (1H, d, J = 8.8 Hz), 8.31  (1H, s), 8.32 (1H, dd, J = 8.8 Hz, \nJ = 2.2 Hz), 8.87 (1H, d, J = 1.8 Hz), 9.69 (1H, s)  \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 42.4, 112.0, 114.4, 115.5, 129.5, 136.4, 1 37.0, 146.2, \n154.5, 155.4, 160.6, 162.5 \nEI-MS:  m/z  313 (M +) \nMelting Point: 148-150 \u00b0C \nHPLC-Retention Time:  4.2 min   \n \n \n1-(5-(2H-tetrazol-5-yl)pyridin-2-yl)-3-(4-methoxybe nzyl)urea (65)  \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.64 (3H, s), 4.33 (2H, d, J = 5.8 Hz), 6. 76 (2H, d,         \nJ = 8.7 Hz), 7.19 (2H, d, J = 8.7 Hz), 7.45 (1H, d,  J = 8.8 Hz), 8.25 (1H, dd, J = 8.7 Hz, J = 2.3 Hz) , \n8.60 (1H, s), 8.77 (1H, d, J = 2.0 Hz), 9.08 (1H, s ) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 44.0, 55.8, 113.5, 115.0, 115.2, 129.9, 13 0.1, 133.0, \n138.3, 146.5, 155.9, 156.6, 160.2 \nEI-MS:  m/z  325 (M +) \nMelting Point: 168-170 \u00b0C \nHPLC-Retention Time:  3.9 min   \n \n  \nSeite 120 O\nH\nNH\nN\nONS\nN\nHNNN1-(6-(1H-tetrazol-5-yl)benzo[d]thiazol-2-yl)-3-(4-m ethoxybenzyl)urea (66) \n \n \n \n1H-NMR (DMSO-d 6, 500 MHz):  \u03b4 [ppm] = 3.67 (3H, s), 4.24 (2H, d, J = 5.8 Hz), 6. 80 (1H, m), 6.85 \n( 2H, m), 7.10 (1H, m), 7.19 (2H, m), 7.72 (1H, d, J = 8.3 Hz), 7.94 (1H, dd, J = 8.4 Hz, J = 1.8 Hz),  \n8.49 (1H, m), 10.90 (1H, s) \n13 C-NMR (DMSO-d 6, 125 MHz):   \u03b4 [ppm] = 44.4, 56.9, 115.5, 115.6, 115.7, 122.2, 12 6.6, 130.5, \n130.6, 149.1, 150.8, 160.3 \nEI-MS:  m/z  Fragmente - 353, 338, 218, 175, 121 \nHPLC-Retention Time:  5.08 min     \n \n \nGSK-3\u03b2 in vitro  assay  \n \nPurified GSK-3 \u03b2 (0.5 \u00b5g) was incubated in a reaction mixture of 50  mM Tris pH 7.3, 10 mM MgAc, \n0.01% \u03b2-mercaptoethanol, 32 P[ \u03b3-ATP](100\u00b5M, 0.5 \u00b5ci/assay), and 100 \u00b5M of peptide substrate, \npIRS-1 (RREGGMSRPAS(p)VDG (1). New molecules  were added at various concentrations (1, 10 \nand 100 \u00b5M), and the reaction mixture was incubated  for 15 min at 30 oC. The reactions were stopped, \nspotted on p81 paper (Whathman), washed with 10 mM phosphoric acid, and counted for \nradioactivity as described (1). GSK-3 \u03b2 activity was calculated as the percentage of GSK-3 \u03b2 activity \nin the absence of inhibitors that was designated to  100%. \n \n \nKinase Panel:  \n \nCompounds are serially diluted 1/3 in neat DMSO (10  serial dilutions) and these dilutions are further \ndiluted 1/25 with reaction buffer. 2.5\u00b5l of these s olutions are added to the reaction mixture describe d \nbelow so that final compound concentration in the a ssay ranges from 100 \u00b5M to 5 nM in 1% (v/v) \nDMSO. The enzymatic activity of the kinases is dete rmined with a commercial system based on the \nZ\u2019-LYTE \u00ae technology, available from Invitrogen Life Technol ogies (Carlsbad, CA, USA), using \nhuman recombinant kinases as the enzyme source. Thi s technology utilizes the fluorescence resonance \nenergy transfer (\u201cFRET\u201d) process between fluorescei n and coumarin. The assay principle is based on \nthe differential sensitivity of phosphorylated and non-phosphorylated peptide to proteolytic cleavage,  \nwhich precludes the energy transfer process between  the two fluorophores attached to both sides of the  \ncleavage site. Hence, enzymatic phosphorylation wil l yield a phosphopeptide, which cannot be  \nSeite 121 hydrolyzed by a suitable protease and energy transf er between the two fluorophores will occur. \nOpposingly, lack of phosphorylation will cause pept ide hydrolysis hence lack of energy transfer as.  \nThe assay is performed in 96-well black plates, in a final volume of 10 \u00b5l, with components as \ndetailed in Table 1. \n \n \nTable 1  \n \nKinase Enzyme \nconc. \n(nM) ATP  \nconc. \n(\u00b5M) Peptide used Peptide \nconc. \n(\u00b5M) Buffer \nGSK3 \u03b2 0.54 26 Ser/Thr 9 peptide 2 50 mM Hepes pH 7.5, \n10 mM MgCl 2, 1 mM \nEGTA, 0.01% (w/v) \nBrij-35 \nCKI \u03b5 18.84 32 Ser/Thr 11 \npeptide 2 50 mM Hepes pH 7.5, \n10 mM MgCl 2, 1 mM \nEGTA, 0.01% (w/v) \nBrij-35 \nCdk5 15.9 12.5 Ser/Thr 12 \npeptide 2 50 mM Hepes pH 7.5, \n10 mM MgCl 2, 1 mM \nEGTA, 0.01% (w/v) \nBrij-35 \nAurKA 20 10 Ser/Thr 1 peptide 2 50 mM Hepes pH 7.5, \n20 mM MgCl 2, 1 mM \nEGTA, 0.01% (w/v) \nBrij-35 \nPKC \u03b1 1.04 1 Ser/Thr 7 peptide 2 50 mM Hepes pH 7.5, \n10 mM MgCl 2, 1 mM \nEGTA, 0.01% (w/v) \nBrij-35 \n \n \n \n \n \n \n \n  \nSeite 122 \n4.1.3 Synthese selektiver GSK-3 \u03b1-Inhibitoren mittels biphenylischer Systeme  \n \nDer Inhalt dieses Kapitels wurde bereits ver\u00f6ffentl icht: \n  \nFabio Lo Monte*,\u2021 , Thomas Kramer, Jiamin Gu, Upendra Rao Anumala, Lu ciana \nMarinelli, Valeria La Pietra, Ettore Novellino, B\u00e9n \u00e9dicte Franco, David Demedts, Fred \nVan Leuven, Ana Fuertes, Juan Manuel Dominguez, Bat ya Plotkin, Hagit Eldar-\nFinkelman, Boris Schmidt \u2021  \nIdentification of Glycogen Synthase Kinase-3 Inhibi tors with a Selective Sting for \nGlycogen Synthase Kinase-3 \u03b1, Journal of Medicinal Chemistry  2012 , 55, 4407-4424. \ndx.doi.org/10.1021/jm300309a \nMit freundlicher Genehmigung von der American Chemi cal Society. \n \n \nDurch die Untersuchung mehrerer Kristallstrukturen von Inhibitoren im Komplex mit  \nGSK-3\u03b2 konnte eine vereinfachte Darstelllung der ATP-Bind etasche entworfen \nwerden, in der nur relevante Bereiche gekennzeichne t sind (Abb. 18).  \n \n \n \n \n \n \n \n \n   \n \n \n \n \nAbb. 18: Relevante Aminos\u00e4uren und Bereiche innerhalb der AT P-Bindetasche. A A D D/ A \nD/ A \nArg141  Glu137  Pro136  Val135  \nLys85  Asp133  \nLeu132  Tyr134  \nGlu97  \nAsp200  \nGln185  Cys199   \nSeite 123 Die Akzeptor (A) und Donor (D) markierten Stellen v erweisen auf erforderliche \nFunktionalit\u00e4ten bzw. Heteroatome, die n\u00f6tig sind, um eine Aktivit\u00e4t und Selektivit\u00e4t \nzu erzielen. Die Mehrzahl aller literaturbekannten GSK-3-Inhibitoren besetzt drei, \nbestenfalls vier dieser Bereiche. Es wurden mehrere  biphenylische Strukturen \nsynthetisiert, die einen gro\u00dfen Teil aller Akzeptor - und Donor-Regionen belegen \nkonnten. Die aktivsten Verbindungen zeigten f\u00fcr GSK -3 IC 50 -Werte im einstelligen \nnanomolaren Bereich. Dar\u00fcber hinaus sind diese Verb indungen in der Lage, \ngleichzeitig mit der Gelenk-Region und Teilen der G lycin-reichen Schleife zu \ninteragieren. Zur Erh\u00f6hung der L\u00f6slichkeit wurden v erschiedene Linkersysteme \neingef\u00fcgt. Einige Biphenylderivate zeigten eine meh r als 2000-fache Selektivit\u00e4t f\u00fcr \nGSK-3 gegen\u00fcber vier nahe verwandten Kinasen. Durch  verschiedene \nSubstitutionsmuster am biphenylischen System konnte n Inhibitoren hergestellt \nwerden, die eine Selektivit\u00e4t gegen\u00fcber GSK-3 \u03b1 aufwiesen. Die beste Verbindung \ndieser Serie war sogar 92-fach selektiver f\u00fcr GSK-3 \u03b1 gegen\u00fcber GSK-3 \u03b2. Die \nbestimmte Selektivit\u00e4t f\u00fcr eine Isoform ist die h\u00f6c hste von der bisher berichtet wurde. \nDiese Beobachtung kann sehr hilfreich sein, falls d ie in vivo  Diskriminierung einer \nGSK-3-Isoform ben\u00f6tigt wird. Zudem ist es nun m\u00f6gli ch, die physiologischen \nFunktionen und pathologischen Rollen von GSK-3 \u03b1 besser in vivo  zu untersuchen. \nBei der in vivo  Evaluation dieser Strukturklasse im Zebrafisch-Emb ryo konnten die \ncharakteristischen Ph\u00e4notypen beobachtet werden, we lche f\u00fcr eine effektive in vivo  \nInhibition von GSK-3 bekannt sind. Ferner konnte fe stgestellt werden, dass diese \nVerbindungen im getesteten Konzentrationsbereich ke ine Toxizit\u00e4t aufweisen.         \n \nIm Rahmen dieser Arbeit wurden alle Verbindungen vo n Fabio Lo Monte \nsynthetisiert: \n \nBSc4258 (2B), BSc4259 (3B), BSc4260 (4B), BSc4261 ( 6a), BSc4263 (15a), \nBSc4392 (4C), BSc4393 (7c), BSc4395 (7b), BSc4396 ( 7a), BSc4399 (16a), \nBSc4401 (4A), BSc4404 (5b), BSc4405 (5a), BSc4407 ( 14c), BSc4408 (8e), \nBSc4410 (6b), BSc4412 (9f), BSc4414 (9a), BSc4415 ( 6c), BSc4416 (9e), BSc4603 \n(22a), BSc4604 (23a), BSc4605 (24a), BSc4606 (22b),  BSc4607 (23b), BSc4608 \n(24b), BSc4609 (25), BSc4615 (14a), BSc4616 (14b), BSc4617 (8c), BSc4618 (8d), \nBSc4619 (9d), BSc4620 (9c), BSc4624 (8a), BSc4625 ( 5c), BSc4634 (26), BSc4676 \n(15b), BSc4681 (14d), BSc4789 (22c), BSc4792 (23c) \nIn Klammern die Verbindungsnummer in der Publikatio n.  \n  \nSeite 124  \n \n \n \n \n \nSeite 125  \n \n \n \n \nSeite 126  \n \n \n \nSeite 127  \n \n \n \n \nSeite 128  \n \n \n \nSeite 129  \n \n \n \nSeite 130  \n \n \n \n \nSeite 131  \n \n \n \nSeite 132  \n \n \n \nSeite 133  \n \n \n \nSeite 134  \n \n \n \n \nSeite 135  \n \n \n \nSeite 136  \n \n \n \n \nSeite 137  \n \n \n \nSeite 138  \n \n \n \nSeite 139  \n \n \n \n \nSeite 140  \n \n \n \nSeite 141  \n \n \n \n \nSeite 142 SUPPORTING INFORMATION  \nIdentification of Glycogen Synthase Kinase-3  \nInhibitors with a Selective Sting for  \nGlycogen Synthase Kinase-3 \u03b1 \nFabio Lo Monte, a, * Thomas Kramer, a Jiamin Gu, a Upendra Rao Anumala, a Luciana \nMarinelli, b Valeria La Pietra, b Ettore Novellino, b B\u00e9n\u00e9dicte Franco, c David Demedts, c Fred \nVan Leuven, c Ana Fuertes, d Juan Manuel Dominguez,d Batya Plotkin, e Hagit Eldar-\nFinkelman e and Boris Schmidt a, * \na Clemens Sch\u00f6pf - Institute of Organic Chemistry an d Biochemistry, Technische Universit\u00e4t    \nDarmstadt, 64287 Darmstadt, Germany \nb Dipartimento di Chimica Farmaceutica e Tossicologic a, Universit\u00e0 di Napoli \u201cFederico II\u201d,  80131 \nNapoli, Italy \nc Experimental Genetics Group, Department of Human Ge netics, Katholieke Universiteit Leuven, \n3000 Leuven, Belgium  \nd Noscira S.A., Drug Discovery, Tres Cantos 28760 - Madrid, Spain \ne  Department of Human Molecular Genetics and Biochemi stry, Sackler School of Medicine,  Tel Aviv \nUniversity, 69978 Tel Aviv, Israel \n \n* To whom correspondence should be addressed. Phone : +496151-164531.  \n  Fax: +496151-163278.  \n  E-Mail: schmidt_boris@t-online.de; Fabio.Lo-Monte @gmx.de \n \nTable of contents  \nHomology Modeling       S2 \nIn Vitro Pharmacology: Screening of compound 14d  S3-6 \nBioavailability profile of compound 14d    S7 \nMonitoring of the heart development on zebrafish em bryos S8-21  \nSeite 143 Homology Modeling \n \nFigure S1 . Superposition of 3D structure of GSK-3 \u03b2 (PDB code 3F88) and the homology-\nbased 3D structure of GSK-3 \u03b1. Both proteins are shown as white cartoons; conser vative \nmutations are displayed as forest and light green s tick, for GSK-3 \u03b2 and GSK-3\u03b1 respectively \n(a),  while non-conservative mutations are represented as  red and pink sticks, for GSK-3 \u03b2 and \nGSK-3\u03b1 respectively ( b). It is evident that the majority of the mutations  are located at the \nloop at the C-terminus fragment of the proteins (D3 45-T363 in GSK-3 \u03b2 and R407-A427 in \nGSK-3\u03b1). \n \nFigure S2. Alignment between GSK-3 \u03b1 (Swiss-Prot code: P49840) and GSK-3 \u03b2 sequences \n(PDB code: 3F88). Identical residues are colored in  red, conservative residues in orange, \nwhile non-conservative residues are not painted. Ga ps are represented as dashes. \n \n \n \nSeite 144 In Vitro Pharmacology: Screening of compound 14d \nThe ExpresS Diversity kinase profile is a fast turn around profile conducted by Cerep. \nPercentage kinase activities of compound 14d  at one concentration (1 \u00b5M) in panels of human \nprotein kinases determined by Cerep. Measurements w ere performed in duplicate and the \naverage was taken.  \n \nCHK1 118,1  FGFR2 100,8 \nSIK 113,6  JAK3 100,8 \nSrc 111,4  ROCK1 100,7 \nCaMK2a 110,4  FLT-3 100,2 \nKDR 110,4  NEK2 100,2 \nMNK2 107,8  EGFR 99 \nMST4 105,8  ERK2 98,9 \nMAPKAPK2  105,5  PKCb2 98,7 \nPDK1 105,2  AurA/Aur2  98,6 \np38a 105  HGK 98,6 \nSGK1 104,6  Akt1/PKBa  98,1 \nJNK1 104,5  CDK2 97,4 \nMKK6 104,5  PKA 97,4 \nCDK1 104,4  EphA2 97,1 \nFGFR3 104,4  EphA3 96,1 \nLck 104,4  Abl 95,7 \nPAK2 104,2  FGFR1 95,6 \nPAK4 103,9  EphB4 91,4 \nMARK1 103,2  RAF-1 91,4 \nIRK 102,6  CHK2 89,8 \nPim2 102,6  c-Met 89,1 \nTRKA 102,4  PLK1 84,2 \nIKKa 102,3  IRAK4 83,3 \nTAOK2 101,3  GSK-3b 27,2 \nCK1a 100,9  GSK-3a 5 \n \n \n \n \n \n \n \n \n  \nSeite 145 Assay \nKinases Source Substrate/Stimulus/Tracer Incubation Measure d Component \nAbl kinase \n(h) human \nrecombinant \n(insect cells) ATP + Ulight-TK peptide (100 \nnM) 60 min  \nRT phospho-Ulight-TK- \npeptide \nAkt1/PKB \n\u03b1 (h) human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 60 min  \nRT phospho-CREBtide \n(CKRREILSRRPSYRK) \nAurA/Aur2 \nkinase (h) human \nrecombinant \n(Sf21 cells) ATP + Ulight-RRRSLLE \n(100 nM) 15 min \n RT phospho-Ulight-\nRRRSLLE \n \nCaMK2 \u03b1 \n(h)  human \nrecombinant \n ATP + Ulight-\nCGSGSGRPRTSSFAEG (50 nM) 30 min  \nRT phospho-Ulight-\nCGSGSGRPRTSSFAEG \nCDC2/CD \nK1 (h) \n(cycB) human \nrecombinant \n(insect cells) ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 15 min \nRT phospho-Ulight- \nCFFKNIVTPRTPPPSQ \nGK-amide \nCDK2 (h) \n(cycA) human \nrecombinant ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(50 nM) 30 min \nRT phospho-Ulight- \nCFFKNIVTPRTPPPSQ \nGK-amide \nCHK1 (h)  human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 30 min \nRT phospho-CREBtide \n(CKRREILSRRPSYRK) \nCHK2 (h)  human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 15 min \nRT phospho-CREBtide \n(CKRREILSRRPSYRK) \nCK1 \u03b1 (h)  human \nrecombinant ATP + Ulight- \nARTKQTARKSTGGKAP \nRKQLAGCG \n(25 nM) 60 min \nRT phospho-Ulight- \nARTKQTARKSTGGKA \nPRKQLAGCG \nc-Met \nkinase (h)  human \nrecombinant \n(insect cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(25 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nEGFR \nkinase (h)  human \nrecombinant \n(insect cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 15 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nEphA2 \nkinase (h)  human \nrecombinant ATP + Ulight-TK peptide \n(50 nM) 30 min \nRT phospho-Ulight-TK- \npeptide \nEphA3 \nkinase (h)  human \nrecombinant ATP + Ulight-TK peptide \n(50 nM) 60 min \nRT phospho-Ulight-TK- \npeptide \nEphB4 \nkinase (h)  human \nrecombinant \n(insect cells) ATP + Ulight-TK peptide \n(100 nM) 90 min \nRT phospho-Ulight-TK- \npeptide \n  \nSeite 146 ERK2 (h) \n(P42 mapk ) human \nrecombinant \n(E. coli ) ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 15 min \nRT phospho-Ulight- \nCFFKNIVTPRTPPPSQ \nGK-amide \nFGFR1 \nkinase (h)  human \nrecombinant \n(insect \ncells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nFGFR2 \nkinase (h)  human \nrecombinant ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(25 nM) 15 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nFGFR3 \nkinase (h)  human \nrecombinant ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 90 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nFLT-3 \nkinase (h)  human \nrecombinant \n(insect \ncells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 90 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nGSK3 \u03b1 (h)  human \nrecombinant ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 60 min \nRT phospho-Ulight- \nCFFKNIVTPRTPPPSQ \nGK-amide \nGSK3 \u03b2 (h)  human \nrecombinant ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 90 min \nRT phospho-Ulight- \nCFFKNIVTPRTPPPSQ \nGK-amide \nHGK (h) \n(MAP4K4) human \nrecombinant ATP + Ulight-FLGFTYVAP \n(50 nM) 90 min \nRT phospho-Ulight-\nFLGFTYVAP \nIKK \u03b1 (h)  human \nrecombinant \n(Sf21 cells) ATP + Ulight-IkappaB-alpha \n(100 nM) 30 min \nRT phospho-Ulight-\nIkappaB-alpha \nIRAK4 (h)  human \nrecombinant \n(insect \ncells) ATP + Ulight-FLGFTYVAP \n(50 nM) 90 min \nRT phospho-Ulight-\nFLGFTYVAP \nIRK (h) \n(InsR) human \nrecombinant ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(50 nM) 10 min \nRT phospho-Ulight-Poly \nGAT[EAY(1:1:1)]n \nJAK3 (h)  human \nrecombinant ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nJNK1 (h) human \nrecombinant ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-60 min \nRT phospho-Ulight- \nCFFKNIVTPRTPPPSQ  \nSeite 147  \nMST4 \nkinase (h)  human \nrecombinant ATP + Ulight \nTM- PKC (50 nM) 30 min \nRT Phospho-Ulight-TM-\nPKC \nNEK2 (h)  human \nrecombinant \n(insect cells) ATP + Ulight-FLGFTYVAP \n(50 nM) 60 min \nRT phospho-Ulight-\nFLGFTYVAP \np38 \u03b1 \nkinase (h)  human \nrecombinant \n(E. coli ) ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 60 min \nRT phospho-Ulight- \nCFFKNIVTPRTPPPSQ \nGKamide \nPAK2 (h)  human \nrecombinant \n(Sf9 cells) ATP + Ulight-RRRSLLE \n(50 nM) 60 min \nRT phospho-Ulight-\nRRRSLLE \nPAK4 (h)  human \nrecombinant \n(insect cells) ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nPDK1 (h)  human \nrecombinant \n(insect cells) ATP + Ulight-FLGFTYVAP \n(400 nM) 90 min \nRT phospho-Ulight-\nFLGFTYVAP \nPim2 \nkinase (h)  human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 60 min \nRT phospho-CREBtide \n(CKRREILSRRPSYRK) (E. coli ) amide \n(100 nM) GK-amide \nKDR \nkinase (h) \n(VEGFR2) human \nrecombinant \n(Sf9 cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKEYYT \nVKD \nLck kinase \n(h)  human \nrecombinant \n(insect \ncells) ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(25 nM) 30 min \nRT phospho-Ulight-Poly \nGAT[EAY(1:1:1)]n \nMAPKAP \nK2 (h)  human \nrecombinant \n(E. coli ) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 15 min \nRT phospho-CREBtide \n(CKRREILSRRPSYK) \nMARK1 \n(h)  human \nrecombinant ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nMKK6 (h)  human \nrecombinant ATP + inactive p38a \n(50 nM) 10 min \nRT phospho-p38a \nMNK2 (h)  human \nrecombinant \n(Sf21 cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 90 min \nRT phospho-CREBtide \n(CKRREILSRRPSYR)  \nSeite 148 PKA (h)  human \nrecombinant \n(E. coli ) ATP + Ulight-RRRSLLE \n(50 nM) 10 min \nRT phospho-Ulight-\nRRRSLLE \nPKC \u03b22 (h)  human \nrecombinant ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 15 min \nRT phospho-CREBtide \n(CKRREILSRRPSYRK) \nPLK1 (h)  human \nrecombinant ATP + Ulight-FLGFTYVAP \n(40 nM) 60 min \nRT phospho-Ulight-\nFLGFTYVAP \nRAF-1 \nkinase (h)  human \nrecombinant ATP + Ulight- \nARTKQTARKSTGGKAPRKQ \nLAGCG \n(50 nM) 180 min \nRT phospho-Ulight- \nARTKQTARKSTGGKA \nPRKQ \nLAGCG \nROCK1 (h)  human \nrecombinant ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nSGK1 (h)  human \nrecombinant ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nSIK (h)  human \nrecombinant \n(Sf21 cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 90 min \nRT phospho-CREBtide \n(CKRREILSRRPSYRK) \nSrc kinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(5 nM) 10 min \nRT phospho-Ulight-Poly \nGAT[EAY(1:1:1)]n \nTAOK2 \n(TAO1) (h)  human \nrecombinant ATP + Ulight-FLGFTYVAP \n(40 nM) 60 min \nRT phospho-Ulight-\nFLGFTYVAP \nTRKA (h)  human \nrecombinant \n(insect cells) ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(5 nM) 10 min \nRT phospho-Ulight-Poly \nGAT[EAY(1:1:1)]n \n \n \nBioavailability profile of compound 14d (conducted by Cerep). \n \nAssay Technique Test concentration Incubation Detec tion mode \nAqueous solubility  \n(PBS, pH 7.4) shake-flask        200 \u00b5M 24hr/RT HPLC-UV/VIS \nPartition coefficient  \n(log D, n-octanol /PBS, \npH 7.4) shake-flask 100 \u00b5M 60min/RT HPLC-UV/VIS \nProtein binding \n(plasma, human) Equilibrium \ndialysis 10 \u00b5M Overnight \n(18 \u00b1 2hr) \n37\u00b0C HPLC-MS/MS \n \n  \nSeite 149  \nAssay Source Incubation Detection mode \nA-B permeability \n(Caco-2, pH 6.5/7.4) Caco-2 cell line 0 and 60 min  \n37\u00b0C HPLC-MS/MS \n \nAssay Source Subtrate Incubation Measured \nComponent Detection \nmode \nMetabolic stability \n(liver microsomes, \nhuman) Human liver \nmicrosomes  \n(0.3 mg/mL) Test \ncompound 0 and 60 min  \n37\u00b0C Test \ncompound HPLC-\nMS/MS \n \nAssay Test Concentration (M) Result \nPartition coefficient \n(logD, n-octanol/PBS, pH 7.4) 1.0E-04 3.58 \nProtein binding (plasma, human) 1.0E-05 91% Protein Bound \n121% Recovery \nA-B permeability \n(Caco-2, pH 6.5/7.4) 1.0E-05 <0.1 Permeability \n68% Recovery \nMetabolic stability \n(liver microsomes, human) 1.0E-06 25% Parent Remaining \nAqueous solubility \n(PBS, pH 7.4) 2.0E-04 Below the limit \nof quantitation \n \n \nMonitoring of the heart development on zebrafish em bryos.  \nThe wt zebrafish was used in this study. The embryo s were collected and placed into 24-well \nplates, ten embryos per well and maintained in E2 m edium at ~28\u00b0C. Compounds were added \n5 hpf (50% epiboly) and the embryos allowed to grow  in chemical compound solution up to 5 \ndays. The phenotypes were compared using the Axio S cope.A1 microscope system from Carl \nZeiss at 48, 72 and 96 hpf. The heart beat was coun ted for one minute and compared to the \ncontrol. - Animal husbandry. All animal experiments were conducted and documente d \naccording to the federal and local regulations. Acc ording to the federal law and regulation all \nembryo testing was stopped at day 5 of embryonic de velopment.    \n \n  \nSeite 150 NMR Data of compounds 5b , 5c , 6b , 6c , 14b , 14c , 14d , 15a , 15b , 16a , 23a , 23b and  23c  \nThe 1H-NMR spectra were recorded on a Bruker AC 300 spec trometer at 300 MHz and \nBruker AC 500 spectrometer at 500 MHz. The 13 C-NMR spectra were recorded on a Bruker \nAC 300 spectrometer at 75 MHz and Bruker AC 500 spe ctrometer at 125 MHz.  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 151 \n            \n            \n            \n            \n            \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 1H-NMR \n13C-NMR  \nSeite 152 \n            \n            \n            \n            \n            \n            \n            \n            \n         \n  \n \n \n \n \n \n \n            \n             \n \n \n \n \n \n \n \n \n \n 1H-NMR \n13C-NMR  \nSeite 153 \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n    \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 1H-NMR \n13C-NMR  \nSeite 154 \nONN\nS compound6cO\nO\nOO      \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 1H-NMR \n13C-NMR  \nSeite 155 \n             \n \n \n \n \n \n \n \n \n \n \n \n \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n           13C-NMR 1H-NMR  \nSeite 156 \nONN\nS compound14cO\nO\nCN           \n \n \n \n \n \n \n \n \n \n \n \n \n            \n            \n            \n            \n          \n \n \n \n \n \n \n \n 1H-NMR \n13C-NMR  \nSeite 157 \n           \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n            \n      \n \n \n \n \n \n \n 1H-NMR \n13C-NMR  \nSeite 158 \n      \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 13C-NMR 1H-NMR  \nSeite 159 \n            \n            \n            \n    \n \n \n \n \n \n \n \n \n \n \nDue to solubility problems it was not possible to m easure a 13 NMR. Compound 15b  was \nverified further via High Resolution Mass Spectrome try (HRMS).   \n       \n \n \n \n \n \n \n \n \n 1H-NMR  \nSeite 160 \n  \n \n \n \n \n \n      \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 1H-NMR \n13C-NMR  \nSeite 161 \n \n \n \n      \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 13C-NMR \nONN\nS compound23a\nCNO\nOO1H-NMR  \nSeite 162 \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ONN\nS compound23b\nCNO\nOO1H-NMR \n13C-NMR  \nSeite 163 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ONN\nS compound23c\nCNO\nOO1H-NMR \n13C-NMR  \nSeite 164 4.1.4 Strukturbasierte Optimierung von Oxadiazolder ivaten \n \nDer Inhalt dieses Kapitels wurde bereits zur Publik ation angenommen: \n \nFabio Lo Monte*,\u2021 , Thomas Kramer, Jiamin Gu, Martin Brodrecht, Johan nes \nPilakowski, Ana Fuertes, Juan Manuel Dominguez, Bat ya Plotkin, Hagit Eldar-\nFinkelman, Boris Schmidt \u2021  \nStructure-based optimization of oxadiazole-based GS K-3 inhibitors, European \nJournal of Medicinal Chemistry 2012 , zur Publikation angenommen. \n \n \nBasierend auf vorherigen Untersuchungen wurde das O xadiazol-Grundger\u00fcst als \nStartpunkt f\u00fcr eine Reihe von Derivaten eingesetzt.  Hierbei wurden verschiedene \nSysteme und funktionelle Gruppen mit dem Oxadiazol gekuppelt und ausgetestet, \num einen genaueren Einblick in die ATP-Bindetasche zu erhalten. Neben den \nheteroaromatischen und aromatischen Strukturen wurd e auch ein Trizyklus getestet, \nder aber keine Aktivit\u00e4t vorweisen konnte. Letztlic h f\u00fchrte die Testung dieser und das \nWissen \u00fcber alte Verbindungen zu drei Fragmenten, v on denen ausgegangen wurde, \ndass sie zu aktiven und selektiven GSK-3-Inhibitore n f\u00fchren k\u00f6nnen (Abb. 19).  \n \n \nAbb. 19: Schematische Darstellung eines \u00fcber drei Fragmente erhaltenen GSK-3-Inhibitors.       \nSeite 165 Die strukturbasierte Strategie mit Hilfe der drei F ragmente konnte zwar nicht auf alle \nZyklen \u00fcbertragen werden, f\u00fchrte jedoch f\u00fcr die Pyr idinderivate zu aktiven und \nselektiven GSK-3-Inhibitoren. Verbindung 39  erwies sich als besonders aktiv und \nkonnte, gegen\u00fcber vier anderen getesteten Kinasen, eine mehr als 5000-fache \nSelektivit\u00e4t f\u00fcr beide Isoformen von GSK-3 aufzeige n. Diese Verbindung verdeutlicht \ndass die verfolgte Strategie, mit den Kenntnissen \u00fc ber die ATP-Bindetasche und \nderen Inhibitoren, verwendet werden kann, um geziel t neue Strukturen zu \nsynthetisieren. Das molekulare Docking  erh\u00e4rtete unsere Ergebnisse und machte \ndeutlich, dass die Amidfunktion, wie die Harnstofff unktion bei AR-A014418 ( 27 ), \nbevorzugt mit der Gelenk-Region wechselwirkt. Bei d er in vivo  Evaluation dieser \nStrukturklasse im Zebrafisch-Embryo wurde festgeste llt, dass diese Verbindungen im \ngetesteten Konzentrationsbereich keine Toxizit\u00e4t au fweisen.         \n  \nDie im Rahmen dieser Arbeit von Fabio Lo Monte synt hetisierten Verbindungen: \n \nBSc4258 (2a), BSc4259 (3a), BSc4260 (4a), BSc4392 ( 4c), BSc4401 (4b), BSc4611 \n(26d), BSc4612 (26b), BSc4613 (26c), BSc4614 (26a),  BSc4670 (9b), BSc4672 (9a), \nBSc4674 (8b), BSc4678 (10e), BSc4680 (9d), BSc4682 (9f), BSc4683 (9c), BSc4684 \n(8e), BSc4685 (8d), BSc4686 (8g), BSc4687 (8c), BSc 4688 (10d), BSc4689 (10c), \nBSc4734 (10a) \nIn Klammern die Verbindungsnummer in der Publikatio n. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 166 Structure-based optimization of  \noxadiazole-based GSK-3 inhibitors   \nFabio Lo Monte, a, * Thomas Kramer, a Jiamin Gu, a Martin Brodrecht, a Johannes \nPilakowski, a Ana Fuertes, b Juan Manuel Dominguez,b Batya Plotkin, c Hagit \nEldar-Finkelman c and Boris Schmidt a, * \na Clemens Sch\u00f6pf - Institute of Organic Chemistry an d Biochemistry, Technische Universit\u00e4t Darmstadt, 6 4287 \nDarmstadt, Germany \nb Noscira S.A., Drug Discovery, Tres Cantos 28760 - Madrid, Spain \nc Department of Human Molecular Genetics and Biochemi stry, Sackler School of Medicine, Tel Aviv Universi ty,  \n69978 Tel Aviv, Israel \n \n* To whom correspondence should be addressed. Phone: +496151-164531. Fax: +496151-163278.  \n   E-Mail: schmidt_boris@t-online.de; Fabio.Lo-Mont e@gmx.de \n \nKeywords:  Glycogen Synthase Kinase-3 (GSK-3); Alzheimer\u00b4s Di sease; Structure-Activity \nRelationship (SAR); Reversible Inhibition; Zebrafis h Phenotype    \nAbstract  \nInhibition of glycogen synthase kinase-3 (GSK-3) in duces neuroprotective effects, e.g. \ndecreases \u03b2-amyloid production and reduces tau hyperphosphoryl ation, which are both \nassociated with Alzheimer\u00b4s disease (AD). The two i soforms of GSK-3 in mammalians are \nGSK-3\u03b1 and \u03b2, which share 98% homology in their catalytic domai ns. We investigated  \nGSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP \nbinding pocket [1]. Particularly, the oxadiazole sc affold provided potent and selective GSK-3 \ninhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d , is \ncharacterized by an IC 50  of 2 nM for GSK-3 \u03b1 and 17 nM for GSK-3 \u03b2. In addition, the \nbenzodioxane 8g  showed up to 27-fold selectivity for GSK-3 \u03b1 over GSK-3\u03b2, with an IC 50  of \n35 nM for GSK-3 \u03b1. Two GSK-3 inhibitors were further profiled for ef ficacy and toxicity in \nthe wild-type (wt) zebrafish embryo assay to evalua te simultaneously permeability and safety. \n  \nSeite 167 1. Introduction  \nAlzheimer\u00b4s disease (AD) is a neurodegenerative dis order and characterized by the presence \nof abnormal filamentous protein inclusions in nerve  cells of the brain [2]. The \nneuropathological hallmarks of AD were first report ed by Alois Alzheimer and date back to \n1907 [3-4]. These inclusions are formed by extracel lular amyloid deposits and intracellular \nmicrotubule-associated protein tau [5]. Early onset  forms of familial Alzheimer\u00b4s disease \n(FAD) have been linked to mutations in the amyloid precursor protein (APP), presenilin-1 \n(PS-1) and presenilin-2 (PS-2). These mutations adv ersely affect APP processing and result in \nthe increased production of the 40-42 amino acid lo ng \u03b2-amyloid (A \u03b2) peptides, which are the \nmajor component of amyloid deposits. Several risk f actors have been associated with sporadic \nAlzheimer\u00b4s disease (SAD). The most prevalent is ag ing and the presence of specific ApoE \nisoforms, which have been implicated in A \u03b2 clearance. The activation of \u03b2-secretase may be \ninvolved in A \u03b2 generation, which in combination with a deficiency  in A \u03b2 clearance will result \nin the accumulation of A \u03b2 aggregates [2, 6]. Partially phosphorylated tau in  the normal adult \nbrain features sequences that support association w ith tubulin, which entails the stabilization \nof microtubules. The pathological hyperphosphorylat ion of tau causes destabilization of \nmicrotubules, which in turn interferes with tubulin  binding. The misfolding of \nhyperphosphorylated tau leads to the formation of i nsoluble neurofibrillary tangles (NFTs) \nand intraneuronal aggregates of paired helical fila ments (PHFs) [7-8]. GSK-3 was shown to \nphosphorylate tau both in  vitro  and in vivo  on multiple sites [7]. Several studies demonstrate  \nthat inhibition of GSK-3 induces decreased A \u03b2 production and a reduction in tau \nhyperphosphorylation [9-10]. GSK-3 was identified i n the late 1970s and is a constitutively \nactive, ubiquitously expressed serine/threonine kin ase, which participates in a number of \nphysiological processes [2, 11]. Two related isofor ms of GSK-3 exist in mammals, GSK-3 \u03b1 \nand \u03b2, which share 98% homology in their catalytic domai ns and have similar biochemical \nproperties [7, 12]. The isoforms differ significant ly outside of their catalytic domains at their \nN-terminal regions [13]. Furthermore, an alternativ e splice variant of GSK-3 \u03b2: GSK-3\u03b22, has \nbeen reported for rodents and humans [14-15]. The c rystal structure of GSK-3 \u03b2 was \ndetermined in 2001 [16-17]. GSK-3 is highly enriche d in the brain and several publications \nindicate that the GSK-3 \u03b2 isoform is a key kinase required for abnormal hype rphosphorylation \nof tau [18-20]. Lithium chloride was the first GSK- 3 inhibitor to be discovered. However \nthere are several other biological targets for lith ium cations, which impose limits on the \ntherapeutic window. Considering the homology of GSK -3\u03b1 and \u03b2 within the ATP-binding  \nSeite 168 pocket it appears difficult to identify an inhibito r that differentiates the two isoforms. All \nGSK-3 inhibitors developed until now are able to in hibit the two isoforms with almost similar \npotency, except compound \u039b\u039b \u039b\u039b-OS1 , which showed up to 7-fold selectivity for GSK-3 \u03b1 and \ncompound 15b , which showed up to 92-fold selectivity for GSK-3 \u03b1 [21-24]. A plethora of \nGSK-3 inhibitors has been described and most of the  effects were observed in vitro  and \ncellular studies (Fig. 1) [5, 25-26]. These studies  and the ongoing patent filing indicate that \nGSK-3 is a potential drug target not just for the t reatment of AD. Several research groups and \npharmaceutical companies are interested in the disc overy of novel GSK-3 inhibitors with \ngood selectivity and bioavailability despite of the  Wnt-pathway associated risks, which may \nresult in adverse cell proliferation. In the presen t study, the 1,3,4-oxadiazole-moiety served as \na scaffold for a variety of GSK-3 inhibitors. This particular heterocycle was chosen because it \nhas favourable properties over 1,2,4-oxadiazoles an d other five-membered heterocycles [27]. \nThe inhibition potencies of these compounds were co mpared to those of the previously \nreported 1,3,4-oxadiazoles and substituted ureas in  the attempt to identify additional \nheterocycles and substituents that enhance GSK-3 in hibition [1, 28-30]. The resulting \ninteractions with the ATP binding pocket of GSK-3 \u03b1 and \u03b2 were also investigated to generate \na hypothesis for isoform discrimination. We employe d the wild-type zebrafish embryo in \norder to validate the utility of these compounds in vivo . \n \n \n \nFig. 1.   Structures of previously reported GSK-3 inhibitors.   \n \n \n \nSeite 169 2. Chemistry \nThe esterfication of the carboxylic acids 1a, b afforded compounds 2a, b which were \nconverted to the hydrazides 3a, b . The hydrazide 3c  was commercially available. Reaction of \nthe hydrazides 3a-c with carbon disulfide (CS 2) afforded the oxadiazoles 4a-c (Scheme 1)  \n[28, 31-32]. \n \nScheme 1.   Reagents and conditions: (a) MeOH, SOCl 2, 0\u00b0C to 50\u00b0C, 83-89%; (b) NH 2NH 2\u2022H 2O, EtOH, reflux, \n67-75%; (c) CS 2, Et 3N, EtOH, reflux, 79-89%.      \n \n \nScheme 2.  Reagents and conditions:  (a) aryl bomide, toluene, EtOH, Pd(PPh 3)4, 2-tolylboronic acid,  \n2 N Na 2CO 3(aq.), 80\u00b0C; (b) NBS, AIBN, CCl 4, reflux; (c) oxadiazoles (4a-c), 1N NaOH, DMF, rt,  27-79%. \n \nSeite 170 The biphenyls 7a-h were prepared in two steps from commercial p-tolylboronic acid and \nbromobenzene bearing substituents at the 1- to 4-po sition [33]. The biphenyl halides 7a-h \nwere coupled with the heterocycles 4a-c to obtain the compounds 8a-h, 9a-f and 10a-f \n(Scheme 2). The thioethers 15-18 (a-d) (Scheme 3) were synthesized similar to method \ndescribed in Scheme 1 and 2 [28, 34-35]. The hydraz ones 20a-d were prepared using \nisoniazid 19  (Scheme 4) and 4 different benzaldehydes [36-38]. The esterification of acid 21  \nto the ester 22 employed  standard conditions, it was followed by reaction wi th acetic \nanhydride to provide the amide 23  (Scheme 5) [39-40]. The thioethers 26a-d were \nsynthesized according to the method described in Sc heme 1 and 2. Esterfication of compound \n27 , followed by cyclization gave compound 29 (Scheme 6)  [41-42]. \n \n \n \nScheme 3.  Reagents and conditions: Reagents and conditions: ( a) MeOH, SOCl 2, 0\u00b0C to 50\u00b0C, 68-76%;  \n(b) NH 2NH 2\u2022H 2O, EtOH, reflux, 81-89%; (c) CS 2, Et 3N, EtOH, reflux, 74-88%; (d) Benzyl halides, 1N NaO H, \nDMF, rt, 32-71%. \n \nCompound 30  was obtained using the conditions described for co mpound 23 [40]. \nSaponification of the ester 30 , followed by reaction with tert -butyl carbazate, gave compound \n32 [28, 43]. Cleavage of the tert -butylamine in 32  by TFA and submission to the reaction \nconditions described in Scheme 1 and 2 provided the  final product 35 [28]. Bromination of \nthe 4-hydroxybenzoic acid 36 , gave compound 37 (Scheme 7) [44]. The dibenzofuran 38  was \nobtained by the combination of two reactions in a o ne-pot synthesis [45-46]. The final \n \nSeite 171 compound 41  was prepared in relation to the method described i n Scheme 1 and 2. The \nstructures of all compounds were verified by mass s pectrometry, 1H-NMR and 13 C-NMR.  \n \n \n \nScheme 4.   Reagents and conditions: (a) EtOH/H 2O, Aldehydes, rt, 83-97%.        \n \n \n \n \nScheme 5.   Reagents and conditions: (a) MeOH, SOCl 2, 0\u00b0C to 50\u00b0C, 89%; (b) acetic anhydride, 105\u00b0C, 69 %; \n(c) NH 2NH 2\u2022H 2O, EtOH, reflux, 74%; (d) CS 2, Et 3N, EtOH, reflux, 92%; (e) Benzyl halides, 1N NaOH, DMF, \nrt, 37-68%. \n            \n3. Results and discussion \n \nThe synthesized compounds were evaluated for GSK-3 inhibition in a commercial system \nbased on the Z\u2019-LYTE \u00ae technology, available from Invitrogen Life Technol ogies (Carlsbad, \nCA, USA), using human recombinant GSK-3 \u03b1 or GSK-3\u03b2 as the enzyme source and further \nfor their inhibitory activity in vitro  against GSK-3 \u03b2. Several compounds displayed more than \n50% inhibitory activity against GSK-3 \u03b2 at 10 \u00b5M concentration. We focussed our interest o n \ninhibitors with potential occupation of the entire ATP-binding pocket, and thereby to enhance \npotency and selectivity (Fig. 2). Heterocycles feat uring the oxadiazole ring typically interact \nwithin the green marked area of GSK3 (Fig. 2). Our goal was to extend our compounds to the \n \nSeite 172 area highlighted in blue. Furthermore, we tried to enhance the potential interaction with the \nbackbone by replacing heterocycles with phenyl ring s bearing different acceptors and to \ninvestigate the contribution deriving from the rigi dity of a tricyclic system [26]. The 3 \nheterocyclic fragments 4a-c were introduced as potential hinge binders in order  to interact \nwith the GSK-3 backbone: Asp133/Tyr134/Val135 (Sche me 1). The oxadiazole moiety is \nassumed to engage with the polar binding pocket, co nsisting of three amino acids \n(Lys85/Glu97/Asp200). Such interactions were previo usly reported for the GSK-3 \u03b2 inhibitor \nII and 20x (Fig. 1). We coupled the compounds 4a-c to biphenyl systems bearing different \nsubstituents on the second phenyl ring (Scheme 2). Most of these compounds showed \nremarkable activities and selectivities (Table 1).   \n \n \n \nScheme 6.   Reagents and conditions: (a) EtOH, H 2SO 4, reflux, 91%; (b) CH 3COOH, KSCN, Br 2, rt, 67%;  \n(c) acetic anhydride, 105\u00b0C, 58%; (d) MeOH, 1N NaOH , rt, 94%; (e) DMF, tert -Butyl carbazate, EDCI, \nHOBt\u2022H 2O, rt, 77%; (f) TFA, rt, 99%; (g) CS 2, Et 3N, EtOH, reflux, 81%; (h) Benzyl halide, 1N NaOH, D MF, rt, \n47%.            \n \nScheme 7.   Reagents and conditions: (a) DCM, Br \nNH 2NH 2\u2022H 2O, rt, 99%; (d) CS 2, Et 3N, EtOH, reflux, 48%; (e) Benzyl halide, 1N NaOH, D MF, rt, 44%.    \n \n \n \n \n \n \n \n \nFig. 2.   Schematic overview of the GSK \nsite of the heterocycle and oxadiazole ring. \nblue. \n \nThe compounds 8f  and 9a-e were found to be potent inhibitors of both isoforms  of GSK \ncharacterized by IC 50 values in the low nanomolar range \nselectivities against other kinases. Substituents i n the ortho \nand 9 lead to potent inhibition of both isoforms as indic ated for compound \nIC 50 value of 5 nM for GSK- 3\u03b1\nonly the interplay respectively combination of diff erent substituents is adequate to gain \nselectivity against one GSK- 3 isoform. Compounds \nSeite 173 \n \nReagents and conditions: (a) DCM, Br 2, rt, 65%; (b) DMF, Pd(OAc) 2, K 2\nN, EtOH, reflux, 48%; (e) Benzyl halide, 1N NaOH, D MF, rt, 44%.    \nSchematic overview of the GSK -3 ATP-binding pocket.  The green marked area reveals the interaction \nsite of the heterocycle and oxadiazole ring. The area we wanted to occupy with our structures is  marked in light \nwere found to be potent inhibitors of both isoforms  of GSK \nvalues in the low nanomolar range . In addition, all of them showed go \nselectivities against other kinases. Substituents i n the ortho - and para- positions of structure \nlead to potent inhibition of both isoforms as indic ated for compound \n3\u03b1 respectively 14 nM and 32 nM for  GSK-3\u03b2\nonly the interplay respectively combination of diff erent substituents is adequate to gain \n3 isoform. Compounds 8b  and 8g  enhance the selectivity for \n \n2CO 3, 130\u00b0C, 30%; (c) \nN, EtOH, reflux, 48%; (e) Benzyl halide, 1N NaOH, D MF, rt, 44%.                \nThe green marked area reveals the interaction \nThe area we wanted to occupy with our structures is  marked in light \nwere found to be potent inhibitors of both isoforms  of GSK -3 as \n. In addition, all of them showed go od \npositions of structure 8 \nlead to potent inhibition of both isoforms as indic ated for compound 8f  and 9e  with an \n3\u03b2. We reasoned that \nonly the interplay respectively combination of diff erent substituents is adequate to gain \nenhance the selectivity for \n \nSeite 174 GSK-3\u03b1 up to 27-fold. An inverse effect was observed for pyridine 10e  where a substituent in \nmeta- and para-position leads to slightly increased  selectivity for inhibition of GSK-3 \u03b2. All \ncompounds lacking the heterocycle (Scheme 3) or oxa diazole ring (Scheme 4) completely lost \nmost of their ability to inhibit GSK-3 and resulted  in a residual GSK-3 \u03b2 activity of more than \n50% at 10 \u00b5M. We attempted the combination of diffe rent lead structures by the addition of \nan amide function at the pyridine and benzothiazole  (Scheme 4 and 5). A similar moiety \nserves as an ambident moiety on Sorafenib. It was r eported to establish hydrogen bonds with \nthe same amide on the target hinge region either vi a the pyridyl nitrogen or through the \ncarbonyl of the acetyl amide [47-48].  \n \nTable 1    \nInhibitory activity against different kinases in vitro  and in silico  parameters (calc. with ChemDraw Ultra 9.0.1).  \n                                                                  IC 50 (\u00b5M)  \n   clogP   tPSA \n   (\u00c5 2)  \nCompound  GSK-3\u03b1 GSK-3\u03b2 Cdk5/p35  CK1 \u03b5 AurKA  PKC \u03b1   \n         8a  0.004  0.090  > 100  > 100  > 100  > 100  4.62 112.2 \n8b  0.009  0.225  > 100  > 100  > 100  > 100  4.31 84.8 \n8c  0.015  0.164  > 100  > 100  > 100  > 100  4.62 112.2 \n8d  0.195  1.995  > 100  > 100  50.0  > 100  4.31 84.8 \n8e  0.019  0.127  > 100  > 100  > 100  > 100  4.80 79.0 \n8f  0.005  0.032  > 100  > 100  > 100  > 100  4.56 98.9 \n8g  0.035  0.966  > 100  > 100  > 100  > 100  5.16 64.9 \n8h  0.051  0.234  > 100  > 100  > 100  > 100  4.88 64.9 \n9a  0.003  0.027  > 100  > 100  > 100  > 100  4.66 112.2 \n9b  0.004  0.029  > 100  > 100  > 100  > 100  4.35 84.8 \n9c  0.015  0.086  > 100  > 100  > 100  > 100  4.66 112.2 \n9d  0.007  0.075  > 100  20.0  40.0  > 100  4.84 79.0 \n9e  0.005  0.014  > 100  50.0  45.0  > 100  4.60 98.9 \n9f  0.051  0.195  > 100  80.0  > 100  > 100  5.21 64.9 \n10a  0.027  0.164  > 100  > 100  5.0  > 100  3.28 95.3 \n10b  0.046  0.084  > 100  > 100  60.0  > 100  2.97 67.9 \n10c  0.077  0.153  > 100  > 100  > 100  > 100  2.97 67.9 \n10d  0.240  0.176  > 100  > 100  > 100  > 100  3.45 62.1 \n10e  0.324  0.056  > 100  > 100  > 100  > 100  3.11 67.9  \nSeite 175 10f  0.052  0.083  > 100 > 100  > 100  > 100  3.53 48.0 \n26a  0.020  0.035  > 100  > 100  60.0  > 100  1.58 83.1 \n26c  0.017  0.019  > 100  > 100  > 100  > 100  1.01 103.0 \n26d  0.002  0.017  > 100  > 100  > 100  > 100  2.90 103.0 \n         \nThus the amide was expected to increase the interac tion with the backbone of GSK-3 as \nobserved in the tight binding of Compound 62  and AR-A014418 (Fig. 1). We determined \npromising activities and selectivities for the pyri dines 26a , 26c  and 26d . Especially compound \n26d  with an IC 50 value of 2 nM for GSK-3 \u03b1 and 17 nM for GSK-3 \u03b2 showed more than  \n5000-fold selectivity against Cdk5/p35, CK1 \u03b5, AurKA and PKC \u03b1 (Table 1). However, the \nadditional amide on the benzothiazole 35  reduced activity for both isoforms indicating  \ntoo close proximity to the backbone. Moreover, the acetamide 26d  is characterized by a  \nclogP of 2.90 and a tPSA of 103.0 \u00c5 2. The letter value exceeds the limits for likely bl ood-\nbrain barrier permeation. In addition, the structur al rigidity of the dibenzofuran 41 resulted in \nloss of inhibitory activity against GSK-3.  \nA docking study of compound 9e  and 26d  into the PDB structure 3F88 of GSK-3 \u03b2 suggested \na binding mode that uses the ATP-binding pocket in its entirety. The oxadiazole interacts in \nboth cases with the polar pocket consisting of Lys8 5 and Asp200. For compound 9e  the amide \nfunctions leads to a binding mode along the hinge r egion of the ATP-binding pocket. The \nbiphenyl system interacts with Ile62, Gly63, Phe67 and Val70, which form part of the flexible \nglycine-rich loop. The methoxy group of compound 9e  is located in close proximity to the salt \nbridge formed by Glu137 and Arg141, which may be re sponsible for the activity of this \ncompound. Nevertheless, this structure does not pro vide insight into the selective inhibition of \nthe GSK-3\u03b2 isoforms as all amino acid residues shown in Figur e 3 are identical in both \nisoforms. Hence, only a complex of GSK-3 \u03b2 co-crystallized with one of these inhibitors, \nsolved by X-ray crystallography, may provide the ne cessary insights. \n \n \n \n \n  \nSeite 176 \n \n \n \n \n \n \n \n \n \n \n \n \nFig. 3.   Docking of compounds 9e and  26d  into PDB structure 3F88 of GSK-3 \u03b2; Hydrogen bond interactions \nof compound 26d  (A) and 9e  (B) with the amino acids of the ATP-binding pocket ; Surface illustration of \nthe ATP-binding pocket with compound 26d  (C) and 9e  (D). The inhibitors are shown in yellow. These fig ures \nwere prepared with Molegro Virtual Docker 5.  \nAfter evaluation of the in vitro  activity and selectivity of these compounds the bi phenyl \nderivatives 9e  and 26d  were further tested for their in vivo  activity on wt zebrafish embryos. \nWe exposed the embryos to these compounds at early stages of development (Figure 4). The \nembryos were collected and maintained in E2 medium at ~28\u00b0C. The compounds were added \n5 hpf (hour post fertilization), and the phenotypes  were compared at 44-48 hpf. Compounds \n9e  and 26d  cause a stunted and crooked tail at 30 \u00b5M. This co rrelates with the observation \nthat Wnt signaling, and thus GSK-3 \u03b2 activity, plays a crucial role in the development of \nmetazoan. This was demonstrated for the known GSK-3  inhibitors LiCl and the ruthenium \ncomplex ( R)-7, which both  perturb zebrafish development [49-50]. However, it must be noted \nthat compound 9e  and 26d  were not completely dissolved in the E2-medium at 30 \u00b5M. Thus, \nan exact concentration cannot be stated for these c ompounds. Nevertheless, both compounds \nexerted no toxicity in the observation range (< 30 \u00b5M).    \n A B \nC D Arg141  Glu137  \nThr138  Pro136  Val135  Tyr134  Asp133  \nLeu132  \nLys85  \nAsp200  \nArg141  \nGlu137  Thr138  Pro136  Val135  Tyr134  Asp133  Leu132  Lys85  Asp200  \nPhe67  Gly63  Val70  \nIle62  Phe67  \nGly63  \nIle62  Val70   \n \n \n \n \n \n \n \n \n \n \n \n \nFig. 4. Effect on the wild- type zebrafish embryo by compounds \nE2 medium at ~28\u00b0C, compound was added 5 hpf, and th e phenotypes were compared at 44 \ncontrol embryos - DMSO (2%). (C, D) Embryo t \nat 30 \u00b5M. (E) Embryo treated with compound \n \n4. Conclusion \nIn this report, we describe the synthesis and evalu ation of ox \nOccupation of the ATP binding pocket in its entiret y led to the identification of several potent \nand selective compounds. These compounds are charac terized by IC \nnanomolar range and good selectivity versu \nthe addition of different functional groups onto th e biphenyl system was adequate to gain \nselectivity against one GSK -\ncompound 8g  for GSK- 3\u03b1 compared to GSK \nobservations will be helpful, if the discrimination  of one GSK \nThe discriminating factor for this isoform selectiv ity is still unknown as the ATP binding \nare almost identical in the two isoforms (Figure 3) . Differences in the amino acid sequence of \nthe channels leading to the binding sites may hold a cue, but the lack of a crystallized GSK \n3\u03b1 makes this hypothesis highly speculative. Furthermo re, amin \nA \nB \nSeite 177 \ntype zebrafish embryo by compounds 9e  and 26d . The embryos were collected and maintained in \nE2 medium at ~28\u00b0C, compound was added 5 hpf, and th e phenotypes were compared at 44 -48 hpf. (A, B) \nDMSO (2%). (C, D) Embryo t reated with compound 9e . This compound causes a stunted and crooked tail \nat 30 \u00b5M. (E) Embryo treated with compound 26d . This compound causes a stunted and crooked tail a t 30 \u00b5M. \nIn this report, we describe the synthesis and evalu ation of ox adiazole based GSK3 inhibitors. \nOccupation of the ATP binding pocket in its entiret y led to the identification of several potent \nand selective compounds. These compounds are charac terized by IC 50  \nnanomolar range and good selectivity versu s other kinases. Surprisingly, we ascertained that \nthe addition of different functional groups onto th e biphenyl system was adequate to gain \n-3 isoform. To the best of our knowledge the selecti vity of \n\u03b1 compared to GSK -3\u03b2 is among the highest ever reported. These \nobservations will be helpful, if the discrimination  of one GSK -3 isoform is needed \nThe discriminating factor for this isoform selectiv ity is still unknown as the ATP binding \nare almost identical in the two isoforms (Figure 3) . Differences in the amino acid sequence of \nthe channels leading to the binding sites may hold a cue, but the lack of a crystallized GSK \nmakes this hypothesis highly speculative. Furthermo re, amin o acids in the second \nC \nD E \n. The embryos were collected and maintained in \n48 hpf. (A, B) Head and tail of \n. This compound causes a stunted and crooked tail \n. This compound causes a stunted and crooked tail a t 30 \u00b5M.  \nadiazole based GSK3 inhibitors. \nOccupation of the ATP binding pocket in its entiret y led to the identification of several potent \n values in the low \ns other kinases. Surprisingly, we ascertained that \nthe addition of different functional groups onto th e biphenyl system was adequate to gain \n3 isoform. To the best of our knowledge the selecti vity of \n is among the highest ever reported. These \n3 isoform is needed in vivo . \nThe discriminating factor for this isoform selectiv ity is still unknown as the ATP binding sites \nare almost identical in the two isoforms (Figure 3) . Differences in the amino acid sequence of \nthe channels leading to the binding sites may hold a cue, but the lack of a crystallized GSK -\no acids in the second -sphere \n \nSeite 178 close to the ATP binding pocket do vary for GSK-3 \u03b1 and thus may contribute to \nconformational changes. The interaction with the gl ycine-rich loop might have significant \neffects on the binding potencies and selectivities of the biphenyl derivatives similar to the \ncompounds reported by Li Feng et al  [22]. The amide function in compound 26d  indicated a \npotential interaction with the backbone exploitable  for further improvement. However, this \nmoiety causes a significant contribution to the tPS A (103.0 \u00c5 2) and thus impairs potential \nblood-brain barrier permeation. We exposed wt zebra fish embryos to two of these compounds \nat early stages of development and obtained desirab le in vivo  efficacy for compound 9e  and \n26d . We suppose that GSK-3 \u03b1 inhibition offers a new approach to reduce the for mation of \nboth amyloid plaques and neurofibrillary tangles an d thus may be valuable in the treatment of \nAD [51]. On the basis of these results the derivati ves 8b , 8g  and 26d were selected for further \npharmacological and structural evaluations.      \n \n5. Experimental \n5.1. Chemistry \n \nAll reactions under anhydrous conditions were carri ed out under argon atmosphere with dry \nsolvents, unless otherwise noted. All the commercia l chemicals were used without further \npurification. The 1H-NMR spectra were recorded on a Bruker AC 300 spec trometer at \n300 MHz and Bruker AC 500 spectrometer at 500 MHz. The 13 C-NMR spectra were recorded \non a Bruker AC 300 spectrometer at 75 MHz and Bruke r AC 500 spectrometer at 125 MHz. \nChemical shifts are reported as ppm downfield from Me 4Si. Abbreviations used to explain the \nmultiplicities: s = singlet, d = doublet, t = tripl et, q = quartet, m = multiplet, br = broad. \nCoupling constants ( J values) are given in hertz (Hz). Mass spectrometry was performed on a \nBruker-Franzen Esquire LC mass spectrometer and a M AT 95 double focusing sector field \nMS. High performance liquid chromatographies were c arried out on an Agilent 1100 \n(column: reversed phase, Zorbax Eclipse XDB-C8, 4.6  x 150 mm; 254 nm). Flash column \nchromatography was carried out using Merck silica g el 60 (40-63 and 15-40 \u00b5m) and 60G  \n(5-40 \u00b5m). Thin-layer chromatography (TLC) was carried out  using aluminum sheets \nprecoated with silica gel 60 F254 (0.2 mm; E. Merck ).  \n \n \n  \nSeite 179 5.2.1    Methyl 2,3-dihydrobenzo[ b][1,4]dioxine-6-carboxylate  (2a )  \nTo a stirred solution of 2,3-dihydrobenzo[ b][1,4]dioxine-6-carboxylic acid 1a  (1.80 g,  \n10 mmol) in MeOH (20 mL) was added SOCl 2 (1.45 mL, 20 mmol) dropwise at  \n0\u00b0C over 1 h. The mixture was further stirred 12 h at 50\u00b0C. The solution was cooled to room \ntemperature and diluted with water (25 mL). MeOH wa s evaporated and the pH adjusted to \n~6 with aqueous NaHCO 3. The mixture was extracted three times with EtOAc and \nsuccessively washed with brine. The organic layer w as dried over MgSO 4 and concentrated \nunder reduced pressure to give 2a  (1.6 g, 83%) as a colorless solid. 1H-NMR (DMSO-d 6,  \n500 MHz): \u03b4 [ppm] = 3.80 (3H, s), 4.19 (2H, m), 4.23 (2H, m), 6.80 (1H, m), 7.47 (2H, m).  \n13 C-NMR (DMSO-d 6, 125 MHz):  \u03b4 [ppm] = 50.5, 62.7, 63.2, 115.7, 117.6, 122.0, 141 .7, \n146.4, 165.2. EI-MS:  m/z 194 (M +). \n \n5.2.2    Compound 2b was prepared in a similar manner to that described for 2a   \nMethyl benzo[ d][1,3]dioxole-5-carboxylate  (2b ).  Yield 89%, colorless solid.   \n1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.81 (3H, s), 6.14 (2H, s), 7.03 (1H, d,  \nJ = 8.1 Hz), 7.38 (1H, d, J = 1.6 Hz), 7.57 (1H, dd, J = 8.1 Hz, J = 1.7 Hz). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 52.0, 102.1, 108.2, 108.5, 123.4, 125.0, 1 47.6, 151.4, 165.6.  \nEI-MS: m/z = 180 (M +). \n \n5.3.1    2,3-Dihydrobenzo[ b][1,4]dioxine-6-carbohydrazide  (3a ) \nTo a solution of 2a  (1.16 g, 6.0 mmol) in EtOH (30 mL) was added hydra zine hydrate \n(2.91 mL, 60 mmol) and the mixture was heated at re flux for 2 days. After cooling to room \ntemperature pure crystals are formed, collected by filtration and washed several times with \nEtOH to give compound 3a  (0.87 g, 75%) as a  light yellow solid.   1H-NMR (DMSO-d 6,  \n500 MHz): \u03b4 [ppm] = 4.28 (2H, m), 4.30 (2H, m), 6.89 (1H, d, J = 8.4 Hz), 7.30 (1H, dd,  \nJ = 8.3 Hz, J = 2.1 Hz), 7.33 (1H, d, J = 2.1 Hz). 13 C-NMR (DMSO-d 6, 125 MHz):   \n\u03b4 [ppm] = 65.9, 66.3, 117.9, 118.6, 121.9, 127.5, 14 5.2, 148.6, 169.6. EI-MS:  m/z 194 (M +). \n \n5.3.2    Compound 3b was prepared in a similar manner to that described for 3a   \nBenzo[ d][1,3]dioxole-5-carbohydrazide  (3b ). Yield 67%, colorless solid.  1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.42 (2H, s), 6.07 (2H, s), 6.96 (1H, d, J = 8.1 Hz), 7.35 \n(1H, d, J = 1.7 Hz), 7.42 (1H, dd, J = 8.1 Hz, J = 1.7 Hz), 9.59 (1H, s). 13 C-NMR (DMSO-d 6,  \n125 MHz): \u03b4 [ppm] = 101.5, 106.9, 107.8, 121.8, 127.2, 147.2, 149.5, 165.2.  \nEI-MS: m/z = 180 (M +).  \nSeite 180 5.4.1     5-(2,3-Dihydrobenzo[ b][1,4]dioxin-6-yl)-1,3,4-oxadiazole-2-thiol  (4a )  \nTo a solution of 3a  (582 mg, 3.00 mmol) in EtOH (5 mL) were added carb on disulfide \n(397 \u00b5L, 6.60 mmol) and Et 3N (469 \u00b5L, 3.30 mmol) and the mixture was heated at  reflux \novernight. The reaction mixture was diluted with Et OAc and the organic layer was washed \nwith 0.1 N HCl, brine and dried over Na 2SO 4. The solvent was evaporated under reduced \npressure, and the obtained residue was recrystalliz ed from CH/EtOAc (1:2) to give 4a (630 \nmg, 89%) as a light brown solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.32 (2H, m), \n4.34 (2H, m), 7.05 (1H, d, J = 8.4 Hz), 7.30 (1H, d, J = 2.0 Hz), 7.36 (1H, dd, J = 8.4 Hz,  \nJ = 2.0 Hz), 14.2 (1H, s, br). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 64.4, 64.8, 115.0, \n115.7, 118.6, 120.0, 144.2, 147.3, 160.6, 177.6. EI -MS:  m/z = 236 (M +).  \n \n5.4.2    Compound 4b was prepared in a similar manner to that described for 4a   \n5-(Benzo[ d][1,3]dioxol-5-yl)-1,3,4-oxadiazole-2-thiol  (4b ).  Yield 79%, pale yellow \nsolid.   1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 6.14 (2H, s), 7.10 (1H, d, J = 8.1 Hz), 7.33  \n(1H, d, J = 1.6 Hz), 7.42 (1H, dd, J = 8.1 Hz, J = 1.6 Hz). 13 C-NMR (DMSO-d 6,  \n125 MHz): \u03b4 [ppm] = 102.1, 105.6, 109.1, 116.1, 121.5, 148.1, 150.6, 160.3, 177.2.  \nEI-MS: m/z = 222 (M +). \n \n5.4.3    Compound 4c was prepared in a similar manner to that described for 4a   \n5-(Pyridin-4-yl)-1,3,4-oxadiazole-2-thiol  (4c ).  Yield 83%, yellow solid.  1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 7.81 (2H, dd, J = 4.4 Hz, J = 1.6 Hz), 8.81 (2H, dd,  \nJ = 4.4 Hz, J = 1.6 Hz). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 119.6, 129.7, 150.8, \n158.7, 177.8. EI-MS: m/z = 179 (M +). \n \n5.5.1.    General procedure for synthesis of compou nds 6a-h [33]  \nTo a solution of the aryl bromide (5 mmol) in 15 mL  of toluene/EtOH (1/1) was added \n0.17 g  (0.14 mmol) of Pd(PPh 3)4, and the mixture was stirred under  argon atmosphere. Then  \n2 N aqueous Na 2CO 3 (7.5 mL) and  0.80 g (6 mmol) of 2-tolylboronic acid were added. The  \nmixture was refluxed at 80\u00b0C for 1-2 days until rea ction was  completed (TLC). After cooling \nto room temperature, the product was diluted with w ater and extracted  with EtOAc. The \norganic layers were dried with  MgSO 4, filtered, and concentrated. Purification was perf ormed  \nby column chromatography using a mixture of CH/EtOA c (9:1). The compounds were used, \nwithout structure determination, directly for the n ext step. \n  \nSeite 181 5.6.1.    General procedure for synthesis of compou nds 7a-h [33] \nTo a stirred solution of the appropriately substitu ted  toluene in CCl 4 (10 mL per mmol) \nwere added 0.95 eq.  of NBS and AIBN (5 mg per mmol). The reaction  mixture was refluxed \nat 80\u00b0C and then cooled  to room temperature. The product was diluted with w ater and \nextracted  with EtOAc. The organic layers were dried with  MgSO 4, filtered, and concentrated. \nPurification was performed  by column chromatography using a mixture of CH/EtOA c (6:1). \nThe compounds were used, without structure determin ation, directly for the next step. \n \n5.7.1.    General procedure for synthesis of compou nds 8a-h, 9a-f and  10a-f  \nTo a solution of compound  4a-c (0.25 mmol) and 1 N NaOH (0.25 mmol) in DMF  \n(1 mL) was added the appropriate substituted biphen yl system (0.38 mmol) at room \ntemperature, and the mixture was stirred for 5 h. T he precipitate formed was collected by \nfiltration and washed once with less DMF and therea fter several times with EtOH to give \ncompounds 8a-h, 9a-f and  10a-f. \nNote:  The compounds which did not precipitate from the s olution were purified as follows. \nThe reaction mixture was diluted with EtOAc and the  organic layer was washed with water \nand brine, dried over MgSO 4 and concentrated in vacuo . The residue was purified by silica \ngel column chromatography (DCM/EtOAc \u2013 20:1).  \n \n5.7.2.    2,3-Dihydrobenzo[ b][1,4]dioxin-6-yl-5-((2'-nitrobiphenyl-4-yl)methylt hio)-1,3,4-\noxadiazole ( 8a ). Yield 77%, yellow solid.  1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.31 \n(4H, m), 4.63 (2H, s), 7.10 (1H, d, J = 8.4 Hz), 7.35 (2H, m), 7.44 (1H, s), 7.41 (1H, d ,  \nJ = 8.4 Hz), 7.53 (3H, m), 7.64 (1H, t,  J = 7.8 Hz), 7.72 (1H, t, J = 7.6 Hz), 8.05 (1H, d,  \nJ = 8.1 Hz). 13 C-NMR (DMSO-d 6, 125 MHz): 36.0, 64.5, 64.9, 115.5, 116.4, 118.6, 120.4, \n124.5, 128.5, 129.4, 129.9, 132.3, 133.4, 135.0, 13 6.8, 137.4, 144.3, 147.2, 149.3, 163.1, \n165.4. EI-MS: m/z = 447 (M +).  \n \n5.7.3.    4'-((5-(2,3-Dihydrobenzo[ b][1,4]dioxin-6-yl)-1,3,4-oxadiazol-2-ylthio)methyl) -\nbiphenyl-3-carbonitrile  (8b ).  Yield 36%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz):  \n\u03b4 [ppm] = 4.30 (4H, m), 4.62 (2H, s), 7.05 (1H, d, J = 8.5 Hz), 7.39 (1H, d, J = 2.1 Hz), 7.44 \n(1H, dd, J = 8.5 Hz, J = 2.1 Hz), 7.59 (2H, d, J = 8.3 Hz), 7.66 (1H, m), 7.74 (2H, d,  \nJ = 8.3 Hz), 7.82 (1H, td, J = 6.6 Hz, J = 1.3 Hz), 8.02 (1H, d, J = 8.0 Hz), 8.14 (1H, s).  \n13 C-NMR (DMSO-d 6, 125 MHz):  \u03b4 [ppm] = 36.0, 64.5, 64.9, 112.6, 115.5, 116.4, 118 .6, \n119.2, 120.4, 127.6, 130.2, 130.6, 130.7, 131.6, 13 1.9, 137.6, 137.8, 141.1, 144.3, 147.2,  \nSeite 182 163.0, 165.4. EI-MS: m/z = 427 (M +). HRMS (EI): m/z calcd for C 24 H17 N3O3S 427.0991, \nfound 427.0976.   \n \n5.7.4.    2-(2,3-Dihydrobenzo[ b][1,4]dioxin-6-yl)-5-((3'-nitrobiphenyl-4-yl)methyl thio)-\n1,3,4-oxadiazole ( 8c ). Yield 37%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz):  \n\u03b4 [ppm] = 4.32 (4H, m), 4.63 (2H, s), 7.05 (1H, d, J = 8.1 Hz), 7.39 (1H, d, J = 2.1 Hz), 7.44 \n(1H, dd, J = 8.4 Hz J = 2.1 Hz), 7.62 (2H, d, J = 8.5 Hz), 7.77 (3H, m), 8.13 (1H, m), 8.21 \n(1H, m), 8.42 (1H, m). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 36.0, 64.5, 64.9, 115.5, \n116.4, 118.6, 120.4, 121.5, 122.7, 127.7, 130.3, 13 0.9, 133.7, 137.6, 137.8, 141.7, 144.3, \n147.2, 148.9, 163.0, 165.5. EI-MS: m/z = 447 (M +).     \n \n5.7.5.    4'-((5-(2,3-Dihydrobenzo[ b][1,4]dioxin-6-yl)-1,3,4-oxadiazol-2-ylthio)methyl) -\nbiphenyl-4-carbonitrile ( 8d ). Yield 36%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz):  \n\u03b4 [ppm] = 4.33 (4H, m), 4.62 (2H, s), 7.05 (1H, d, J = 8.3 Hz), 7.39 (1H, d, J = 2.1 Hz), 7.44 \n(1H, dd, J = 8.5 Hz, J = 2.1 Hz), 7.61 (2H, d, J = 8.5 Hz), 7.74 (2H, d, J = 8.5 Hz), 7.90 (4H, \nm). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 36.0, 64.5, 64.9, 110.6, 115.5, 116.4, 118 .6, \n119.3, 120.4, 127.7, 128.0, 130.3, 133.3, 138.0, 13 8.1, 144.3, 144.5, 147.2, 163.0, 165.4.  \nEI-MS: m/z = 427 (M +).      \n \n5.7.6.    2-(2,3-Dihydrobenzo[ b][1,4]dioxin-6-yl)-5-((4'-methoxybiphenyl-4-yl)meth ylthio)-\n1,3,4-oxadiazole  (8e ).  Yield 39%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz):  \n\u03b4 [ppm] = 3.87 (3H, s), 4.31 (4H, m), 4.58, (2H, s),  7.01 (2H, d, J = 8.8 Hz), 7.04 (1H, d, \nJ = 8.3 Hz), 7.43 (2H, m), 7.51 (2H, m), 7.58 (4H, m ). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 36.2, 55.6, 64.5, 64.9, 114.8, 115.5, 116. 4, 118.6, 120.4, 126.6, 128.2, 130.0, 132.4, \n135.5, 139.7, 144.3, 147.1, 159.4, 163.1, 165.4. EI -MS: m/z = 432 (M +).      \n \n5.7.7.    4'-((5-(2,3-Dihydrobenzo[ b][1,4]dioxin-6-yl)-1,3,4-oxadiazol-2-ylthio)methyl) -4-\nmethoxybiphenyl-2-carbonitrile ( 8f ). Yield 50%, colorless solid. 1H-NMR (DMSO-d 6,  \n500 MHz): \u03b4 [ppm] = 3.85 (3H, s), 4.33 (4H, m), 4.64 (2H, s), 7.05 (1H, d, J = 8.4 Hz), 7.35 \n(1H, dd, J = 8.7 Hz, J = 2.8 Hz), 7.41 (1H, d, J = 2.0 Hz), 7.44 (1H, dd, J = 8.4 Hz,  \nJ = 2.1 Hz), 7.53 (4H, m), 7.61 (2H, d, J = 8.3 Hz). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 36.0, 56.4, 64.5, 64.9, 111.3, 115.5, 116. 4, 118.5, 118.6, 118.8, 120.4, 120.6, 129.3, \n129.8, 131.9, 137.0, 137.4, 144.3, 147.2, 159.0, 16 3.1, 165.4. EI-MS: m/z = 457 (M +). HRMS \n(EI): m/z calcd for C 25 H19 N3O4S 457.1097, found 457.1122.    \nSeite 183 5.7.8.    2-((3',5'-Difluorobiphenyl-4-yl)methylthi o)-5-(2,3-dihydrobenzo[ b][1,4]dioxin-6-\nyl)-1,3,4-oxadiazole  (8g ). Yield 41%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz):  \n\u03b4 [ppm] = 4.33 (4H, m), 4.61 (2H, s), 7.05 (1H, d, J = 8.5 Hz), 7.22 (1H, m),  7.38 (1H, d, \nJ = 2.1 Hz), 7.43 (3H, m), 7.57 (2H, d, J = 8.2 Hz), 7.73 (2H, d, J = 8.2 Hz). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 36.0, 64.5, 64.9, 103.2, 110.1, 110.3, 115 .5, 116.4,  \n118.6, 120.4, 127.5, 130.2, 137.4, 137.9, 143.7, 14 4.3, 147.2, 162.4, 163.0, 164.3, 165.4.  \nEI-MS: m/z = 438 (M +).      \n \n5.7.9.    2-(Biphenyl-4-ylmethylthio)-5-(2,3-dihydr obenzo[ b][1,4]dioxin-6-yl)-1,3,4-oxadi-\nazole (8h). Yield 38%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.31 (4H, \nm), 4.60 (2H, s), 7.03 (1H, d, J = 8.4 Hz), 7.33-7.68 (11H, m). 13 C-NMR (DMSO-d 6, 125 \nMHz): \u03b4 [ppm] = 36.1, 64.5, 64.9, 115.5, 116.4, 118.6, 120 .4, 127.1, 127.3, 127.5, 128.0, \n129.4, 130.1, 136.4, 140.1, 144.3, 147.2, 163.1, 16 5.4. EI-MS: m/z = 402 (M +).       \n \n5.7.10.    2-(Benzo[ d][1,3]dioxol-5-yl)-5-((2'-nitrobiphenyl-4-yl)methyl thio)-1,3,4-oxadiazole  \n(9a ). Yield 27%, yellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.62 (2H, s), 6.15 \n(2H, s), 7.11 (1H, d, J = 8.13 Hz), 7.32 (2H, d, J = 6.4 Hz), 7.42-7.66 (6H, m), 7.75 (1H, td,  \nJ = 7.6 Hz, J = 1.3 Hz), 7.97 (1H, dd, J = 8.0 Hz, J = 1.2 Hz). 13 C-NMR (DMSO-d 6,  \n125 MHz): \u03b4 [ppm] = 36.0, 102.6, 106.6, 109.6, 117.1, 122.2, 1 24.5, 128.5, 129.4, 129.9, \n132.3, 133.4, 135.0, 136.8, 137.3, 148.6, 149.3, 15 0.9, 163.1, 165.6. EI-MS: m/z = 433 (M +).     \n \n5.7.11.    4'-((5-(Benzo[ d][1,3]dioxol-5-yl)-1,3,4-oxadiazol-2-ylthio)methyl) biphenyl-3-carbo-\nnitrile  (9b ). Yield 41%, off-white. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.62 (2H, s), \n6.16 (2H, s), 7.11 (1H, d, J = 8.1 Hz), 7.43 (1H, d, J =1.7 Hz), 7.51 (1H, dd, J = 8.2 Hz,  \nJ = 1.7 Hz), 7.60 (2H, d, J = 8.2 Hz), 7.66 (1H, m), 7.73 (2H, d, J = 8.2 Hz), 7.82 (1H, d,  \nJ = 7.7 Hz), 8.01 (1H, d, J = 8.0 Hz), 8.14 (2H, m). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 36.0, 102.5, 106.6, 109.61, 112.5, 117.0, 119.2, 122.1, 127.5, 130.2, 130.5, 130.6, \n131.5, 131.8, 137.5, 137.8, 141.1, 148.5, 150.9, 16 3.0, 165.5. EI-MS: m/z = 413 (M +). HRMS \n(EI): m/z calcd for C 23 H15 N3O3S 413.0835, found 413.0828.   \n        \n5.7.12.    2-(Benzo[ d][1,3]dioxol-5-yl)-5-((3'-nitrobiphenyl-4-yl)methyl thio)-1,3,4-oxadiazole  \n(9c ).  Yield 48%, grey/brown solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.64 (2H, s), \n6.16 (2H, s), 7.11 (1H, d, J = 8.6 Hz), 7.44 (1H, d, J = 1.7 Hz), 7.52 (1H, dd, J = 8.1 Hz, \nJ = 1.6 Hz), 7.63 (2H, d, J = 8.4 Hz), 7.77 (3H, m), 8.14 (1H, m), 8.22 (1H, m ), 8.43 (1H, m).  \nSeite 184 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 36.0, 102.6, 106.6, 109.6, 117.1, 121.5, 1 22.2, \n122.7, 127.7, 130.4, 131.0, 133.7, 137.6, 137.8, 14 1.4, 148.6, 148.9, 150.9, 163.0, 165.6.  \nEI-MS: m/z = 433 (M +).   \n \n5.7.13.    2-(Benzo[ d][1,3]dioxol-5-yl)-5-((4'-methoxybiphenyl-4-yl)meth ylthio)-1,3,4-oxadi-\nazole  (9d ).  Yield 48%, grey/brown solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.79 \n(3H, s), 4.60 (2H, s), 6.16 (2H, s), 7.01 (2H, dd, J = 2.1 Hz, J = 8.8 Hz), 7.11 (1H, d,  \nJ = 8.2 Hz), 7.44 (1H, d, J = 1.8 Hz), 7.52 (3H, m), 7.59 (4H, m). 13 C-NMR (DMSO-d 6,  \n125 MHz): \u03b4 [ppm] = 36.2, 53.6, 102.6, 106.6, 109.6, 114.8, 11 7.1, 122.2, 126.7, 128.2, \n130.0, 132.4, 135.5, 139.7, 148.6, 150.9, 159.4, 16 3.1, 165.5. EI-MS: m/z = 418 (M +).            \n \n5.7.14.    4'-((5-(Benzo[ d][1,3]dioxol-5-yl)-1,3,4-oxadiazol-2-ylthio)methyl) -4-methoxybiphe-\nnyl-2-carbonitrile  (9e ). Yield 47%, off-white. 1H-NMR (DMSO-d 6, 500 MHz):  \n\u03b4 [ppm] = 3.86 (3H, s), 4.64 (2H, s), 6.16 (2H, s), 7.11 (1H, d, J = 8.2 Hz), 7.35(1H, dd,  \nJ = 8.7 Hz, J = 2.8 Hz), 7.45 (1H, d, J = 1.7 Hz), 7.52 (5H, m), 7.61 (2H, d, J = 8.3 Hz).  \n13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 35.9, 56.3, 102.6, 106.6, 109.6, 111.3, 11 7.1, \n118.5, 118.8, 120.6, 122.2, 129.3, 129.8, 131.9, 13 7.0, 137.3, 137.4, 148.6, 150.9, 159.0, \n163.1, 165.6. EI-MS: m/z = 443 (M +). HRMS (EI): m/z calcd for C 24 H17 N3O4S 443.0940, \nfound 443.0902.              \n   \n5.7.15.    2-(Benzo[ d][1,3]dioxol-5-yl)-5-((3',5'-difluorobiphenyl-4-yl) methylthio)-1,3,4-oxa-\ndiazole  (9f ). Yield 50%, grey/brown solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.62 \n(2H, s), 6.16 (2H, s), 7.11 (1H, d J = 8.1 Hz), 7.22 (1H, m), 7.44 (3H, m), 7,52 (1H,  \ndd, J = 8.1 Hz, J = 1.8 Hz), 7.58 (2H, d, J = 8.3 Hz), 7.73 (2H, d, J = 8.3 Hz). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 35.9, 102.6, 103.2, 106.6, 109.6, 110.1, 1 10.3, 117.1,  \n122.2, 127.5, 130.2, 137.4, 137.9, 143.7, 148.6, 15 0.9, 162.3, 163.0, 164.2, 165.6.  \nEI-MS: m/z = 424 (M +).             \n5.7.16.    2-((2'-Nitrobiphenyl-4-yl)methylthio)-5- (pyridine-4-yl)-1,3,4-oxadiazole  (10a) . \nYield 79%, yellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.7 (2H, s), 7.3 (2H, d,  \nJ = 8.2 Hz), 7.5 (1H, d, J = 7.7 Hz), 7.6 (2H, d, J = 8.2 Hz), 7.6 (1H, t, J = 7.8 Hz), 7.8 (1H, t, \nJ = 7.6 Hz), 7.9 (2H, d, J = 6.1 Hz), 8.0 (1H, d, J = 8.1 Hz), 8.8 (2H, d, J = 6.1 Hz). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 36.0, 120.5, 124.6, 128.5, 129.4, 130.0, 1 30.5, 132.2, 133.4, \n135.0, 136.9, 137.2, 149.3, 151.4, 164.3, 165.3. EI -MS: m/z = 390 (M +).     \n           \nSeite 185 5.7.17.    4'-((5-(Pyridine-4-yl)-1,3,4-oxadiazol-2 -ylthio)methyl)biphenyl-3-carbonitrile  (10b ). \nYield 53%, yellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.68 (2H, s), 7.64 (3H, \nm), 7.74 (2H, d), 7.82 (1H, dt, J = 7.7 Hz, J = 1.3 Hz), 7.90 (2H, dd, J = 4.5 Hz, J = 1.7 Hz), \n8.01 (1H, m), 8.15 (1H, m), 8.82 (2H, dd, J = 4.5 Hz, J = 1.7 Hz). 13 C-NMR (DMSO-d 6,  \n125 MHz):  \u03b4 [ppm] = 36.0, 112.6, 119.2, 120.4, 127.6, 130.3, 1 30.5, 130.6, 130.7, 131.6, \n131.9, 137.3, 137.9, 141.1, 151.4, 164.2, 165.2. EI -MS: m/z = 370 (M +).              \n \n5.7.18.    4'-((5-(Pyridine-4-yl)-1,3,4-oxadiazol-2 -ylthio)methyl)biphenyl-4-carbonitrile  (10c ). \nYield 32%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.69 (2H, s), 7.64 \n(2H, d, J = 8.1 Hz), 7.75 (2H, d, J = 8.1 Hz), 7.86-7.93 (6H, m), 8.82 (2H, m). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 35.9, 110.6, 119.3, 120.4, 127.8, 128.0, 1 30.4, 130.5, 133.3, \n137.8, 138,1, 144.5, 151.4, 165.2, 164.3. EI-MS: m/ z = 370 (M +).              \n \n5.7.19.    2-((4'-Methoxybiphenyl-4-yl)methylthio)- 5-(pyridine-4-yl)-1,3,4-oxadiazole  (10d ). \nYield 37%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.79 (3H, s), 4.66 \n(2H, s), 7.01 (2H, d, J = 8.6 Hz), 7.55 (2H, d, J = 8.2 Hz), 7.60 (4H, m), 7.90 (2H, d, \nJ = 5.8 Hz), 8.82 (2H, d, J = 5.8 Hz). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 36.1, 55.6, \n114.8, 120.4, 126.8, 128.2, 130.1, 130.5, 132.4, 13 5.3, 139.8, 151.4, 159.5, 164.2, 165.3.  \nEI-MS: m/z = 375 (M +).               \n \n5.7.20.    4-Fluoro-4'-((5-(pyridine-4-yl)-1,3,4-ox adiazol-2-ylthio)methyl)biphenyl-2-carbonit-\nrile ( 10e ). Yield 31%, yellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.71 (2H, s), \n7.57 (2H, d, J = 1.8 Hz), 7.67 (4H, m), 7.90 (2H, dd, J = 4.4 Hz, J = 1.7 Hz), 7.97 (1H, m), \n8.82 (2H, dd, J = 4.4 Hz, J = 1.7 Hz). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 35.9, \n112.1, 117.9, 120.5, 121.0, 121.5, 129.5, 129.9, 13 0.5, 132.9, 136.8, 137.8, 141.3, 151.4, \n164.3, 165.3. EI-MS: m/z = 388 (M +). HRMS (EI): m/z calcd for C 21 H13 N4OFS 388.0795, \nfound 388.0825.   \n                 \n5.7.21.    2-(Biphenyl-4-ylmethylthio)-5-(pyridine- 4-yl)-1,3,4-oxadiazole  (10f ).  Yield 32%, \nyellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.67 (2H, s), 7.36 (1H, m), 7.46 \n(2H, m), 7.66-7.70 (6H, m), 7.9 (2H, d, J = 6.1 Hz), 8.8 (2H, d, J = 6.1 Hz). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 36.1, 120.5, 127.1, 127.3, 128.0, 129.4, 1 30.2, 130.5, 136.2, \n140.0, 140.1, 151.4, 164.1, 165.3. EI-MS: m/z = 345  (M +).                   \n  \nSeite 186 5.8.1.    Compounds 1 2a-d were prepared in a similar manner to that described  for 2a . The \ncompounds were used, without structure determinatio n, directly for the next step. \n \n5.9.1.    Compounds 13a-d were prepared in a similar manner to that described  for 3a . The \ncompounds were used, without structure determinatio n, directly for the next step. \n \n5.10.1.    Compounds 14a-d were prepared in a similar manner to that described  for 4a . The \ncompounds were used, without structure determinatio n, directly for the next step.  \n \n5.11.1.    Compounds 15-18 (a-d) were prepared in a similar manner to that described  for \ncompounds 8a-h, 9a-f and  10a-f. \n \n5.11.2.    2-(Benzylthio)-5-phenyl-1,3,4-oxadiazole  ( 15a ). Yield 67%, colorless solid. 1H-\nNMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.59 (2H, s), 7.29 (1H, m), 7.35 (2H, m), 7.48 (2H, \nm), 7.60 (3H, m), 7.95 (2H, m). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 35.9, 122.9, \n126.3, 127.7, 128.5, 129.0, 129.4, 132.0, 136.5, 16 3.2, 165.2. EI-MS: m/z = 268 (M +).                \n \n5.11.3.    4'-((5-Phenyl-1,3,4-oxadiazol-2-ylthio)m ethyl)biphenyl-2-carbonitrile ( 15b ).  Yield \n58%, colorless solid. 1H-NMR (DMSO-d 6, 300 MHz): \u03b4 [ppm] = 4.68 (2H, s), 7.53-7.69 (9H, \nm, br), 7.78 (1H, td, J = 7.7 Hz, J = 1.4 Hz), 7.95 (3H, m). 13 C-NMR (DMSO-d 6, 75 MHz):  \n\u03b4 [ppm] = 35.4, 110.0, 118.4, 122.9, 126.3, 128.2, 1 28.8, 129.3, 130.0, 131.9, 133.4, 133.8, \n137.1, 137.3, 143.9, 163.2, 165.2. EI-MS: m/z = 369  (M +).                        \n \n5.11.4.    2-(3-Methoxybenzylthio)-5-phenyl-1,3,4-o xadiazole ( 15c ). Yield 51%, colorless \nsolid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.72 (3H, s), 4.55 (2H, s), 6.84 (1H, m), \n7.05 (2H, m), 7.26 (1H, t, J = 7.8 Hz), 7.62 (3H, m), 7.97 (2H, m). 13 C-NMR (DMSO-d 6,  \n125 MHz): \u03b4 [ppm] = 35.9, 55.0, 113.2, 114.6, 121.1, 122.9, 12 6.3, 129.4, 129.6, 132.0, \n138.0, 159.2, 163.2, 165.2. EI-MS: m/z = 298 (M +).      \n \n5.11.5.    3-((5-Phenyl-1,3,4-oxadiazol-2-ylthio)me thyl)benzonitrile ( 15d ). Yield 38%, \ncolorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.63 (2H, s), 7.60 (4H, m), 7.77 \n(1H, d, J = 7.7 Hz), 7.85 (1H, d, J = 7.9 Hz), 7.94 (2H, m), 7.98 (1H, s). 13 C-NMR (DMSO-\nd6, 125 MHz): \u03b4 [ppm] = 34.8, 111.3, 118.4, 122.9, 126.3, 129.3, 1 29.7, 131.4, 132.0, 132.6, \n133.9, 138.8, 162.9, 165.3. EI-MS: m/z = 293 (M +).     \nSeite 187 5.11.6.    2-(Benzylthio)-5-(4-methoxyphenyl)-1,3,4 -oxadiazole ( 16a). Yield 63%, colorless \nsolid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.85 (3H, s), 4.56 (2H, s), 7.13 (2H, m), \n7.28 (1H, m), 7.33 (2H, m), 7.47 (2H, m), 7.89 (2H,  m). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 35.9, 55.5, 114.8, 115.3, 127.7, 128.2, 12 8.5, 128.9, 136.6, 162.0, 162.3, 165.1.  \nEI-MS: m/z = 298 (M +).  \n               \n5.11.7.    4'-((5-(4-Methoxyphenyl)-1,3,4-oxadiazol -2-ylthio)methyl)biphenyl-2-carbonitrile \n(16b ).  Yield 71%, orange solid. 1H-NMR (DMSO-d 6, 300 MHz): \u03b4 [ppm] = 4.62 (2H, s), \n7.22-7.43 (3H, m, br), 7.50 (2H, m), 8.22 (2H, m), 8.41 (2H, m). 13 C-NMR (DMSO-d 6,  \n75 MHz): \u03b4 [ppm] = 35.8, 124.5, 127.7, 127.7, 128.4, 128.5, 1 29.0, 136.3, 149.1, 163.8, \n164.7. EI-MS: m/z = 399 (M +).                        \n \n5.11.8.    2-(3-Methoxybenzylthio)-5-(4-methoxyphen yl)-1,3,4-oxadiazole ( 16c ). Yield 57%, \ncolorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.72 (3H, s), 3.85 (3H, s), 4.53 \n(2H, s), 6.84 (1H, m), 7.03 (2H, t, J = 5.0 Hz), 7.13 (2H, m), 7.25 (1H, t, J = 7.9 Hz), 7.90 \n(2H, m). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 35.9, 55.0, 55.5, 113.2, 114.6, 114.8, \n115.3, 121.1, 128.2, 129.6, 138.0, 159.2, 162.0, 16 2.4, 165.1. EI-MS: m/z = 328 (M +).  \n     \n5.11.9.    3-((5-(4-Methoxyphenyl)-1,3,4-oxadiazol- 2-ylthio)methyl)benzonitrile ( 16d ). Yield \n41%, colorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.84 (3H, s), 4.60 (2H, s), \n7.13 (1H, m), 7.57 (2H, t, J = 7.8 Hz), 7.76 (1H, dt, J = 7.7 Hz, J = 1.3 Hz), 7.83 (1H, m), \n7.88 (2H, m), 7.96 (1H, t, J = 1.5 Hz). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 34.8,  \n55.5, 111.3, 114.8, 115.2, 118.4, 128.2, 129.7, 131 .4, 132.6, 133.9, 138.8, 162.0, 165.3.  \nEI-MS: m/z = 323 (M +).                \n \n5.11.10. 4-(5-(Benzylthio)-1,3,4-oxadiazol-2-yl)ben zonitrile  (17a ). Yield 32%, colorless \nsolid. 1H-NMR (DMSO-d 6, 300 MHz): \u03b4 [ppm] = 4.61 (2H, s), 7.31 (3H, m), 7.49 (2H, d,  \nJ = 7.3 Hz), 8.09 (4H, td, J = 8.2 Hz, J = 0.9 Hz). 13 C-NMR (DMSO-d 6, 75 MHz):  \n\u03b4 [ppm] = 35.8, 114.0, 118.0, 126.9, 127.0, 127.7, 1 28.5, 129.0, 133.3, 136.4, 164.0, 164.4. \nEI-MS: m/z = 293 (M +).                \n \n5.11.11. 4'-((5-Phenyl-1,3,4-oxadiazol-2-ylthio)met hyl)biphenyl-2-carbonitrile ( 17b ).  Yield \n53%, orange solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.72 (2H, s), 7.48 (1H, m), \n7.51 (1H, m), 7.57 (2H, m), 7.62 (2H, m), 7.67 (1H,  dt, J = 7.7 Hz, J = 1.3 Hz), 7.79 (1H, dd,  \nSeite 188 J = 7.7 Hz, J = 0.9 Hz), 7.81 (2H, m), 8.13 (2H, m). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 36.4, 111.2, 115.1, 117.8, 118.5, 127.1, 1 27.4, 127.8, 129.2, 129.5, 129.9, 132.8, \n132.9, 133.8, 136.0, 138.0, 144.6, 164.3, 165.1. EI -MS: m/z = 394 (M +).                        \n \n5.11.12. 4-(5-(3-Methoxybenzylthio)-1,3,4-oxadiazol -2-yl)benzonitrile ( 17c ). Yield 47%, \ncolorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 (ppm) = 3.77 (3H, s), 4.49 (2H, s), 6.82 \n(1H, dd, J = 8.3 Hz, J = 2.0 Hz), 6.97 (1H, m), 7.00 (1H, d, J = 7.6 Hz), 7.23 (1H, t,  \nJ = 7.9 Hz), 7.75 (2H, m), 8.08 (2H, m). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 (ppm) = 36.9, \n55.3, 113.8, 114.7, 115.1, 117.9, 121.4, 127.1, 127 .5, 129.9, 132.9, 136.7, 159.9, 164.3, 165.3.  \nEI-MS: m/z = 323 (M +).                   \n \n5.11.13. 3-((5-(4-Cyanophenyl)-1,3,4-oxadiazol-2-yl thio)methyl)benzonitrile ( 17d ). Yield \n45%, colorless solid. 1H-NMR (DMSO-d 6, 300 MHz): \u03b4 [ppm] = 4.47 (2H, s), 7.40 (1H, t,  \nJ = 7.8 Hz), 7.52 (1H, m), 7.70 (4H, m), 8.03 (2H, d t, J = 6.8 Hz, J = 0.9 Hz). 13 C-NMR \n(DMSO-d 6, 75 MHz): \u03b4 [ppm] = 34.9, 112.2, 114.5, 117.1, 117.6, 126.4, 1 26.5, 129.0, 131.1, \n131.9, 132.2, 133.0, 136.8, 163.8, 163.9. EI-MS: m/ z = 318 (M +).                \n \n5.11.14. 2-(Benzylthio)-5-(4-nitrophenyl)-1,3,4-oxa diazole ( 18a ). Yield 46%, light yellow \nsolid. 1H-NMR (DMSO-d 6, 300 MHz): \u03b4 [ppm] = 4.62 (2H, s), 7.32 (3H, m), 7.49 (2H, m), \n8.21 (2H, m), 8.41 (2H, m). 13 C-NMR (DMSO-d 6, 75 MHz): \u03b4 [ppm] = 35.8, 124.5, 127.7, \n127.7, 128.4, 128.5, 129.0, 136.3, 149.1, 163.8, 16 4.7. EI-MS: m/z = 313 (M +).                \n \n5.11.15. 4'-((5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-y lthio)methyl)biphenyl-2-carbonitrile \n(18b ).  Yield 58%, orange solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 4.71 (2H, s), 7.60 \n(4H, m), 7.68 (2H, d, J = 8.2 Hz), 7.78 (1H, dt, J = 7.7 Hz, J = 1.2 Hz), 7.94 (1H, dd,  \nJ = 7.7 Hz, J = 0.9 Hz), 8.22 (2H, m), 8.41 (2H, m).  13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 35.9, 110.5, 118.9, 125.0, 128.2, 128.7, 1 29.0, 129.4, 129.9, 130.5, 134.0, 134.3, \n137.7, 137.7, 144.4, 149.6, 164.4, 165.2. EI-MS: m/ z = 414 (M +).               \n          \n5.11.16. 2-(3-Methoxybenzylthio)-5-(4-nitrophenyl)1 ,3,4-oxadiazole ( 18c ). Yield 33%, \nyellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 (ppm) = 3.73 (3H, s), 4.59 (2H, s), 6.86 (1H, \nm), 7.07 (2H, m), 7.27 (1H, t, J = 7.9 Hz), 8.23 (2H, m), 8.40 (2H, m). 13 C-NMR (DMSO-d 6, \n125 MHz): 35.8, 55.0, 113.3, 114.6, 121.2, 124.5, 1 27.7, 128.4, 129.7, 137.8, 149.1, 159.2, \n163.9, 154.7. EI-MS: m/z = 343 (M +).   \nSeite 189 5.11.17. 3-((5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-yl thio)methyl)benzonitrile ( 18d ). Yield \n47%, orange solid. 1H-NMR (DMSO-d 6, 300 MHz): \u03b4 [ppm] = 4.66 (2H, s), 7.58 (1H, t,  \nJ = 7.8 Hz), 7.76 (1H, m), 7.86 (1H, m), 7.99 (1H, d d, J = 2.3 Hz, J = 1.1 Hz), 8.20 (2H, m), \n8.41 (2H, m). 13 C-NMR (DMSO-d 6, 75 MHz): \u03b4 [ppm] = 34.7, 111.3, 118.4, 124.5, 127.7, \n128.4, 129.7, 131.4, 132.6, 134.0, 138.6, 149.1, 16 4.0, 164.4. EI-MS: m/z = 338 (M +).  \n \n5.12.1.    General procedure for synthesis of compo unds 20a-d [52]  \nThe appropriate benzaldehyde (1.0 eq.) was dissolve d in 5 mL EtOH and isoniazid  \n(1.0 eq.) was added slowly to the solution. The rea ction mixture was stirred at room \ntemperature for 16 h. The solvent was removed under  vacuum and the residue was purified by \nrecrystallization in EtOH. \n \n5.12.2.    (E)-N'-Benzylideneisonicotinohydrazide ( 20a ). Yield 85%, colorless solid. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 7.47 (3H, m), 7.76 (2H, m,), 7.83 (2H, dd,  J = 4.3 Hz,  \nJ = 1.5 Hz), 8.47 (1H, s), 8.79 (2H, dd, J = 4.5 Hz, J = 1.5 Hz), 12.09 (1H, s). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 121.4, 127.1, 128.7, 130.2, 133.9, 140.3, 148.9, 150.2, \n161.5. EI-MS: m/z = 225 (M +).                \n \n5.12.3.    (E)-N'-(4-Methoxybenzylidene)isonicotino hydrazide ( 20b ). Yield 97%, yellow \nsolid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 3.83 (3H, s), 7.03 (2H, d, J = 9.0 Hz), 7.70 \n(2H, d, J = 9.0 Hz), 7.81 (2H, dd, J = 4.5 Hz,  J = 1.5 Hz), 8.42 (1H, s), 8.78 (2H, dd,  \nJ = 4.5 Hz, J = 1.5 Hz), 11.93 (1H, s). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 55.24, \n114.31, 121.3, 126.4, 128.2, 140.5, 148.8, 150.2, 1 61.0, 161.3. EI-MS: m/z = 255 (M +).  \n               \n5.12.4.    (E)-N'-(4-Cyanobenzylidene)isonicotinohy drazide ( 20c ). Yield 83%, colorless solid. \n1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 7.83 (2H, dd, J = 4.3 Hz, J = 1.5 Hz), 7.94 (4H, \ns), 8.51 (1H, s), 8.80 (2H, dd, J = 4.5 Hz, J = 1.5 Hz), 12.27 (1H, s). 13 C-NMR (DMSO-d 6, \n125 MHz): \u03b4 [ppm] = 112.1, 118.4, 121.4, 127.7, 128.3, 132.6, 140.0, 146.9, 150.2, 161.8.  \nEI-MS: m/z = 250 (M +).  \n \n5.12.5.    (E)-N'-(4-Ethylbenzylidene)isonicotinohy drazide ( 20d ). Yield 96%, colorless solid.  \n1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 1.20 (3H, t, J = 7.5 Hz), 2.65 (2H, m), 7.32 (2H, \nd, J = 8.1 Hz), 7.67 (2H, d, J = 8.1 Hz), 7.82 (2H, dd, J = 4.5 Hz, J = 1.8 Hz), 8.44 (1H, s),  \nSeite 190 8.78 (2H, dd, J = 4.5 Hz, J = 1.8 Hz),  11.99 (1H, s). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 15.2, 28.0, 121.4, 127.2, 128.2, 131.4, 14 0.4, 146.4, 149.0, 150.2, 161.4.  \nEI-MS: m/z = 253 (M +).    \n \n5.13.1.    Compound 22  was prepared in a similar manner to that described  for 2a . \nMethyl 2-aminoisonicotinate  (22 ).  Yield 89%, colorless solid. 1H-NMR (DMSO-d 6,  \n500 MHz): \u03b4 [ppm] = 3.84 (3H, s), 6.28 (2H, s), 6.87 (1H, dd, J = 5.2 Hz, J = 1.5 Hz), 6.96 \n(1H, m), 8.05 (1H, dd, J = 5.2 Hz, J = 0.6 Hz). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 52.4, 107.4, 110.0, 137.8, 148.9, 160.5, 1 65.7. EI-MS: m/z = 152 (M +).    \n \n5.14.1.    Methyl 2-acetamidoisonicotinate ( 23 )  \nA solution of compound 22 (760 mg, 5 mmol) in acetic anhydride (20 mL) was he ated at \n80\u00b0C for 6 h. The reaction was cooled to room tempe rature and the precipitate formed was \nfiltered off and well washed with water to obtain c ompound 23  (0.67 g, 69%)  as yellow solid. \n1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 2.12 (3H, s), 3.89 (3H, s), 7.52 (1H, dd, J = 5.0 Hz,  \nJ = 1.4 Hz), 8.48 (1H, d,  J = 5.0 Hz), 8.57 (1H, s), 10.74 (1H, s). 13 C-NMR (DMSO-d 6,  \n125 MHz): \u03b4 [ppm] = 23.8, 52.7, 112.2, 117.9, 138.6, 149.0, 15 3.0, 165.1, 169.6.  \nEI-MS: m/z = 154 (M +).    \n \n5.15.1.    Compound 24 was prepared in a similar manner to that described for 3a .  \nN-(4-(Hydrazinecarbonyl)pyridin-2-yl)acetamide ( 24 ). Yield 74%, light yellow solid.  \n1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 2.11 (3H, s), 4.58 (2H, s), 7.38 (1H, dd,  \nJ = 5.1 Hz, J = 1.5 Hz), 8.38 (1H, dd, J = 5.1 Hz, J = 0.7 Hz), 8.41 (1H, s), 9.99 (1H, s), 10.59 \n(1H, s). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 23.9, 111.3, 116.2, 142.8, 148.2, 152.7, \n164.2, 169.3. EI-MS: m/z = 194 (M +).   \n  \n5.16.1.    Compound 25 was prepared in a similar manner to that described for 4a .  \nN-(4-(5-Mercapto-1,3,4-oxadiazol-2-yl)pyridin-2-yl)a cetamide ( 25 ).  Yield 92%, yellow solid. \n1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 2.14 (3H, s), 7.49 (1H, dd, J = 5.1 Hz,  \nJ = 1.5 Hz), 8.53 (1H, dd, J = 5.1 Hz, J = 0.7 Hz), 8.54 (1H, s), 10.82 (1H, s), 14.90 (1H,  s). \n13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 23.9, 108.8, 114.9, 131.4, 149.4, 153.0, 1 58.8, \n169.8, 177.7. EI-MS: m/z = 236 (M +).    \n  \nSeite 191 5.17.1.    Compounds 26a-d were prepared in a similar manner to that described  for \ncompounds 8a-h, 9a-f and  10a-f. \n \n5.17.2.    N-(4-(5-(Benzylthio)-1,3,4-oxadiazol-2-yl)pyridin-2- yl)acetamide ( 26a ). Yield 68%, \ncolorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 2.15 (3H, s), 4.61 (2H, s), 7.30 \n(1H, m), 7.36 (2H, m), 7.51 (2H, m), 7.58 (1H, dd, J = 5.1 Hz, J = 1.5 Hz), 8.52 (1H, dd,  \nJ = 5.1 Hz, J = 0.8 Hz), 8.63 (1H, s), 10.80 (1H, s). 13 C-NMR (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 24.0, 35.9, 109.2, 115.4, 127.8, 128.6, 12 9.1, 131.7, 136.4, 149.4, 153.0, 163.8, \n164.4, 169.8. EI-MS: m/z = 326 (M +). \n \n5.17.3.    N-(4-(5-(3-Methoxybenzylthio)-1,3,4-oxadiazol-2-yl)p yridin-2-yl)acetamide ( 26b ). \nYield 51%, yellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 2.14 (3H, s), 3.73 (3H, s), \n4.58 (2H, s), 6.86 (1H, m), 7.07 (2H, m),  7.27 (1H , m), 7.58 (1H, dd, J = 5.1 Hz, J = 1.5 Hz), \n8.52 (1H, dd, J = 5.1 Hz, J = 0.7 Hz), 8.63 (1H, s), 10.80 (1H, s). 13 C-NMR (DMSO-d 6,  \n125 MHz): \u03b4 [ppm] = 24.0, 35.9, 55.0, 109.2, 113.3, 114.6, 115 .4, 121.2, 129.7, 131.8, 137.8, \n149.4, 153.0, 159.3, 163.8, 164.7, 169.8. EI-MS: m/ z = 356 (M +). \n \n5.17.4.    N-(4-(5-(Benzylthio)-1,3,4-oxadiazol-2-yl)pyridin-2- yl)acetamide ( 26c ). Yield 37%, \ncolorless solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 2.14 (3H, s), 4.64 (2H, s), 7.57 \n(2H, m),  7.77 (1H, d, J = 7.8 Hz), 7.87 (1H, d, J = 7.8 Hz), 7.97 (1H, s), 8.51 (1H, d,  \nJ = 5.1 Hz), 8.61 (1H, s), 10.81 (1H, s). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 23.9, \n34.8, 109.2, 111.4, 115.4, 118.5, 129.8, 131.5, 131 .8, 132.6, 134.1, 138.6, 149.5, 153.0, 163.9, \n164.4, 169.8. EI-MS: m/z = 351 (M +). HRMS (EI): m/z calcd for C 17 H13 N5O2S 351.0791, \nfound 351.0787.   \n \n5.17.5.    N-(4-(5-((2'-Cyanobiphenyl-4-yl)methylthio)-1,3,4-ox adiazol-2-yl)pyridin-2-yl)acet-\namide ( 26d) . Yield 62%, light yellow solid. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 2.14 \n(3H, s), 4.70 (2H, s), 7.56-7.61 (5H, m), 7.68 (2H,  d, J = 8.2 Hz), 7.78 (1H, td, J = 7.6 Hz,  \nJ = 1.3 Hz), 7.94 (1H, dd, J = 7.6 Hz,  J = 1.1 Hz), 8.52 (1H, dd, J = 5.1 Hz, J = 0.7 Hz), 8.64 \n(1H, s), 10.80 (1H, s). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 23.9, 35.5, 109.3, 110.1, \n115.4, 118.5, 128.3, 128.9, 129.4, 130.1, 131.8, 13 3.5, 133.9, 137.2, 144.0, 149.5, 153.1, \n163.9, 164.7, 169.8. EI-MS: m/z = 427 (M +). HRMS (EI): m/z calcd for C 23 H17 N5O2S \n427.1104, found 427.1104.   \n  \nSeite 192 5.18.1.    Ethyl 4-aminobenzoate ( 28 )     \nTo a solution of compound 27  (3.4 g, 25 mmol) in ethanol (30 mL) was added drop wise \nconcentrated sulfuric acid (2.4 mL). The mixture wa s heated under reflux for 6 h. The \nresulting solution was diluted with water (200 mL) and made neutral by addition of \nconcentrated ammonia water. The precipitation was c ollected by filtration and then washed \nwith water and subsequently dried to afford compoun d 28  (3.68 g, 91%) as colorless solid. \nThe compound was used, without structure determinat ion, directly for the next step. \n \n5.18.2.    Ethyl 2-aminobenzo[ d]thiazole-6-carboxylate ( 29 ) \nCompound 28  (2.0 g, 12 mmol) was dissolved in 16 mL of acetic acid, and to the \nresulting solution was suspended potassium thiocyan ate (4.67 g, 48 mmol). A solution of  \n0.61 mL of bromine in 8 ml of acetic acid was slowl y added, and the reaction mixture was \nstirred at room temperature overnight. Water was ad ded and the mixture was made neutral by \naddition of aqueous ammonium hydroxide. The precipi tation was collected by filtration and \nthen washed with water and subsequently dried to af ford compound 29  (1.80 g, 67%) as light \nyellow solid. The compound was used, without struct ure determination, directly for the next \nstep. \n \n5.18.3.    Compound 30 was prepared in a similar manner to that described for 23 .  \nEthyl 2-acetamidobenzo[ d]thiazole-6-carboxylate ( 30 ). Yield 58%, light brown solid. The \ncompound was used, without structure determination,  directly for the next step. \n \n5.18.4.    2-Acetamidobenzo[ d]thiazole-6-carboxylic acid ( 31 )  \nA solution of compound 30  (1.0 g, 3.8 mmol), 1 N NaOH (40 mL), and MeOH (15 mL) \nwas stirred at room temperature for 4 h and then th e solvent was evaporated. To the resulting \naqueous layer was added water (10 mL) and the solut ion acidified with 1 N HCl to pH 2. The \nresulting solid was collected by filtration and was hed with water. The solid was dried to \nafford compound 31 (0.84 g, 94%) as light brown solid. The compound wa s used, without \nstructure determination, directly for the next step . \n \n5.18.5.    N-(6-(2-tert -Butylhydrazinecarbonyl)benzo[ d]thiazol-2-yl)acetamide ( 32 ) \n  To a solution of 31  (0.80 g, 3.3 mmol), tert -butyl carbazate (0.47 g, 3.6 mmol) and  \n1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydro chloride (EDCI) (0.74 g, 3.9 mmol) in \nDMF (10 mL) was added 1-hydroxybenzotriazole hydrat e (HOBt\u2022H 2O) (0.59 g, 3.9 mmol)  \nSeite 193 and the mixture stirred overnight at room temperatu re. The reaction mixture was diluted with \nEtOAc and the organic layer was washed with water a nd brine, dried over Na 2SO 4 and \nconcentrated in vacuo. The residue was recrystalliz ed in EtOAc/CH to give 32  (0.79 g, 77%) \nas light brown solid. The compound was used, withou t structure determination, directly for \nthe next step. \n \n5.18.6.    N-(6-(Hydrazinecarbonyl)benzo[ d]thiazol-2-yl)acetamide ( 33 ) \n A solution of 32  (0.75 g, 2.4 mmol) in trifluoroacetic acid (5 mL) was stirred at room \ntemperature for 1 h. The solvent was concentrated t o give 33  (0.59 g, 99%) as colorless solid. \nThe compound was used, without structure determinat ion, directly for the next step. \n \n5.18.7.    Compound 34 was prepared in a similar manner to that described for 4a .  \nN-(6-(5-Mercapto-1,3,4-oxadiazol-2-yl)benzo[ d]thiazol-2-yl)acetamide ( 34 ). Yield 81%, light \nbrown solid. The compound was used, without structu re determination, directly for the next \nstep. \n \n5.18.8.    Compounds 35 was prepared in a similar manner to that described for compounds \n8a-h, 9a-f and  10a-f. N-(6-(5-((2'-Cyanobiphenyl-4-yl)methylthio)-1,3,4-ox adiazol-2-\nyl)benzo[ d]thiazol-2-yl)acetamide ( 35 ). Yield 47%, light brown solid. 1H-NMR (DMSO-d 6, \n500 MHz): \u03b4 [ppm] = 2.23 (3H, s), 4.69 (2H, s), 7.59 (4H, m), 7.67 (2H, d,  J = 8.3 Hz), 7.78 \n(1H, td, J = 7.7 Hz, J = 1.4 Hz), 7.88 (1H, d, J = 8.5 Hz), 7.94 (1H, dd, J = 7.8 Hz,  \nJ = 1.1 Hz), 8.01 (1H, dd, J = 8.5 Hz, J = 1.8 Hz), 8.64 (1H, d, J = 1.5 Hz), 12.56 (1H, s).  \n13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 22.7, 35.5, 110.0, 117.8, 118.4, 120.6, 12 1.0, \n124.3, 128.2, 128.9, 129.4, 130.0, 132.4, 133.5, 13 3.8, 137.1, 137.3, 143.9, 151.1, 160.7, \n162.9, 165.4, 169.7. EI-MS: m/z = 483 (M +). \n \n5.19.1.    Methyl 3-bromo-4-hydroxybenzoate ( 37 )  \nTo a solution of 36  (3.15 g, 20.7 mmol) in DCM (230 mL) was added slow ly at -5\u00b0C a \nsolution of bromine (1.1 mL, 21 mmol) in DCM (50 mL ). The mixture was stirred for 4.5 h at \nroom temperature. The reaction mixture was diluted with EtOAc and the organic layer was \nwashed with water and brine, dried over MgSO 4 and concentrated in vacuo . The residue was \npurified by silica gel column chromatography (DCM /  EtOAc) to give 37  (3.10 g, 65%) as \ncolorless solid. The compound was used, without str ucture determination, directly for the next \nstep.  \nSeite 194 5.19.2.    Methyl 8-nitrodibenzo[ b,d]furan-2-carboxylate ( 38 )  \nA mixture of compound 37  (0.51 g, 2.2 mmol), 1-fluoro-4-nitrobenzene (0.36 g,  \n2.2 mmol) and Palladium(II) acetate (0.05 g, 0.22 m mol) in N,N-dimethylacetamide (2 mL) \nwas stirred overnight at 130\u00b0C. The reaction mixtur e was diluted with EtOAc (20 mL) and \nfiltered over celite. The solvent was removed in vacuo  and the resulting oil was diluted with \nwater (7 mL). The precipitate formed was collected by filtration and recrystallized in EtOH to \ngive compound 38  (0.18 g, 30%) as colorless solid. The compound was  used, without \nstructure determination, directly for the next step .  \n \n5.19.3.    8-Nitrodibenzo[ b,d]furan-2-carbohydrazide ( 39 ) \nTo compound 38  (160 mg, 0.59 mmol) was added hydrazine hydrate (1 .5 mL) and the \nmixture was heated at reflux for 6 h. After cooling  to room temperature pure crystals are \nformed, collected by filtration and washed several times with EtOH to give compound 39  \n(158 mg, 99%) as a  yellow solid. The compound was used, without struct ure determination, \ndirectly for the next step.  \n \n5.19.4.    Compound 40 was prepared in a similar manner to that described for 4a .  \n5-(8-Nitrodibenzo[ b,d]furan-2-yl)-1,3,4-oxadiazole-2-thiol ( 40 ). Yield 48%, light brown \nsolid. The compound was used, without structure det ermination, directly for the next step. \n \n5.19.5.    Compound 41 was prepared in a similar manner to that described for compounds  \n8a-h, 9a-f and  10a-f. 3-({[5-(8-Nitrodibenzo[ b,d]furan-2-yl)-1,3,4-oxadiazol-2-yl] \nsulfanyl}methyl)benzonitril ( 41 ). Yield 44%, yellow solid. 1H-NMR (DMSO-d 6, 500 MHz):  \n\u03b4 [ppm] = 4.71 (2H, s), 7.63 (1H, t, J = 7.8 Hz), 7.81 (1H, m), 7.96 (1H, m), 8.03 (3H, m) , \n8.25 (1H, d, J = 8.7 Hz), 8.58 (1H, d, J = 9.1 Hz), 9.11 (1H, s), 9.42 (1H, s). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 35.7, 64.5, 114.0, 119.7, 122.3, 125.0, 12 8.3, 130.7, 132.4, \n133.6, 134.9. EI-MS: m/z = 428 (M +). \n \n5.20.1. Determination of GSK-3 inhibition \nGSK-3\u03b2 in vitro assay : Purified GSK-3 \u03b2 (0.5 \u00b5g) was incubated in a reaction mixture of \n50 mM Tris pH 7.3, 10 mM MgAc, 0.01% \u03b2-mercaptoethanol, 32 P[ \u03b3-ATP](100 \u00b5M,  \n0.5 \u00b5ci/assay), and 100 \u00b5M of peptide substrate, pI RS-1 (RREGGMSRPAS(p)VDG). New \nmolecules were added at various concentrations (1, 10 and 100 \u00b5M), and the reaction mixture  \nSeite 195 was incubated for 15 min at 30 oC. The reactions were stopped, spotted on p81 paper  \n(Whatman), washed with 10 mM phosphoric acid, and c ounted for radioactivity [53]. \nGSK-3\u03b2 activity was calculated as the percentage of GSK-3 \u03b2 activity in the absence of \ninhibitors that was designated to 100%. \n \nKinase Panel : Compounds are serially diluted 1/3 in neat DMSO ( 10 serial dilutions) \nand these dilutions are further diluted 1/25 with r eaction buffer. 2.5 \u00b5L of these solutions are \nadded to the reaction mixture described below so th at final compound concentration in the \nassay ranges from 100 \u00b5M to 5 nM in 1 % (v/v) DMSO.  The enzymatic activity of the kinases \nis determined with a commercial system based on the  Z\u2019-LYTE \u00ae technology, available from \nInvitrogen Life Technologies (Carlsbad, CA, USA), u sing human recombinant kinases as the \nenzyme source.  \n \nKinase Enzyme \nconc. (nM)  ATP \nconc. ( \u00b5M) Peptide used Peptide \nconc. ( \u00b5M) Buffer \nGSK-3\u03b2 2 12.5 Ser/Thr 9 \npeptide 2 50 mM Hepes  \npH 7.5,10 mM \nMgCl 2,1 mM EGTA, \n0.01% (w/v) Brij-35 \nGSK-3\u03b1 0.5 12.5 Ser/Thr 9 \npeptide 2 \u201c \nCKI \u03b5 12 32 Ser/Thr 11 \npeptide 2 \u201c \nCdk5 10 12.5 Ser/Thr 12 \npeptide 2 \u201c \nAurKA 20 10 Ser/Thr 1 \npeptide 2 \u201c \nPKC \u03b1 0.15 10 Ser/Thr 7 \npeptide 2 \u201c \n \nThis technology utilizes the fluorescence resonance  energy transfer (\u201cFRET\u201d) process \nbetween fluorescein and coumarin. The assay princip le is based on the differential sensitivity \nof phosphorylated and non-phosphorylated peptide to  proteolytic cleavage, which precludes \nthe energy transfer process between the two fluorop hores attached to both sides of the \ncleavage site. Hence, enzymatic phosphorylation wil l yield a phosphopeptide, which cannot \nbe hydrolyzed by a suitable protease and energy tra nsfer between the two fluorophores will \noccur. Opposingly, lack of phosphorylation will cau se peptide hydrolysis hence lack of \nenergy transfer as. The assay is performed in 96-we ll black plates, in a final volume of 10 \u00b5L.  \nSeite 196 5.20.2 Determination of the in vivo  activity on wt Zebrafish Embryos \nIn Vivo Activity on Zebrafish Embryos:  The wt zebrafish was used in this study. The \nembryos were collected and placed into 24-well plat es, ten embryos per well and maintained \nin E2 medium at ~28\u00b0C. Compounds were added 5 hpf ( 50% epiboly) and the embryos \nallowed to grow in chemical compound solution up to  2 days. The phenotypes were compared \nusing the Axio Scope.A1 microscope system from Carl  Zeiss at 44-48 hpf [49-50, 54].  \n \n5.20.3 Docking simulations \nMolecular docking  of 9e  and 26d into the X-ray structure of GSK-3 \u03b2 (PDB code: 3F88) \nwas carried out using Molegro Virtual Docker 5. \n \nAcknowledgments \nThis work was supported by a collaborative project financed by the 7th Framework Program \nof the European Union: NeuroGSK3. \n \nReferences \n \n[1]  F. Lo Monte, T. Kramer, A. Bol\u00e4nder, B. Plotki n, H. Eldar-Finkelman, A. Fuertes, J. \nDominguez, B. Schmidt, Synthesis and biological eva luation of glycogen synthase kinase 3 \n(GSK-3) inhibitors: An fast and atom efficient acce ss to 1-aryl-3-benzylureas, Bioorg. Med. \nChem. Lett. 21 (2011) 5610-5615. \n[2] C. Hooper, R. Killick, S. Lovestone, The GSK3 h ypothesis of Alzheimer\u2019s disease, J. \nNeurochem. 104 (2008) 1433-1439. \n[3]  A. Alzheimer, \u00dcber eine eigenartige Erkankung der Hirnrinde, Allgemeine Zeitschrift f\u00fcr \nPsychiatrie und psychisch-gerichtliche Medizin (Ber lin) 64 (1907) 146-148. \n[4]  A. Alzheimer, R.A. Stelzmann, H.N. Schnitzlein , F.R. Murtagh, An English translation of \nAlzheimer's 1907 paper, \"\u00dcber eine eigenartige Erka nkung der Hirnrinde\", Clin. Anat. 8 (1995) \n429-431. \n[5]  P. Cohen, M. Goedert, GSK3 Inhibitors: Develop ment and Therapeutical Potential, Nature Rev. \nDrug Discov. 3 (2004) 479-487. \n[6]  F. Hern\u00e1ndez, J. Avila, The role of glycogen s ynthase kinase 3 in the early stages of \nAlzheimers\u2019 disease, FEBS Letters 582 (2008) 3848-3 854. \n[7]  Eldar-Finkelman, Glycogen synthase kinase 3: a n emerging therapeutic target, Trends Mol. \nMed. 8 (2002) 126-132. \n[8]  M. Mazanetz, P. Fischer, Untangling tau hyperp hosphorylation in drug design for \nneurodegenerative diseases, Nature Rev. Drug Discov . 6 (2007) 464-479. \n[9]  L. Chico, L. Van Eldik, D. Watterson, Targetin g protein kinases in central nervous system \ndisorders, Nature Rev. Drug Discov. 8 (2009) 892-80 9. \n[10]  L. Meijer, M. Flajolet, P. Greengard, Pharmac ological inhibitors of glycogen synthase kinase 3, \nTRENDS. Pharmacol. Sci. 25 (2004) 471-480.  \nSeite 197 [11]  A. Martinez, C. Gil, D.I. Perez, Glycogen Syn thase Kinase 3 Inhibitors in the Next Horizon for \nAlzheimer\u2019s Disease Treatment, International Journa l of Alzheimer\u00b4s Disease 2011 (2011) 1-7. \n[12]  K.F. Lau, C.C.J. Miller, B.H. Anderton, P.C. Shaw, Expression analysis of glycogen synthase \nkinase-3 in human tissues, J. Peptide Res. 54 (1999 ) 85-91. \n[13]  S. Frame, P. Cohen, GSK3 takes centre stage m ore than 20 years after its discovery, Biochem. J. \n359 (2001) 1-16. \n[14]  E. Hur, F. Zhou, GSK3 signalling in neural de velopment, Nature Rev. Neurosci. 11 (2010) 539-\n551. \n[15]  F. Mukai, K. Ishiguro, Y. Sano, S.C. Fujita, Alternative splicing isoform of tau protein kinase \nI/glycogen synthase kinase 3 beta, J. Neurochem. 81  (2002) 1073-1083. \n[16]  E. ter Haar, J.T. Coll, D.A. Austen, H. Hsiao , L. Swenson, J. Jain, Structure of GSK3 \u03b2 reveals a \nprimed phosphorylation mechanism, Nature Struct. Bi ol. 8 (2001) 593-596. \n[17]  R. Dajani, E. Fraser, S.M. Roe, N. Young, V. Good, T.C. Dale, L.H. Pearl, Crystal Structure of \nGlycogen Synthase Kinase 3: Structural Basis for Ph osphate-Primed Substrate Specificity and \nAutoinhibition, Cell 105 (2001) 721-732. \n[18]  Takashima, A., Drug Development Targeting the  Glycogen Synthase Kinase-3 \u03b2 (GSK-3\u03b2)-\nMediated Signal Transduction Pathway: Role of GSK-3 \u03b2 in Adult Brain, J. Pharmacol. Sci. 109 \n(2009) 174-178. \n[19]  L. Seren\u00f3, M. Coma, M. Rodriguez, P. S\u00e1nchez- Ferrer, M.B. S\u00e1nchez, I. Gich, J.M. Agull\u00f3, ,J. \nAvila M. P\u00e9rez, C. Guardia-Laguarta, J. Clarim\u00f3n, A . Lle\u00f3, T. G\u00f3mez-Isla, A novel GSK-3 \u03b2 \ninhibitor reduces Alzheimer's pathology and rescues  neuronalloss in vivo, Neurobiol. Dis. 35 \n(2009) 359-367. \n[20]  H. Yamaguchi, K. Ishiguro, T. Uchida, A. Taka shima, C.A. Lemere, K. Imahori, Preferential \nlabeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) \nI/glycogen synthase kinase-3 \u03b2 and cyclin-dependent kinase 5, a component of TPK II, Acta \nNeuropathol. 92 (1996) 232-241. \n[21]  A. Martinez, A. Castro, I. Dorronsoro, M. Alo nso, Glycogen Synthase Kinase 3 (GSK-3) \nInhibitors as New Promising Drugs for Diabetes, Neu rodegeneration, Cancer, and \nInflammation, Med. Res. Rev. 22 (2002) 373-384. \n[22]  L. Feng, Y. Geisselbrecht, S. Blanck, A. Wilb uer, G.E. Atilla-Gokcumen, P. Filippakopoulos, \nK. Krling, M.A. Celik, K. Harms, J. Maksimoska, R. Marmorstein, G. Frenking, S. Knapp, L. \nEssen, E. Meggers, Structurally sophisticated octah edral metal complexes as highly selective \nprotein kinase inhibitors, J. Am. Chem. Soc. 133 (2 011) 5976-5986. \n[23]  R.V. Bhat, S.L. Budd Haeberlein, J. Avila, Gl ycogen synthase kinase 3: a drug target for CNS \ntherapies, J. Neurochem. 89 (2004) 1313-1317. \n[24]  F. Lo Monte, T. Kramer, J. Gu, U. Rao Anumala , L. Marinelli, V. La Pietra, E. Novellino, B. \nFranco, D. Demedts, F. Van Leuven,  A. Fuertes, J.M . Dominguez, B. Plotkin, H. Eldar-\nFinkelman, B. Schmidt, Identification of Glycogen S ynthase Kinase-3 Inhibitors with a \nSelective Sting for Glycogen Synthase Kinase-3 \u03b1, J. Med. Chem. 55 (2012) 4407-4424. \n[25]  T. Kramer, B. Schmidt, F. Lo Monte, Small-mol ecule inhibitors of GSK-3 - Structural insights \nand their application to Alzheimer\u00b4s disease models , International Journal of Alzheimer\u00b4s \nDisease, accepted (2012) http://www.hindawi.com/jou rnals/ijad/aip/381029/. \n[26]  B. Voigt, M. Krug, C. Sch\u00e4chtele, F. Totzke, A. Hilgeroth, Probing Novel 1-Aza-9-\noxafluorenes as Selective GSK-3 \u03b2 Inhibitors, ChemMedChem 3 (2008) 120-126. \n[27]  J. Bostr\u00f6m, A. Hogner, A. Llin\u00e1s, E. Wellner,  A.T. Plowright, Oxadiazoles in Medicinal \nChemistry, J. Med. Chem. 55 (2012) 1817-1830. \n[28]  M. Saitoh, J. Kunitomo, E. Kimura, Y. Hayase,  H. Kobayashi, N. Uchiyama, T. Kawamoto, T. \nTanaka, C.D. Mol, D.R. Dougan, G.S. Textor, G.P. Sn ell, F. Itoh, Design, synthesis and \nstructure\u2013activity relationships of 1,3,4-oxadiazol e derivatives as novel inhibitors of glycogen \nsynthase kinase-3 \u03b2, Bioorg. Med. Chem. 17 (2009) 2017-2029. \n[29]  L. Naerum, L. Norskov-Lauritsen, P.H. Olesen,  Scaffold Hopping and Optimization towards \nLibraries of Glycogen Synthase Kinase-3 Inhibitors,  Bioorg. Med. Chem. Lett. 12 (2002) 1525-\n1528. \n[30]  R. Bhat, X. Xue, S. Berg, S. Hellberg, M. Orm \u00f6, Y. Nilsson, A. Rades\u00e4ter, E. Jerning, P. \nMarkgren, M. Nyl\u00f6f, T. Borgegard, A. Gim\u00e9nez-Cassin a, F. Hern\u00e1ndez, J.J. Lucas, J. D\u00edaz- \nSeite 198 Nido, J. Avila, Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-\nspecific Inhibitor AR-A014418, J. Biol. Chem. 278 ( 2003) 45937-45945. \n[31]  H.B. Konig, W. Seifken, H.A. Offe, Sulfur-con taining derivatives of pyridine carboxylic acids \nand compounds derived therefrom, Chem. Berichte 87 (1954) 825-834. \n[32]  G. Mazzone, F. Bonina, R. Arrigo-Reina, Synth esis and pharmacological activities of some 2-\n(alkylaminoalkyl)mercapto-5-aryl-(1,3,4-oxadiazoles ), Farmaco, Ed. Scient. 32 (1977) 414-429. \n[33]  R.A. Tromp, S.van Ameijde, C. P\u00fctz, C. Sunder mann, B. Sundermann, J.K. von Frijtag Drabbe \nK\u00fcnzel, P. IJzerman, Inhibition of Nucleoside Trans port by New Analogues of 4-\nNitrobenzylthioinosine: Replacement of the Ribose M oiety by Substituted Benzyl Groups, J. \nMed. Chem. 47 (2004) 5441-5450. \n[34]  S. Chao, S. Li, X. Hui, P. Xu, L. Dong Synthe sis and antibacterial activities of 2-phenyl-5-[[2' -\ncyano(1,1'-biphenylyl)-4-]methyl]mercapto-1,3,4-oxa diazole, Xinxiang Yixueyuan Xuebao 23 \n(2006) 5-6. \n[35]  S. Giri, H. Singh, L.D.S. Yadav, Studies in o xadiazoles. Synthesis of some 2-mercapto-1,3,4-\noxadiazoles and related compounds as potential fung icides, Agr. Biol. Chem. 40 (1976) 17-21. \n[36]  M.C. da Silva Lourenco, M. de Lima Ferreira, M.V.N. de Souza, M.A. Peralta, T.R.A. \nVasconcelos, M. das Gracas Henriques, Synthesis and  anti-mycobacterial activity of (E)-N'-\n(monosubstituted-benzylidene)isonicotinohydrazide d erivatives, Eur. J. Med. Chem. 43 (2008) \n1344-1347. \n[37]  I. Ninomiya, O. Yamamoto, Photochemistry of i sonicotinohydrazide and its analogs in alcohol, \nHeterocycles 4 (1976) 475-481. \n[38]  R.R. Shah, R.D. Mehta, A.R. Parikh, Studies o n isoniazid derivatives. Preparation and \nantimicrobial activity of 2-aryl-3-(pyridylcarbomyl )-5-carboxymethyl-4-thiazolidinones, J. Ind. \nChem. Soc. 62 (1985) 255-257. \n[39]  S.K. Boovanahalli, X. Jin, Y. Jin, J.H. Kim, N.T. Dat, Y. Hong, J.H. Lee, S. Jung, K. Lee, J.J. \nLee, Synthesis of (aryloxyacetylamino)-isonicotinic /nicotinic acid analogues as potent hypoxia-\ninducible factor (HIF)-1a inhibitors, Bioorg. Med. Chem. Lett. 17 (2007) 6305-6310. \n[40]  M.A. Chowdhury, K.R.A. Abdellatif, Y. Dong, M . Rahman, D. Das, M.R. Suresh, E.E. Knaus, \nSynthesis of 1-(methanesulfonyl- and aminosulfonylp henyl)acetylenes that possess a 2-(N-\ndifluoromethyl-1,2-dihydropyridin-2-one pharmacopho re: Evaluation as dual inhibitors of \ncyclooxygenases and 5-lipoxygenase with anti-inflam matory activity, Bioorg. Med. Chem. Lett. \n19 (2009) 584-588. \n[41]  Q. Zheng, F. Zhang, K. Cheng, Y. Yang, Y. Che n, Y. Qian, H. Zhang, L. Li, C. Zhou, S. An, Q. \nJiao, H. Zhu, Synthesis, biological evaluation and molecular docking studies of amide-coupled \nbenzoic nitrogen mustard derivatives as potential a ntitumor agents, Bioorg. Med. Chem. 18 \n(2010) 880-886. \n[42]  A. Molinos-G\u00f3mez, X. Vidal, M. Maym\u00f3, D. Vela sco, J.Martorell, F. L\u00f3pez-Calahorra, \nTautomeric enhancement of the hyperpolarizability i n new acridine-benzothiazolylamine based \nNLO chromophores, Tetrahedron 61 (2005) 9075-9081. \n[43]  K. Yamazaki, Y. Kaneko, K. Suwa, S. Ebara, K.  Nakazawa, K. Yasuno, Synthesis of potent and \nselective inhibitors of Candida albicans N-myristoy ltransferase based on the benzothiazole \nstructure, Bioorg. Med. Chem. 13 (2005) 2509-2522. \n[44]  P. Basabe, A. Diego, S. Delgado, D. D\u00edez, I. S. Marcos, J. G. Urones, Short and efficient \nsynthesis of (+)-subersic acids, Tetrahedron 59 (20 03) 9173-9177. \n[45] M. Ebisawa, M. Ueno, Y. Oshimo, Y. Kondo, Synt hesis of dictyomedins using phosphazene \nbase catalyzed diaryl ether formation, Tetrahedron Lett. 48 (2007) 8918-8921. \n[46]  L. Campeau, M. Parisien, A. Jean, K. Fagnou, Catalytic Direct Arylation with Aryl Chlorides, \nBromides, and Iodides: Intramolecular Studies Leadi ng to New Intermolecular Reactions, J. \nAm. Chem. Soc. 128 (2006) 581-590. \n[47]  H. V. Namboodiri, M. Bukhtiyarova, J. Ramchar an, M. Karpusas, Y. Lee, E. B. Springman, \nAnalysis of Imatinib and Sorafenib Binding to p38a Compared with c-Abl and b-Raf Provides \nStructural Insights for Understanding the Selectivi ty of Inhibitors Targeting the DFG-Out Form \nof Protein Kinases, Biochemistry 49 (2010) 3611-361 8.  \nSeite 199 [48]  J. R. Simard, M. Getlik, C. Gr\u00fctter, V. Pawar , S. Wulfert, M. Rabiller, D. Rauh, Development \nof a Fluorescent-Tagged Kinase Assay System for the  Detection and Characterization of \nAllosteric Kinase Inhibitors, J. Am. Chem. Soc. 131  (2009) 13286-13296. \n[49]  D. Paquet, R. Bhat, A. Sydow, E. Mandelkow, S . Berg, S. Hellberg, J. F\u00e4lting, M. Distel, R.W. \nK\u00f6ster, B. Schmid, C. Haass, A zebrafish model of t auopathy allows in vivo imaging of \nneuronal cell death and drug evaluation, J. Clin. I nvest. 119 (2009) 1382\u20131395. \n[50]  G.E. Atilla-Gokcumen, D.S. Williams, H.  Breg man, N. Pagano, E. Meggers, Organometallic \nCompounds with Biological Activity: A Very Selectiv e and Highly Potent Cellular Inhibitor for \nGlycogen Synthase Kinase 3, ChemBioChem 7 (2006) 14 43-1450. \n[51]  C.J. Phiel, C.A. Wilson, V.M.Y. Lee, P.S. Kle in, GSK-3 alpha regulates production of \nAlzheimer's disease amyloid-beta peptides, Nature 4 23 (2003) 435-439. \n[52]  M. Cristina da Silva Lourenco, M. de Lima Fer reira, M. Vin\u00edcius Nora de Souza, M. Amado \nPeralta, T. Rocha Alves Vasconcelos, M.O. das Graca s, M. Henriques, Synthesis and anti-\nmycobacterial activity of (E)-N\u00b4-(monosubstituted-b enzylidene)isonicotinohydrazide \nderivatives, Eur. J. Med. Chem. 43 (2008) 1344-1347 . \n[53]  Z. Liberman, H. Eldar-Finkelman, Serine 332 p hosphorylation of insulin receptor substrate-1 by \nglycogen synthase kinase-3 attenuates insulin signa ling, J. Biol. Chem. 280 (2005) 4422-4428. \n[54]  C.B. Kimmel, W.W. Ballard, S.R. Kimmel, B. Ul lmann, T.F. Schilling, Stages of Embryonic \nDevelopment of the Zebrafish, Develop. Dynamics 203  (1995) 253-310. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 200 Supporting Information \nStructure-based optimization of  \noxadiazole-based GSK-3 inhibitors   \nFabio Lo Monte, a, * Thomas Kramer, a Jiamin Gu, a Martin Brodrecht, a Johannes \nPilakowski, a Ana Fuertes, b Juan Manuel Dominguez,b Batya Plotkin, c Hagit \nEldar-Finkelman c and Boris Schmidt a, * \n \na Clemens Sch\u00f6pf - Institute of Organic Chemistry an d Biochemistry, Technische Universit\u00e4t \nDarmstadt, 64287 Darmstadt, Germany \nb Noscira S.A., Drug Discovery, Tres Cantos 28760 - Madrid, Spain \nc Department of Human Molecular Genetics and Biochemi stry, Sackler School of Medicine, Tel Aviv \nUniversity,  69978 Tel Aviv, Israel \n \n \n*To whom correspondence should be addressed. Phone:  +496151-164531. Fax: +496151-\n163278. E-Mail: schmidt_boris@t-online.de; Fabio.Lo -Monte@gmx.de \n \n \n \n \nNMR Data of compounds 8a-h , 9a-f, 10a-f, 26a  and  26c-d.    \nThe 1H-NMR spectra were recorded on a Bruker AC 300 spec trometer at 300 MHz and \nBruker AC 500 spectrometer at 500 MHz. The 13 C-NMR spectra were recorded on a Bruker \nAC 300 spectrometer at 75 MHz and Bruker AC 500 spe ctrometer at 125 MHz.  \n  \nSeite 201  \n \n \nO\nO\nONN\nS\nN+O\u2013Ocompound8a1H-NMR \n13 C-NMR  \nSeite 202  \n \n \n1H-NMR \n13 C-NMR  \nSeite 203  \n \n \n1H-NMR \n13 C-NMR O\nO\nONN\nScompound8c\nN+\nO\u2013O \nSeite 204  \n \n \n1H-NMR \n13 C-NMR  \nSeite 205  \n \n \n1H-NMR \n13 C-NMR  \nSeite 206  \n \n \n1H-NMR \n13 C-NMR O\nO\nONN\nScompound8f\nOCN \nSeite 207  \n \n \n1H-NMR \n13 C-NMR O\nO\nONN\nScompound8g\nFF \nSeite 208  \n \n \n1H-NMR \n13 C-NMR  \nSeite 209  \n \n \n1H-NMR \n13 C-NMR  \nSeite 210  \n \n \n1H-NMR \n13 C-NMR  \nSeite 211  \n \n \n1H-NMR \n13 C-NMR  \nSeite 212  \n \n \n1H-NMR \n13 C-NMR ONN\nScompound9dO\nO\nO \nSeite 213  \n \n \n1H-NMR \n13 C-NMR  \nSeite 214  \n \n \n1H-NMR \n13 C-NMR  \nSeite 215  \n \n \n1H-NMR \n13 C-NMR  \nSeite 216  \n \n \n1H-NMR \n13 C-NMR N\nONN\nScompound10b\nCN \nSeite 217  \n \n \n1H-NMR \n13 C-NMR  \nSeite 218  \n \n \n1H-NMR \n13 C-NMR  \nSeite 219  \n \n \n1H-NMR \n13 C-NMR N\nONN\nScompound10e\nFCN \nSeite 220  \n \n \n1H-NMR \n13 C-NMR  \nSeite 221  \n \n \n1H-NMR \n13 C-NMR  \nSeite 222 \n \n \n \n \n \n1H-NMR \n13 C-NMR  \nSeite 223  \n \n \n1H-NMR \n13 C-NMR  \nSeite 224 4.1.5 Oxadiazolderivate und deren Verwendung als GS K-3-Inhibitoren \n \nDer Inhalt dieses Kapitels enth\u00e4lt Ausz\u00fcge aus der Patentanmeldung: \n \nBoris Schmidt, Fabio Lo Monte, Thomas Kramer, Hagit  Eldar-Finkelman, Fred Van \nLeuven  \nVerbindungen als Glykogen Synthase Kinase 3 (GSK-3)  Inhibitoren f\u00fcr die \nBehandlung von GSK-3-vermittelten Erkrankungen Deutsche Patentanmeldung  \n2011 , Nr. 10 2011 106 990.2. \n \n \nDie Untersuchungen zum Oxadiazol-Grundger\u00fcst f\u00fchrte n zur Synthese potenter und \nselektiver GSK-3-Inhibitoren. Die aktivsten Verbind ungen haben ein biphenylisches \nSystem und zeigten ihre in vivo  Effektivit\u00e4t bereits im Zebrafisch-Embryo. Viele d er \nBiphenylderivate inhibieren beide Isoformen von GSK -3 bereits im nanomolaren \nBereich (Abb. 20). Dar\u00fcber hinaus konnten durch ein e Variation der Substituenten \nam biphenylischen System selektive GSK-3 \u03b1-Inhibitoren synthetisiert werden.  \n \n \nAbb. 20: Beispiele einiger zur Patentanmeldung eingereichten  GSK-3-Inhibitoren.    \n \n \nSeite 225 Durch diese \u03b1-Selektivit\u00e4t er\u00f6ffnen sich neue M\u00f6glichkeiten f\u00fcr in vivo \nUntersuchungen dieser Isoform. Ferner konnte belegt  werden, dass die \nDiskriminierung einer GSK-3-Isoform m\u00f6glich ist. Di ese Tatsache l\u00e4sst vermuten, \ndass auch die Synthese selektiver GSK-3 \u03b2-Inhibitoren durchf\u00fchrbar ist.      \nNeben der Verwendung dieser GSK-3-Inhibitoren im Be reich der Alzheimer-Demenz \nwurden auch andere GSK-3-vermittelte Erkrankungen i n die Patentanmeldung mit \naufgenommen.        \n \nDie im Rahmen dieser Arbeit von Fabio Lo Monte synt hetisierten Verbindungen: \n \nBSc4260, BSc4261, BSc4262, BSc4263, BSc4293, BSc430 6, BSc4392, BSc4393, \nBSc4394, BSc4395, BSc4396, BSc4397, BSc4398, BSc439 9, BSc4401, BSc4402, \nBSc4403, BSc4404, BSc4405, BSc4406, BSc4407, BSc440 8, BSc4409, BSc4410, \nBSc4411, BSc4412, BSc4413, BSc4414, BSc4415, BSc441 6, BSc4603, BSc4604, \nBSc4605, BSc4606, BSc4607, BSc4608, BSc4609, BSc461 0, BSc4611, BSc4612, \nBSc4613, BSc4614, BSc4615, BSc4616, BSc4617, BSc461 8, BSc4619, BSc4620, \nBSc4621, BSc4622, BSc4623, BSc4624, BSc4625, BSc462 6, BSc4634, BSc4670, \nBSc4672, BSc4674, BSc4676, BSc4678, BSc4680, BSc468 1, BSc4682, BSc4683, \nBSc4684, BSc4686, BSc4687, BSc4688, BSc4689, BSc473 4, BSc4788, BSc4789 \nBSc4790, BSc4791, BSc4792, BSc4793, BSc4794 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 226 Verbindungen als Glykogen Synthase Kinase 3 (GSK-3)  Inhibitoren \nf\u00fcr die Behandlung von GSK-3-vermittelten Erkrankun gen \n \n \n1. Beschreibung \n \nDie vorliegende Erfindung betrifft Verbindungen, di e als selektive Liganden der \nGlykogen Synthase Kinase 3 (GSK-3) wirken und f\u00fcr d ie Behandlung von GSK-3-\nvermittelten Erkrankungen verwendet werden k\u00f6nnen. Die erfindungsgem\u00e4\u00dfen \nVerbindungen wirken als Inhibitoren der Glykogen Sy nthase Kinase 3 (GSK-3). \nGSK-3 ist eine hoch konservierte Familie von Serin/ Threoninproteinkinasen. Beim \nMenschen kodieren zwei Gene zwei unterschiedliche, aber eng miteinander \nverbundenen GSK-3 Formen, die so genannte GSK-3 \u03b1 und GSK-3 \u03b2. Sie zeigen \ninsgesamt 84% Identit\u00e4t und 98% Identit\u00e4t innerhalb  ihrer katalytischen Dom\u00e4ne, der \nHauptunterschied zwischen den beiden Proteinkinasen  besteht in einem Glycin-\nreichen Abschnitt in der N-terminalen Dom\u00e4ne von GS K-3\u03b1. Dennoch hat sich in \nembryonal letalen Ph\u00e4notypen der GSK-3 \u03b2 gezeigt, dass beide Formen der GSK-3 \nnicht funktionell austauschbar sind. \nGSK-3 spielt eine wichtige Funktion im Wnt-Signalwe g. Durch die Stimulation des \nWnt-Signalweges wird GSK-3 inaktiviert, wodurch sic h \u03b2-Catenin im Zellkern \nansammelt, um dort mit TCF / LEF einen Transkriptio nsfaktor zu formen, der eine \nVielzahl von Genen reguliert. GSK-3 phosphoryliert unter anderem den \nZellzyklusregulator \u03b2-Catenin, Cyclin D1, Cyclin E, p21CIP1 und c-Myc, w odurch \ndiese Ubiquitin-abh\u00e4ngig abgebaut werden. In Abwese nheit von Insulin \nphosphoryliert aktive GSK-3 die Glykogen-Synthase u nd eIF2B, wodurch diese \ninaktiviert werden.   Die Bindung von Insulin an se inen Plasmamembran Rezeptor \nf\u00fchrt zur Aktivierung von PKB / Akt, was wiederum z ur Phosphorylierung und \nInaktivierung von GSK-3 f\u00fchrt. Folglich sind dadurc h die Glykogen-Synthase und \neIF2B aktiviert, wodurch die Glykogen und Protein-S ynthese stimuliert werden.   \nGSK-3 hat weiterhin pro-apoptotische Funktion in ne uronalen Zellen. Im Gegensatz \ndazu ist GSK-3 auch f\u00fcr das \u00dcberleben von Zellen be schrieben worden. In GSK-3 \u03b2-\nKnockout-M\u00e4usen f\u00fchrte die TNF \u03b1-induzierte Apoptose von Hepatozyten zu einem  \nSeite 227 fr\u00fchen Tod w\u00e4hrend der Embryonalentwicklung der M\u00e4u se. Zudem wird der GSK-3 \nund CK1 eine Funktion bei der Regelung der zirkadia nen Uhr bei Drosophila und in \nS\u00e4ugetieren nachgesagt. Schlie\u00dflich spielt sowohl d ie GSK-3 Aktivit\u00e4t/Inaktivit\u00e4t als \nauch die r\u00e4umliche Verteilung eine wesentliche Roll e w\u00e4hrend der Entwicklung, \ninsbesondere im Rahmen der Polarit\u00e4tsbestimmung.  \nKaum ein anderes Enzym besitzt einen so gro\u00dfen Einf luss auf eine Vielzahl \nzellul\u00e4rer Vorg\u00e4nge wie GSK-3. Unter anderem wurde ein Einfluss von GSK-3 auf \nfolgende physiologischen Funktionen beschrieben: de n Wnt und Hedgehog \nSignalweg, in der Transkription, der Regulation des  Zellteilungszyklus, der Antwort \nauf DNA-Sch\u00e4den, der Regulation des Zelltods und de m \u00dcberleben der Zelle, \nkardiovaskul\u00e4re und neuronale Funktionen, dem Insul in-Transduktionsweg, der \nDifferenzierung, Regulation des zirkadianen Rhythmu s und der \nEntwicklung/Erhaltung von Stammzellen. Bis heute wu rden rund 40 Substrate \nidentifiziert, die von GSK-3 phosphoryliert werden.   \nF\u00fcnf Studien haben die Suche nach pharmakologischen  Inhibitoren der GSK-3 \nbesonders angeregt: Erstens, die Stimmungsstabilisi erenden Eigenschaften von \nLithium, dem ersten GSK-3-Inhibitor \u00fcberhaupt. Zwei tens die Insulin-mimetischen \nEigenschaften von GSK-3-Inhibitoren. Drittens die W echselwirkung von GSK-3 mit \nPresenilin-1, die GSK-3-abh\u00e4ngigen Amyloid- \u03b2 Produktion und abnorme tau-\nPhosphorylierung in der Alzheimer-Krankheit. Vierte ns, die Beteiligung der GSK-3 im \nneuronalen Zelltod und der Neuroprotektion durch GS K-3-Inhibitoren und f\u00fcnftens \ndie Aufrechterhaltung der Pluripotenz von embryonal en Stammzellen in der \nAbwesenheit von Feeder-Zellen durch GSK-3-Inhibitor en. \u00dcber 30 GSK-3-Inhibitoren \nwurden bisher identifiziert. An der Identifizierung  neuer GSK-3-Inhibitoren besteht \ndaher nach wie vor ein fortlaufend gro\u00dfes Interesse . \nZu den Krankheiten, die mit GSK-3 Inhibitoren behan delt werden k\u00f6nnen, geh\u00f6ren \ninsbesondere die Alzheimer-Krankheit und andere Tau opathien, Asthma, bipolare \naffektive St\u00f6rungen, Depression, Nervenzelltod und Schlaganfall, Parkinson, \nHuntington, Skelettmuskelatrophie, Kardioprotektion , Haarverlust, verringerte \nSpermienmotilit\u00e4t, Diabetes und damit in Zusammenha ng stehende \nFolgeerkrankungen, z.B. Syndrom X und Adipositas, E rkrankungen, die durch  \nSeite 228 einzellige Parasiten verursacht werden, transmissib le spongiforme Enzephalopathie, \nSchizophrenie, Krankheiten des zirkadianen Rhythmus  und Krebs. \nIm Stand der Technik sind bereits einige GSK-3 Inhi bitoren und ihr therapeutisches \nPotential beschrieben worden. In einem Review von C ohen and Goedert, Nat. Rev. \nDrug. Discov. , 2004, 3: 480-87, wurden einige potentielle GSK-3 Inhibitoren, wie z.B. \nSB 216763, SB 415286, CHIR 98014, CHIR 99021, AR A0 14418, 1-Azakenpaullone \nund Bis-7-indolylmaleimide f\u00fcr eine Vielzahl von th erapeutischen Anwendungen \nbeschrieben.  \nIm Stand der Technik sind (R)-Roscovitin, Aloisin A , Indirubin-3\u00b4-oxim, \nPyrazolpyridin, Aminothiazol, Alsterpaullon und 1-A za-9-oxafluoren als GSK-3 \nInhibitoren identifiziert worden. \nObwohl bereits einige GSK-3 Inhibitoren im Stand de r Technik bekannt sind, spielt \ndie GSK-3 bei klassischen Krankheiten wie Alzheimer  und Krebs eine so \nentscheidende Rolle, dass weiterhin und auch zuk\u00fcnf tig ein gro\u00dfes Interesse daran \nbesteht, weitere GSK-3 Inhibitoren zu identifiziere n. \nAufgabe der vorliegenden Erfindung ist es daher, we itere Verbindungen \nbereitzustellen, die in der Lage sind, die GSK-3 zu  inhibieren. \nDiese Aufgabe wird erfindungsgem\u00e4\u00df durch die techni sche Lehre der unabh\u00e4ngigen \nAnspr\u00fcche gel\u00f6st.   Weitere vorteilhafte Ausgestalt ungen der Erfindung ergeben sich \naus den abh\u00e4ngigen Anspr\u00fcchen, der Beschreibung, de n Figuren sowie den \nBeispielen.  \n\u00dcberraschend wurde gefunden, dass die Verbindungen gem\u00e4\u00df allgemeiner Formel \n(I) Inhibitoren der Glykogen Synthase Kinase 3 (GSK -3) sind und damit auch f\u00fcr die \nProphylaxe und Behandlung von GSK-3-vermittelten Er krankungen geeignet sind. \n \n \n \n \n  \nSeite 229 Somit betrifft die vorliegende Erfindung Verbindung en der allgemeinen Formel (I) \n \n \nworin \nR1 f\u00fcr einen der folgenden Reste steht: \n \n    \n    \n    \n    \n   \n N NOS R1R2X1\nX4\nX2\nX3\nO\nNONNON\nNON\nNONON\nNNO\nN\nNO\nN\nNO\nNNON\nN\nNON\nN\nNON\nN\nNNO\nN\nNNO\nN\nN NO\nN\nNNON\nN NON\nNNON\nNOR23\nR10R22\nR24R25 \nSeite 230     \n    \n    \n    \n    S\nS\nNS S\nNSN\nNSN\nNSN\nNSNSN\nN\nNS\nN\nNS\nN\nNS\nNNSN\nN\nNSN\nN\nNSN\nN\nNNS\nN\nNNS\nN\nN NS\nN\nNNSN\nN NSN\nNNSN\nNO\nN\nR8NO\nN\nR8\nNO\nN\nR8O\nN\nR8\nNNO\nN\nR8\nNNO\nN\nR8\nN NO\nN\nR8NS\nN\nR8\nNS\nN\nR8\nNS\nN\nR8S\nN\nR8NNS\nN\nR8 \nSeite 231  \n \n   \n \n \n    \n   NO\nOHNO\nOR8\nNNS\nN\nR8\nN NS\nN\nR8\nNNS\nN\nH\nN NN\nN\nHH\nNNN\nN\nHH\nNN\nN\nHH\nN NN\nN\nR8H\nNNN\nN\nR8H\nNN\nNR8\nR9\nN NN\nNR8\nH\nNNN\nNR8\nHNNN\nNR8\nR9\nN NN\nNR8\nR9\nNNN\nNR8\nR9\nN\nN\nR8NN\nN\nR8\nNN\nN\nR8\nNN\nN\nR8\nN\nNR8\nNN\nNR8\nNN\nNR8\nNN\nNR8\nNNN\nNR8\nN NN\nNR8\nNNN\nNR8\nN NN\nN\nR8 \nSeite 232   \n \n   \n    \n    \n    \n    \n    \n \n   NNN\nN\nR8\nNNN\nN\nR8N\nNN\nN\nN\nN N\nNN\nN\nN N N\nN\nNN\nNN\nNN\nNN\nNN\nNN\nNNN\nN N N\nNNN\nN\nN\nNN\nN\nNN\nN\nNN\nN\nNN N\nNN\nN\nNN\nN\nNN\nN\nNNN\nN\nNN N\nN\nNNN\nN \nSeite 233     \n    \n    \n    \n    \n \n   \n   N NN N\nN NN\nN\nN NN\nN\nN NN\nN\nNNN N\nNNN\nN\nNN N\nN\nNNN\nN\nNN\nN NN\nN\nNNN\nN\nNNN\nN\nNN\nN\nNN\nN\nNN\nN\nN NN\nN\nNN\nN\nNN\nN\nNNN\nN\nNNN\nN\nO\nOR10\nR11O\nOR11R10\nO\nOR10\nR11\nN\nNR10\nR11R8\nHN\nNR10\nR11\nR8H\nN\nNR10\nR11R8\nR9 \nSeite 234    \n \n   \n   \n   \n   O\nR22\nR23\nR24R25N\nNR22R23\nR24R25R26\nNN\nNR22R23\nR25R26\nO\nOR23R22\nR24R25O\nNR22R23\nR24R25N\nOR22R23\nR24R25\nO OR22\nR23\nR24R25O NR22\nR23\nR24R25N OR22\nR23\nR24R25\nS\nNR22R23\nR24R25N\nSR22R23\nR24R25NO\nNR22R23\nR25\nS NR22\nR23\nR24R25N SR22\nR23\nR24R25NO NR22\nR24R25 \nSeite 235    \n   \n   \n   \n \n    NN\nOR22R23\nR25NS\nNR22R23\nR25NN\nSR22R23\nR25\nNN OR22\nR24R25NS NR22\nR24R25NN SR22\nR24R25\nNN NR22\nR24R25R26\nN NR22\nR23\nR24R25R26\nN NR22\nR23\nR24R25R26\nNN\nNR22R23\nR25R26\nN\nNR22R23\nR24R25R26\nNN NR22\nR24R25R26\nNNR26\nR23R22NNR26\nR23R22NN\nR26R22\nR23 \nSeite 236     \n    \n    \n    \n    \n \n   \n \nR2 f\u00fcr einen der folgenden Reste steht  \u2013X15 , \n N\nNR26R22\nR23N\nNR22\nR23\nR26N\nN\nR24R23R22\nNN\nNR22\nR23\nNNNR22R26\nNNO\nR22 NO\nNR22\nNON\nR22\nOR24\nR23R22OR24\nR23R22SR22\nR24R23SR22\nR24R23\nOR22\nR23\nR24R25OR22R23\nR24R25SR22\nR23\nR24R25SR22R23\nR24R25\nNNR22\nR24R25NR22\nR23\nR24R25NR22R23\nR24R25NNNR22\nR24\nNN\nR23\nR24R25NNR22\nR24R25NNR22\nR23\nR25NNR22\nR23\nR25 \nSeite 237     \n    \n    \n    \n  \n  \n    \n    NH\nNH\nNN\nN\nNR8\nR10R11R12\nNR8R10\nR11R12N\nR10R11R12R13\nN\nN\nR10R11R12\nNNH\nNNH\nNN\nHN\nNH\nNNR8\nR10R11NNR8\nR10R11NN\nR8R10\nR11N\nN\nR10R11R12\nN\nNHN\nN\nHNNNR10H\nN\nNR8R10\nR11N\nNR10\nR11\nR8N\nN\nR8R10\nR11\nNNNR10R8\nNN\nNR10\nR11NNO\nR10 NO\nNR10\nNON\nR10 \nSeite 238     \n    \n    \n \n   \n    \n    \n    \n    OOSS\nO\nR10R11R12\nOR10\nR11R12S\nR10R11R12\nSR10\nR11R12\nNS\nNS\nSN NNN\nNH\nNS\nR10R11 NSR10\nR11SNR10\nR11\nNNN\nNR8\nNO O\nNO\nN NN\nN\nNR10\nNO\nR10R11\nO\nNR10\nR11O\nNR10\nR11NN\nN\nNR10\nNS S\nNS\nN NNOR10\nNS\nR10R11\nS\nNR10\nR11S\nNR10\nR11 NS\nNR10 \nSeite 239     \n \n   \n   \n   \n   \n   NH\nNN\nR11\nR10O\nR11\nR10S\nNR8\nR10R11N\nNR8 R11\nR10NR8\nR10R11\nS\nR10R11\nN\nNH\nNH\nO\nN\nR10R11\nO\nR10R11\nS\nN\nR10R11\nN\nN\nR10R11\nN\nN\nR10R11\nR10R11\nN\nR10R11\nN\nR10R11\nN\nR10R11 \nSeite 240  \n  \n \n  \n   \n   \n   \n   N\nO\nNO\nNO\nHN\nOO\nH\nN\nS\nNO\nNO\nR8N\nOO\nR8\nR11\nR10NN\nNN\nR10R11R11\nR10NN\nR11\nR10NNR11\nR10N\nNR11\nR10N\nN\nR11\nR10N N\nNN\nR10R11\nNN\nN\nR10R11\nR11\nR10NN\nNR11\nR10NN\nN NN\nN\nR10R11 \nSeite 241    \n   \n   \n   \n   \n   NN\nN\nR10R11R11\nR10N\nNN\nN\nNN\nR10R11\nN\nNN\nR10R11 R11\nR10N\nNN\nN\nNN\nR10R11\nR11\nR10N\nNNR3R4\nR5\nR6R7NNNR3\nR4\nR11\nR10N\nNN\nNN\nNN\nN\nR10R11\nN\nNN\nN\nR10R11\nN\nNN\nN\nR10R11R11\nR10N\nNN\nNR11\nR10N\nNN\nN\nN\nNN\nN\nR10R11R11\nR10N\nNN\nNR11\nR10N\nNN\nN \nSeite 242    \n   \n \n  \n   \n \n \nR3, R 4, R 5, R 6, R 7, R 10 , R 11 , R 12 , R 13  unabh\u00e4ngig voneinander folgende Reste \nbedeuten: \n\u2212R14 ,   \u2212R15 ,   \u2212R16 ,   \u2212R17 ,   \u2212R18 ,   \u2212R19 ,   \u2212R20 ,   \u2212(CH 2)n\u2212R14 ,   \u2212(CH 2)n\u2212R15 ,    \n\u2212(CH 2)n\u2212R16 ,   \u2212(CH 2)n\u2212R17 ,   \u2212(CH 2)n\u2212R18 ,   \u2212(CH 2)n\u2212R19 ,   \u2212(CH 2)n\u2212R20 ; \n \n    R11\nR10N\nNN\nNN\nNN\nN\nR10R11\nN\nNN\nN\nR10R11\nNR3\nR4\nR5R6NR3\nR4\nR5R6NR3R4\nR5R6\nNN\nR3\nR4R5NNR3\nR4R5NNR3\nR4R5\nNNR3\nR4\nR5NNR3\nR4\nR5NNR3\nR4\nR5\nNNH\nNH\nNN\nH \nSeite 243     \n    \n     \n     \n     \n     \n     \n     \n \nR8, R 9 und R 26  unabh\u00e4ngig \nvoneinander folgende Reste \nbedeuten: \n  NNOR10\nNNN\nNH\nNNN\nNH\nNNNR10H\nNN\nNR10\nR11NNO\nR10 NO\nNR10\nNON\nR10\nN N\nNNN\nNN\nNN\nNN\nNN\nNN\nNNN\nNH\nNNH\nN\nNH\nN\nNHN\nN\nH\nOOSS\nN\nNS\nNS\nSN NO O\nN\nO\nNNS S\nNS\nNN\nN\nX5X6\nX7\nX8X9X10X11\nX12\nX13X14 \nSeite 244 \u2013H,   \u2212CH 2F,   \u2212CHF 2,   \u2212CF 3,   \u2212CH 2Cl,   \u2212CH 2Br,   \u2212CH 2I,   \u2212CH 2\u2212CH 2F,    \n\u2212CH 2\u2212CHF 2,   \u2212CH 2\u2212CF 3,   \u2212CH 2\u2212CH 2Cl,   \u2212CH 2\u2212CH 2Br,   \u2212CH 2\u2212CH 2I,    \ncyclo-C 3H5,  cyclo-C 4H7,  cyclo-C 5H9,  cyclo-C 6H11 ,  cyclo-C 7H13 ,  cyclo-C 8H15 ,   \u2212Ph,   \u2212CH 2\u2212\nPh,   \u2212CH 2\u2212CH 2\u2212Ph,   \u2212CH 2\u2212CH 2\u2212CH 2\u2212Ph,   \u2212CH=CH \u2212Ph,    \n\u2212C\u2261C\u2212Ph,   \u2212CPh 3,   \u2212CH 3,   \u2212C2H5,   \u2212C3H7,   \u2212CH(CH 3)2,   \u2212C4H9,   \u2212CH 2\u2212CH(CH 3)2,   \u2212\nCH(CH 3)\u2212C2H5,   \u2212C(CH 3)3,   \u2212C5H11 ,  \u2212CH(CH 3)\u2013C3H7,   \u2013CH 2\u2013CH(CH 3)\u2013C2H5,    \n\u2013CH(CH 3)\u2013CH(CH 3)2,   \u2013C(CH 3)2\u2013C2H5,   \u2013CH 2\u2013C(CH 3)3,   \u2013CH(C 2H5)2,    \n\u2013C2H4\u2013CH(CH 3)2,  \u2212C6H13 , \u2212C7H15 , \u2212C8H17 ,  \u2013C 3H6\u2013CH(CH 3)2,  \n\u2013C2H4\u2013CH(CH 3)\u2013C2H5,   \u2013CH(CH 3)\u2013C4H9,   \u2013CH 2\u2013CH(CH 3)\u2013C3H7,  \n\u2013CH(CH 3)\u2013CH 2\u2013CH(CH 3)2, \u2013CH(CH 3)\u2013CH(CH 3)\u2013C2H5,   \u2013CH 2\u2013CH(CH 3)\u2013CH(CH 3)2,   \u2013CH 2\u2013\nC(CH 3)2\u2013C2H5,   \u2013C(CH 3)2\u2013C3H7,   \u2013C(CH 3)2\u2013CH(CH 3)2,   \u2013C 2H4\u2013C(CH 3)3,   \n \u2013CH(CH 3)\u2013C(CH 3)3,   \u2212CH=CH 2,   \u2212CH 2\u2212CH=CH 2,   \u2212C(CH 3)=CH 2,   \u2212CH=CH \u2212CH 3,   \u2013C2H4\u2013\nCH=CH 2,   \u2013CH 2\u2013CH=CH\u2013CH 3,   \u2013CH=CH\u2013C 2H5,   \u2013CH 2\u2013C(CH 3)=CH 2,    \n\u2013CH(CH 3)\u2013CH=CH,   \u2013CH=C(CH 3)2,   \u2013C(CH 3)=CH\u2013CH 3,   \u2013CH=CH\u2013CH=CH 2,    \n\u2212C3H6\u2013CH=CH 2,   \u2013C 2H4\u2013CH=CH\u2013CH 3,   \u2013CH 2\u2013CH=CH\u2013C 2H5,   \u2013CH=CH\u2013C 3H7,    \n\u2013CH 2\u2013CH=CH\u2013CH=CH 2,   \u2013CH=CH\u2013CH=CH\u2013CH 3,   \u2013CH=CH\u2013CH 2\u2013CH=CH 2,    \n\u2013C(CH 3)=CH\u2013CH=CH 2,  \u2013CH=C(CH 3)\u2013CH=CH 2,   \u2013CH=CH\u2013C(CH 3)=CH 2,    \n\u2013C2H4\u2013C(CH 3)=CH 2,  \u2013CH 2\u2013CH(CH 3)\u2013CH=CH 2,   \u2013CH(CH 3)\u2013CH 2\u2013CH=CH 2,    \n\u2013CH 2\u2013CH=C(CH 3)2,   \u2013CH 2\u2013C(CH 3)=CH\u2013CH 3,   \u2013CH(CH 3)\u2013CH=CH\u2013CH 3,    \n\u2013CH=CH\u2013CH(CH 3)2,   \u2013CH=C(CH 3)\u2013C2H5,   \u2013C(CH 3)=CH\u2013C 2H5,    \n\u2013C(CH 3)=C(CH 3)2,   \u2013C(CH 3)2\u2013CH=CH 2,   \u2013CH(CH 3)\u2013C(CH 3)=CH 2,    \n\u2013C(CH 3)=CH\u2013CH=CH 2,   \u2013CH=C(CH 3)\u2013CH=CH 2,   \u2013CH=CH\u2013C(CH 3)=CH 2,    \n\u2013C4H8\u2013CH=CH 2,   \u2013C 3H6\u2013CH=CH\u2013CH 3,   \u2013C 2H4\u2013CH=CH\u2013C 2H5,   \n\u2013CH 2\u2013CH=CH\u2013C 3H7,   \u2013CH=CH\u2013C 4H9,   \u2013C 3H6\u2013C(CH 3)=CH 2,   \n\u2013C2H4\u2013CH(CH 3)\u2013CH=CH 2, \u2013CH 2\u2013CH(CH 3)\u2013CH 2\u2013CH=CH 2, \u2013CH(CH 3)\u2013C2H4\u2013CH=CH 2, \u2013\nC2H4\u2013CH=C(CH 3)2, \u2013C2H4\u2013C(CH 3)=CH\u2013CH 3, \u2013CH 2\u2013CH(CH 3)\u2013CH=CH\u2013CH 3,   \u2013CH(CH 3)\u2013\nCH 2\u2013CH=CH\u2013CH 3,   \u2013CH 2\u2013CH=CH\u2013CH(CH 3)2,   \u2013CH 2\u2013CH=C(CH 3)\u2013C2H5, \u2013CH 2\u2013\nC(CH 3)=CH\u2013C 2H5, \u2013CH(CH 3)\u2013CH=CH\u2013C 2H5,   \u2013CH=CH\u2013CH 2\u2013CH(CH 3)2,   \u2013CH=CH\u2013\nCH(CH 3)\u2013C2H5,   \u2013CH=C(CH 3)\u2013C3H7,   \u2013C(CH 3)=CH\u2013C 3H7,   \u2013CH 2\u2013CH(CH 3)\u2013C(CH 3)=CH 2,   \n\u2013CH(CH 3)\u2013CH 2\u2013C(CH 3)=CH 2,   \u2013CH(CH 3)\u2013CH(CH 3)\u2013CH=CH 2,   \u2013CH 2\u2013C(CH 3)2\u2013CH=CH 2,   \u2013\nC(CH 3)2\u2013CH 2\u2013CH=CH 2,   \u2013CH 2\u2013C(CH 3)=C(CH 3)2,   \u2013CH(CH 3)\u2013CH=C(CH 3)2,   \u2013C(CH 3)2\u2013\nCH=CH\u2013CH 3,   \u2013CH(CH 3)\u2013C(CH 3)=CH\u2013CH 3,  \u2013CH=C(CH 3)\u2013CH(CH 3)2,  \u2013C(CH 3)=CH\u2013\nCH(CH 3)2,   \n\u2013C(CH 3)=C(CH 3)\u2013C2H5,   \u2013CH=CH\u2013C(CH 3)3,   \u2013C(CH 3)2\u2013C(CH 3)=CH 2,   \u2013CH(C 2H5)\u2013\nC(CH 3)=CH 2,   \u2013C(CH 3)(C 2H5)\u2013CH=CH 2,   \u2013CH(CH 3)\u2013C(C 2H5)=CH 2,   \u2013CH 2\u2013C(C 3H7)=CH 2,   \n\u2013CH 2\u2013C(C 2H5)=CH\u2013CH 3,   \u2013CH(C 2H5)\u2013CH=CH\u2013CH 3,    \n\u2013C(C 4H9)=CH 2, \u2013C(C 3H7)=CH\u2013CH 3, \u2013C(C 2H5)=CH\u2013C 2H5, \u2013C(C 2H5)=C(CH 3)2,    \n\u2013C[C(CH 3)3]=CH 2,   \u2013C[CH(CH 3)(C 2H5)]=CH 2,   \u2013C[CH 2\u2013CH(CH 3)2]=CH 2,     \nSeite 245 \u2013C2H4\u2013CH=CH\u2013CH=CH 2, \u2013CH 2\u2013CH=CH\u2013CH 2\u2013CH=CH 2, \u2013CH=CH\u2013C 2H4\u2013CH=CH 2,   \u2013CH 2\u2013\nCH=CH\u2013CH=CH\u2013CH 3, \u2013CH=CH\u2013CH 2\u2013CH=CH\u2013CH 3, \u2013CH=CH\u2013CH=CH\u2013C 2H5,    \n\u2013CH 2\u2013CH=CH\u2013C(CH 3)=CH 2, \u2013CH 2\u2013CH=C(CH 3)\u2013CH=CH 2, \u2013CH 2\u2013C(CH 3)=CH\u2013CH=CH 2,   \u2013\nCH(CH 3)\u2013CH=CH\u2013CH=CH 2,   \u2013CH=CH\u2013CH 2\u2013C(CH 3)=CH 2,   \u2013CH=CH\u2013CH(CH 3)\u2013CH=CH 2,   \n\u2013CH=C(CH 3)\u2013CH 2\u2013CH=CH 2,   \u2013C(CH 3)=CH\u2013CH 2\u2013CH=CH 2,    \n\u2013CH=CH\u2013CH=C(CH 3)2,   \u2013CH=CH\u2013C(CH 3)=CH\u2013CH 3,   \u2013CH=C(CH 3)\u2013CH=CH\u2013CH 3,   \u2013\nC(CH 3)=CH\u2013CH=CH\u2013CH 3, \u2013CH=C(CH 3)\u2013C(CH 3)=CH 2, \u2013C(CH 3)=CH\u2013C(CH 3)=CH 2,   \u2013\nC(CH 3)=C(CH 3)\u2013CH=CH 2,   \u2013CH=CH\u2013CH=CH\u2013CH=CH 2,   \u2212C\u2261CH,  \u2212C\u2261C\u2212CH 3,    \n\u2212CH 2-C\u2261CH,   \u2013C 2H4\u2013C\u2261CH,   \u2013CH 2\u2013C\u2261C\u2013CH 3,   \u2013C\u2261C\u2013C2H5,   \u2013C 3H6\u2013C\u2261CH,    \n\u2013C2H4\u2013C\u2261C\u2013CH 3,   \u2013CH 2\u2013C\u2261C\u2013C2H5,   \u2013C\u2261C\u2013C3H7,   \u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH 2\u2013CH(CH 3)\u2013\nC\u2261CH,   \u2013CH(CH 3)\u2013CH 2\u2013C\u2261CH,   \u2013CH(CH 3)\u2013C\u2261C\u2013CH 3,   \u2013C4H8\u2013C\u2261CH,   \u2013C 3H6\u2013C\u2261C\u2013CH 3,   \n\u2013C2H4\u2013C\u2261C\u2013C2H5,   \u2013CH 2\u2013C\u2261C\u2013C3H7,   \u2013C \u2261C\u2013C4H9,    \n\u2013C2H4\u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH 2\u2013CH(CH 3)\u2013CH 2\u2013C\u2261CH,   \u2013CH(CH 3)\u2013C2H4\u2013C\u2261CH,    \n\u2013CH 2\u2013CH(CH 3)\u2013C\u2261C\u2013CH 3, \u2013CH(CH 3)\u2013CH 2\u2013C\u2261C\u2013CH 3, \u2013CH(CH 3)\u2013C\u2261C\u2013C2H5,  \n\u2013CH 2\u2013C\u2261C\u2013CH(CH 3)2,   \u2013C \u2261C\u2013CH(CH 3)\u2013C2H5,   \u2013C \u2261C\u2013CH 2\u2013CH(CH 3)2,    \n\u2013C\u2261C\u2013C(CH 3)3,   \u2013CH(C 2H5)\u2013C\u2261C\u2013CH 3,   \u2013C(CH 3)2\u2013C\u2261C\u2013CH 3,    \n\u2013CH(C 2H5)\u2013CH 2\u2013C\u2261CH,   \u2013CH 2\u2013CH(C 2H5)\u2013C\u2261CH,   \u2013C(CH 3)2\u2013CH 2\u2013C\u2261CH,    \n\u2013CH 2\u2013C(CH 3)2\u2013C\u2261CH,   \u2013CH(CH 3)\u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH(C 3H7)\u2013C\u2261CH,    \n\u2013C(CH 3)(C 2H5)\u2013C\u2261CH,   \u2013C \u2261C\u2013C\u2261CH,   \u2013CH 2\u2013C\u2261C\u2013C\u2261CH,   \u2013C \u2261C\u2013C\u2261C\u2013CH 3,    \n\u2013CH(C \u2261CH) 2, \u2013C 2H4\u2013C\u2261C\u2013C\u2261CH, \u2013CH 2\u2013C\u2261C\u2013CH 2\u2013C\u2261CH, \u2013C \u2261C\u2013C2H4\u2013C\u2261CH,   \n\u2013CH 2\u2013C\u2261C\u2013C\u2261C\u2013CH 3, \u2013C\u2261C\u2013CH 2\u2013C\u2261C\u2013CH 3, \u2013C\u2261C\u2013C\u2261C\u2013C2H5, \u2013C\u2261C\u2013CH(CH 3)\u2013C\u2261CH,   \n\u2013CH(CH 3)\u2013C\u2261C\u2013C\u2261CH,   \u2013CH(C \u2261CH)\u2013CH 2\u2013C\u2261CH,   \u2013C(C \u2261CH) 2\u2013CH 3,    \n\u2013CH 2\u2013CH(C \u2261CH) 2,   \u2013CH(C \u2261CH)\u2013C\u2261C\u2013CH 3,   \u2013O\u2013CH 2\u2013CH(OCH 3)2,    \n\u2013O\u2013CH 2\u2013CH(OC 2H5)2,   \u2013O\u2013C 2H4\u2013CH(OCH 3)2,   \u2013O\u2013C 2H4\u2013CH(OC 2H5)2,    \n\u2013NH\u2013CH 2\u2013CH(OCH 3)2,   \u2013NH\u2013CH 2\u2013CH(OC 2H5)2,   \u2013NH\u2013C 2H4\u2013CH(OCH 3)2,    \n\u2013NH\u2013C 2H4\u2013CH(OC 2H5)2,      \u2013CH 2\u2013CH(OCH 3)2      oder      \u2013CH 2\u2013CH(OC 2H5)2; \n \nR23   ist  \u2013R27   oder \n oder  \n \n \nR14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 24 , R 25 , R 27  unabh\u00e4ngig voneinander \nfolgende Reste bedeuten: \n\u2013H,   \u2212CH 2F,   \u2212CHF 2,   \u2212CF 3,   \u2212CH 2Cl,   \u2212CH 2Br,   \u2212CH 2I,   \u2212CH 2\u2212CH 2F,    \n\u2212CH 2\u2212CHF 2,   \u2212CH 2\u2212CF 3,   \u2212CH 2\u2212CH 2Cl,   \u2212CH 2\u2212CH 2Br,   \u2212CH 2\u2212CH 2I,    \ncyclo-C 3H5,  cyclo-C 4H7,  cyclo-C 5H9,  cyclo-C 6H11 ,  cyclo-C 7H13 ,  cyclo-C 8H15 ,   \u2212Ph,   \u2212CH 2\u2212\nPh,   \u2212CH 2\u2212CH 2\u2212Ph,   \u2212CH 2\u2212CH 2\u2212CH 2\u2212Ph,   \u2212CH=CH \u2212Ph,    NHCH2 R27NHCH2\nR27 \nSeite 246 \u2212C\u2261C\u2212Ph,   \u2212CPh 3,   \u2212CH 3,   \u2212C2H5,   \u2212C3H7,   \u2212CH(CH 3)2,    \n\u2212C4H9,   \u2212CH 2\u2212CH(CH 3)2,   \u2212CH(CH 3)\u2212C2H5,   \u2212C(CH 3)3,   \u2212C5H11 ,   \n\u2212CH(CH 3)\u2013C3H7,   \u2013CH 2\u2013CH(CH 3)\u2013C2H5,   \u2013CH(CH 3)\u2013CH(CH 3)2,    \n\u2013C(CH 3)2\u2013C2H5,   \u2013CH 2\u2013C(CH 3)3,   \u2013CH(C 2H5)2,   \u2013C 2H4\u2013CH(CH 3)2,  \u2212C6H13 ,  \n\u2212C7H15 , \u2212C8H17 ,  \u2013C 3H6\u2013CH(CH 3)2, \u2013C 2H4\u2013CH(CH 3)\u2013C2H5,   \u2013CH(CH 3)\u2013C4H9,    \n\u2013CH 2\u2013CH(CH 3)\u2013C3H7, \u2013CH(CH 3)\u2013CH 2\u2013CH(CH 3)2, \u2013CH(CH 3)\u2013CH(CH 3)\u2013C2H5,    \n\u2013CH 2\u2013CH(CH 3)\u2013CH(CH 3)2,   \u2013CH 2\u2013C(CH 3)2\u2013C2H5,   \u2013C(CH 3)2\u2013C3H7,    \n\u2013C(CH 3)2\u2013CH(CH 3)2,   \u2013C 2H4\u2013C(CH 3)3,   \u2013CH(CH 3)\u2013C(CH 3)3,   \u2212CH=CH 2,    \n\u2212CH 2\u2212CH=CH 2,   \u2212C(CH 3)=CH 2,   \u2212CH=CH \u2212CH 3,   \u2013C 2H4\u2013CH=CH 2,    \n\u2013CH 2\u2013CH=CH\u2013CH 3,   \u2013CH=CH\u2013C 2H5,   \u2013CH 2\u2013C(CH 3)=CH 2,   \u2013CH(CH 3)\u2013CH=CH,    \n\u2013CH=C(CH 3)2,   \u2013C(CH 3)=CH\u2013CH 3,   \u2013CH=CH\u2013CH=CH 2,   \u2212C3H6\u2013CH=CH 2,    \n\u2013C2H4\u2013CH=CH\u2013CH 3,   \u2013CH 2\u2013CH=CH\u2013C 2H5,   \u2013CH=CH\u2013C 3H7,    \n\u2013CH 2\u2013CH=CH\u2013CH=CH 2,   \u2013CH=CH\u2013CH=CH\u2013CH 3,   \u2013CH=CH\u2013CH 2\u2013CH=CH 2,    \n\u2013C(CH 3)=CH\u2013CH=CH 2,  \u2013CH=C(CH 3)\u2013CH=CH 2,   \u2013CH=CH\u2013C(CH 3)=CH 2,    \n\u2013C2H4\u2013C(CH 3)=CH 2,  \u2013CH 2\u2013CH(CH 3)\u2013CH=CH 2,   \u2013CH(CH 3)\u2013CH 2\u2013CH=CH 2,    \n\u2013CH 2\u2013CH=C(CH 3)2,   \u2013CH 2\u2013C(CH 3)=CH\u2013CH 3,   \u2013CH(CH 3)\u2013CH=CH\u2013CH 3,    \n\u2013CH=CH\u2013CH(CH 3)2,   \u2013CH=C(CH 3)\u2013C2H5,   \u2013C(CH 3)=CH\u2013C 2H5,    \n\u2013C(CH 3)=C(CH 3)2,   \u2013C(CH 3)2\u2013CH=CH 2,   \u2013CH(CH 3)\u2013C(CH 3)=CH 2,    \n\u2013C(CH 3)=CH\u2013CH=CH 2,   \u2013CH=C(CH 3)\u2013CH=CH 2,   \u2013CH=CH\u2013C(CH 3)=CH 2,    \n\u2013C4H8\u2013CH=CH 2,   \u2013C 3H6\u2013CH=CH\u2013CH 3,   \u2013C 2H4\u2013CH=CH\u2013C 2H5,    \n\u2013CH 2\u2013CH=CH\u2013C 3H7,   \u2013CH=CH\u2013C 4H9,   \u2013C 3H6\u2013C(CH 3)=CH 2,    \n\u2013C2H4\u2013CH(CH 3)\u2013CH=CH 2,   \u2013CH 2\u2013CH(CH 3)\u2013CH 2\u2013CH=CH 2,    \n\u2013CH(CH 3)\u2013C2H4\u2013CH=CH 2,   \u2013C 2H4\u2013CH=C(CH 3)2,  \u2013C 2H4\u2013C(CH 3)=CH\u2013CH 3,   \n\u2013CH 2\u2013CH(CH 3)\u2013CH=CH\u2013CH 3,   \u2013CH(CH 3)\u2013CH 2\u2013CH=CH\u2013CH 3,    \n\u2013CH 2\u2013CH=CH\u2013CH(CH 3)2,   \u2013CH 2\u2013CH=C(CH 3)\u2013C2H5, \u2013CH 2\u2013C(CH 3)=CH\u2013C 2H5,  \n\u2013CH(CH 3)\u2013CH=CH\u2013C 2H5,   \u2013CH=CH\u2013CH 2\u2013CH(CH 3)2,   \u2013CH=CH\u2013CH(CH 3)\u2013C2H5,    \n\u2013CH=C(CH 3)\u2013C3H7,   \u2013C(CH 3)=CH\u2013C 3H7,   \u2013CH 2\u2013CH(CH 3)\u2013C(CH 3)=CH 2,    \n\u2013CH(CH 3)\u2013CH 2\u2013C(CH 3)=CH 2,   \u2013CH(CH 3)\u2013CH(CH 3)\u2013CH=CH 2,    \n\u2013CH 2\u2013C(CH 3)2\u2013CH=CH 2,   \u2013C(CH 3)2\u2013CH 2\u2013CH=CH 2,   \u2013CH 2\u2013C(CH 3)=C(CH 3)2,    \n\u2013CH(CH 3)\u2013CH=C(CH 3)2,   \u2013C(CH 3)2\u2013CH=CH\u2013CH 3,   \u2013CH(CH 3)\u2013C(CH 3)=CH\u2013CH 3,   \n\u2013CH=C(CH 3)\u2013CH(CH 3)2,  \u2013C(CH 3)=CH\u2013CH(CH 3)2,  \u2013C(CH 3)=C(CH 3)\u2013C2H5,    \n\u2013CH=CH\u2013C(CH 3)3,   \u2013C(CH 3)2\u2013C(CH 3)=CH 2,   \u2013CH(C 2H5)\u2013C(CH 3)=CH 2,    \n\u2013C(CH 3)(C 2H5)\u2013CH=CH 2,   \u2013CH(CH 3)\u2013C(C 2H5)=CH 2,   \u2013CH 2\u2013C(C 3H7)=CH 2,    \n\u2013CH 2\u2013C(C 2H5)=CH\u2013CH 3,   \u2013CH(C 2H5)\u2013CH=CH\u2013CH 3,    \n\u2013C(C 4H9)=CH 2, \u2013C(C 3H7)=CH\u2013CH 3, \u2013C(C 2H5)=CH\u2013C 2H5, \u2013C(C 2H5)=C(CH 3)2,    \n\u2013C[C(CH 3)3]=CH 2,   \u2013C[CH(CH 3)(C 2H5)]=CH 2,   \u2013C[CH 2\u2013CH(CH 3)2]=CH 2,    \n\u2013C2H4\u2013CH=CH\u2013CH=CH 2,   \u2013CH 2\u2013CH=CH\u2013CH 2\u2013CH=CH 2,    \n\u2013CH=CH\u2013C 2H4\u2013CH=CH 2,   \u2013CH 2\u2013CH=CH\u2013CH=CH\u2013CH 3,   \u2013CH=CH\u2013CH 2\u2013CH=CH\u2013CH 3,   \u2013 \nSeite 247 CH=CH\u2013CH=CH\u2013C 2H5,   \u2013CH 2\u2013CH=CH\u2013C(CH 3)=CH2,   \u2013CH 2\u2013CH=C(CH 3)\u2013CH=CH 2,   \u2013\nCH 2\u2013C(CH 3)=CH\u2013CH=CH 2,   \u2013CH(CH 3)\u2013CH=CH\u2013CH=CH 2,    \n\u2013CH=CH\u2013CH 2\u2013C(CH 3)=CH 2,   \u2013CH=CH\u2013CH(CH 3)\u2013CH=CH 2,   \u2013CH=C(CH 3)\u2013CH 2\u2013CH=CH 2,   \n\u2013C(CH 3)=CH\u2013CH 2\u2013CH=CH 2,   \u2013CH=CH\u2013CH=C(CH 3)2,    \n\u2013CH=CH\u2013C(CH 3)=CH\u2013CH 3,   \u2013CH=C(CH 3)\u2013CH=CH\u2013CH 3,   \u2013C(CH 3)=CH\u2013CH=CH\u2013CH 3,   \u2013\nCH=C(CH 3)\u2013C(CH 3)=CH 2,   \u2013C(CH 3)=CH\u2013C(CH 3)=CH 2,    \n\u2013C(CH 3)=C(CH 3)\u2013CH=CH 2,   \u2013CH=CH\u2013CH=CH\u2013CH=CH 2,   \u2212C\u2261CH,   \n\u2212C\u2261C\u2212CH 3,   \u2212CH 2-C\u2261CH,   \u2013C 2H4\u2013C\u2261CH,   \u2013CH 2\u2013C\u2261C\u2013CH 3,   \u2013C \u2261C\u2013C2H5,    \n\u2013C3H6\u2013C\u2261CH,   \u2013C 2H4\u2013C\u2261C\u2013CH 3,   \u2013CH 2\u2013C\u2261C\u2013C2H5,   \u2013C \u2261C\u2013C3H7,    \n\u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH 2\u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH(CH 3)\u2013CH 2\u2013C\u2261CH,    \n\u2013CH(CH 3)\u2013C\u2261C\u2013CH 3,   \u2013C 4H8\u2013C\u2261CH,   \u2013C 3H6\u2013C\u2261C\u2013CH 3,   \u2013C 2H4\u2013C\u2261C\u2013C2H5,   \n\u2013CH 2\u2013C\u2261C\u2013C3H7,   \u2013C\u2261C\u2013C4H9,   \u2013C2H4\u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH 2\u2013CH(CH 3)\u2013CH 2\u2013C\u2261CH,   \u2013\nCH(CH 3)\u2013C2H4\u2013C\u2261CH,   \u2013CH 2\u2013CH(CH 3)\u2013C\u2261C\u2013CH 3,  \n\u2013CH(CH 3)\u2013CH 2\u2013C\u2261C\u2013CH 3, \u2013CH(CH 3)\u2013C\u2261C\u2013C2H5, \u2013CH 2\u2013C\u2261C\u2013CH(CH 3)2,    \n\u2013C\u2261C\u2013CH(CH 3)\u2013C2H5,   \u2013C \u2261C\u2013CH 2\u2013CH(CH 3)2,   \u2013C \u2261C\u2013C(CH 3)3,    \n\u2013CH(C 2H5)\u2013C\u2261C\u2013CH 3,   \u2013C(CH 3)2\u2013C\u2261C\u2013CH 3,   \u2013CH(C 2H5)\u2013CH 2\u2013C\u2261CH,    \n\u2013CH 2\u2013CH(C 2H5)\u2013C\u2261CH,   \u2013C(CH 3)2\u2013CH 2\u2013C\u2261CH,   \u2013CH 2\u2013C(CH 3)2\u2013C\u2261CH,    \n\u2013CH(CH 3)\u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH(C 3H7)\u2013C\u2261CH,   \u2013C(CH 3)(C 2H5)\u2013C\u2261CH,    \n\u2013C\u2261C\u2013C\u2261CH,   \u2013CH 2\u2013C\u2261C\u2013C\u2261CH,   \u2013C \u2261C\u2013C\u2261C\u2013CH 3,   \u2013CH(C \u2261CH) 2,  \n\u2013C2H4\u2013C\u2261C\u2013C\u2261CH, \u2013CH 2\u2013C\u2261C\u2013CH 2\u2013C\u2261CH, \u2013C \u2261C\u2013C2H4\u2013C\u2261CH,    \n\u2013CH 2\u2013C\u2261C\u2013C\u2261C\u2013CH 3,   \u2013C \u2261C\u2013CH 2\u2013C\u2261C\u2013CH 3,   \u2013C \u2261C\u2013C\u2261C\u2013C2H5,    \n\u2013C\u2261C\u2013CH(CH 3)\u2013C\u2261CH,   \u2013CH(CH 3)\u2013C\u2261C\u2013C\u2261CH,   \u2013CH(C \u2261CH)\u2013CH 2\u2013C\u2261CH,   \n\u2013C(C \u2261CH) 2\u2013CH 3,  \u2013CH 2\u2013CH(C \u2261CH) 2,  \u2013CH(C \u2261CH)\u2013C\u2261C\u2013CH 3,   \u2013OH,   \u2013OCH 3,    \n\u2013OC2H5,   \u2013OC 3H7,   \u2013O\u2013cyclo-C 3H5,   \u2013OCH(CH 3)2,   \u2013OC(CH 3)3,   \u2013OC 4H9,    \n\u2212OPh,   \u2212OCH 2\u2212Ph,   \u2212OCPh 3,   \u2013SH,   \u2013NO 2,  \u2013SCH 3,  \u2013SC 2H5,  \u2013SC 3H7,    \n\u2013S\u2013cyclo-C 3H5,   \u2013SCH(CH 3)2,   \u2013SC(CH 3)3,   \u2013F,  \u2013Cl,  \u2013Br,  \u2013I,   \u2013P(O)(OH) 2,    \n\u2013P(O)(OCH 3)2,   \u2013P(O)(OC 2H5)2,   \u2013P(O)(OCH(CH 3)2)2,   \u2013C(OH)[P(O)(OH) 2]2,    \n\u2212Si(CH 3)2(C(CH 3)3),   \u2212Si(C 2H5)3,   \u2212Si(CH 3)3,  \u2013N 3,   \u2013CN,  \u2013OCN,  \u2013NCO,    \n\u2013SCN,   \u2013NCS,  \u2013CHO,  \u2013COCH 3,  \u2013COC 2H5,   \u2013COC 3H7,   \u2013CO\u2013cyclo-C 3H5,    \n\u2013COCH(CH 3)2,   \u2013COC(CH 3)3,  \u2013COOH,  \u2013COCN,  \u2013COOCH 3,  \u2013COOC 2H5,    \n\u2013COOC 3H7,   \u2013COO\u2013cyclo-C 3H5,   \u2013COOCH(CH 3)2,   \u2013COOC(CH 3)3,   \u2013OOC\u2013CH 3,    \n\u2013OOC\u2013C 2H5,   \u2013OOC\u2013C 3H7,   \u2013OOC\u2013cyclo-C 3H5,   \u2013OOC\u2013CH(CH 3)2,    \n\u2013OOC\u2013C(CH 3)3,   \u2013CONH 2,   \u2013CONHCH 3,   \u2013CONHC 2H5,   \u2013CONHC 3H7,    \n\u2013CONH\u2013cyclo-C 3H5,   \u2013CONH[CH(CH 3)2],   \u2013CONH[C(CH 3)3],   \u2013CON(CH 3)2,    \n\u2013CON(C 2H5)2,   \u2013CON(C 3H7)2,   \u2013CON(cyclo-C 3H5)2,   \u2013CON[CH(CH 3)2]2,    \n\u2013CON[C(CH 3)3]2,   \u2013NHCOCH 3,   \u2013NHCOC 2H5,   \u2013NHCOC 3H7,   \u2013NHCO\u2013cyclo-C 3H5,   \u2013\nNHCO\u2013CH(CH 3)2,   \u2013NHCO\u2013C(CH 3)3,   \u2013NHCO\u2013OCH 3,   \u2013NHCO\u2013OC 2H5,    \n\u2013NHCO\u2013OC 3H7,  \u2013NHCO\u2013O\u2013cyclo-C 3H5,  \u2013NHCO\u2013OCH(CH 3)2,  \u2013NHCO\u2013OC(CH 3)3,     \nSeite 248 \u2013NH 2,   \u2013NHCH 3,   \u2013NHC 2H5,   \u2013NHC 3H7,   \u2013NH\u2013cyclo-C 3H5,   \u2013NHCH(CH 3)2,    \n\u2013NHC(CH 3)3,   \u2013N(CH 3)2,   \u2013N(C 2H5)2,   \u2013N(C 3H7)2,   \u2013N(cyclo-C 3H5)2,   \u2013N[CH(CH 3)2]2,    \n\u2013N[C(CH 3)3]2,   \u2013SOCH 3,   \u2013SOC 2H5,   \u2013SOC 3H7,   \u2013SO\u2013cyclo-C 3H5,   \u2013SOCH(CH 3)2,   \n\u2013SOC(CH 3)3,   \u2013SO 2CH 3,   \u2013SO 2C2H5,   \u2013SO 2C3H7,   \u2013SO 2\u2013cyclo-C 3H5,    \n\u2013SO2CH(CH 3)2,   \u2013SO 2C(CH 3)3,   \u2013SO 3H,   \u2013SO 3CH 3,   \u2013SO 3C2H5,   \u2013SO 3C3H7,    \n\u2013SO3\u2013cyclo-C 3H5,   \u2013SO 3CH(CH 3)2,   \u2013SO 3C(CH 3)3,   \u2013O\u2013SO 2CH 3,   \u2013O\u2013SO 2C2H5,    \n\u2013O\u2013SO 2C3H7,   \u2013O\u2013SO 2\u2013cyclo-C 3H5,   \u2013O\u2013SO 2CH(CH 3)2,   \u2013O\u2013SO 2C(CH 3)3,    \n\u2013SO 2NH 2,   \u2013OCF 3,   \u2013OC 2F5,  \u2013O\u2013COOCH 3,   \n\u2013O\u2013COOC 2H5,  \u2013O\u2013COOC 3H7,  \u2013O\u2013COO\u2013cyclo-C 3H5,  \u2013O\u2013COOCH(CH 3)2,   \n\u2013O\u2013COOC(CH 3)3,  \u2013NH\u2013CO\u2013NH 2,   \u2013NH\u2013CO\u2013NHCH 3,   \u2013NH\u2013CO\u2013NHC 2H5,    \n\u2013NH\u2013CO\u2013NHC 3H7,   \u2013NH\u2013CO\u2013NH\u2013cyclo-C 3H5,   \u2013NH\u2013CO\u2013NH[CH(CH 3)2],    \n\u2013NH\u2013CO\u2013NH[C(CH 3)3],   \u2013NH\u2013CO\u2013N(CH 3)2,   \u2013NH\u2013CO\u2013N(C 2H5)2,    \n\u2013NH\u2013CO\u2013N(C 3H7)2,   \u2013NH\u2013CO\u2013N(cyclo-C 3H5)2,   \u2013NH\u2013CO\u2013N[CH(CH 3)2]2,    \n\u2013NH\u2013CO\u2013N[C(CH 3)3]2,  \u2013NH\u2013CS\u2013NH 2,   \u2013NH\u2013CS\u2013NHCH 3,   \u2013NH\u2013CS\u2013NHC 2H5,    \n\u2013NH\u2013CS\u2013NHC 3H7,   \u2013NH\u2013CS\u2013NH\u2013cyclo-C 3H5,   \u2013NH\u2013CS\u2013NH[CH(CH 3)2],    \n\u2013NH\u2013CS\u2013NH[C(CH 3)3],   \u2013NH\u2013CS\u2013N(CH 3)2,   \u2013NH\u2013CS\u2013N(C 2H5)2,    \n\u2013NH\u2013CS\u2013N(C 3H7)2,   \u2013NH\u2013CS\u2013N(cyclo-C 3H5)2,   \u2013NH\u2013CS\u2013N[CH(CH 3)2]2,    \n\u2013NH\u2013CS\u2013N[C(CH 3)3]2,  \u2013NH\u2013C(=NH)\u2013NH 2,   \u2013NH\u2013C(=NH)\u2013NHCH 3,    \n\u2013NH\u2013C(=NH)\u2013NHC 2H5,   \u2013NH\u2013C(=NH)\u2013NHC 3H7,   \u2013NH\u2013C(=NH)\u2013NH\u2013cyclo-C 3H5,    \n\u2013NH\u2013C(=NH)\u2013NH[CH(CH 3)2],   \u2013NH\u2013C(=NH)\u2013NH[C(CH 3)3],    \n\u2013NH\u2013C(=NH)\u2013N(CH 3)2,   \u2013NH\u2013C(=NH)\u2013N(C 2H5)2,   \u2013NH\u2013C(=NH)\u2013N(C 3H7)2,    \n\u2013NH\u2013C(=NH)\u2013N(cyclo-C 3H5)2,  \u2013O\u2013CO\u2013NH 2,   \u2013NH\u2013C(=NH)\u2013N[CH(CH 3)2]2,    \n\u2013NH\u2013C(=NH)\u2013N[C(CH 3)3]2,   \u2013O\u2013CO\u2013NHCH 3,   \u2013O\u2013CO\u2013NHC 2H5,    \n\u2013O\u2013CO\u2013NHC 3H7,   \u2013O\u2013CO\u2013NH\u2013cyclo-C 3H5,   \u2013O\u2013CO\u2013NH[CH(CH 3)2],    \n\u2013O\u2013CO\u2013NH[C(CH 3)3],   \u2013O\u2013CO\u2013N(CH 3)2,   \u2013O\u2013CO\u2013N(C 2H5)2,   \u2013O\u2013CO\u2013N(C 3H7)2,    \n\u2013O\u2013CO\u2013N(cyclo-C 3H5)2, \u2013O\u2013CO\u2013N[CH(CH 3)2]2, \u2013O\u2013CO\u2013N[C(CH 3)3]2, \u2013O\u2013CO\u2013OCH 3,   \n\u2013O\u2013CO\u2013OC 2H5,  \u2013O\u2013CO\u2013OC 3H7,  \u2013O\u2013CO\u2013O\u2013cyclo-C 3H5,  \u2013O\u2013CO\u2013OCH(CH 3)2,   \n\u2013O\u2013CO\u2013OC(CH 3)3,   \u2013O\u2013CH 2\u2013CH(OCH 3)2,   \u2013O\u2013CH 2\u2013CH(OC 2H5)2,    \n\u2013O\u2013C2H4\u2013CH(OCH 3)2,   \u2013O\u2013C 2H4\u2013CH(OC 2H5)2,   \u2013NH\u2013CH 2\u2013CH(OCH 3)2,    \n\u2013NH\u2013CH 2\u2013CH(OC 2H5)2,   \u2013NH\u2013C 2H4\u2013CH(OCH 3)2,   \u2013NH\u2013C 2H4\u2013CH(OC 2H5)2,    \n\u2013CH 2\u2013OPh,   \u2013CH 2\u2013O\u2013CH 2Ph,   \u2013NH\u2013CH 2\u2013OH,   \u2013NH\u2013C 2H4\u2013OH,   \u2013NH\u2013C 3H6\u2013OH,    \n\u2013NH\u2013C 4H8\u2013OH,   \u2013NH\u2013C 5H10 \u2013OH,   \u2013NH\u2013CH 2\u2013OCH 3,   \u2013NH\u2013C 2H4\u2013OCH 3,    \n\u2013NH\u2013C 3H6\u2013OCH 3,   \u2013NH\u2013C 4H8\u2013OCH 3,   \u2013NH\u2013C 5H10 \u2013OCH 3,   \u2013NH\u2013CH 2\u2013OC2H5,    \n\u2013NH\u2013C 2H4\u2013OC2H5,   \u2013NH\u2013C 3H6\u2013OC2H5,   \u2013NH\u2013C 4H8\u2013OC2H5,   \u2013NH\u2013C 5H10 \u2013OC2H5,    \n\u2013CH 2\u2013OH,   \u2013C 2H4\u2013OH,   \u2013C 3H6\u2013OH,   \u2013C 4H8\u2013OH,   \u2013C 5H10 \u2013OH,   \u2013CH 2\u2013CH(OCH 3)2    \noder    \u2013CH 2\u2013CH(OC 2H5)2; \n  \nSeite 249 X1, X 2, X 3, X 4, X 5, X 6, X 7, X 8, X 9, X 10 , X 11 , X 12 , X 13  und X 14  unabh\u00e4ngig voneinander \nfolgende Reste bedeuten: \n\u2013H,   \u2212CF 3,   \u2212CH 3,   \u2212C2H5,   \u2212C3H7,   \u2212CH(CH 3)2,   \u2013OH,   \u2013OCH 3,   \u2013OC 2H5,    \n\u2013OC3H7,   \u2212OPh,   \u2013NO 2,  \u2013F,  \u2013Cl,  \u2013Br,  \u2013I,   \u2013CN,  \u2013COCH 3,  \u2013COC 2H5,    \n\u2013COC3H7,   \u2013COOH,  \u2013COOCH 3,  \u2013COOC 2H5,   \u2013COOC 3H7,   \u2013OCF 3,   \u2212Ph,    \noder   \u2212CH 2\u2212Ph,   Tetrazol; \n \nX15   f\u00fcr einen der folgenden Reste steht: \n\u2013H,   \u2212CF 3,   \u2212CH 3,   \u2212C2H5,   \u2212C3H7,   \u2212CH(CH 3)2,   \u2013OH,   \u2013OCH 3,   \u2013OC 2H5,    \n\u2013OC3H7,   \u2212OPh,   \u2013NO 2,  \u2013F,  \u2013Cl,  \u2013Br,  \u2013I,   \u2013CN,  \u2013COCH 3,  \u2013COC 2H5,    \n\u2013COC3H7,   \u2013COOH,  \u2013COOCH 3,  \u2013COOC 2H5,   \u2013COOC 3H7,   \u2013OCF 3,    \n\u2013CO\u2013NH\u2013R21 ,   \u2212CH 3,   \u2212C2H5,   \u2212C3H7,   \u2212CH(CH 3)2,   \u2212C4H9,   \u2212CH 2\u2212CH(CH 3)2,    \n\u2212CH(CH 3)\u2212C2H5,    \u2212C(CH 3)3,   \u2212C5H11 ,   \u2212CH=CH 2,   \u2212CH 2\u2212CH=CH 2,   \u2212Ph,    \n\u2212CH 2\u2212Ph,   \u2212CH 2\u2212CH 2\u2212Ph,   \u2212CH 2\u2212CH 2\u2212CH 2\u2212Ph,   \u2212CH=CH \u2212Ph  oder  \u2013NH\u2013CO\u2013R21 ; \n \nn ist eine ganze Zahl ausgew\u00e4hlt aus 1, 2, 3, 4 ode r 5; \nsowie deren Metallkomplexe, Salze, Enantiomere, Ena ntiomerengemische, \nDiastereomere, Diastereomerengemische, Tautomere, H ydrate, Solvate, und \nRacemate der vorgenannten Verbindungen. \nDie vorliegende Erfindung betrifft ferner Verbindun gen gem\u00e4\u00df der allgemeinen \nFormel (I) zur Verwendung als Inhibitoren oder Anta gonisten, insbesondere \nbevorzugt als kompetitive Antagonisten oder inverse  Agonisten von GSK-3. \nAntagonisten sind hierbei Verbindungen, welche durc h vorrangige Interaktion mit der \nKinase deren Aktivierung durch einen Agonisten verh indern oder hemmen k\u00f6nnen.   \nEin kompetitiver Antagonist konkurriert mit einem A gonisten um die Bindung an die \nKinase und kann durch h\u00f6here Agonistenkonzentration en entsprechend dem \nMassenwirkungsgesetz wieder verdr\u00e4ngt werden. Es ko mmt durch einen \nkompetitiven Antagonisten zu einer Parallelverschie bung der Dosis-Wirkungskurve \neines Agonisten.    \nInverse Agonisten sind hierin Verbindungen, die an die Kinase mit konstitutiver \nAktivit\u00e4t binden und deren Aktivit\u00e4t herabsetzen. E in inverser Agonist f\u00fchrt im \nGegensatz zu einem vollen Agonisten somit zu einem negativen Effekt, bzw. einem  \nSeite 250 pharmakologischen Effekt, welcher dem des Agonisten  entgegengesetzt ist. Dies \nkann stattfinden, indem solche Verbindungen die Bin dung eines Korepressors \nbewirken bzw. f\u00f6rdern. Die Verbindungen gem\u00e4\u00df allge meiner Formel (I) werden \nhierin allgemein als Inhibitoren von GSK-3 bezeichn et. \nGSK-3 Inhibitoren sind f\u00fcr die Verwendung in der Me dizin relevant, da GSK-3 in den \nletzten Jahren zunehmend mit schwer wiegenden Erkra nkungen, wie Alzheimer-\nKrankheit und andere Tauopathien, Asthma, bipolare affektive St\u00f6rungen, \nDepression, Nervenzelltod und Schlaganfall, Parkins on, Huntington, \nSkelettmuskelatrophie, Kardioprotektion, Haarverlus t, verringerte Spermienmotilit\u00e4t, \nDiabetes und damit in Zusammenhang stehende Folgeer krankungen, wie Syndrom X \nund Adipositas, Erkrankungen, die durch einzellige Parasiten verursacht werden, \ntransmissible spongiforme Enzephalopathie, Schizoph renie, Krankheiten des \nzirkadianen Rhythmus und Krebs in Verbindung gebrac ht wurde. \n \nDes weiteren sind die folgenden subgenerischen Form eln der allgemeinen Formel (I) \nbevorzugt: \n \n \nFormel B \n \nFormel C  \nFormel A \n  \nFormel D N NOSR2\nN\nNR23\nH\nN NOS R1R3R4R5R6\nR7\nN NOSR2\nO\nOR10\nN NOSR2\nO\nO \nSeite 251  \nFormel E  \nFormel F \n \n \nFormel G  \nFormel H \n \n Formel J \n Formel K N NOSR2\nN\nSR23 N NOSR2\nR22R23\nR10\nR24\nR25\nN NOSR2\nN\nOR23\nN NOSR2\nNR23\nN NOSR3R4R5R6\nR7\nO\nOR10\nN NOSR3R4R5R6\nR7\nO\nO \nSeite 252  Formel L \n Formel M \n Formel N \n Formel O N NOSR3R4R5R6\nR7\nNR23\nN NOSR3R4R5R6\nR7\nR22R23\nR10\nR24\nR25\nN NOSR3R4R5R6\nR7\nN\nSR23\nN NOSR3R4R5R6\nR7\nN\nOR23 \nSeite 253  Formel P \n Formel Q \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n N NOSR3R4R5R6\nR7\nNNNR23\nN NOSR3R4R5R6\nR7\nO\nR22\nR23\nR24R25 \nSeite 254 4.2 Untersuchungen zu anderen Kinasen \n \n4.2.1 Die Parkinson-Krankheit und das Potential von  LRRK2 \n \nDer Inhalt dieses Kapitels wurde bereits ver\u00f6ffentl icht: \n \nThomas Kramer*, Fabio Lo Monte*, Stefan G\u00f6ring, Ghi slaine Marlyse Okala \nAmombo, Boris Schmidt \u2021  \nSmall molecule kinase inhibitors for LRRK2 and thei r application to  \nParkinson\u00b4s disease models, ACS Chemical Neuroscience 2012 , 3, 151-160.  \nDOI: 10.1021/cn200117j \nMit freundlicher Genehmigung von der American Chemi cal Society. \n \n \nDie Parkinson-Krankheit ist die zweith\u00e4ufigste neur odegenerative Erkrankung und \nzirka 4% der Menschen \u00fcber 80 Jahre sind davon betr offen. 129-130  Diese Krankheit ist \ndurch mehrere motorische und nicht-motorische Sympt ome charakterisiert.  \nVier dieser Symptome, Tremor, Rigor, Bradykinesie u nd posturale Instabilit\u00e4t werden \nals Kardinalsyndrome bezeichnet.131  Die typischen Kennzeichen dieser Erkrankung \nin post mortem  Gehirngewebe sind der Verlust der dopaminergen Neu ronen und der \nsubstantia nigra . Dar\u00fcber hinaus wurden verschiedene Proteinablager ungen wie  \n\u03b1-synuclein  mit dieser Krankheit assoziiert. 132-133  Gegenw\u00e4rtig gibt es keine Heilmittel \nf\u00fcr die Parkinson-Krankheit, sondern nur Therapiem\u00f6 glichkeiten zur Linderung der \nSymptome. 129,134   \nViele Mutationen wurden bereits mit der Parkinson-K rankheit in Verbindung \ngebracht, jedoch scheinen die Mutationen in dem f\u00fcr  das LRRK2-Protein ( leucine-\nrich repeat kinase 2 ) kodierenden Gen die aussichtsreichsten Kandidaten  f\u00fcr eine \nTarget -gerichtete Therapie zu sein. 135-137  LRRK2 ist ein gro\u00dfes und komplexes \nProtein, welches aus der ankyrin-like- Dom\u00e4ne (ANK), der leucin-rich repeat -Dom\u00e4ne \n(LRR), der Ras of complex -Dom\u00e4ne (Roc), der C-terminal of Roc -Dom\u00e4ne (COR), \nder Kinase-Dom\u00e4ne und der C-terminal WD40 -Dom\u00e4ne (WD40) besteht (Abb. 21). \nBisher wurden nur sehr wenige in vitro  und in vivo  Daten zu diesem Protein \nver\u00f6ffentlicht, da es erst seit einiger Zeit im Fok us der Parkinson-Forschung steht.  \nSeite 255       \nAbb. 21: Schematische Darstellung der LRRK2-Dom\u00e4nen. \n    \nDas Review befasst sich mit den bisher publizierten  Inhibitoren zu LRRK2 und den \nwichtigsten Mutationen dieser Kinase. Bestehende Ti ermodelle werden vorgestellt \nund das Potential dieser Kinase als Target f\u00fcr die Parkinson-Krankheit kritisch \ndiskutiert. Diese Themen wurden im Rahmen eines neu  gestarteten Projekts \nuntersucht und zusammengefasst, um eine Grundlage f \u00fcr die Synthese neuer \nLRRK2-Inhibitoren zu schaffen.   \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ANK  LRR   Roc  Kinase    WD40  COR   \nSeite 256  \n \n \n \n \nSeite 257  \n \n \n \n \nSeite 258  \n \n \n \n \nSeite 259  \n \n \n \n \nSeite 260  \n \n \n \n \nSeite 261  \n \n \n \n \nSeite 262  \n \n \n \n \nSeite 263  \n \n \n \n \nSeite 264  \n \n \n \n \nSeite 265  \n \n \n \n \nSeite 266 4.2.2 Die Behandlung der akuten myeloischen Leuk\u00e4mi e durch FLT-3 \n \nDer Inhalt dieses Kapitels wird voraussichtlich im Juli 2012 eingereicht und befindet \nsich derzeit in der Rohfassung: \n \nGhislaine Marlyse Okala Amombo*, Thomas Kramer*, Fa bio Lo Monte*, Stefan \nG\u00f6ring, Steven Smith, Stephanie Kolb, Robert Schube nel, Karlheinz Baumann, Boris \nSchmidt \u2021  \nInhibitor modification - An inhibition shift from \u03b3-secretase to FLT-3, Bioorganic & \nMedicinal Chemistry Letters , wird voraussichtlich im Juli eingereicht.  \n \n \nDie akute myeloische Leuk\u00e4mie (AML) ist eine aggres sive und b\u00f6sartige Erkrankung \ndes blutbildenden Systems mit einer Langzeit\u00fcberleb ensdauer von 25-70% bei \nPatienten unter 60 Jahren. 138-139  Aktivierende Mutationen von FLT-3 ( FMS-like \ntyrosine kinase-3 ) sind h\u00e4ufige molekulare Anomalien, die bei AML-Pa tienten \ngefunden werden k\u00f6nnen. 140  Infolgedessen stellt diese Kinase ein interessante s \nTarget zur Behandlung der AML dar. FLT-3-Inhibitoren aus v erschiedenen \nStrukturklassen erzielten bereits erste Erfolge in den pr\u00e4klinischen und klinischen \nStudien.141    \n \n \nAbb. 22: Strukturen durch die das FLT-3-Projekt initiiert wu rde.    \n \nDurch vorherige Untersuchungen des Indolinon-Grundg er\u00fcsts im Bereich der \nAlzheimer-Demenz wurde durch ein Kinase-Panel  festgestellt, dass Derivate dieser \nStrukturklasse das Potential f\u00fcr selektive FLT-3-In hibitoren besitzen (Abb. 22).  \n \nSeite 267 Mit Hilfe einer Struktur-Aktivit\u00e4ts-Beziehung konnt en durch dieses Grundger\u00fcst \nmehrere ATP-kompetitive FLT-3-Inhibitoren synthetis iert werden. Es wurden \nAktivit\u00e4ten im nanomolaren Bereich erhalten und die  in vivo  Evaluation einiger \nVerbindungen im Wildtyp-Zebrafisch-Embryo belegte, dass diese Inhibitoren im \ngetesteten Konzentrationsbereich keine Toxizit\u00e4t au fweisen.  \n \nDie im Rahmen dieser Arbeit von Fabio Lo Monte synt hetisierten Verbindungen: \n \nBSc4533 (16m), BSc4535 (16o), BSc4537 (16g), BSc453 9 (16h), BSc4541 (16b)  \nIn Klammern die Verbindungsnummer in der Publikatio n.  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 268 Inhibitor modification \u2013 An inhibition shift from \u03b3\u03b3 \u03b3\u03b3-secretase to FLT-3  \n \nGhislaine Marlyse Okala Amombo a, *, Thomas Kramer a, *, Fabio Lo Monte a, *, Stefan \nG\u00f6ring a, Steven Smith a, Stephanie Kolb a, Robert Schubenelb, Karlheinz Baumann b \nand Boris Schmidt a, \u2020  \n \na Clemens Sch\u00f6pf-Institute of Organic Chemistry and B iochemistry, Technische \nUniversit\u00e4t Darmstadt, Petersenstr. 22, D-64287 Dar mstadt, Germany \nb F. Hoffmann-La Roche Ltd., Pharmaceutical Division,  Preclinical Research CNS, \nBldg. 70/345, CH-4070 Basel, Switzerland \n \n* These authors contributed equally to this work. \n\u2020 Corresponding author. Tel.: +49 6151 163075; fax: + 49 6151 163278 \nE-mail address: Schmidt_boris@t-online.de (B. Schmi dt). \n+ Electronic supplementary information (ESI) availa ble: Experimental section and assay \nconditions. \n \nKeywords: Acute myeloid leukaemia, FLT-3, kinase inhibitor, \u03b3-secretase \n \n \nAbstract   \n \nFLT-3 is an interesting target for the treatment of  acute myeloid leukaemia (AML). Due to \nprevious findings concerning the \u03b3-secretase we use the indolinone scaffold as patter n to \nsynthesize several FLT-3 inhibitors. We analyzed th e SAR of these inhibitors and decreased \ntheir impact on \u03b3-secretase activity. Simultaneously, we increased t he inhibitory activity \nversus FLT-3.   \n \n   \nAcute myeloid leukaemia (AML) is an aggressive haem atological malignancy with long-term \nsurvival rates of 25%-70% in patients younger than 60 years and only 5%-15% in older \npatients. 1,2  Activating mutations of FLT-3 (FMS-like tyrosine k inase-3) are abundant \nmolecular abnormalities found in AML. 3 FLT-3 is essential for the normal function of stem  \ncells and the immune system and is primarily expres sed in immature hematopoietic cells.4 It \ncontains an extracellular ligand binding domain, a transmembrane domain, and,  \nSeite 269 intracellularly, a juxtamembrane domain followed by  the tyrosine kinase domain, which is \ninterrupted by a kinase insert region. 5,6  Internal-tandem duplications (ITDs) and tyrosine \nkinase domain (TKD) point mutations are the two maj or classes of activating FLT-3 \nmutations identified in AML patients. 7 FLT-3/ITD mutations can be estimated to occur in \n~23% of de novo  AML. 8 Several ATP-competitive FLT-3 inhibitors were deve loped from a \nnumber of research groups to afford a molecularly t argeted therapy for this disease.9 \nCompounds of several structural families are potent  inhibitors of the FLT-3 kinase and some \nof them have been promising in preclinical as well as clinical trials, Scheme 1. 5-10   \n \nScheme 1 : FLT-3 inhibitors evaluated in preclinical or clin ical trials. 5-7,9,10   \n \n \n \nSeite 270 Altogether the published data suggest that FLT-3 is  an attractive therapeutic target for the \ndevelopment of kinase inhibitors for AML and other associated diseases. 11   \n \nWorking on \u03b3-secretase inhibitors in the research field of Alzh eimer\u00b4s disease we synthesized \nseveral compounds based on an indolinone scaffold. During the evaluation of different \ninhibitors on a kinase panel two substances display ed significant inhibition (98% and 89% at \n10 \u00b5M) of the tyrosine kinase FLT-3, Scheme 2. 11   \n \nScheme 2 : Screening hits of potential FLT-3 inhibitors in a  kinase panel of 43 kinases. 11   \n \nRegarding this and the fact that FLT-3 is not known  to exert effects on the amyloid precursor \nprotein metabolism we exploit these structures to s ynthesize various FLT-3 inhibitors. One \nobjective of our research was to decrease the effec t on \u03b3-secretase and to improve \nmeanwhile the inhibitory activity against FLT-3. Th e inhibitor structure of 2 guided the \nvariation of the structure-activity relationship (S AR) study. \n \nSeveral synthesis conditions were utilized to gener ate various aldehydes as starting \nmaterials for the Knoevenagel condensation. Initial ly, alkyl or benzyl halides were coupled \nwith 4-hydroxybenzaldehydes ( 3) under basic conditions to obtain a series of elon gated \nbenzaldehydes ( 4a-l), Scheme 3. 11  The ether ( 6) was formed in a microwave reactor by \nsubstitution of an aromatic fluoride ( 5) with a 4-(4-methyl-1H-imidazol-1-yl)phenole.12  A \nfluoride benzaldehyde ( 7) was substituted to its corresponding sulfonyl ( 8) and imidazol \nbenzaldehyde ( 9), Scheme 3. A two step synthesis resulted in the a zobenzene derivative 11 . \nThe 4-aminobenzaldehyde 10  was converted to its diazonium derivative via diaz otation and \nthe final azobenzene ( 11 ) was formed by an azo coupling reaction. 13  Finally, 9-methyl-9H-\ncarbazole ( 12 ) was converted to the bulky aldehyde 13  in a two step procedure under \nVilsmeier-Haack conditions, Scheme 3. 14   \n \n \nSeite 271  \nScheme 3 : Aldehyde syntheses (R 1 = H, OMe; R 2 = H, OMe; R 3 = alkyl/benzyl moieties). 11-14   \n \n \n \nSeite 272 Commercially available and previously synthesized b enzaldehydes were coupled with the \nindolinones 15  under microwave supported Knoevenagel conditions, Scheme 4.11  \nAfterwards, the product 16f  was further derivatized and we obtained the tetraz ole 16v . The \nresulting products ( 16a-u) were obtained in yields up to 97%, Table 1. \n \n \nScheme 4 : Synthesis of indolinone derivatives under microwa ve conditions (R 1 = H, Cl; R 2 = Phenyl \nmoieties).11   \n \n \nScheme 5 : Tetrazole synthesis under microwave conditions. 15   \n \nHuman recombinant FLT-3 was used in the FLT-3 in vitro  kinase assay to ascertain the \ninhibitor activity. After 90 min incubation time at  room temperature the phosphorylated \nsubstrate peptides phospho-Ulight-CAGAGAIETDKEYYTVK D (Starting unphosphorylated \npeptide concentration: 100 nM) were determined with  the LANCE detection method.16  The \nresults are expressed as a percent of control (Stau rosporine) specific activity ((measured \nspecific activity/control specific activity) x 100)  obtained in the presence of the test \ncompounds (10 \u00b5M), Table 1. \n \n \n \n \n \nSeite 273 Table 1:  Synthesized indolinones, their chemical properties  and in vitro assay results .11,16   \n \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \na Percent of control (Stauroporine) specific activit y ((measured specific activity/control specific act ivity) x 100); activity at a \nconcentration of 10 \u00b5M; b A\u03b2 liquid phase electrochemiluminescence (LPECL) assa y, H4 APP#9 cells; c Determined in H4-cells, \nY = Yes, N = No; d Calculated by ChemDraw Ultra (9.0.1); e Control; f n.t. = not tested. \n \nSeite 274 Table 1:  continued .11,16   \n \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \na Percent of control (Stauroporine) specific activit y ((measured specific activity/control specific act ivity) x 100); activity at a \nconcentration of 10 \u00b5M; b A\u03b2 liquid phase electrochemiluminescence (LPECL) assa y, H4 APP#9 cells; c Determined in H4-cells, \nY = Yes, N = No; d Calculated by ChemDraw Ultra (9.0.1); e Control; f n.t. = not tested. \n \n \nSeite 275 To approve the observed FLT-3 inhibition-ratio we d etermined the IC 50  values of compounds \n16e  and 16k . Both compounds showed good IC 50  values, 4.1 nM for 16e  and  \n17.0 nM for 16k . These activities indicated that we have synthesiz ed a series of potent FLT-3 \ninhibitors. Indolinones are well known kinase inhib itors with diverse application.17  To \ndetermine the broader selectivity of our most activ e FLT-3 inhibitor 16e  we screened at a \nconcentration of 1 \u00b5M against 50 human protein kinases, Figure 1. Most of the 50 kinases in \nthis panel showed an activity higher than 80%, wher eas FLT-3 displayed a residual activity of \nonly 14.7%. The only kinases, which were also signi ficantly inhibited by this compound, were \nthe Ser/Thr kinase HGK (MAP4K4) and the Tyr kinase JAK3. \n \nFigure 1:  Screening of compound 16e  against a panel of human protein kinases. Each bar  represents \nthe activity of one individual protein kinase (Dete rmination method: Percent of control (Staurosporine ) \nspecific activity [(measured specific activity/cont rol specific activity) x 100]). Compound 16e  was tested \nagainst 50 protein kinases at a concentration of 1 \u00b5M. See the Supporting Information for more \ndetails. 16  \n \nIn addition to the H4 APP#9 cell-based toxicity ass ay, we established a zebrafish embryo \nphenotype assay, which enabled the toxicity determi nation in whole organisms.11  The \nembryos were collected and maintained in E2 medium at 28\u00b0C. Compound 16e  was added \n4-5 hpf (hours post fertilization) and the phenotyp es were compared after 48 hpf. Compound \n16e  causes a development delay at 20 \u00b5M, Figure 2. Compared to the control, zebrafish \nembryos treated with 16e  were still covered by the chorion. Nevertheless, t hey did not reveal \nother abnormalities. The zebrafish embryos exhibit no lethality and peculiarities at a \nconcentration below 20 \u00b5M of 16e . \n \nFigure 2:  Exposure of zebrafish embryos to A) 20 \u00b5M of \nwere collected and maintained in E2 medium at 28\u00b0C.  Compound \nfertilization) and the phenotypes were compared a \n \nThe docking studies of the FLT \nrevealed the possibility to determine potential inh ibitor \n \nFigure 3:  Docking of compound \n3; important interactions are highlighted; Software : Molegro Virtual Docker 5. \n \nIn both cases the docking result offers four possib le interactions. The indolinone motif \ninteracts edge-to- face with the Phe830 of the DFG motif. In addition,  the indolinone fits to the \nFLT-3 hinge region by face \nLys644. 8 The phenyl group of the inhi\nresults revealed that an electron donor motif is ne eded at the end \n16c , which lacks this motif, showed a decrease inhibit ion activity compared to \ncould be explained by a polar area formed by Glu573  and Gln577, which is in close vicinity. \nSeite 276 Exposure of zebrafish embryos to A) 20 \u00b5M of 16e , B) 5 \u00b5M of 16e , C) control. \nwere collected and maintained in E2 medium at 28\u00b0C.  Compound 16e was added 4 \nfertilization) and the phenotypes were compared a fter 48 hpf.  \nThe docking studies of the FLT -3 crystal structure (PDB: 1RJB) and compounds \nrevealed the possibility to determine potential inh ibitor -enzyme interactions, Figure 3.\nof compound 16e  (left) and 16k  (right) into the PDB crystal structure 1RJB of FLT \n3; important interactions are highlighted; Software : Molegro Virtual Docker 5.  \n \nIn both cases the docking result offers four possib le interactions. The indolinone motif \nface with the Phe830 of the DFG motif. In addition,  the indolinone fits to the \n3 hinge region by face -to-face interplay with Phe691 and hydrogen bonding wit h \nThe phenyl group of the inhi bitors interacts with Met665. 18  The FLT \nresults revealed that an electron donor motif is ne eded at the end . For example compound \n, which lacks this motif, showed a decrease inhibit ion activity compared to \ncould be explained by a polar area formed by Glu573  and Gln577, which is in close vicinity. \n \n, C) control. The embryos \nwas added 4 -5 hpf (hours post \n3 crystal structure (PDB: 1RJB) and compounds 16e  and 16k  \nenzyme interactions, Figure 3.8  \n \n(right) into the PDB crystal structure 1RJB of FLT -\nIn both cases the docking result offers four possib le interactions. The indolinone motif \nface with the Phe830 of the DFG motif. In addition,  the indolinone fits to the \nface interplay with Phe691 and hydrogen bonding wit h \nThe FLT -3 in vitro  assay \n. For example compound \n, which lacks this motif, showed a decrease inhibit ion activity compared to 16d,f . This \ncould be explained by a polar area formed by Glu573  and Gln577, which is in close vicinity. \n \nSeite 277 A comparison of the FLT-3 inhibition results and th e docking studies offers the possible \nsuggestion that the benzylidene indolinone moiety c ould cover the entrance of the ATP-\nbinding site (compound 16a,b,h ) and the elongated alkyl chain could act as an \u201can chor\u201d in \nthe inner side of the ATP-binding pocket, e.g. 16d-g. Furthermore, a comparison of the  \nFLT-3 inhibition results of Table 1 revealed that b ulky residues at the phenyl moiety lead to a \ndecreased inhibition activity. \n \nFigure 4:  Correlation plot of FLT-3 activity inhibition and A \u03b242  inhibition (IC 50 ); a Values at 40 are >40, \nsee Table 1; b Determination method: Percent of control (Staurosp orine) specific activity \n[(measuredspecific activity/control specific activi ty) x 100]).  \n \nThe inhibitory activity of the synthesized compound s in the secretase assay cannot be \ncorrelated to the FLT-3 inhibition-ratio, Figure 4.  In the case of compounds 16f  and 16k  we \nexpected the same result, but surprisingly, they we re not active against the \u03b3-secretase, \nTable 1 and Figure 4. In comparison with other comp ounds, e.g. 16d,i  and 16m,o , the nitrile \nand alkyl chain combination is important for this s electivity and good FLT-3 inhibition activity. \n \nIn conclusion, starting from the screening hit 2 we have synthesized in a short time manner \nseveral potent FLT-3 inhibitors. We could limit the  toxicity level of 16e  using a H4 APP#9 \ncell-based and a zebrafish embryo phenotype assay. The combination of FLT-3 in vitro  \nresults and docking studies revealed some possible enzyme-inhibitor interactions with the \namino acids Lys644, Met665, Phe691 and Phe830. Furt hermore, we could realize our aim to \nbe selective towards the \u03b3-secretase. Future work could be the further \nderivatisation/substitution of the chloride at the indolinone motif. \n \nSeite 278 References and notes \n \n1. Kindler, T.; Lipka, D. B.; Fischer, T. Blood  2010 , 116 , 5089. \n2. Levis, M.; Small, D. Expert Opin Investig Drugs  2003 , 12 , 1951. \n3. Pratz, K. W.; Levis, M. J. Curr. Drug Targets  2010 , 11 , 781. \n4. Griffith, J.; Black, J.; Faerman, C.; Swenson, L .; Wynn, M.; Lu, F.; Lippke, J.; Saxena, \nK. Mol. Cell 2004 , 13 , 169. \n5. Advani, A. S. Curr. Pharm. Des.  2005 , 11 , 3449. \n6. Paz, K.; Zhu, Z. Expert Opin. Ther. Targets  2005 , 9, 1147. \n7. Zarrinkar, P. P.; Gunawardane, R. N.; Cramer, M.  D.; Gardner, M. F.; Brigham, D.; \nBelli, B.; Karaman, M. W.; Pratz, K. W.; Pallares, G.; Chao, Q.; Sprankle, K. G.; Patel, \nH. K.; Levis, M.; Armstrong, R. C.; James, J.; Bhag wat, S. S. Blood  2009 , 114 , 2984. \n8. Mahboobi, S.; Uecker, A.; Sellmer, A.; Cenac, C. ; Hocher, H.; Pongratz, H.; Eichhorn, \nE.; Hufsky, H.; Trumpler, A.; Sicker, M.; Heidel, F .; Fischer, T.; Stocking, C.; Elz, S.; \nBohmer, F. D.; Dove, S. J Med Chem  2006 , 49 , 3101. \n9. Zhang, W.; Konopleva, M.; Shi, Y. X.; McQueen, T .; Harris, D.; Ling, X.; Estrov, Z.; \nQuintas-Cardama, A.; Small, D.; Cortes, J.; Andreef f, M. J Natl Cancer Inst  2008 , \n100 , 184. \n10. www.clinicaltrail.gov Nov. 2011 . \n11. Hottecke, N.; Liebeck, M.; Baumann, K.; Schuben el, R.; Winkler, E.; Steiner, H.; \nSchmidt, B. Bioorg Med Chem Lett  2010 , 20 , 2958. \n12. Fischer, C.; Munoz, B.; Zultansky, S.; Methot, J.; Zhou, H.; Brown, W. C. WO \n2008/156580 A1  2008 . \n13. Perez-Moreno, J.; Zhao, Y.; Clays, K.; Kuzyk, M . G.; Shen, Y.; Qiu, L.; Hao, J.; Guo, \nK. J Am Chem Soc  2009 , 131 , 5084. \n14. Langendoen, A.; Plug, J. P. M.; Koomen, G.-J.; Pandit, U. K. Tetra  1989 , 45 , 1759. \n15. Monte, F. L.; Kramer, T.; Bolander, A.; Plotkin , B.; Eldar-Finkelman, H.; Fuertes, A.; \nDominguez, J.; Schmidt, B. Bioorg Med Chem Lett  2011 , 21 , 5610. \n16. www.cerep.fr. \n17. Prakash, C. R.; Raja, S. Mini Rev Med Chem  2012 , 12 , 98. \n18. Salonen, L. M.; Ellermann, M.; Diederich, F. Angew. Chem.  2011 , 123 , 4908. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 279 Supporting Information \n \nInhibitor modification \u2013 An inhibition shift from \u03b3\u03b3 \u03b3\u03b3-secretase to FLT-3 \nGhislaine Marlyse Okala Amombo*a, Thomas Kramer* a, Fabio Lo Monte* a, Stefan G\u00f6ring a, \nSteven Smith a, Stephanie Kolb a, Robert Schubenelb, Karlheinz Baumann b and Boris \nSchmidt \u2020a  \na Clemens Sch\u00f6pf - Institute of Organic Chemistry and  Biochemistry, Technische Universit\u00e4t \nDarmstadt, 64287 Darmstadt, Hessen, Germany, Fax: + 496151-163278; Tel: +496151 \n164531 \nb F. Hoffmann-La Roche Ltd, Pharmaceutical Division, Preclinical Research CNS,  \nBldg. 70/345, CH- 4070 Basel, Switzerland, \n\u2020 E-mail: schmidt_boris@t-online.de \n*These authors contributed equally to this work. \n \n \n \nTable of Content: \nI. General comments \nII. Experimental methods and chemical data  \nIII. FTL-3 in vitro  assay conducted by Cerep \nIV. Selectivity screening of compound 16e  conducted by Cerep \nV. \u03b3-Secretase assay and cell-based toxicity assay cond ucted by Roche \nVI. Toxicity assay: Determination of the in vivo  activity on wt zebrafish embryos \n \n \n \n \n \n \n  \nSeite 280 I. General comments \n \nThe 1H-NMR spectra were recorded on a Bruker AC 300 spec trometer at 300 MHz and \nBruker AC 500 spectrometer at 500 MHz. The 13 C-NMR spectra were recorded on a Bruker \nAC 300 spectrometer at 75 MHz and Bruker AC 500 spe ctrometer at 125 MHz. Chemical \nshifts are reported as ppm downfield from Me 4Si. Mass spectrometry was performed on a \nBruker-Franzen Esquire LC mass spectrometer and a M AT 95 double focussing sector field \nMS. Microwave experiments were carried out using a Biotage \u00ae Initiator \u2122 microwave \napparatus. All microwave experiments were carried o ut in sealed microwave process vials \nutilizing the standard absorbance level (300 W maxi mum power). High performance liquid \nchromatographies were carried out in an Agilent 110 0 (column: reversed phase, Zorbax \nEclipse XDB-C8, 4.6 x 150 mm; 254 nm).  The eluent is composed of: a) H 2O (1% TFA) (A) \nand acetonitrile (B) with a gradient: 30 to 90% B w ithin 12 min. All reagents and solvents \nwere purchased at ABCR, Acros, Sigma Aldrich and VW R. \n \n \nII. Experimental methods and chemical data \n \n1. General Procedure for synthesis of benzaldehyds 4a-l \nK2CO 3 (2.40 eq.) and the aldehyde 3 (1.00 eq.) were suspended in acetone or \ndimethylformamide. Then an alkyl/benzyl bromide/chl oride (1.00 eq.) was added. This \nreaction suspension was stirred at 70\u00b0C over night.  After complete turnover water was added \nand the aqueous solution was extracted with chlorof orm. The combined organic layers were \ndried with MgSO 4 and the solvent was removed in vacuo. The resultin g residue was purified \nby column chromatography on silica gel or recrystal lized in an appropriate solvent to provide \nthe desired product. \n4-butoxybenzaldehyde  4a \nThe resulting product is a bright yellow oil (51%).  HPLC : R t = 6.85 min. 1H-NMR (CDCl 3, \n300 MHz): \u03b4 [ppm] = 9.88 (s, 1H), 7.82 (d, 2H,  J = 8.8 Hz), 6.98 (d, 2H, J = 8.8 Hz), 4.05 (t, \n2H, J = 6.4 Hz), 1.85-1.75 (m, 2H), 1.57-1.44 (m, 2H), 0 .99 (t, 3H). 13 C-NMR (CDCl 3, \n75 MHz): \u03b4 [ppm] = 191.0, 164.4, 132.1, 129.9, 114.9, 68.3, 3 1.2, 19.3, 13.9. MS (EI, 70 eV): \nm/z = 178 [M +]. \n \n 4-(2-(diethylamino)ethoxy)benzaldehyde 4b  \nThe resulting brown oil (78%) was used in the next step without further analysis. \n  \nSeite 281 4-(3-chloropropoxy)benzaldehyde 4c  \nThe resulting bright yellow oil (57%) was used in t he next step without further analysis. \n \n4-(4-formylphenoxy)butannitrile 4d \nThe resulting product is a bright yellow oil (65%).  HPLC : R t = 4.71 min. 1H-NMR (CDCl 3, \n300 MHz): \u03b4 [ppm] = 9.89 (s, 1H), 7.84 (d, 2H,  J = 8.8 Hz), 7.01 (d, 2H, J = 8.8 Hz), 4.17 (t, \n2H, J = 5.7 Hz), 2.61 (t, 2H,  J = 7.1 Hz), 2.23-2.14 (m, 2H). 13 C-NMR (CDCl 3, 75 MHz): \n\u03b4 [ppm] = 190.8, 163.4, 132.2, 130.5, 119.0, 114.9, 65.7, 25.4, 14.3. MS (EI, 70 eV):  \nm/z = 189 [M +]. \n \n 4-(2-morpholinoethoxy)benzaldehyde 4f  \nThe resulting bright yellow oil (52%) was used in t he next step without further analysis. \n \n 4-((4-formylphenoxy)methyl)benzonitrile 4g \nThe resulting product is a colorless solid (51%). HPLC : R t = 6.76 min. 1H-NMR (CDCl 3, \n500 MHz): \u03b4 [ppm] = 9.90 (s, 1H), 7.86 (d, 2H,  J = 8.8 Hz), 7.70 (d, 2H, J = 8.4 Hz), 7.55 (d, \n2H, J = 8.4 Hz), 7.07 (d, 2H, J = 8.8 Hz), 5.21 (s, 2H). 13 C-NMR (CDCl 3, 125 MHz): \n\u03b4 [ppm] = 190.8, 163.2, 141.5, 132.7, 132.2, 130.8, 127.7, 118.6, 115.2, 112.3, 69.2, 52.3. \nMS (EI, 70 eV): m/z = 237 [M +]. \n \n Methyl 4-((4-formylphenoxy)methyl)benzoate 4h \nThe resulting product is a colorless solid (43%). HPLC : R t = 6.90 min.  1H-NMR (CDCl 3, \n500 MHz): \u03b4 [ppm] = 9.89 (s, 1H), 8.07 (d, 2H, J = 8.4 Hz), 7.84 (d, 2H,  J = 8.8 Hz), 7.50 (d, \n2H, J = 8.4 Hz), 7.07 (d, 2H, J = 8.8 Hz), 5.21 (s, 2H), 3.93 (s, 3H). 13 C-NMR (CDCl 3, \n125 MHz): \u03b4 [ppm] = 190.8, 166.8, 163.4, 141.2, 132.2, 130.5, 130.2, 130.2, 127.1, 115.3, \n69.7, 52.3. MS (EI, 70 eV): m/z = 270 [M +]. \n \n 3-((4-formylphenoxy)methyl)benzonitrile 4i  \nThe resulting product is a colorless solid (30%). HPLC : Rt = 6.76 min. 1H-NMR (CDCl 3, \n500 MHz): \u03b4 [ppm] = 9.91 (s, 1H), 7.86 (d, 2H,  J = 8.8 Hz), 7.75 (s, 1H), 7.69-7.64 (m, 2H), \n7.54-7.51 (m, 1H), 7.50 (d, 2H, J = 8.4 Hz), 7.08 (d, 2H, J = 8.8 Hz), 5.18 (s, 2H). 13 C-NMR \n(CDCl 3, 125 MHz): \u03b4 [ppm] = 190.8, 163.1, 137.8, 132.2, 132.0, 131.6, 130.9, 130.7, 129.7, \n118.6, 115.2, 113.1, 69.0.  MS (EI, 70 eV): m/z = 237 [M +]. \n \n 4-(2-(dimethylamino)ethoxy)-3-methoxybenzaldehyde 4 j  \nThe resulting bright brown oil (47%) was used in th e next step without further analysis.  \nSeite 282  4-(2-(diethylamino)ethoxy)-3-methoxybenzaldehyde 4k  \nThe resulting bright brown oil (45%) was used in th e next step without further analysis. \n \n 4-(4-formyl-2-methoxyphenoxy)butannitrile 4l  \nThe resulting product is a bright yellow oil (69%).  HPLC : R t = 4.34 min. 1H-NMR (CDCl 3, \n500 MHz): \u03b4 [ppm] = 9.86 (s, 1H), 7.44 (dd, 1H, J = 1.8 Hz, J = 8.1 Hz), 7.42 (d, 1H, \nJ = 1.8 Hz), 6.98 (d, 1H, J = 8.1 Hz), 4.21 (t, 2H, J = 5.8 Hz), 3.92 (s, 3H), 2.65 (t, 2H, \nJ = 7.1 Hz), 2.25-2.20 (m, 2H). 13 C-NMR (CDCl 3, 125 MHz): \u03b4 [ppm] = 191.0, 153.4, 150.2, \n130.8, 126.7, 119.1, 112.2, 109.6, 66.6, 56.1, 25.5 , 14.3. \n \n2. Synthesis of 4-(2-(dimethylamino)ethoxy)benzalde hyde 4m and 4-(2-(dimethyl  \namino)- ethoxy)-2-methoxybenzaldehyde 4n  \nFor the synthesis of 4-(2-(dimethylamino)ethoxy)ben zaldehyde 4m  see the mentioned \nreference. The resulting brown oil (63%) was used i n the next step without further analysis. \nFor the synthesis of 4-(2-(dimethylamino)ethoxy)-2- methoxybenzaldehyde 4n  see the \nmentioned reference. The resulting product is a bri ght brown oil (66%).  HPLC : R t =  0.75 min, \n1.11 min. 1H-NMR (CDCl 3, 300 MHz): \u03b4 [ppm] = 10.28 (s, 1H), 7.79 (d, 1H, J = 8.7 Hz), 6.54 \n(dd, 1H, J = 2.2 Hz, J = 8.7 Hz), 6.49 (d, 1H, J = 2.2 Hz), 4.13 (t, 2H, J = 5.7 Hz), 3.88 (s, \n3H), 2.75 (t, 2H, J = 5.7 Hz), 2.35 (s, 6H). 13 C-NMR (CDCl 3, 75 MHz): \u03b4 [ppm] = 188.4, 165.5, \n163.7, 130.9, 119.3, 106.2, 98.9, 66.4, 58.2, 55.8,  46.0. \n \n3. Synthesis of 4-(4-(4-methyl-1 H-imidazol-1-yl)phenoxy)benzaldehyde 6  \nA mixture of 4-(4-methyl-1H-imidazol-1-yl)phenole ( 1.74 g, 10 mmol), 4-fluorobenzaldehyde \n(1.24 g, 10 mmol) and anhydrous K 2CO 3 (1.38 g, 10 mmol) in abs. dimethylformamide  \n(5 mL) was heated at 140\u00b0C under microwave irradiat ion for 2 h. The cooled reaction mixture \nwas diluted with ethyl acetate (5 mL), filtered thr ough a plug of silica gel, and washed with \nethyl acetate (10-20 mL). The combined organic extr acts were concentrated, and the \nresulting residue was purified by column chromatogr aphy on silica gel to provide the desired \nproduct in 80% as a brown oil. HPLC : R t = 2.64 min. 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] \n= 9.94 (s, 1H), 8.26 (m, 1H), 7.95 (m, 2H), 7.75 (m , 3H), 7.31 (m, 2H), 7.18 (m, 2H), 2.14 (s, \n3H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 191.5, 162.1, 153.2, 135.6, 133.8, 132.0, \n131.4, 129.9, 129.3, 122.4, 122.2, 121.5, 118.1, 11 7.6, 116.0, 13.6.  MS (EI, 70 eV):  \nm/z = 278 [M +]. \n \n \n  \nSeite 283 4. Synthesis of 3-methoxy-4-(methylsulfonyl)benzald ehyde 8  \nMethanesulfinic acid sodium salt (125 mg, 0.81 mmol ) and 4-fluoro-3-methoxybenzaldehyde \n7 (91.06 mg, 0.89 mmol) were dissolved in dry DMSO ( 3 mL), under nitrogen. The mixture \nwas stirred at 100\u00b0C for 16h and then poured into i ce. The formed precipitate was collected \nby filtration, washed with water and dried to affor d 258 mg (98%) of white solid. The crude \nsolid was used in next step without any further pur ification. HPLC : R t = 2.66 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.00 (s, 1H), 8.11 (d, 1H, J = 7.9 Hz), 7.53 (dd, 1H,  \nJ = 1.3 Hz, J = 7.9 Hz), 7.49 (d, 1H, J = 1.2 Hz), 4.02 (s, 3H), 3.18 (s, 3H). 13 C-NMR (DMSO-\nd6, 125 MHz): \u03b4 [ppm] = 190.8, 184.4, 157.7, 141.5, 133.5, 130.7, 123.3, 110.9, 56.7, 42.9. \n \n5. Synthesis of 2-methoxy-4-(4-methyl-1H-imidazol-1 -yl)benzaldehyde 9  \nA mixture of 4-fluoro-3-methoxybenzaldehyde 7 (1.22 g, 7.92 mmol) and 4-methylimidazole \n(1.24 g, 15.07 mmol) in dry dimethylformamide was d egassed and flushed with argon for  \n20 min. Afterwards K 2CO 3 (1.66 g, 11.98 mmol) was added and the reaction su spension was \nheated at 140\u00b0C under microwave irradiation for 10 h. Then water was added and the \naqueous solution was extracted with ethyl acetate. The combined organic layers were \nwashed with brine, dried with Na 2SO 4 and the solvent was removed in vacuo. The resultin g \nresidue was purified by column chromatography on si lica gel (solvent: ethyl acetate) and \nprovide 411 mg (24%) of the orange product. The pro duct was used in the next step without \ndetailed analysis. HPLC : Rt = 1.37 min. MS (EI, 70 eV): m/z = 216 [M +]. \n \n6. Synthesis of (E)-4-((4-(dimethylamino)phenyl)dia zenyl)benzaldehyde 11  \nFor the synthesis of compound 11  see the mentioned reference in the publication. Us ed in \nthe next step without further analysis. \n \n7. Synthesis of 9-methyl-9H-carbazole-3-carbaldehyd e 13  \nFor the synthesis of compound 13  see the mentioned reference in the publication. Us ed in \nthe next step without further analysis. \n \n8. General Procedure for synthesis of 3-substituted  indol-2-ones  \nEquimolar amounts (0.3 mmol) of 5-chlorooxindole/ox indole and aldehyde were dissolved in \nmethanol (1 ml), a drop of piperidine (30 \u00b5l) was added and the mixture heated at 100\u00b0C \nunder microwave irradiation for 30 min. The reactio n mixture was cooled to room \ntemperature and the resulting precipitate was remov ed by filtration, carefully washed with \nmethanol and recrystallized at least once from meth anol to give the desired product in good \nyield. \n  \nSeite 284 5-chloro-3-(4-(3-chloropropoxy)benzyliden)indolin-2 -one 2 \nThe resulting product is a yellow solid (30%). HPLC : R t = 8.06 min, 8.44 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.69 (s, 2H), 8.49 (d, 2H,  J = 8.9 Hz), 7.89 (s, 1H), 7.80 (d, \n1H, J = 2.0 Hz), 7.70 (d, 2H,  J = 8.9 Hz), 7.66 (s, 1H), 7.56 (d, 1H, J = 2.0 Hz), 7.27 (dd, 1H, \nJ = 2.0 Hz, J = 8.3 Hz), 7.20 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.13 (d, 2H, J = 8.9 Hz), 7.07 \n(d, 2H, J = 8.9 Hz),  6.89 (d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 4.20 (t, 4H, J = 5.9 Hz), \n3.81 (m, 4H), 2.20 (m, 4H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.5, 167.1, 160.6, \n160.0, 141.4, 138.8, 138.7, 137.9, 134.8, 131.6, 12 9.2, 127.5, 127.3, 127.0, 126.3, 125.3, \n124.9, 124.8, 123.0, 122.8, 121.4, 119.3, 114.8, 11 4.3, 111.4, 110.5, 64.6, 64.5, 41.9, 31.6.  \nMS (EI, 70 eV): m/z = 347 [M +]. \n \n5-chloro-3-(4-hydroxybenzylidene)indolin-2-one 16a \nThe resulting product is an orange solid (28%). HPLC : R t = 5.39 min, 6.15 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.69 (s, 2H), 8.41 (d, 2H,  J = 8.9 Hz),  7.80 (s, 1H), 7.76 (d, \n1H, J = 2.0 Hz), 7.60 (m, 4H), 7.25 (dd, 1H, J = 2.0 Hz, J = 8.3 Hz), 7.15 (dd, 1H,  J = 2.0 Hz, \nJ = 8.3 Hz), 6.88 (m, 3H), 6.80 (m, 3H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.8, \n167.3, 162.1, 160.7, 141.1, 139.6, 138.7, 138.4, 13 5.4, 132.1, 128.7, 127.8, 126.9, 125.1, \n124.8, 124.8, 124.1, 123.3, 123.1, 121.3, 120.9, 11 8.8, 116.0, 115.7, 111.2, 110.3. MS  \n(EI, 70 eV): m/z = 271 [M +]. \n \n5-chloro-3-(4-methoxybenzyliden)indolin-2-one 16b \nThe resulting product is a yellow solid (88%). HPLC : R t = 7.06 min, 7.50 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.69 (s, 2H, NH E/Z ), 8.49 (d, 2H,  J = 8.9 Hz),  7.88 (s, 1H), \n7.80 (d, 1H, J = 2.0 Hz), 7.70 (d, 2H,  J = 8.9 Hz), 7.66 (s, 1H), 7.56 (d, 1H, J = 2.0 Hz), 7.27 \n(dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.19 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.12 (d, 2H, \nJ = 8.9 Hz), 7.05 (d, 2H, J = 8.9 Hz),  6.89 (d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 3.85 \n(d, 6H).  13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6, 167.1, 161.6, 160.9, 141.4, 138.3, \n137.9, 134.8, 131.6, 129.2, 127.5, 127.3, 126.8, 12 6.2, 125.3, 124.9, 124.7, 122.9, 122.8, \n121.4, 119.3, 114.4, 113.7, 111.4, 110.5, 55.4, 55. 4. MS (EI, 70 eV): m/z = 285 [M +]. \n \n 3-(4-butoxybenzyliden)-5-chloroindolin-2-one 16c \nThe resulting product is a yellow solid (83%). HPLC : R t = 8.42 min, 8.71 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.60 (s, 2H), 8.46 (d, 2H,  J = 8.9 Hz),  7.79 (s, 1H), 7.71 (d, \n2H,  J = 8.9 Hz), 7.65 (s, 1H), 7.63 (d, 1H, J = 2.0 Hz), 7.56 (d, 1H, J = 2.0 Hz), 7.20 (dd, 1H, \nJ = 2.0 Hz, J = 8.3 Hz), 7.13 (dd, 1H, J = 2.0 Hz, J = 8.3 Hz), 7.05 (d, 2H, J = 8.9 Hz), 6.98 \n(d, 2H, J = 8.9 Hz),  6.85 (d, 1H, J = 8.3 Hz), 6.78 (d, 1H, J = 8.3 Hz), 4.05 (t, 4H, J = 6.5 Hz),  \nSeite 285 1.75-1.71 (m, 4H), 1.50-1.43 (m, 4H), 0.96-0.94 (m,  6H). 13 C-NMR (DMSO-d 6, 125 MHz): \n\u03b4 [ppm] = 168.5, 167.1, 161.0, 160.3, 141.3, 138.7, 138.6, 137.6, 134.7, 131.3, 128.8, 127.2, \n127.0, 126.6, 126.0, 125.2, 124.9, 124.7, 122.8, 12 1.4, 119.0, 114.6, 114.0, 111.1, 110.3, \n67.4, 67.3, 41.9, 41.9, 30.6, 18.6, 13.6.  MS (EI, 70 eV): m/z = 327 [M +]. \n \n5-chloro-3-(4-(2-(dimethylamino)ethoxy)benzyliden)i ndolin-2-one 16d \nThe resulting product is a yellow solid (65%). HPLC : R t = 3.28 min, 4.38 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.69 (s, 2H), 8.48 (d, 2H,  J = 8.9 Hz),  7.89 (s, 1H), 7.80 (d, \n1H, J = 2.0 Hz), 7.69 (d, 2H,  J = 8.9 Hz), 7.66 (s, 1H), 7.56 (d, 1H, J = 2.0 Hz), 7.27 (dd, 1H, \nJ = 2.0 Hz, J = 8.3 Hz), 7.20 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.12 (d, 2H, J = 8.9 Hz), 7.05 \n(d, 2H, J = 8.9 Hz),  6.89 (d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 4.16-4.13 (m, 4H), \n2.66-2.63 (m, 4H), 2.22 (d, 12H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6, 167.1, \n160.9, 160.2, 141.4, 138.8, 137.9, 134.8, 131.6, 12 9.2, 127.5, 127.3, 126.8, 126.1, 125.3, \n125.2 124.9, 124.7, 122.9, 122.8, 121.4, 119.3, 114 .8, 114.3, 111.4, 110.5, 66.1, 66.0, 57.6, \n57.6, 45.5.  MS (EI, 70 eV): m/z = 342 [M +]. \n \n5-chloro-3-(4-(2-(diethylamino)ethoxy)benzyliden)in dolin-2-one  16e  \nThe resulting product is an orange solid (55%). HPLC : R t = 4.28 min, 4.92 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.69 (s, NH), 8.48 (d, 2H, J = 8.9 Hz,), 7.87 (s, 1H),  7.80 \n(d, 1H, J = 2.0 Hz), 7.68 (d, 2H, J = 8.9 Hz), 7.66 (s, 1H), 7.56 (d, 1H, J = 2.0 Hz), 7.27 (dd, \n1H, J = 2.0 Hz, J = 8.3 Hz), 7.20 (dd, 1H, J = 2.0 Hz, J = 8.3 Hz), 7.11 (d, 2H, J = 8.9 Hz), \n7.04 (d, 2H, J = 8.9 Hz), 6.88 (d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 4.13-4.10 (m, 4H), \n2.80-2.78 (m, 4H), 2.57-2.53 (m, 8H), 0.99-0.96 (m,  12H). 13 C-NMR (DMSO-d 6, 125 MHz): \n\u03b4 [ppm] = 168.5, 167.1, 160.9, 160.2, 141.4, 138.8, 137.9, 134.8, 131.6, 129.1, 127.5, 127.3, \n126.7, 126.1, 125.2, 124.8, 124.7, 122.8, 122.8, 12 1.4, 119.2, 114.8, 114.3, 111.3, 110.5, \n66.7, 66.6, 51.2, 47.0, 46.9, 11.9, 11.9.  MS (EI, 70 eV): m/z = 370 [M +]. \n \n4-(4-((5-chloro-2-oxoindolin-3-yliden)methyl)phenox y)butannitrile 16f \nThe resulting product is a yellow solid (90%). HPLC : R t = 6.99 min, 7.48 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.69 (s, 2H), 8.49 (d, 2H,  J = 8.9 Hz), 7.89 (s, 1H), 7.80 (d, \n1H, J = 2.0 Hz), 7.70 (d, 2H,  J = 8.9 Hz), 7.66 (s, 1H), 7.56 (d, 1H, J = 2.0 Hz), 7.26 (dd, 1H, \nJ = 2.0 Hz, J = 8.3 Hz), 7.20 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.13 (d, 2H, J = 8.9 Hz), 7.06 \n(d, 2H, J = 8.9 Hz),  6.89 (d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 4.14 (t, 4H, J = 5.9 Hz), \n2.73 (m, 4H), 2.50 (m, 4H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6, 167.1, 160.6, \n159.9, 141.4, 138.9, 138.7, 137.8, 134.8, 131.6, 12 9.2, 127.6, 127.3, 127.0, 126.4, 125.3,  \nSeite 286 124.9, 123.0, 122.8, 121.4, 120.2, 119.3, 114.8, 11 4.3, 111.4, 110.5, 66.1, 24.6, 13.4.   \nMS (EI, 70 eV): m/z = 338 [M +]. \n \n5-chloro-3-(4-(2-morpholinoethoxy)benzyliden)indoli n-2-one 16g \nThe resulting product is a yellow solid (84%). HPLC : R t = 3.35 min, 4.65 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.69 (s, 2H), 8.48 (d, 2H,  J = 8.9 Hz), 7.88 (s, 1H), 7.80 (d, \n1H, J = 2.0 Hz), 7.69 (d, 2H,  J = 8.9 Hz), 7.66 (s, 1H), 7.56 (d, 1H, J = 2.0 Hz), 7.27 (dd, 1H, \nJ = 2.0 Hz, J = 8.3 Hz), 7.20 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.13 (d, 2H, J = 8.9 Hz), 7.06 \n(d, 2H, J = 8.9 Hz),  6.89 (d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 4.21-4.18 (m, 4H), 3.59 \n(m, 8H), 2.72 (m, 4H), 2.50 (m, 8H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6,  \n167.1, 160.8, 160.0, 141.4, 138.8, 137.9, 134.8, 13 1.6, 129.2, 127.5, 127.3, 126.8, 125.3, \n124.9, 122.9, 122.8, 121.4, 119.3, 114.9, 114.4, 11 1.3, 110.5, 66.2, 65.5, 56.9, 53.9.   \nMS (EI, 70 eV): m/z = 384 [M +]. \n \n5-chloro-3-(3,5-dibromo-4-hydroxybenzylidene)indoli n-2-one 16h \nThe resulting product is an orange solid (97%). HPLC : R t = 6.98 min, 7.65 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.50 (d, 2H), 8.75 (s, 2H), 8.49 (s, 2H),  7.84 (s, 1H), 7.59 \n(s, 1H), 7.60 (m, 2H), 7.20 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.05 (dd, 1H,  J = 2.0 Hz, \nJ = 8.3 Hz), 6.85 (d, 1H, J = 8.3 Hz), 6.76 (d, 1H, J = 8.3 Hz). 13 C-NMR (DMSO-d 6, \n125 MHz): \u03b4 [ppm] = 168.9, 167.4, 159.1, 155.3, 138.2, 137.4, 134.2, 128.6 125.1, 124.7, \n120.6, 117.6, 114.1, 110.9, 109.9.  MS (EI, 70 eV): m/z = 429 [M +]. \n \n5-chloro-3-(4-(2-(dimethylamino)ethoxy)-3-methoxybe nzyliden)indolin-2-one 16i \nThe resulting product is a dark yellow solid (31%).  HPLC : R t = 3.40 min, 4.53 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.67 (s, NH), 8.66 (d,  1H,  J = 2.1 Hz), 7.87-7.85 (m, 2H), \n7.80 (d, 1H,  J = 2.1 Hz), 7.69 (d, 1H, J = 2.1 Hz), 7.65 (s, 1H), 7.35 (d,1H, J = 1.9 Hz), \n7.32-7.31 (m, 1H), 7.28 (dd, 1H, J = 2.1 Hz, J = 8.3 Hz), 7.20 (dd, 1H, J = 2.1 Hz, \nJ = 8.3 Hz), 7.16 (d, 1H, J = 8.5 Hz), 7.10 (d, 1H, J = 8.5 Hz), 6.89 (d, 1H, J = 8.3 Hz), 6.83 \n(d, 1H, J = 8.3 Hz), 4.14 (t, 4H, J = 5.9 Hz), 3.83 (s, 3H), 3.81 (s, 3H), 2.65 (m, 4H ), 2.23 (s, \n6H), 2.22 (s, 6H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6, 167.2, 150.8, 150.0, \n148.7, 148.1, 141.4, 139.4, 138.8, 138.2, 129.0, 12 7.9, 127.4, 127.1, 126.3, 125.3, 124.8, \n124.6, 123.6, 122.9, 122.7, 121.7, 119.2, 115.4, 11 3.1, 112.8, 112.1, 111.4, 110.5, 66.7, \n66.6, 67.6, 55.6, 55.4, 45.6.  MS (EI, 70 eV): m/z = 271 [M +]. \n \n \n  \nSeite 287 5-chloro-3-(4-(2-(diethylamino)ethoxy)-3-methoxyben zyliden)indolin-2-one 16j \nThe resulting product is a dark yellow solid (42%).  HPLC : R t = 4.32 min, 5.07 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.67 (s, NH), 8.66 (d, 1H,  J = 2.0 Hz), 7.87-7.85 (m, 2H), \n7.80 (d, 1H,  J = 2.0 Hz), 7.69 (d, 1H, J = 2.0 Hz), 7.65 (s, 1H), 7.35 (d, 1H, J = 1.9 Hz), \n7.32-7.31 (m, 1H), 7.28 (dd, 1H, J = 2.0 Hz, J = 8.3 Hz), 7.20 (dd, 1H, J = 2.0 Hz, \nJ = 8.3 Hz),  7.16 (d, 1H, J = 8.5 Hz), 7.10 (d, 1H, J = 8.5 Hz), 6.89 (d, 1H, J = 8.3 Hz), 6.83 \n(d, 1H, J = 8.3 Hz), 4.11 (m, 4H), 3.83 (s, 3H), 3.81 (s, 3H ), 2.80 (m, 4H), 2.56 (m, 8H), 0.98 \n(m, 12H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6, 167.2, 150.9, 150.0, 148.7, \n148.1, 141.4, 139.4, 138.8, 138.2, 129.0, 128.0, 12 7.4, 127.0, 126.3, 125.3, 124.8, 124.6, \n123.6, 122.9, 122.7, 121.7, 119.2, 115.4, 113.2, 11 2.8, 112.1, 111.4, 110.5, 67.2, 67.1, 55.6, \n55.5, 51.2, 47.1, 11.9.  MS (EI, 70 eV): m/z = 400 [M +]. \n \n4-(4-((5-chloro-2-oxoindolin-3-yliden)methyl)-2-met hoxyphenoxy)      \nbutannitrile 16k \nThe resulting product is a bright orange solid (67% ). HPLC : R t = 6.78 min, 7.24 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.67 (s, NH), 8.67 (d, 1H,  J = 2.0 Hz), 7.88 (s, 1H), \n7.86 (dd, 1H, J = 2.0 Hz, J = 8.5 Hz), 7.80 (d, 1H,  J = 2.1 Hz), 7.69 (d, 1H, J = 2.1 Hz), 7.66 \n(s, 1H), 7.37 (d, 1H, J = 1.9 Hz), 7.35-7.33 (m, 1H), 7.28 (dd, 1H, J = 2.1 Hz, J = 8.3 Hz), \n7.20 (dd, 1H, J = 2.1 Hz, J = 8.3 Hz), 7.17 (d, 1H, J = 8.5 Hz), 7.12 (d, 1H, J = 8.5 Hz), 6.89 \n(d, 1H, J = 8.3 Hz), 6.83 (d, 1H, J = 8.3 Hz), 4.13 (t, 4H, J = 6.1 Hz), 3.85 (s, 3H), 3.82 (s, \n3H), 2.66 (m, 4H), 2.06 (m, 4H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6, 167.2, \n150.4, 149.6, 148.8, 148.2, 141.5, 139.3, 138.8, 13 8.0, 129.1, 127.8, 127.5, 127.4, 126.8, \n125.3, 124.8, 123.5, 123.0, 122.8, 121.7, 120.1, 11 9.2, 115.5, 113.2, 112.5, 111.4, 110.5, \n66.7, 66.5, 55.6, 55.5, 24.7, 24.7.  MS (EI, 70 eV): m/z = 368 [M +]. \n \n5-chloro-3-(4-(2-(dimethylamino)ethoxy)-2-methoxybe nzyliden)indolin-2-one 16l \nThe resulting product is a yellow solid (71%). HPLC : R t = 3.58 min, 4.80 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.65 (d, NH), 8.82 (d, 1H,  J = 8.7 Hz), 7.96 (s, 1H), 7.69 (s, \n1H), 7.64-7.62 (m, 2H), 7.43 (d, 1H, J = 2.1 Hz), 7.24 (dd, 1H, J = 2.1 Hz, J = 8.3 Hz), \n7.18 (dd, 1H, J = 2.1 Hz, J = 8.3 Hz), 6.87 (d, 1H, J = 8.3 H), 6.80 (d, 1H, J = 8.3 H), 6.72 (m, \n2H), 6.62 (m, 2H), 4.15 (m, 4H), 3.91 (s, 3H), 3.87  (s, 3H), 2.65 (t, 4H), 2.23 (s, 6H), 2.22 (s, \n6H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.6, 167.1, 162.9, 162.4, 160.3, 159.6, \n141.2, 138.8, 133.7, 133.6, 132.3, 130.8, 128.8, 12 7.4, 127.3, 125.3, 124.8, 124.3, 123.1, \n122.2, 121.4, 118.9, 115.0, 114.9, 111.2, 110.5, 10 6.0, 105.6, 99.0, 98.1, 66.2, 66.1, 57.7, \n56.0, 55.8, 45.6.  MS (EI, 70 eV): m/z = 372 [M +]. \n  \nSeite 288 4-((4-((5-chloro-2-oxoindolin-3-yliden)methyl)pheno xy)methyl)benzonitrile 16m \nThe resulting product is a yellow solid (93%). HPLC : R t = 8.17 min, 8.54 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.70 (s, 2H), 8.49 (d, 2H,  J = 8.9 Hz), 7.88 (m, 5H), 7.80 (d, \n1H, J = 2.0 Hz), 7.71 (d, 2H,  J = 8.9 Hz), 7.69 (s, 1H), 7.67 (d, 4H), 7.53 (d, 1H , J = 2.0 Hz), \n7.27 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.20 (m, 3H), 7.14 (d, 2H, J = 8.9 Hz), 6.89 (d, 1H, \nJ = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 5.33 (d, 4H, J = 2.9 Hz). 13C-NMR (DMSO-d 6, \n125 MHz): \u03b4 [ppm] = 168.5, 167.1, 160.2, 159.5, 142.4, 141.4, 138.9, 138.6, 137.7, 134.7, \n132.4, 131.6, 129.2, 128.2, 127.6, 127.3, 126.7, 12 5.3, 125.1, 124.9, 123.2, 122.8, 121.4, \n119.3, 118.7, 115.2, 114.7, 111.4, 110.6, 110.5, 68 .5, 68.4, 52.1.  MS (EI, 70 eV):  \nm/z = 386 [M +]. \n \nMethyl 4-((4-((5-chloro-2-oxoindolin-3-yliden)methy l)phenoxy)methyl)- \nbenzoate 16n  \nThe resulting product is a yellow solid (70%). HPLC : R t = 8.31 min, 8.66 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.70 (s, 2H), 8.49 (d, 2H,  J = 8.9 Hz), 8.00 (m, 4H), 7.89 (s, \n1H), 7.80 (d, 1H, J = 2.0 Hz), 7.70 (d, 2H,  J = 8.9 Hz), 7.66 (s, 1H), 7.62 (m, 4H), 7.53 (d, 1H , \nJ = 2.0 Hz), 7.27 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.20 (m, 3H), 7.14 (d, 2H, J = 8.9 Hz), 6.89 \n(d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 5.13 (d, 4H, J = 3.0 Hz), 3.86 (s, 6H). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.5, 167.1, 166.0, 160.4, 159.7, 142.2, 141.4, 138.9, \n138.6, 137.8, 134.7, 131.9, 131.6, 129.3, 129.2, 12 9.1, 127.6, 127.3, 127.2, 126.6, 125.3, \n125.0, 124.9, 123.1, 122.8, 121.4, 119.3, 115.2, 11 4.7, 111.4, 110.5, 68.8, 68.7, 52.1.   \nMS (EI, 70 eV): m/z = 419 [M +]. \n \n3-((4-((5-chloro-2-oxoindolin-3-yliden)methyl)pheno xy)methyl)benzonitrile 16o \nThe resulting product is a yellow solid (90%). HPLC : R t = 8.12 min, 8.53 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.70 (s, 2H), 8.50 (d, 2H,  J = 8.9 Hz),  7.96 (d, 2H), 7.89 (s, \n1H), 7.85-7.81 (m, 5H), 7.72 (d, 2H,  J = 8.9 Hz), 7.67 (s, 1H), 7.63 (m, 2H), 7.54 (d, 1H , \nJ = 2.0 Hz), 7.27 (dd, 1H,  J = 2.0 Hz, J = 8.3 Hz), 7.21 (m, 3H), 7.15 (d, 2H, J = 8.9 Hz), 6.89 \n(d, 1H, J = 8.3 Hz), 6.81 (d, 1H, J = 8.3 Hz), 5.28 (d, 4H, J = 3.0 Hz). 13 C-NMR (DMSO-d 6, \n125 MHz): \u03b4 [ppm] = 168.5, 167.1, 160.2, 159.6, 141.4, 138.9, 138.6, 138.4, 137.8,  \n134.7, 132.6, 132.5, 131.8, 131.6, 131.2, 129.8, 12 9.2, 127.6, 127.2, 126.7, 125.3, 125.0,  \n124.9, 123.2, 122.8, 121.4, 119.3, 118.6, 115.2, 11 4.7, 111.5, 111.4, 110.5, 68.3, 68.2.   \nMS (EI, 70 eV): m/z = 386 [M +]. \n \n \n  \nSeite 289 5-chloro-3-(4-(4-methyl-1H-imidazol-1-yl)phenoxy)be nzylidene)indolin-2-one 16p \nThe resulting product is a yellow solid (41%). HPLC : R t = 5.53 min, 6.15 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.76 (s, 2H), 8.11 (dd, 2H, J = 1.3 Hz, J = 6.8 Hz), 7.92 (m, \n1H), 7.84 (m, 1H), 7.75 (m, 1H), 7.66 (m, 4H), 7.50  (m, 2H), 7.41 (m, 2H), 7.24 (m, 10H), \n7.16 (m, 2H), 7.08 (m, 2H), 6.89 (m, 2H),  6.81 (m,  1H), 2.16 (s, 6H). 13 C-NMR (DMSO-d 6, \n125 MHz): \u03b4 [ppm] = 172.4, 168.87, 167.47, 159.55, 158.97, 154 .17, 154.10, 142.0, 139.6, \n138.8, 138.5, 137.6, 135.2, 133.9, 132.2, 129.9, 12 9.6, 129.3, 127.9, 127.7, 127.5, 126.4, \n125.9, 125.4, 124.8, 123.0, 122.4, 122.4, 121.9, 12 1.9, 120.6, 118.4, 117.8, 114.8, 111.9, \n111.09, 14.52, 14.04.  MS (EI, 70 eV): m/z = 427 [M +]. \n \n3-(4-(4-(dimethylamino)phenyl)diazenyl)benzylidene) indolin-2-one 16q \nThe resulting product is a red solid (9%). 1H-NMR (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.65 (s, \n1H), 7.86 (m, 6H), 7.66 (m, 2H), 7.22 (m, 2H), 6.87  (m, 5H), 3.09 (s, 6H). 13 C-NMR (DMSO-\nd6, 125 MHz): \u03b4 [ppm] = 168.6, 152.8, 143.0, 142.7, 135.4, 134.9, 130.6, 130.3, 127.9, 125.0, \n122.56, 122.0, 121.2, 120.9, 120.8, 111.6, 110.2, 2 9.8. MS (EI, 70 eV): m/z = 368 [M +]. \n \n5-chloro-3-(3-methoxy-4-(methylsulfonyl)benzylidene )indolin-2-one 16r \nThe resulting product is an orange solid (85%). HPLC : R t = 4.75 min, 6.48 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.81 (s, 2H), 8.59 (s, 1H), 8.01 (s, 1H),  7.94 (d, 1H,  \nJ = 8.0 Hz), 7.88 (m, 3H), 7.72 (s, 1H), 7.63 (s, 1H ), 7.50 (d, 1H, J = 8.0 Hz), 7.46 (d, 1H,  \nJ = 2.1 Hz), 7.33 (dd, 1H,  J = 2.1 Hz, J = 8.3 Hz), 7.29 (dd, 1H, J = 2.1, J = 8.3 Hz), 6.91 (d, \n1H, J = 8.3 Hz), 6.86 (d, 1H, J = 8.3 Hz), 4.02 (s, 3H), 3.32 (s, 3H), 3.31 (s, 3H ). 13 C-NMR \n(DMSO-d 6, 125 MHz): \u03b4 [ppm] = 168.4, 167.0, 157.3, 156.7, 142.6, 141.7, 140.7, 140.4, \n136.9, 135.9, 130.8, 129.7, 129.6, 129.5, 129.12, 1 29.1, 128.6, 126.7, 126.1, 125.5, 124.6, \n122.9, 122.4, 121.5, 120.9, 116.0, 114.4, 112.1, 11 1.5, 56.6, 56.3.  MS (EI, 70 eV):  \nm/z = 363 [M +]. \n \n5-chlor-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)b enzylidene)indoline 16s \nThe resulting product is an orange solid (55%). HPLC : R t = 4.10 min, 4.89 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.78 (s, 2H), 8.70 (d, 1H, J = 1.7 Hz), 7.99 (s, 1H), 7.96 (d, \n1H, J = 8.5 Hz), 7.92 (d, 1H, J = 1.3 Hz), 7.91 (d, 1H, J = 1.3 Hz), 7.86 (d, 1H, J = 2.1 Hz), \n7.73 (s, 1H), 7.63 (d, 1H, J = 2.1 Hz), 7.61 (d, 1H, J = 1.5 Hz), 7.57 (d, 1H, J = 8.1 Hz), 7.51 \n(d, 1H, J = 8.2 Hz), 7.43 (d, 1H, J = 10.4 Hz), 7.32 (dd, 1H, J = 2.1 Hz, J = 8.3 Hz), 7.26 (m, \n3H), 6.92 (d, 1H, J = 8.3 Hz), 6.86 (d, 1H, J = 8.3 Hz), 3.92 (s, 3H), 3.90 (s, 3H), 2.17 (s, 6H ). \n13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] = 170.0, 168.7, 152.6, 154.4, 141.1, 143.6, 139.5, \n138.7, 138.6, 138.5, 138.4, 135.6, 135.4, 131.5, 13 0.2, 129.2, 129.0, 128.7, 128.5, 127.8,  \nSeite 290 127.7, 127.3, 126.8, 126.7, 125.8, 123.9, 124.1, 12 1.6, 118.2, 118.0, 117.9, 115.7, 113.3, \n112.6, 57.9, 57.7, 50.3, 15.3.  MS (ESI, 70 eV): m/z = 366 [M +]. \n \n5-chloro-3-((9-methyl-9H-carbazol-3-yl)methylene)in dolin-2-one 16t \nThe resulting product is a yellow solid (17%). HPLC : R t = 8.61 min, 8.90 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.70 (s, 1H), 8.12 (d, 1H, J = 7.8 Hz), 7.79 (m, 5H), 7.54 \n(m, 1H), 7.25 (m, 2H), 6.88 (m, 1H), 3.95 (s, 3H). 13 C-NMR (DMSO-d 6, 125 MHz): \u03b4 [ppm] \n= 138.7, 167.3, 142.2, 141.6, 141.3, 140.6, 139.7, 138.6, 131.1, 128.8, 127.7, 127.4, 127.1, \n127.5, 126.3, 125.7, 125.2, 124.8, 124.3, 124.0, 12 3.1, 122.8, 122.2, 121.9, 121.8, 121.0, \n120.4, 119.9, 119.7, 118.9, 111.2, 110.4, 109.9, 10 9.8, 109.5, 29.2.  MS (EI, 70 eV):  \nm/z = 358 [M +]. \n \n3-((9-methyl-9H-carbazol-3-yl)methylene)indolin-2-o ne 16u \nThe resulting product is a yellow solid (15%). HPLC : R t = 8.13 min, 8.32 min. 1H-NMR \n(DMSO-d 6, 500 MHz): \u03b4 [ppm] = 10.51 (s, 1H), 8.51 (m, 1H), 8.16 (d, 1H, J = 7.7 Hz), 7.80 (s, \n1H), 7.67 (m, 4H), 7.48 (m, 1H), 7.18 (m, 3H), 6.82  (m, 2H), 3.88 (s, 3H). 13 C-NMR (DMSO-\nd6, 125 MHz): \u03b4 [ppm] = 169.4, 142.9, 141.7, 141.6, 138.1, 131.2, 129.8, 127.7, 126.7, 125.4, \n122.9, 122.6, 122.2, 121.9, 121.8, 121.4, 120.9, 11 9.9, 110.4, 109.9, 29.5.  MS (EI, 70 eV): \nm/z = 324 [M +]. \n \n9. Synthesis of 3-(4-(3-(1 H-tetrazol-5-yl)propoxy)benzyliden)-5-chloroindolin- 2-one 16v  \n4-(4-((5-chloro-2-oxoindolin-3-ylidene)methyl)pheno xy)butannitrile 16f  (20 mg, 0.06 mmol), \nsodium azide (46 mg, 0.71 mmol) und ammonium chlori de (38 mg, 0.71 mmol) were added \nto dimethylformamide (0.7 mL) and stirred for 2 h a t 100\u00b0C under microwave irradiation. After \ncooling to room temperature the reaction solution w as added to water, acidified with 2 N HCl \nand extracted three times with ethyl acetate. The c ombined organic layers were dried over \nsodium sulphate, filtered and the solvent was remov ed in vacuo. The resulting residue was \npurified by column chromatography on silica gel to provide the desired product in 62% as \nbrown solid. HPLC : R t = 6.61 min. 1H-NMR  (DMSO-d 6, 500 MHz): \u03b4 [ppm] = 12.10 (s, NH), \n10.13 (s, NH), 7.95 (s, 1H), 7.28 (d, 1H,  J = 8.6 Hz), 7.24 (d, 2H, J = 8.8 Hz), 7.20 (dd, 1H, \nJ = 2.3 Hz, J = 8.6 Hz), 7.15 (d, 2H, J = 8.8 Hz), 6.77 (d, 1H, J = 2.3 Hz) 4.13 (t, 2H, \nJ = 6.0 Hz), 2.70 (t, 2H, J = 7.1 Hz), 2.08 (m, 2H). 13 C-NMR  (DMSO-d 6, 125 MHz):  \n\u03b4 [ppm] = 162.3, 157.9, 157.5, 135.4, 131.0, 130.6, 126.4, 126.0, 124.1, 123.6, 121.5, 120.3, \n116.7, 115.5, 65.8, 30.8, 24.8. MS  (EI, 70 eV): m/z = 353 (M +). \n \n  \nSeite 291 III. FTL3 in vitro  assay conducted by Cerep  \n \n1. Reference compound Data  \nAssay:  FLT-3 Kinase (h)   \nReference compound:  Staurosporine  \n \nIC 50  (M) =  9.1E-10  \nnH =  1.7 \n \n2. Experimental conditions  \nAssay:  FLT-3 Kinase (h)  \nSource:  human recombinant (insect cells) \nSubstrate: ATP + Ulight-CAGAGAIETDKEYYTVKD (100 nM) \nIncubation:  90 min, RT \nMeasured Component: Phospho-Ulight- CAGAGAIETDKEYYTVKD \nDetection Method:  LANCE \n \n3. Analysis and expression of results  \nThe results are expressed as a percent of control s pecific activity ((measured specific \nactivity/control specific activity) x 100) obtained  in the presence of the compounds. \nThe IC 50  value (concentration causing a half-maximal inhibit ion of control specific activity) \nand Hill coefficient(s) (nH) were determined by non -linear regression analysis of the inhibition \ncurve generated with mean replicate values using Hi ll equation curve fitting (Y D + [(A-D)/ \n(1-(IC 50 )nH )], where Y = specific activity, D = minimum specif ic, A = maximum specific activity,  \nC = compound concentration, C 50  = IC 50 , and nH = slope factor). \nThis analysis was performed using software develope d at Cerep (Hill software) and validated \nby comparison with data generated by the commercial  software SigmaPlot\u00ae 4.0 for \nWindows \u00ae (1997 by SPSS inc.). \n \n  \nSeite 292  \nIV. Selectivity screening of compound 16e conducted  by Cerep  \n \nThe ExpresS Diversity kinase profile is a fast turn around profile conducted by Cerep. \nPercentage kinase activities of compound 16e  at 1 \u00b5M in panels of human protein kinases \ndetermined by Cerep. Measurements were performed in  duplicate and the average was \ntaken.  \n \nKinase % of Control \nValues 1  Kinase % of Control \nValues 1 \nAbl kinase (h)  95.4  JAK3 (h)  67.3 \nAkt1/PKB \u03b1 (h)  101.1  JNK1 (h)  96.4 \nAurA/Aur2 kinase \n(h)  99.6  KDR kinase (h)  \n(VEGFR2) 88.4 \nCaMK2 \u03b1 (h)  103.4  Lck kinase (h)  103.8 \nCDC2/CDK1 (h)  \n(cycB) 105.5  MAPKAPK2 (h)  95.3 \nCDK2 (h)  (cycA) 93.5  MARK1 (h)  99.6 \nCHK1 (h)  95.8  MKK6 (h)  100.7 \nCHK2 (h)  94.0  MNK2 (h)  107.4 \nCK1 \u03b1 (h)  102.6  MST4 kinase (h)  103.7 \nc-Met kinase (h)  97.2  NEK2 (h)  106.9 \nEGFR kinase (h)  102.1  p38 \u03b1 kinase (h)  99.4 \nEphA2 kinase (h)  101.2  PAK2 (h)  103.7 \nEphA3 kinase (h)  101.3  PAK4 (h)  101.2 \nEphB4 kinase (h)  101.8  PDK1 (h)  106.9 \nERK 2 (h)  (P42 mapk) 100.6  Pim2 kinase (h)  94.7 \nFGFR1 kinase (h)  98.2  PKA (h)  98.7 \nFGFR2 kinase (h)  100.1  PKC \u03b22 (h)  99.4 \nFGFR3 kinase (h)  92.9  PLK1 (h)  100.5 \nFLT-3 kinase (h)  14.7  RAF-1 kinase (h)  108.6 \nGSK3 \u03b1 (h)  103.7  ROCK1 (h) 102.4 \nGSK3 \u03b2 (h)  97.0  SGK1 (h)  96.0 \nHGK (h)  MAP4K4 27.8  SIK (h)  118.9 \nIKK \u03b1 (h)  103.6  Src kinase (h)  100.8 \nIRAK4 (h)  91.8  TAOK2 (TAO1) (h)  95.1 \nIRK (h)  (InsR) 112.9  TRKA (h)  87.0 \n1 The results are expressed as a percent of control specific activity ((measured specific \nactivity/control specific activity) x 100) obtained  in the presence of the compounds  \n(control = staurosporine). \n \n \n  \nSeite 293  \nAssay  \nKinase Source Substrate/Stimulus/Tracer  Incubation Measured \nComponent \nAbl \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight-TK peptide \n(100 nM) 60 min  \nRT phospho-Ulight-\nTK- peptide \nAkt1/ \nPKB \u03b1 (h)  human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 60 min  \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nAurA/Aur \n2 kinase \n(h)  human \nrecombinant \n(Sf21 cells) ATP + Ulight-RRRSLLE \n(100 nM) 15 min \n RT phospho-Ulight-\nRRRSLLE \n \nCaMK2 \u03b1\n(h) human \nrecombinant \n ATP + Ulight-\nCGSGSGRPRTSSFAEG \n(50 nM) 30 min  \nRT phospho-Ulight-\nCGSGSGRPRTS \nSFAEG \nCDC2/C \nDK1 (h) \n(cycB) human \nrecombinant \n(insect cells) ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 15 min \nRT phospho-Ulight- \nCFFKNIVTPRTP \nPPSQGK-amide \nCDK2 (h)  \n(cycA) human \nrecombinant ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(50 nM) 30 min \nRT phospho-Ulight- \nCFFKNIVTPRTP \nPPSQGK-amide \nCHK1 (h)  human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 30 min \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nCHK2 (h)  human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 15 min \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nCK1 \u03b1 (h)  human \nrecombinant ATP + Ulight- \nARTKQTARKSTGGKAP \nRKQLAGCG \n(25 nM) 60 min \nRT phospho-Ulight- \nARTKQTARKST \nGGKAPRKQLAG \nCG \nc-Met \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(25 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nEGFR \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 15 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nEphA2 \nkinase \n(h)  human \nrecombinant ATP + Ulight-TK peptide \n(50 nM) 30 min \nRT phospho-Ulight-\nTK- peptide \nEphA3 \nkinase human \nrecombinant ATP + Ulight-TK peptide \n(50 nM) 60 min \nRT phospho-Ulight-\nTK- peptide  \nSeite 294 (h)  \nEphB4 \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight-TK peptide \n(100 nM) 90 min \nRT phospho-Ulight-\nTK- peptide \nERK2 (h)  \n(P42 mapk ) human \nrecombinant \n(E. coli) ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 15 min \nRT phospho-Ulight- \nCFFKNIVTPRTP \nPPSQGK-amide \nFGFR1 \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nFGFR2 \nkinase \n(h)  human \nrecombinant ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(25 nM) 15 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nFGFR3 \nkinase \n(h)  human \nrecombinant ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 90 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nFLT-3 \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 90 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nGSK3 \u03b1 \n(h)  human \nrecombinant ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 60 min \nRT phospho-Ulight- \nCFFKNIVTPRTP \nPPSQGK-amide \nGSK3 \u03b2 \n(h)  human \nrecombinant ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 90 min \nRT phospho-Ulight- \nCFFKNIVTPRTP \nPPSQGK-amide \nHGK (h) \n(MAP \n4K4) human \nrecombinant ATP + Ulight-FLGFTYVAP \n(50 nM) 90 min \nRT phospho-Ulight-\nFLGFTYVAP \nIKK \u03b1 (h)  human \nrecombinant \n(Sf21 cells) ATP + Ulight-IkappaB-alpha \n(100 nM) 30 min \nRT phospho-Ulight-\nIkappaB-alpha \nIRAK4 \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight-FLGFTYVAP \n(50 nM) 90 min \nRT phospho-Ulight-\nFLGFTYVAP \nIRK (h) \n(InsR) human \nrecombinant ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(50 nM) 10 min \nRT phospho-Ulight-\nPoly \nGAT[EAY(1:1:1)]\nn \nJAK3 (h)  human \nrecombinant ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nJNK1 (h)  human \nrecombinant \n(E. coli) ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide 60 min \nRT phospho-Ulight- \nCFFKNIVTPRTP \nPPSQGK-amide  \nSeite 295 (100 nM) \nKDR \nkinase \n(h) \n(VEGFR \n2) human \nrecombinant \n(Sf9 cells) ATP + Ulight- \nCAGAGAIETDKEYYTVKD \n(100 nM) 60 min \nRT phospho-Ulight- \nCAGAGAIETDKE \nYYTVKD \nLck \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(25 nM) 30 min \nRT phospho-Ulight-\nPoly \nGAT[EAY(1:1:1)]\nn \nMAPKA \nPK2 (h)  human \nrecombinant \n(E. coli) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 15 min \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nMARK1 \n(h)  human \nrecombinant ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nMKK6 \n(h)  human \nrecombinant ATP + inactive p38a \n(50 nM) 10 min \nRT phospho-p38a \nMNK2 \n(h)  human \nrecombinant \n(Sf21 cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 90 min \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nMST4 \nkinase \n(h)  human \nrecombinant ATP + Ulight \nTM- PKC (50 nM) 30 min \nRT Phospho-Ulight-\nTM-PKC \nNEK2 (h)  human \nrecombinant \n(insect cells) ATP + Ulight-FLGFTYVAP \n(50 nM) 60 min \nRT phospho-Ulight-\nFLGFTYVAP \np38 \u03b1 \nkinase \n(h)  human \nrecombinant \n(E. coli) ATP + Ulight- \nCFFKNIVTPRTPPPSQGK-\namide \n(100 nM) 60 min \nRT phospho-Ulight- \nCFFKNIVTPRTP \nPPSQGKamide \nPAK2 (h)  human \nrecombinant \n(Sf9 cells) ATP + Ulight-RRRSLLE \n(50 nM) 60 min \nRT phospho-Ulight-\nRRRSLLE \nPAK4 (h)  human \nrecombinant \n(insect cells) ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nPDK1 (h)  human \nrecombinant \n(insect cells) ATP + Ulight-FLGFTYVAP \n(400 nM) 90 min \nRT phospho-Ulight-\nFLGFTYVAP \nPim2 \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 60 min \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nPKA (h)  human \nrecombinant ATP + Ulight-RRRSLLE \n(50 nM) 10 min \nRT phospho-Ulight-\nRRRSLLE  \nSeite 296 (E. coli) \nPKC \u03b22 \n(h)  human \nrecombinant ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 15 min \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nPLK1 (h)  human \nrecombinant ATP + Ulight-FLGFTYVAP \n(40 nM) 60 min \nRT phospho-Ulight-\nFLGFTYVAP \nRAF-1 \nkinase \n(h)  human \nrecombinant ATP + Ulight- \nARTKQTARKSTGGKAPRK \nQLAGCG \n(50 nM) 180 min \nRT phospho-Ulight- \nARTKQTARKST \nGGKAPRKQ \nLAGCG \nROCK1 \n(h)  human \nrecombinant ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nSGK1 (h)  human \nrecombinant ATP + Ulight-RRRSLLE \n(50 nM) 30 min \nRT phospho-Ulight-\nRRRSLLE \nSIK (h)  human \nrecombinant \n(Sf21 cells) ATP + CREBtide \n(CKRREILSRRPSYRK) \n(25 nM) 90 min \nRT phospho-\nCREBtide \n(CKRREILSRRP \nSYRK) \nSrc \nkinase \n(h)  human \nrecombinant \n(insect cells) ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(5 nM) 10 min \nRT phospho-Ulight-\nPoly \nGAT[EAY(1:1:1)]\nn \nTAOK2 \n(TAO1) \n(h)  human \nrecombinant ATP + Ulight-FLGFTYVAP \n(40 nM) 60 min \nRT phospho-Ulight-\nFLGFTYVAP \nTRKA (h)  human \nrecombinant \n(insect cells) ATP + Ulight-Poly \nGAT[EAY(1:1:1)]n \n(5 nM) 10 min \nRT phospho-Ulight-\nPoly \nGAT[EAY(1:1:1)]\nn \n \nV. \u03b3\u03b3 \u03b3\u03b3-Secretase assay and cell-based toxicity assay cond ucted by Roche \n \nSee Ref. 11 in the publication. \n \nVI. Toxicity assay: Determination of the in vivo  activity on wt zebrafish embryos \n \nThe wt zebrafish embryos were collected and placed into 24-well plates, ten embryos per \nwell and maintained in E2 medium at 28\u00b0C. Compounds  were added 5 hpf (50% epiboly) and \nthe embryos allowed to grow in chemical compound so lution up to 2 days. The phenotypes \nwere compared using the Axio Scope.A1 microscope sy stem from Carl Zeiss at 48 hpf. \nAnimal husbandry. All animal experiments were conducted and documente d according to \nthe federal and local regulation.  \nSeite 297 5. Zusammenfassung  \n \nDie vorliegende Arbeit beschreibt die erfolgreiche Entwicklung von hochaktiven und \nselektiven GSK-3-Inhibitoren, die im Jahre 2011 zu einer Patentanmeldung f\u00fchrte. \nDurch eine neu etablierte Synthese konnten, ausgehe nd von Verbindung 27 , schnell \nund effizient viele Harnstoffderivate synthetisiert  und optimiert werden. Der Hauptteil \ndieser Verbindungen zeigte eine analoge bzw. h\u00f6here  Aktivit\u00e4t f\u00fcr GSK-3 \u03b2 (Abb. 23). \nDar\u00fcber hinaus konnte im Vergleich zu Verbindung 27 , bei \u00e4hnlicher Selektivit\u00e4t, \neine verringerte Toxizit\u00e4t im Wildtyp-Zebrafisch-Em bryo nachgewiesen werden. \n \n \n \nAbb. 23: Ausgangspunkt und Ergebnis der Harnstoffderivatisie rung.   \n  \nDie durch die Harnstoffderivatisierung gewonnenen K enntnisse \u00fcber die ATP-\nBindungstasche und die Anfertigung des GSK-3-Review s stellten sehr gute \nAnsatzpunkte f\u00fcr die Folgeprojekte dar. Mit Hilfe d ieser Daten konnte ein \nvereinfachtes Schema der ATP-Bindungstasche angefer tigt werden, in dem \nrelevante Bindungsbereiche f\u00fcr GSK-3-Inhibitoren ma rkiert wurden. Diese Strategie \ndiente der Synthese neuer Verbindungen, die das Oxa diazol-Grundger\u00fcst als \nAusgangspunkt hatten. Auf diese Weise gelang die He rstellung zahlreicher \n \nSeite 298 biphenylischer Systeme, die nanomolare Aktivit\u00e4ten gegen\u00fcber GSK3- \u03b1 und GSK-3 \u03b2 \naufweisen konnten (Abb. 24).  \n \n \n \nAbb. 24: \u00dcbersicht einiger der aktivsten Biphenylderivate. \n \nDiese GSK-3-Inhibitoren zeigten gegen\u00fcber vier ande ren Kinasen keine bzw. geringe \nAktivit\u00e4t und konnten auch im Wildtyp-Zebrafisch-Em bryo sehr gute Ergebnisse \nerzielen. Um die Interaktion dieser Inhibitoren mit  der Gelenk-Region zu steigern und \nderen L\u00f6slichkeit zu erh\u00f6hen, wurden unterschiedlic he Linkersysteme in die \nInhibitoren eingef\u00fcgt. F\u00fcr Verbindung 39  konnte hierdurch die Aktivit\u00e4t im Vergleich \nzu Verbindung 52  gesteigert werden. Dieser Inhibitor zeigte zudem e ine mehr als \n5000-fache Selektivit\u00e4t f\u00fcr GSK-3. Das eingef\u00fcgte L inkersystem in Verbindung 42  \nerh\u00f6hte, im Vergleich zu Struktur 40 , die L\u00f6slichkeit um das 10-fache, senkte jedoch \ngeringf\u00fcgig die Aktivit\u00e4t (Abb. 25).  \n        \n \n \nAbb. 25: Erzieltes  Ergebnis der Linkersysteme. \n \n \nDurch die Variation des Substitutionsmusters am bip henylischen System konnte die \nbisher h\u00f6chste Selek tivit\u00e4t f\u00fcr ein \nVerbindung dieser Serie , GSK \ngegen\u00fcber GSK-3 \u03b2 (Abb. 26 \n \n \nAbb. 26: Diskriminierung einer GSK \n \nVerbindung 44  zeigte zwar eine geringere Selektivit\u00e4t f\u00fcr GSK \ngegen\u00fcber 48 von 50 Kinasen keine oder eine sehr geringe inhibitoris che Aktiv \nauf (Abb. 27). Eine Inhibition unter \nf\u00fcr klinische Entwicklung ) als nicht signifikant betrachtet und erh\u00e4rtet som it die \nAussage, dass der GSK-3- Inhibitor \n \n \nAbb. 27: Aktivit\u00e4t von Verbindung \nSeite 299 Durch die Variation des Substitutionsmusters am bip henylischen System konnte die \ntivit\u00e4t f\u00fcr ein e GSK-3- Isoform erzielt werden. \n, GSK -3-Inhibitor 41 , war 92-fach s elektiver f\u00fcr GSK \n26 ).  \nDiskriminierung einer GSK -3-Isoform. \nzeigte zwar eine geringere Selektivit\u00e4t f\u00fcr GSK -\n50 Kinasen keine oder eine sehr geringe inhibitoris che Aktiv \nEine Inhibition unter  25% wird von Cerep ( Dienstleistungsunternehmen \n) als nicht signifikant betrachtet und erh\u00e4rtet som it die \nInhibitor 44  ein au\u00dferordentlich selektiver Inhibitor ist. \nAktivit\u00e4t von Verbindung 44  gegen\u00fcber 50 Kinasen. \nDurch die Variation des Substitutionsmusters am bip henylischen System konnte die \nIsoform erzielt werden. Die beste \nelektiver f\u00fcr GSK -3\u03b1 \n \n-3\u03b1, wies jedoch \n50 Kinasen keine oder eine sehr geringe inhibitoris che Aktiv it\u00e4t \nDienstleistungsunternehmen \n) als nicht signifikant betrachtet und erh\u00e4rtet som it die \nein au\u00dferordentlich selektiver Inhibitor ist.  \n \n \nSeite 300 Die GSK-3-Inhibitoren 39 , 41 , 42  und 44  wurden ebenfalls im Wildtyp-Zebrafisch-\nEmbryo evaluiert und waren im Messbereich (< 30 \u00b5M) nicht toxisch. Einige der \nbiphenylischen Derivate wurden bereits in transgene n AD-M\u00e4usen getestet. Zu \ndiesem Zweck wurden scale-up -Synthesen von einigen Verbindungen durchgef\u00fchrt, \num eine f\u00fcr die in vivo  Versuche entsprechende Menge zur Verf\u00fcgung zu stel len. Die \nUntersuchungen ergaben jedoch, dass keine Penetrati on der Blut-Hirn-Schranke \nstattgefunden hat. Drei weitere Verbindungen werden  derzeit in transgenen M\u00e4usen \nevaluiert.  \nIm Rahmen eines neuen Projekts wurde ein LRRK2-Revi ew angefertigt, in dem die \nbisher publizierten Inhibitoren dieser Kinase zusam mengefasst sind. Alle relevanten \nDaten zu diesen Verbindungen, Tiermodelle f\u00fcr LRRK2  und Mutationen im LRRK2-\nGen werden diskutiert. Hierbei wurde das Potential von LRRK2-Inhibitoren im \nBereich der Parkinson-Krankheit kritisch diskutiert  und eine Grundlage f\u00fcr neue \nProjekte geschaffen. \nDurch die Verwendung des Indolinon-Grundger\u00fcsts kon nten sehr aktive  \nFLT-3-Inhibitoren synthetisiert werden (Abb. 28). D ie Evaluierung einer dieser \nInhibitoren im Kinase-Panel  best\u00e4tigte zudem eine gute Selektivit\u00e4t gegen\u00fcber  \nFLT-3. Die in vivo  Evaluation im Wildtyp-Zebrafisch-Embryo belegte, d ass diese \nInhibitoren im getesteten Konzentrationsbereich (< 30 \u00b5M) nicht toxisch sind. \n \n \n \nAbb. 28: Beispiele f\u00fcr die Aktivit\u00e4t der synthetisierten FLT -3-Inhibitoren. \n \n \n \n \n \nSeite 301 6. Ausblick  \n \nDie in dieser Arbeit hergestellten Verbindungen z\u00e4h len zu den aktivsten und \nselektivsten GSK-3-Inhibitoren, die bisher ver\u00f6ffen tlicht und patentiert worden sind. \nGSK-3 wird mit einer Vielzahl von Krankheiten assoz iiert, wodurch die Anwendung \ndieser Inhibitoren f\u00fcr viele Indikationsgebiete den kbar w\u00e4re. Somit liegt es nahe, \nweitere Arbeiten an diesen Strukturen voranzutreibe n. \nIm Bereich der Wirkstoffforschung ist vor allem die  Penetration der Blut-Hirn-\nSchranke eine Herausforderung f\u00fcr viele Verbindunge n. Obwohl die in-vivo  \nEffektivit\u00e4t dieser Verbindungen bereits im Wildtyp -Zebrafisch-Embryo gezeigt \nwerden konnte, wurde in transgenen AD-M\u00e4usen noch k ein Effekt beobachtet. \nAufgrund dessen sollte der Fokus auf die L\u00f6slichkei t dieser Verbindungen gelegt \nwerden. Hierbei k\u00f6nnte die Insertion von Stickstoff atomen in das biphenylische \nSystem schon zu einer Erh\u00f6hung der L\u00f6slichkeit f\u00fchr en. Auch ein Austausch der \nersten Phenylgruppe durch Piperazin w\u00e4re eine denkb are Option (Abb. 29).        \n \n \n \n             \n \nAbb. 29: Optionen zum Erh\u00f6hen der L\u00f6slichkeit bestehender Ve rbindungen. \n \nDurch die Einf\u00fchrung verschiedener Linkersysteme ko nnte in dieser Arbeit bereits \ngezeigt werden, dass die L\u00f6slichkeit und Interaktio n mit der Gelenk-Region \ngesteigert werden kann. Aus diesem Grunde w\u00e4re eine  Untersuchung verschiedener \nLinker eine weitere M\u00f6glichkeit zur L\u00f6slichkeitsste igerung. \n \n \nSeite 302 Aus der Literatur ist bekannt, dass bislang noch ke ine effektive Diskriminierung einer \nGSK-3-Isoform durch einen Inhibitor erzielt wurde. Desweiteren ist momentan nicht \nvollst\u00e4ndig gekl\u00e4rt, ob beide Isoformen in der Path ologie der AD involviert sind. Sollte \njedoch eine Diskriminierung f\u00fcr eine Therapie notwe ndig sein, um eventuelle \nNebenwirkungen zu vermeiden, ist eine Selektivit\u00e4t unerl\u00e4sslich. Durch die im \nRahmen dieser Arbeit synthetisierten selektiven GSK -3\u03b1-Inhibitoren er\u00f6ffnet sich \nsomit die M\u00f6glichkeit der direkten Inhibition. Zu d iesem Zweck sollte die Variation der \nSubstituenten am biphenylischen System weiter verfo lgt werden (Abb. 30). Bislang \nkonnte die Kristallstruktur von GSK-3 \u03b1 noch nicht gel\u00f6st werden. Diese k\u00f6nnte aber \nin Zukunft eine Erkl\u00e4rung f\u00fcr die Selektivit\u00e4t biet en.  \n \n \n \nAbb. 30: Variation der Substituenten am biphenylischen Syste m. \n \nErste Hinweise einiger hergestellter Verbindungen w eisen bereits darauf hin,  \ndass auch eine selektive GSK-3 \u03b2 Inhibition m\u00f6glich sein k\u00f6nnte. Eine  \nKristallstruktur des Inhibitors im Komplex mit GSK- 3\u03b2 k\u00f6nnte Hinweise f\u00fcr weitere \nselektivit\u00e4tssteigernde Interaktionen geben. Die St eigerung der Selektivit\u00e4t f\u00fcr eine \nGSK-3-Isoform ist jedoch nicht nur auf das biphenyl ische System zu beschr\u00e4nken. \nEs k\u00f6nnten auch \u00dcberlegungen angestrebt werden den Heterozyklus bzw. das \nOxadiazol auszutauschen (Abb. 31).  \n \n \nAbb. 31: Variation des Heterozyklus und Oxadiazols. \n \nBestehende Verbindungen sollten zudem in Tiermodell en anderer Krankheiten \nevaluiert werden, um das Potential dieser GSK-3-Inh ibitoren auszusch\u00f6pfen.  \n \nSeite 303 7. Literaturverzeichnis  \n \n1. Stelzmann, R. A.; Schnitzlein, H. N.; Murtagh, F . R. An English Translation of \nAlzheimer\u00b4s 1907 Paper, \"\u00dcber eine eigenartige Erkr ankung der Hirnrinde\". Clinical \nAnatomy 1995,  8, 429-431. \n2. Alzheimer, A. . \u00dcber eine eigenartige Erkrankung  der Hirnrinde. Allgemeine Zeitschrift \nf\u00fcr Psychiatrie und psychisch-gerichtliche Medizin 1907,  64, 146-148. \n3. Zur Verf\u00fcgung gestellt von M. Sc. Jiamin Gu und M. Sc. Upendra Rao Anumala in \nKooperation mit dem Klinikum Darmstadt. \n4. Ittner, L. M.; G\u00f6tz, J. Amyloid- \u03b2 and tau - a toxic pas de deux in Alzheimer\u00b4s diseas e. \nNature Reviews Neuroscience 2011,  12, 67-72. \n5. LaFerla, F. M.; Green, K. N.; Oddo, S. Intracell ular amyloid- \u03b2 in Alzheimer\u00b4s disease  \nNature Reviews Neuroscience 2007,  8, 499-509. \n6. Perrin, R. J.; Fagan, A. M.; Holtzman, D. M. Mul timodal techniques for diagnosis and \nprognosis of Alzheimer\u00b4s disease. Nature 2009,  461, 916-922. \n7. Jakob-Roetne, R.; Jacobsen, H. Die Alzheimer-Dem enz: von der Pathologie zu \ntherapeutischen Ans\u00e4tzen. Angew. Chem. 2009,  121, 3074-3105. \n8. Citron, M. Alzheimer\u00b4s disease: strategies for d isease modification. Nature Reviews \nDrug Discovery 2010,  9, 387-398. \n9. Mangialasche, F.; Solomon, A.; Winblad, B.; Meco cci, P.; Kivipelta, M. Alzheimer\u00b4s \ndisease: clinical trials and drug development. Lancet Neurol. 2010,  9, 702-716. \n10. Qizilbash, N.; Whitehead, A.; Higgins, J.; Wilc ock, G.; Schneider, L.; Farlow, M. \nCholinesterase Inhibition for Alzheimer Disease. JAMA 1998,  280, 1777-1782. \n11. Candelario-Jalil, E. A role for cyclooxygenase- 1 in \u03b2-amyloid-induced \nneuroinflammation. Aging 2009,  1, 350-353. \n12. Frautschy, S. A. Thinking outside the box about  COX-1 in Alzheimer's disease. \nNeurobiology of Disease 2010,  38, 492-494. \n13. M\u00fcller, T.; Meyer, H. E.; Egensperger, R.; Marc us, K. . The amyloid precursor protein \nintracellular domain (AICD) as modulator of gene ex pression, apoptosis, and \ncytoskeletal dynamics\u2014Relevance for Alzheimer\u2019s dis ease. Progress in Neurobiology \n2008,  85, 393-406. \n14. De Strooper, B.; Vassar, R.; Golde, T. The secr etases: enzymes with therapeutic \npotential in Alzheimer disease. Nature Reviews Neurology 2010,  6, 99-107. \n15. Li, H.; Wolfe, M. S.; Selkoe, D. J. Toward Stru ctural Elucidation of the \u03b3-Secretase \nComplex. Structure 2009,  17, 326-334. \n16. Small, D. H.; Klaver, D. W.; Foa, L. Presenilin s and the  \u03b3-secretase: still a complex \nproblem. Molecular Brain 2010,  3, 1-6. \n17. Shah, S.; Lee, S.; Tabuchi, K.; Hao, Y.; Yu, C. ; LaPlant, Q.; Ball, H.; Dann III, C. E.; \nS\u00fcdhof, T.; Yu, G. Nicastrin Functions as a \u03b3-Secretase-Substrate Receptor. Cell \n2005,  122, 435-447. \n18. Herreman, A.; Van Gassen, G.; Bentahir, M.; Nya bi, O.; Craessaerts, K.; Mueller, U.; \nAnnaert, W.; De Strooper, B. \u03b3-Secretase activity requires the presenilin-depende nt \ntrafficking of nicastrin through the Golgi apparatu s but not its complex glycosylation. \nJournal of Cell Science 2002,  116, 1127-1136. \n19. Brammens, L.; Ch\u00e1vez-Guti\u00e9rrez, L.; Tolia, A.; Zwijsen, A.; De Strooper, B. \nFunctional and Topological Analysis of Pen-2, the F ourth Subunit of the \u03b3-Secretase \nComplex. JBC 2011,  286, 12271-12282. \n20. Martocchia, A.; Falaschi, P. Current Strategies  of Therapy in Alzheimer\u2019s Disease \nThe Open Neuropsychopharmacology Journal 2008,  1, 19-23. \n21. Melnikova, I. Therapies for Alzheimer\u00b4s disease . Nature Reviews Drug Discovery \n2007,  6, 341-342. \n22. Dovey, H. F.; John, V.; Anderson, J. P.; Chen, L. Z.; De Saint Andrieu, P.; Fang, L. \nY.; Freedman, S. B.; Folmer, B.; Goldbach, E.; Hols ztynska, E. J.; Hu, K. L.; Johnson- \nSeite 304 Wood, K. L.; Kennedy, S. L.; Kholodenko, D.; Knops,  J. E.; Latimer, L. H.; Lee, M.; \nLiao, Z.; Lieberburg, I. M.; Motter, R. N.; Mutter,  L. C.; Nietz, J.; Quinn, K. P.; Sacchi, \nK. L.; Seubert, P. A.; Shopp, G. M.; Thorsett, E. D .; Tung, J. S.; Wu, J.; Yang, S.; Yin, \nC. T.; Schenk, D. B.; May, P. C.; Altstiel, L. D.; Bender, M. H.; Boggs, L. N.; Britton, T. \nC.; Clemens, J. C.; Czilli, D. L.; Dieckman-McGinty , D. K.; Droste, J. J.; Fuson, K. S.; \nGitter, B. D.; Hyslop, P. A.; Johnstone, E. M.; Li,  W.-Y.; Little, S. P.; Mabry, T. E.; \nMiller, F. D.; Ni, B.; Nissen, J. S.; Porter, W. J. ; Potts, B. D.; Reel, J. K.; Stephenson, \nD.; Su, Y.; Shipley, L. A.; Whitesitt, C. A.; Yin, T.; Audia, J. E. Functional gamma-\nsecretase inhibitors reduce beta-amyloid peptide le vels in brain. Journal of \nNeurochemistry 2001,  76, 173-181. \n23. Best, J. D.; Jay, M. T.; Otu, F.; Ma, J.; Nadin , A.; Ellis, S.; Lewis, H. D.; Pattison, C.; \nReilly, M.; Harrison, T.; Shearman, M. S.; Williams on, T. L.; Atack, J. R. Quantitative \nMeasurement of Changes in Amyloid- \u03b2(40) in the Rat Brain and Cerebrospinal Fluid \nfollowing Treatment with the \u03b3-Secretase Inhibitor LY-411575 [N 2-[(2S)-2-(3,5-\nDifluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-\ndibenzo[b,d]azepin-7-yl]-L-alaninamide]. JPET 2005,  313, 902-908. \n24. Artavanis-Tsakonas, S.; Rand, M. D.; Lake, R. J . Notch Signaling: Cell Fate Control \nand Signal Integration in Development. Science 1999,  284, 770-776. \n25. Best, J. D.; Jay, M. T.; Otu, F.; Churcher, I.;  Reilly, M.; Morentin-Gutierrez, P.; \nPattison, C.; Harrison, T.; Shearman, M. S.; Atack,  J. R. In Vivo Characterization of \nA\u03b2(40) Changes in Brain and Cerebrospinal Fluid Using  the Novel \u03b3-Secretase \nInhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2, 5-difluorophenyl)cyclohexyl]-1,1,1-\ntrifluoromethanesulfonamide (MRK-560) in the Rat. JPET 2006,  317, 786-790. \n26. Venugopal, C.; Demos, C. M.; Jagannatha Rao, K.  S.; Papolla, M. A. Beta-secretase: \nStructure, Function, and Evolution. CNS Neurol Disord Drug Targets 2008, 7, 278-\n294. \n27. Cole, S. L.; Vassar, R. The Alzheimer's disease  \u03b2-secretase enzyme, BACE1. \nMolecular Neurodegeneration 2007,  2, 1-25. \n28. Hemming, M. L.; Elias, J. E.; Gygi, S. P.; Selk oe, D. J. Identification of \u03b2-Secretase \n(BACE1) Substrates Using Quantitative Proteomics. PLoS ONE 2009,  4, e8477. \n29. Stanton, R. A.; Gernert, K. M.; Nettles, J. H.;  Aneja, R. Drugs That Target Dynamic \nMicrotubules: A New  Molecular  Perspective. Medicinal Research Reviews 2011, 31, \n443-481. \n30. Mazanetz, M. P.; Fischer, P. Untangling tau hyp erphosphorylation in drug design for \nneurodegenerative diseases. Nature Reviews Drug Discovery 2007,  6, 464-479. \n31. Schneider, A.; Mandelkow, E. Tau-Based Treatmen t Strategies in Neurodegenerative \nDiseases. Neurotherapeutics 2008,  5, 443-457. \n32. Drechsel, D. N.; Hyman, A. A.; Cobb, M. H.; Kir schner, M. W. Modulation of the \nDynamic Instability of Tubulin Assembly by the Micr otubule-Associated Protein Tau. \nMolecular Biology of the Cell 1992,  3, 1141-1154. \n33. Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M. Y. Advances in tau-focused drug \ndiscovery for Alzheimer\u00b4s and related disease. Nature Reviews Drug Discovery 2009, \n8, 783-793. \n34. Schneider, A.; Biernat, J.; von Bergen, M.; Man delkow, E. M. Phosphorylation that \nDetaches Tau Protein from Microtubules (Ser262, Ser 214) Also Protects It against \nAggregation into Alzheimer Paired Helical Filaments . Biochemistry 1999, 38, 3549-\n3558. \n35. Schneider, A.; Falkai, P.; Papassotiropoulos, A . Molekulare Grundlagen Tau-Protein-\nvermittelter Toxizit\u00e4t. Nervenarzt 2010,  81, 1289-1297. \n36. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter , T.; Sudarsanam, S. The Protein \nKinase Complement of the Human Genome. Science 2002,  298, 1912-1934. \n37. Bossemeyer, D. Protein kinases - structure and function. FEBS Letters 1995, 369, \n57-61. \n38. Cohen, P. Protein kinases - the major drug targ ets of the twenty-first century. Nature \nReviews Drug Discovery 2002,  1, 309-315.  \nSeite 305 39. Ubersax, J. A.; Ferrell Jr, J. E. Mechanism of specificity in protein phosphorylation. \nNature Reviews Molecular Cell Biology 2007,  8, 530-541. \n40. Ghose, A. K.; Herbertz, T.; Pippin, D. A.; Salv ino, J. M.; Mallamo, J. P. Knowledge \nBased Prediction of Ligand Binding Modes and Ration al Inhibitor Design for Kinase \nDrug Discovery. J. Med. Chem 2008,  51, 5149-5171. \n41. ter Haar, E.; Coll, J. T.; Austen, D. A.; Hsiao , H.; Jain, J. Structure of GSK3 \u03b2 reveals \na primed phoshorylation mechanism. Nature Structural Biology 2001,  8, 593-596. \n42. Grant, S. K. Therapeutic Protein Kinase Inhibit ors. Cell. Mol. Life Sci. 2009, 66, 1163-\n1177. \n43. Rauh, D. Inaktive Kinasekonformationen stabilis ieren. Nachrichten aus der Chemie \n2010,  58, 118-121. \n44. Liu, Y.; Gray, N. S. Rational design of inhibit ors that bind to inactive kinase \nconformations. Nature Chemical Biology 2006,  2, 358-364. \n45. Morphy, R. Selectively Nonselective Kinase Inhi bition: Striking the Right Balance. J. \nMed. Chem 2010,  53, 1413-1437. \n46. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini , M. Through the \"Gatekeeper Door\": \nExploiting the Active Kinase Conformation. J. Med. Chem 2010,  53, 2681-2694. \n47. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting c ancer with small molecule kinase \ninhibitors. Nature Reviews Cancer 2009,  9, 28-39. \n48. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitt y, A. The resurgence of covalent drugs. \nNature Reviews Drug Discovery 2011,  10, 307-317. \n49. Frame, S.; Cohen, P. GSK3 takes centre stage mo re than 20 years after its \ndiscovery. Biochem. J. 2001,  359, 1-16. \n50. Doble, B. W.; Woodgett, J. R. GSK-3: tricks of the trade fo a multi-tasking kinase. \nJournal of Cell Science 2003,  116, 1175-1186. \n51. Cohen, P.; Frame, S. The renaissance of GSK3. Nature Reviews Molecular Cell \nBiology 2001,  2, 769-776. \n52. Ali, A.; Hoeflich, K. P.; Woodgett, J. R. Glyco gen Synthase Kinase-3: Properties, \nFunctions, and Regulation. Chem. Rev. 2001,  101, 2527-2540. \n53. Mukai, F.; Ishiguro, K.; Sano, Y.; Fujita, S. C . Alternative splicing isoform of tau \nprotein kinase I/glycogen synthase kinase 3 \u03b2. Journal of Neurochemistry 2002, 81, \n1073-1083. \n54. Dajani, R.; Fraser, E.; Roe, S. M.; Young, N.; Good, V.; Dale, T. C.; Pearl, L. H. \nCrystal Structure of Glycogen Synthase Kinase 3 \u03b2: Structural Basis for Phosphate-\nPrimed Substrate Specificity and Autoinhibition. Cell 2001,  105, 721-732. \n55. Bax, B.; Carter, P. S.; Lewis, C.; Guy, A. R.; Bridges, A.; Tanner, R.; Pettman, G.; \nMannix, C.; Culbert, A. A.; Brown, M. J. B.; Smith,  D. G.; Reith, A. D. . The Structure \nof Phosphorylated GSK-3 \u03b2 Complexed with a Peptide, FRATtide, that Inhibits \u03b2-\nCatenin Phosphorylation. Structure 2001, 9, 1143-1152. \n56. Jope, R. S.; Johnson, G. V. W. The glamour and gloom of glycogen synthase kinase-\n3. Trends in Biochemical Sciences 2004,  29, 95-102. \n57. Martinez, A. Preclinical Efficacy on GSK-3 Inhi bitors: Towards a Future Generation of \nPowerful Drugs. Medicinal Research Reviews 2008,  28, 773-796. \n58. Jope, R. S.; Yuskaitis, C. J.; Beurel, E. Glyco gen Synthase Kinase-3 (GSK3): \nInflammation, Diseases, and Therapeutics. Neurochem Res. 2007,  32, 577-595. \n59. Hur, E.; Zhou, F. GSK3 signalling in neural dev elopment. Nature Reviews \nNeuroscience 2010,  11, 539-551. \n60. Klein, P. S.; Melton, D. A. A molecular mechani sm for the effect of lithium on \ndevelopment. Proc. Natl. Acad. Sci. 1996,  93, 8455-8459. \n61. Mora, A.; Sabio, G.; Gonz\u00e1lez-Polo, R. A.; Cuen da, A.; Alessi, D. R.; Alonso, J. C.; \nFuentes, J. M.; Soler, G.; Centeno, F. Lithium inhi bits caspase 3 activation and \ndephosphorylation of PKB and GSK3 induced by K + deprivation in cerebellar granule \ncells. Journal of Neurochemistry 2001,  78, 199-206.  \nSeite 306 62. Ryves, W. J.; Harwood, A. J. Lithium Inhibits G lycogen Synthase Kinase-3 by \nCompetition for Magnesium. Biochemical and Biophysical Research Communications  \n2001,  280, 720-725. \n63. Ryves, W. J.; Dajani, R.; Pearl, L.; Harwood, A . J. Glycogen Synthase Kinase-3 \nInhibition by Lithium and Beryllium Suggests the Pr esence of Two Magnesium \nBinding Sites. Biochemical and Biophysical Research Communications  2002, 290, \n967-972. \n64. Bhat, R. V.; Budd, S. L. GSK3 \u03b2 Signalling: Casting a Wide Net in Alzheimer\u00b4s \nDisease. Neurosignals 2002,  11, 251-261. \n65. Kremer, A.; Louis, J. V.; Jaworski, T.; Van Leu ven, F. GSK3 and Alzheimer\u00b4s \ndisease: facts and fiction... Frontiers in Molecular Neuroscience 2011,  4, 1-10. \n66. Bhat, R.V.; Budd Haeberlein, S. L.; Avila, J. G lycogen synthase kinase 3: a drug \ntarget for CNS therapies. Journal of Neurochemistry 2004,  89, 1313-1317. \n67. Lucas, J. J.; Hern\u00e1ndez, F.; G\u00f3mez-Ramos, P.; M or\u00e1n, M. A.; Hen, R.; Avila, J. \nDecreased nuclear \u03b2-catenin, tau hyperphosphorylation and neurodegener ation in \nGSK-3\u03b2 conditional transgenic mice. The EMBO Journal 2001,  20, 27-39. \n68. Engel, T.; Goni-Oliver, P.; Lucas, J. J.; Avila , J.; Hern\u00e1ndez, F. Chronic lithium \nadministration to FTDP-17 tau and GSK-3beta overexp ressing mice prevents tau \nhyperphosphorylation and neurofibrillary tangle for mation, but pre-formed \nneurofibrillary tangles do not revert. Journal of Neurochemistry 2006,  99, 1445-1455. \n69. Hooper, C.; Killick, R.; Lovestone, S. The GSK3  hypothesis of Alzheimer\u00b4s disease. \nJournal of Neurochemistry 2008,  104, 1433-1439. \n70. Jackson, G. R.; Wiedau-Pazos, M.; Sang, T.; Wag le, N.; Brown, C. A.; Massachi, S.; \nGeschwind, D. H. Human Wild-Type Tau Interacts with  wingless Pathway \nComponents and Produces Neurofibrillary Pathology i n Drosophila. Neuron 2002, 34, \n509-519. \n71. Wang, Y.; Zhang, J.; Du, X.; Zhao, L.; Tian, Q. ; Zhu, L.; Wang, S.; Wang, J. Temporal \ncorrelation of the memory deficit with Alzheimer-li ke lesions induced by activation of \nglycogen synthase kinase-3. Journal of Neurochemistry 2008,  106, 2364-2374. \n72. Cohen, P.; Goedert, M. GSK3 Inhibitors: Develop ment and Therapeutic Potential. \nNature Reviews Drug Discovery 2004,  3, 479-487. \n73. Bhat, R. V.; Berg, S.; Burrows, J.; Lindquist, J. GSK-3 Inhibitors for the treatment of \nAlheimer\u00b4s Disease. Top Med Chem 2008,  2, 137-174. \n74. Cross, D. A. E.; Culbert, A. A.; Chalmers, K. A .; Facci, L.; Skaper, S. D.; Reith, A. D. \nSelective small-molecule inhibitors of glycogen syn thase kinase-3 activity protect \nprimary neurones from death. Journal of Neurochemistry 2001,  77, 94-102. \n75. Meijer, L.; Flajolet, M.; greengard, P. Pharmac ological inhibitors of glycogen synthase \nkinase 3. Trends in Pharmacological Sciences 2004,  25, 471-480. \n76. Grimes, C. A.; Jope, R. S. The multifaceted rol es of glycogen synthase kinase 3 \u03b2 in \ncellular signaling. Progress in Neurobiology 2001,  65, 391-426. \n77. Koh, S.; Noh, M. Y.; Kim, S. H. Amyloid-beta-in duced neurotoxicity is reduced by \ninhibition of glycogen synthase kinase-3. Brain Research 2008,  1188, 254-262. \n78. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Orm\u00f6 , M.; Nilson, Y.; Rades\u00e4ter, A.; Jerning, \nE.; Markgren, P.; Borgegard, T.; Nyl\u00f6f, M.; Gim\u00e9nez -Cassina, A.; Hern\u00e1ndez, F.; \nLucas, J. J.; D\u00edaz-Nido, J.; Avila, J. Structural I nsights and Biological Effects of \nGlycogen Synthase Kinase 3-specific Inhibitor AR-A0 14418. JBC 2003,  278, 45937-\n45945. \n79. Phiel, C. J.; Wilson, C. A.; Lee, V. M.-Y.; Kle in, P. S. GSK-3 \u03b1 regulates production of \nAlzheimer's disease amyloid- \u03b2 peptides. Nature 2003,  423, 435-439. \n80. Jaworski, T.; Dewachter, I.; Lechat, B.; Gees, M.; Kremer, A.; Demedts, D.; \nBorghgraef, P.; Devijver, H.; K\u00fcgler, S.; Patel, S. ; Woodgett, J. R.; Van Leuven, F. \nGSK-3\u03b1/\u03b2 kinases and amyloid production in vivo. Nature 2011,  480, E4-E5. \n81. Phiel, C. J.; Wilson, C. A.; Lee, V. M.-Y.; Kle in, P. S. Phiel et al. reply Nature 2011, \n480, E6.  \nSeite 307 82. Saitoh, M.; Kunitomo, J.; Kimura, E.; Hayase, Y .; Kobayashi, H.; Uchiyama, N.; \nKawamoto, T.; Tanaka, T.; Mol, C. D.; Dougan, D. R. ; Textor, G. S.; Snell, G. P.; Itoh, \nF. Design, synthesis and structure-activity relatio nship of 1,3,4-oxadiazole derivatives \nas novel inhibitors of glycogen synthase kinase-3 \u03b2. Bioorg. Med. Chem. 2009, 17, \n2017-2029. \n83. Saitoh, M.; Kunitomo, J.; Kimura, E.; Iwashita,  H.; Uno, Y.; Onishi, T.; Uchiyama, N.; \nKawamoto, T.; Tanaka, T.; Mol, C. D.; Dougan, D. R. ; Textor, G. S.; Snell, G. P.; \nTakizawa, M.; Itoh, F.; Kori, M. 2-{3-[4-(Alkylsulf inyl)phenyl]-1-benzofuran-5-yl}-5-\nmethyl-1,3,4-oxadiazole Derivatives as novel Inhibi tors of glycogen Synthase Kinase-\n3\u03b2 with Good Brain Permeability. J. Med. Chem 2009,  52, 6270-6286. \n84. Onishi, T.; Iwashita, H.; Uno, Y.; Kunitomo, J. ; Saitoh, M.; Kimura, E.; Fujita, H.; \nUchiyama, N.; Kori, M.; Takizawa, M. A novel glycog en synthase kinase-3 inhibitor 2-\nmethyl-5-(3-{4-[(S \u200a)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-o xadiazole \ndecreases tau phosphorylation and ameliorates cogni tive deficits in a transgenic \nmodel of Alzheimer\u2019s disease. Journal of Neurochemistry 2011,  119, 1330-1340. \n85. Khanfar, M. A.; Hill, R. A.; Kaddoumi, A.; El S ayed, K. A. Discovery of novel GSK-3 \u03b2 \ninhibitors with potent in vitro and in vivo activit ies and excellent brain permeability \nusing combined ligand- and structure-based virtual screening. J. Med. Chem 2010, \n53, 8534-8545. \n86. Naerum, L.; Norskov-Lauritsen, L.; Olesen, P. H . Scaffold Hopping and Optimization \ntowards Libraries of Glycogen Synthase Kinase-3 Inh ibitors. Bioorg. Med. Chem. Lett. \n2002,  12, 1525-1528. \n87. Bregman, H.; Williams, D. S.; Ekin Atilla, G.; Carroll, P. J.; Meggers, E. An \nOrganometallic Inhibitor for Glycogen Synthase Kina se 3. J. Am. Chem. Soc. 2004, \n126, 13594-13595. \n88. Ekin, Atilla-Gokcumen, G.; Williams, D. S.; Bre gman, H.; Pagano, N.; Meggers, E. \nOrganometallic Compounds with Biological Activity: A Very Selective and Hoghly \nPotent Cellular Inhibitor for Glycogen Synthase Kin ase 3. ChemBioChem 2006, 7, \n1443-1450. \n89. Martinez, A.; Gil, C.; Perez, D. I. Glycogen Sy nthase Kinase 3 Inhibitors in the Next \nHorizon for Alzheimer\u2019s Disease Treatment. International Journal of Alzheimer\u00b4s \nDisease 2011,  2011, 1-7. \n90. Eldar-Finkelman, H.; Licht-Murava, A.; Pietroko vski, S.; Eisenstein, M. Substrate \ncompetitive GSK-3 inhibitors - strategy and implica tions. Biochim. Biophys. Acta \n2010,  1804, 598-603. \n91. Feng, L.; Geisselbrecht, Y.; Blanck, S.; Wilbue r, A.; Atilla-Gokcumen, G. E.; \nFilippakopoulos, P.; Kr\u00e4ling, K.; Celik, M. A.; Mak simoska, J.; Marmorstein, R.; \nFrenking, G.; Knapp, S.; Essen, L.; Meggers, E. Str ucturally Sophisticated Octahedral \nMetal Complexes as Highly Selective Protein Kinase Inhibitors. J. Am. Chem. Soc. \n2011,  133, 5976-5986. \n92. Eldar-Finkelman, H. Glycogen synthase kinase 3:  an emerging therapeutic target. \nTrends in Molecular Medicine 2002,  8, 126-132. \n93. Cao, Q.; Lu, X.; Feng, Y. Glycogen synthase kin ase-3\u03b2 positively regulates the \nproliferation of human ovarian cancer cells. Cell Research 2006,  16, 671-677. \n94. Garcea, G.; Manson, M. M.; Neal, C. P.; Pattend en, C. J.; Sutton, C. D.; Dennison, A. \nR.; Berry, D. P. Glycogen Synthase Kinase-3  Beta; A New Target in Pancreatic \nCancer? Current Cancer Drug Targets 2007,  7, 209-215. \n95. Martinez, A.; Castro, A.; Dorronsoro, I.; Alons o, M. Glycogen Synthase Kinase 3 \n(GSK-3) Inhibitors as New Promising Drugs for Diabe tes, Neurodegeneration, \nCancer, and Inflammation. Medicinal Research Reviews 2002,  22, 373-384. \n96. Force, T.; Woodgett, J. R. Unique and Overlappi ng Functions of GSK-3 Isoforms in \nCell Differentiation and Proliferation and Cardiova scular Development. JBC 2009, \n284, 9643-9647. \n97. Sato, N.; Meijer, L.; Skaltsounis, L.; Greengar d, P.; Brivanlou, A. H. Maintenance of \npluripotency in human and mouse embryonic stem cell s through activation of Wnt  \nSeite 308 signaling by a pharmacological GSK-3 specific inhib itor. Nature Medicine 2004, 10, \n55-63. \n98. Rib\u00e9, E. M.; P\u00e9rez, M.; Puig, B.; Gich, I.; Lim , F.; Cuadrado, M.; Sesma, T.; Catena, \nS.; S\u00e1nchez, B.; Nieto, M.; G\u00f3mez-Ramos, P.; Mor\u00e1n,  M. A.; Cabodevilla, F.; \nSamaranch, L.; Ortiz, L.; P\u00e9rez, A.; Ferrer, I.; Av ila, J.; G\u00f3mez-Isla, T. . Accelerated \namyloid deposition, neurofibrillary degeneration an d neuronal loss in double mutant \nAPP/tau transgenic mice. Neurobiology of Disease 2005,  20, 814-822. \n99. P\u00e9rez, M.; Ribe, E.; Rubio, A.; Lim, F.; Mor\u00e1n,  M. A.; G\u00f3mez-Ramos, P.; Ferrer, I.; \nIsla, M. T. G.; Avila, J. . Characterization of a D ouble (Amyloid Precursor Protein-Tau) \nTransgenic: Tau Phosphorylation and Aggregation. Neuroscience 2005, 130, 339-\n347. \n100. Terwel, D.; Muyllaert, D.; Dewachter, I.; Borg hgraef, P.; Croes, S.; Devijver, H.; Van \nLeuven, F. Amyloid Activates GSK-3 \u03b2 to Aggravate Neuronal Tauopathy in Bigenic \nMice. The American Journal of Pathology 2008,  172, 786-798. \n101. Oddo, S.; Caccamo, A.; Shepherd, J. D.; Murphy , M. P.; Golde, T. E.; Kayed, R.; \nMetherate, R.; Mattson, M. P.; Akbari, Y.; LaFerla,  F. M. Triple-Transgenic Model of \nAlzheimer's Disease with Plaques and Tangles: Intra cellular A \u03b2 and Synaptic \nDysfunction. Neuron 2003, 39, 409-421. \n102. Lewis, J.; Dickson, D. W.; Lin, W.; Chisholm, L.; Corral, A.; Jones, G.; Yen, S.; \nSahara, N.; Skipper, L.; Yager, D.; Eckman, C.; Har dy, J.; Hutton, M.; McGowan, E. \nEnhanced Neurofibrillary Degeneration in Transgenic  Mice Expressing Mutant Tau \nand APP. Science 2001,  293, 1487-1491. \n103. Lewis, J.; McGowan, E.; Rockwood, J.; Melrose,  H.; Nacharaju, P.; Van Slegtenhorst, \nM.; Gwinn-Hardy, K.; Murphy, M. P.; Baker, M.; Yu, X.; Duff, K.; Hardy, J.; Corral, A.; \nLin, W.; Yen, S.; Dickson, D. W.; Davies, P.; Hutto n, M. Neurofibrillary tangles, \namyotrophy and progressive motor disturbance in mic e expressing mutant (P301L) \ntau protein. Nature Genetics 2000,  25, 402-405. \n104. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meye rson, J.; Suleman, F.; Gaynor, K.; \nWang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.;  Krishnamurthy, P.; Wen, Y.; Bhat, \nR.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium \ncorrelates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. \n2005,  102, 6990-6995. \n105. Paquet, D.; Schmid, B.; Haass, C. Transgenic Z ebrafish as a Novel Animal Model to \nStudy Tauopathies and Other Neurodegenerative Disor ders in vivo. \nNeurodegenerative Disease 2010,  7, 99-102. \n106. Paquet, D.; Bhat, R.; Sydow, A.; Mandelkow, E. ; Berg, S.; Hellberg, S.; F\u00e4lting, J.; \nDistel, M.; K\u00f6ster, R. W.; Schmid, B.; Haass, C. A zebrafish model of tauopathy \nallows in vivo imaging of neuronal cell death and d rug evaluation. J. Clin. Invest. \n2009,  119, 1382-1395. \n107. Lee, H.; Tsai, J.; Liao, P.; Tsai, W.; Lin, K. ; Chuang, C.; Sun, C.; Chang, W.; Tsai, H. \nGlycogen synthase kinase 3 \u03b1 and 3 \u03b2 have distinct functions during cardiogenesis of \nzebrafish embryo. BMC Development Biology 2007,  7, 1-15. \n108. G\u00f6tz, J.; Ittner, L. M. Animal models of Alzhe imer\u00b4s disease and frontotemporal \ndementia. Nature Reviews Neuroscience 2008,  9, 532-544. \n109. Bissantz, C.; Kuhn, B.; Stahl, M. A Medicinal Chemist\u00b4s Guide to Molecular \nInteractions. J. Med. Chem 2010,  53, 5061-5084. \n110. Salonen, L. M.; Ellermann, M.; Diederich, F. A romatische Ringe in chemischer und \nbiologischer Erkennung: Energien und Strukturen. Angew. Chem. 2011,  123, 4908-\n4944. \n111. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular H ydrogen Bonding in Medicinal \nChemistry. J. Med. Chem 2010,  53, 2601-2611. \n112. Hardegger, L. A.; Kuhn, B.; Spinnler, B.; Anse lm, L.; Ecabert, R.; Stihle, M.; Gsell, B.; \nThoma, R.; Diez, J.; Benz, J.; Plancher, J.; Hartma nn, G.; Banner, D. W.; Haap, W.; \nDiederich, F. Systematische Untersuchung von Haloge nbr\u00fccken in Protein-Ligand-\nWechselwirkungen. Angew. Chem. 2011,  123, 329-334.  \nSeite 309 113. Meyer, E. A.; Castellano, R. K.; Diederich, F.  Wechselwirkungen mit aromatischen \nRingen in chemischen und biologischen Erkennungspro zessen. Angew. Chem. 2003, \n115, 1244-1287. \n114. Paulini, R.; M\u00fcller, K.; Diederich, F. Orthogo nal Multipolar Interactions in Structural \nChemistry and Biology. Angew. Chem. Int. Ed. 2005,  44, 1788-1805. \n115. Hof, F.; Scofield, D. M.; Schweizer, B.; Diede rich, F. A Weak Attractive Interaction \nbetween Organic Fluorine and an Amide Group. Angew. Chem. 2004,  116, 5166-\n5169. \n116. Fischer, F. R.; Schweizer, W. B.; Diederich, F . Molecular Torsion Balances: Evidence \nfor Favorable Orthogonal Dipolar Interactions Betwe en Organic Fluorine and Amide \nGroups. Angew. Chem. Int. Ed. 2007,  46, 8270-8273. \n117. Weinmann, H.; Metternich, R. Drug Discovery Pr ocess for Kinase Inhibition. \nChemBioChem 2005,  6, 455-459. \n118. Perola, E. An Analysis of the Binding Efficien cies of Drugs and Their Leads in \nSuccessful Drug Discovery Programs. J. Med. Chem 2010,  53, 2986-2997. \n119. Bleicher, K. H.; B\u00f6hm, H.; M\u00fcller, K.; Alanine , A. I. Hit and Lead Generation: Beyond \nHigh-Throughput Screening. Nature Reviews Drug Discovery 2003,  2, 369-378. \n120. Bhal, S. K.; Kassam, K.; Peirson, I. G.; Pearl , G. M. The Rule of five Revisited: \nApplying Log D in Place of Log P in Drug-Likeness F ilters. Molecular Pharmaceutics \n2007,  4, 556-560. \n121. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and \ncomputational approaches to estimate solubility and  permeability in drug discovery \nand development settings. Advanced Drug Delivery Reviews 2001,  46, 3-26. \n122. Edwards, R. H. Drug delivery via the blood-bra in barrier. Nature Neuroscience 2001, \n4, 221-222. \n123. Fernandes, J.; Gattass, C. R. Topological Pola r Surface Area Defines Substrate \nTransport by Multidrug Resistance Associated Protei n 1 (MRP1/ABCC1). J. Med. \nChem 2009,  52, 1214-1218. \n124. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculati on of Molecular Polar Surface Area as a \nSum of Fragment-Based Contributions and Its Applica tion to the Prediction of Drug \nTransport Properties. J. Med. Chem 2000,  43, 3714-3717. \n125. M\u00fcller, K.; Faeh, C.; Diederich, F. Fluorine i n Pharmaceuticals: Looking Beyond \nIntuition. Science 2007,  317, 1881-1886. \n126. Hagmann, W. K. The Many Roles for Fluorine in Medicinal Chemistry. J. Med. Chem \n2008,  51, 4359-4369. \n127. Morgenthaler, M.; Schweizer, E.; Hoffmann-R\u00f6de r, A.; Benini, F.; Martin, R. E.; \nJaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.;  Zimmerli, D.; Schneider, J.; \nDiederich, F.; Kansy, M.; M\u00fcller, K. Predicting and  tuning Physicochemical Properties \nin Lead Optimization: Amine Basicities. ChemMedChem 2007,  2, 1100-1115. \n128. Alavijeh, M. S.; Chishty, M.; Qaiser, M. Z.; P almer, A. M. Drug Metabolism and \nPharmacokinetics, the Blood-Brain-Barrier, and Cent ral Nervous System Drug \nDiscovery. NeuroRx 2005,  2, 554-571. \n129. Ross, O. A.; Farrer, M. J. Pathophysiology, pl eiotrophy and paradigm shifts: genetic \nlessons from Parkinson\u00b4s disease. Biochem. Soc. Trans. 2005,  33, 586-590. \n130. Davie, C. A. A review of Parkinson\u00b4s disease. Br. Med. Bull. 2008,  86, 109-127. \n131. Jankovic, J. Parkinson\u00b4s disease: clinical fea tures and diagnosis. J. Neurol. \nNeurosurg. Psychiatry 2008,  79, 368-376. \n132. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtne r, P.; Farrer, M.; Lincoln, S.; Kachergus, \nJ.; Hulihan, M.; Uitti, R. J.; Calne, D. B.; Stoess l, A. J.; Pfeiffer, R. F.; Patenge, N.; \nCarbajal, I. C.; Vieregge, P.; Asmus, F.; M\u00fcller-My hsok, B.; Dickson, D. W.; Meitinger, \nT.; Strom, T. M.; Wszolek, Z. K.; Gasser, T. Mutati ons in LRRK2 cause autosomal-\ndominant parkinsonism with pleomorphic pathology. Neuron 2004,  44, 601-607. \n133. Berwick, D. C.; Harvey, K. LRRK2 signalling pa thways: the key to unlocking \nneurodegeneration? Trends Cell Biol. 2011,  21, 257-265.  \nSeite 310 134. Smith, K. Treatment frontiers - Parkinson\u00b4s Di sease Outlook. Nature 2010, 466, 15-\n18. \n135. Giasson, B. I.; Van Deerlin, V. M. Mutations i n LRRK2 as a cause of Parkinson\u00b4s \ndisease. Neurosignals 2008,  16, 99-105. \n136. Mata, I. F.; Wedemeyer, W. J.; Farrer, M. J.; Taylor, J. P.; Gallo, K. A. LRRK2 in \nParkinson\u00b4s disease: protein domains and functional  insights. Trends Neurosci. 2006, \n29, 286-293. \n137. Taylor, J. P.; Mata, I. F.; Farrer, M. J. LRRK 2: a common pathway for parkinsonism, \npathogenesis and prevention? Trends Mol. Med. 2006,  12, 76-82. \n138. Levis, M.; Small, D. Novel FLT3 tyrosine kinas e inhibitors. Expert Opin. Investig. \nDrugs 2003,  12, 1951-1962. \n139. Kindler, T.; Lipka, D. B.; Fischer, T. FLT3 as  a therapeutic target in AML: still \nchallenging after all these years. Blood 2010,  116, 5089-5102. \n140. Pratz, K. W.; Levis, M. J. Bench to bedside ta rgeting of FLT3 in acute leukemia. Curr \nDrug Targets 2010,  11, 781-789. \n141. Mahboobi, S.; Uecker, A.; Sellmer, A.; C\u00e9nac, C.; H\u00f6cher, H.; Pongratz, H.; Eichhorn, \nE.; Hufsky, H.; Tr\u00fcmpler, A.; Sicker, M.; Heidel, F .; Fischer, T. Stocking, C.; Elz, S.; \nB\u00f6hmer, F. D.; Dove, S. Novel Bis(1H-indol-2-yl)met hanones as Potent Inhibitors of \nFLT3 and Platelet-Derived Growth Factor Receptor Ty rosine Kinase. J. Med. Chem \n2006,  49, 3101-3115. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 311 Fabio Lo Monte                Frankfurt am Main, de n 26.03.2012 \nEschersheimer Landstra\u00dfe 511 \n60431 Frankfurt am Main \n \n \nEidesstattliche Erkl\u00e4rung \n \n \nIch erkl\u00e4re hiermit an Eides statt, dass ich meine Dissertation selbstst\u00e4ndig und nur mit den \nangegebenen Hilfsmitteln angefertigt habe. \n \n \nFabio Lo Monte \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 312 Fabio Lo Monte                Frankfurt am Main, de n 26.03.2012 \nEschersheimer Landstra\u00dfe 511 \n60431 Frankfurt am Main  \n \n \nErkl\u00e4rung \n \n \nIch erkl\u00e4re hiermit, noch keinen Promotionsversuch unternommen zu haben. \n \n \nFabio Lo Monte \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nSeite 313 Fabio Lo Monte \nEschersheimer Landstra\u00dfe 511 \n60431 Frankfurt am Main \n \n \nGeburtsdatum/-ort 16. September 1980, Hilden \n        \nNationalit\u00e4t Italienisch  \n \nFamilienstand ledig \n \nPromotion 3/2009-3/2012  Durchf\u00fchrung der Doktorarbeit am  \n Clemens Sch\u00f6pf-Institut der organischen Chemie und  \nBiochemie an der TU Darmstadt unter Anleitung von  \nProf. Dr. Boris Schmidt; Schwerpunkt meiner Arbeit \nmedizinische/organische Chemie \n \nAufbaustudium 9/2007-2/2009 Master of Science (Angewandte Chemie)  an \nder Hochschule Niederrhein in 3. Semestern abgeschl ossen; \nAnfertigung der Masterarbeit in Chemical and Analyt ical \nSciences (CAS) der Sanofi-Aventis Deutschland GmbH \n  \n \nEnde Erststudium  9/2006-4/2007  Praktikum und Erstellung der Diplomarbeit in \nder medizinischen Chemie der Merck KGaA Darmstadt; \nAbschluss zum  Dipl. Chemie-Ingenieur zu Beginn des 8. \nSemesters; Aufnahme in das Student Excellence Progr am \nvon Merck (STEP) \n \nStudium 10/2003-2/2005 Beginn des Bachelorstudiums Biochemi e an \nder Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf \n3/2005 Wechsel an die Hochschule Niederrhein in Kre feld \nzum Studiengang Chemieingenieurwesen; Anrechnung al ler \nerbrachten Leistungen und Einstufung in das 4. Seme ster  \n \nBerufsausbildung       9/2000-6/2003 Ausbildung zum Chemielaboranten  beim         \nLandesumweltamt NRW  \n  \nSeite 314 Schulausbildung 9/1997-7/2000 Abitur am Dietrich-Bonhoeffer-Gymnasi um \n   \nBerufserfahrung  7/2003-9/2003 Chemielaborant - Landesumweltamt NRW   \n 9/2007-9/2008 Wissenschaftlicher Mitarbeiter am In stitut f\u00fcr \nHochpolymere und Hygieneprodukte (IHHP) \n3/2008-8/2008 Tutor in der organischen Chemie \n  \nSprachkenntnisse                    Italienisch (Muttersprache) \n Deutsch (Muttersprache)  \n Englisch (Flie\u00dfend)  \n Spanisch (Flie\u00dfend)  \n Portugiesisch (Verst\u00e4ndnis) \n Franz\u00f6sisch (Verst\u00e4ndnis) \n   \nReferenzen Professor Boris Schmidt; Technische Universit\u00e4t Dar mstadt; \nschmidt_boris@mac.com \n Dr. Wolfgang St\u00e4hle; Merck KGaA; \nstaehle@merck.de  \n  Professor Michael Lindemann; Hochschule Niederrhein ; \nmichael.lindemann@hs-niederrhein.de \n  Professor Andrea Wanninger; Hochschule Niederrhei n; \n  andrea.wanninger@hs-niederrhein.de \n \n \nFrankfurt am Main, den 26.03.2012 \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}